Our O
data O
suggest O
that O
lipoxygenase B
metabolites I
activate O
ROI O
formation O
which O
then O
induce O
IL B
- I
2 I
expression O
via O
NF B
- I
kappa I
B I
activation O
. O

Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV B
- I
1 I
gp120 I
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc B
adaptor I
protein I
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV B
- I
1 I
gp120 I
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc B
adaptor I
protein I
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV B
- I
1 I
gp120 I
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc B
adaptor I
protein I
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

To O
address O
potential O
mechanisms O
by O
which O
estrogens O
suppress O
erythropoiesis O
, O
we O
have O
examined O
their O
effects O
on O
GATA B
- I
1 I
, O
an O
erythroid B
transcription I
factor I
that O
participates O
in O
the O
regulation O
of O
the O
majority O
of O
erythroid B
cell I
- I
specific I
genes I
and O
is O
necessary O
for O
full O
maturation O
of O
erythrocytes O
. O

To O
address O
potential O
mechanisms O
by O
which O
estrogens O
suppress O
erythropoiesis O
, O
we O
have O
examined O
their O
effects O
on O
GATA B
- I
1 I
, O
an O
erythroid B
transcription I
factor I
that O
participates O
in O
the O
regulation O
of O
the O
majority O
of O
erythroid B
cell I
- I
specific I
genes I
and O
is O
necessary O
for O
full O
maturation O
of O
erythrocytes O
. O

ER B
- O
mediated O
repression O
of O
GATA B
- I
1 I
activity O
occurs O
on O
an O
artificial B
promoter I
containing O
a O
single O
GATA B
- I
binding I
site I
, O
as O
well O
as O
in O
the O
context O
of O
an O
intact B
promoter I
which O
is O
normally O
regulated O
by O
GATA B
- I
1 I
. O

ER B
- O
mediated O
repression O
of O
GATA B
- I
1 I
activity O
occurs O
on O
an O
artificial B
promoter I
containing O
a O
single O
GATA B
- I
binding I
site I
, O
as O
well O
as O
in O
the O
context O
of O
an O
intact B
promoter I
which O
is O
normally O
regulated O
by O
GATA B
- I
1 I
. O

In O
coimmunoprecipitatio O
experiments O
using O
transfected O
COS O
cells O
, O
GATA B
- I
1 I
and O
ER B
associate O
in O
a O
ligand O
- O
dependent O
manner O
. O

The O
transcriptional O
response O
of O
the O
IL B
- I
2R I
alpha I
gene I
to O
stimulation O
by O
IL B
- I
1 I
+ O
IL B
- I
2 I
is O
biphasic O
. O

The O
transcriptional O
response O
of O
the O
IL B
- I
2R I
alpha I
gene I
to O
stimulation O
by O
IL B
- I
1 I
+ O
IL B
- I
2 I
is O
biphasic O
. O

It O
also O
primes O
cells O
to O
become O
IL B
- I
2 I
responsive O
and O
thereby O
prepares O
the O
second O
phase O
, O
in O
which O
IL B
- I
2 I
induces O
a O
100 O
- O
fold O
further O
increase O
in O
IL B
- I
2R I
alpha I
transcripts I
. O

It O
also O
primes O
cells O
to O
become O
IL B
- I
2 I
responsive O
and O
thereby O
prepares O
the O
second O
phase O
, O
in O
which O
IL B
- I
2 I
induces O
a O
100 O
- O
fold O
further O
increase O
in O
IL B
- I
2R I
alpha I
transcripts I
. O

Transient O
transfection O
experiments O
show O
that O
several O
elements O
in O
the O
promoter B
- I
proximal I
region I
of O
the O
IL B
- I
2R I
alpha I
gene I
contribute O
to O
IL B
- I
1 I
responsiveness O
, O
most O
importantly O
an O
NF B
- I
kappa I
B I
site I
conserved O
in O
the O
human B
and I
mouse I
gene I
. O

IL B
- I
2 I
responsiveness O
, O
on O
the O
other O
hand O
, O
depends O
on O
a O
78 B
- I
nucleotide I
segment I
1 O
. O
3 O
kilobases O
upstream O
of O
the O
major B
transcription I
start I
site I
. O

Transcripts O
encoding O
gp350 B
/ I
220 I
, O
the O
major B
coat I
protein I
of O
EBV O
, O
were O
identified O
, O
but O
we O
did O
not O
find O
any O
evidence O
of O
transcription O
from O
the O
LMP B
- I
2A I
or O
EBER B
- I
1 I
loci I
in O
infected O
thymocytes O
. O

Transcripts O
encoding O
gp350 B
/ I
220 I
, O
the O
major B
coat I
protein I
of O
EBV O
, O
were O
identified O
, O
but O
we O
did O
not O
find O
any O
evidence O
of O
transcription O
from O
the O
LMP B
- I
2A I
or O
EBER B
- I
1 I
loci I
in O
infected O
thymocytes O
. O

Transcripts O
encoding O
gp350 B
/ I
220 I
, O
the O
major B
coat I
protein I
of O
EBV O
, O
were O
identified O
, O
but O
we O
did O
not O
find O
any O
evidence O
of O
transcription O
from O
the O
LMP B
- I
2A I
or O
EBER B
- I
1 I
loci I
in O
infected O
thymocytes O
. O

Several O
recent O
studies O
have O
implicated O
Jak O
kinases O
in O
the O
signaling O
pathway O
induced O
by O
IL B
- I
2 I
. O

We O
demonstrate O
, O
through O
the O
deletion O
of O
the O
human B
UDG I
promoter I
sequences I
, O
that O
expression O
of O
E2F B
- I
1 I
activates O
the O
UDG B
promoter I
through O
several O
E2F B
sites I
. O

Cellular O
and O
molecular O
mechanisms O
of O
IFN B
- I
gamma I
production O
induced O
by O
IL B
- I
2 I
and O
IL B
- I
12 I
in O
a O
human O
NK O
cell O
line O
. O

Cellular O
and O
molecular O
mechanisms O
of O
IFN B
- I
gamma I
production O
induced O
by O
IL B
- I
2 I
and O
IL B
- I
12 I
in O
a O
human O
NK O
cell O
line O
. O

Cellular O
and O
molecular O
mechanisms O
of O
IFN B
- I
gamma I
production O
induced O
by O
IL B
- I
2 I
and O
IL B
- I
12 I
in O
a O
human O
NK O
cell O
line O
. O

In O
addition O
, O
when O
used O
together O
IL B
- I
2 I
and O
IL B
- I
12 I
synergized O
in O
the O
induction O
of O
IFN B
- I
gamma I
and O
GM B
- I
CSF I
and O
this O
synergy O
was O
attributed O
to O
an O
increased O
accumulation O
and O
stability O
of O
the O
IFN B
- I
gamma I
and I
GM I
- I
CSF I
mRNAs I
. O

In O
addition O
, O
when O
used O
together O
IL B
- I
2 I
and O
IL B
- I
12 I
synergized O
in O
the O
induction O
of O
IFN B
- I
gamma I
and O
GM B
- I
CSF I
and O
this O
synergy O
was O
attributed O
to O
an O
increased O
accumulation O
and O
stability O
of O
the O
IFN B
- I
gamma I
and I
GM I
- I
CSF I
mRNAs I
. O

In O
addition O
, O
when O
used O
together O
IL B
- I
2 I
and O
IL B
- I
12 I
synergized O
in O
the O
induction O
of O
IFN B
- I
gamma I
and O
GM B
- I
CSF I
and O
this O
synergy O
was O
attributed O
to O
an O
increased O
accumulation O
and O
stability O
of O
the O
IFN B
- I
gamma I
and I
GM I
- I
CSF I
mRNAs I
. O

In O
addition O
, O
when O
used O
together O
IL B
- I
2 I
and O
IL B
- I
12 I
synergized O
in O
the O
induction O
of O
IFN B
- I
gamma I
and O
GM B
- I
CSF I
and O
this O
synergy O
was O
attributed O
to O
an O
increased O
accumulation O
and O
stability O
of O
the O
IFN B
- I
gamma I
and I
GM I
- I
CSF I
mRNAs I
. O

To O
investigate O
the O
signaling O
pathways O
involved O
in O
the O
gene O
induction O
, O
five O
inhibitors O
, O
cyclosporin O
A O
( O
CsA O
) O
, O
transforming B
growth I
factor I
- I
beta I
, O
cycloheximide O
, O
genistein O
, O
and O
staurosporine O
A O
, O
were O
used O
in O
analyzing O
the O
effects O
of O
IL B
- I
2 I
and O
IL B
- I
12 I
on O
NK3 O
. O
3 O
cells O
. O

To O
investigate O
the O
signaling O
pathways O
involved O
in O
the O
gene O
induction O
, O
five O
inhibitors O
, O
cyclosporin O
A O
( O
CsA O
) O
, O
transforming B
growth I
factor I
- I
beta I
, O
cycloheximide O
, O
genistein O
, O
and O
staurosporine O
A O
, O
were O
used O
in O
analyzing O
the O
effects O
of O
IL B
- I
2 I
and O
IL B
- I
12 I
on O
NK3 O
. O
3 O
cells O
. O

In O
addition O
, O
IL B
- I
2 I
but O
not O
IL B
- I
12 I
induced O
nuclear B
factors I
NF B
- I
kappa I
B I
and O
AP1 B
, O
and O
regulation O
of O
the O
nuclear O
levels O
of O
these O
two O
DNA B
binding I
protein I
complexes I
is O
correlated O
with O
IFN O
- O
gamma O
and O
GM O
- O
CSF O
gene O
expression O
. O

In O
addition O
, O
IL B
- I
2 I
but O
not O
IL B
- I
12 I
induced O
nuclear B
factors I
NF B
- I
kappa I
B I
and O
AP1 B
, O
and O
regulation O
of O
the O
nuclear O
levels O
of O
these O
two O
DNA B
binding I
protein I
complexes I
is O
correlated O
with O
IFN O
- O
gamma O
and O
GM O
- O
CSF O
gene O
expression O
. O

alpha B
B I
is O
the O
mouse B
homologue I
of O
human B
AML1 I
gene I
detected O
at O
the O
breakpoints O
of O
t O
( O
8 O
; O
21 O
) O
and O
t O
( O
3 O
; O
21 O
) O
myeloid O
leukemias O
. O

Although O
further O
studies O
are O
required O
to O
determine O
the O
precise O
role O
of O
PEBP2 B
in O
the O
GM B
- I
CSF I
promoter O
activity O
, O
the O
present O
findings O
suggested O
the O
importance O
of O
the O
relative O
ratio O
of O
different O
PEBP2 B
isoforms I
in O
regulating O
the O
levels O
of O
the O
promoter O
activity O
. O

IFN B
- I
gamma I
priming O
of O
monocytes O
enhances O
LPS O
- O
induced O
TNF B
production O
by O
augmenting O
both O
transcription O
and O
MRNA O
stability O
. O

Since O
the O
terminal O
events O
of O
erythropoiesis O
are O
controlled O
by O
the O
glycoprotein B
hormone I
erythropoietin I
( O
Epo B
) O
, O
we O
investigated O
whether O
the O
expression O
or O
activity O
of O
the O
TAL1 B
gene I
and O
its O
protein B
products I
were O
affected O
by O
Epo B
in O
splenic O
erythroblasts O
from O
mice O
infected O
with O
an O
anemia O
- O
inducing O
strain O
of O
Friend O
virus O
( O
FVA O
cells O
) O
. O

The O
role O
of O
shared B
receptor I
motifs I
and O
common B
Stat I
proteins I
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

The O
role O
of O
shared B
receptor I
motifs I
and O
common B
Stat I
proteins I
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

The O
role O
of O
shared B
receptor I
motifs I
and O
common B
Stat I
proteins I
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

The O
role O
of O
shared B
receptor I
motifs I
and O
common B
Stat I
proteins I
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

The O
role O
of O
shared B
receptor I
motifs I
and O
common B
Stat I
proteins I
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

The O
role O
of O
shared B
receptor I
motifs I
and O
common B
Stat I
proteins I
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

The O
role O
of O
shared B
receptor I
motifs I
and O
common B
Stat I
proteins I
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

IL B
- I
13 I
Induced O
the O
same O
complexes O
as O
IL B
- I
4 I
, O
a O
finding O
explained O
by O
our O
studies O
implicating O
IL B
- I
4R I
as O
a O
shared O
component O
of O
the O
receptors B
. O

IL B
- I
13 I
Induced O
the O
same O
complexes O
as O
IL B
- I
4 I
, O
a O
finding O
explained O
by O
our O
studies O
implicating O
IL B
- I
4R I
as O
a O
shared O
component O
of O
the O
receptors B
. O

IL B
- I
13 I
Induced O
the O
same O
complexes O
as O
IL B
- I
4 I
, O
a O
finding O
explained O
by O
our O
studies O
implicating O
IL B
- I
4R I
as O
a O
shared O
component O
of O
the O
receptors B
. O

Erythropoietin B
( O
Epo B
) O
, O
the O
primary O
regulator O
of O
the O
production O
of O
erythroid O
cells O
, O
acts O
by O
binding O
to O
a O
cell B
surface I
receptor I
( O
EpoR B
) O
on O
erythroid O
progenitors O
. O

Interestingly O
, O
when O
we O
mutated O
the O
Sp1 B
site I
, O
resulting O
in O
a O
marked O
decrease O
in O
hEpoR B
promoter I
activity O
, O
we O
could O
restore O
transactivation O
by O
increasing O
GATA B
- I
1 I
levels O
in O
OCIM1 O
cells O
. O

These O
data O
suggest O
that O
while O
GATA B
- I
1 I
can O
transactivate O
the O
EpoR B
promoter I
, O
the O
level O
of O
hEpoR B
gene I
expression O
does O
not O
depend O
on O
GATA B
- I
1 I
alone O
. O

These O
data O
suggest O
that O
while O
GATA B
- I
1 I
can O
transactivate O
the O
EpoR B
promoter I
, O
the O
level O
of O
hEpoR B
gene I
expression O
does O
not O
depend O
on O
GATA B
- I
1 I
alone O
. O

Treatment O
of O
U937 O
with O
IFN B
- I
gamma I
for O
9 O
hr O
in O
the O
presence O
of O
cycloheximide O
led O
to O
super O
- O
induction O
of O
Fc B
gamma I
RI I
expression O
. O

Treatment O
of O
U937 O
with O
IFN B
- I
gamma I
for O
9 O
hr O
in O
the O
presence O
of O
cycloheximide O
led O
to O
super O
- O
induction O
of O
Fc B
gamma I
RI I
expression O
. O

Genomic O
sequence O
upstream O
of O
the O
Fc B
gamma I
RIC I
gene I
was O
cloned O
and O
subjected O
to O
primer O
extension O
analysis O
, O
which O
demonstrated O
a O
single O
transcription B
initiation I
site I
without O
a O
TATA B
box I
. O

The O
Fc B
gamma I
RIC I
GIRE I
is O
homologous O
to O
the O
IFN B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
of O
the O
guanylate B
binding I
protein I
and O
to O
X B
box I
elements I
of O
class B
II I
MHC I
genes I
. O

The O
Fc B
gamma I
RIC I
GIRE I
is O
homologous O
to O
the O
IFN B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
of O
the O
guanylate B
binding I
protein I
and O
to O
X B
box I
elements I
of O
class B
II I
MHC I
genes I
. O

In O
HTLV O
- O
I O
- O
infected O
cord O
blood O
lymphocytes O
, O
the O
transition O
from O
IL B
- I
2 I
- O
dependent O
to O
IL B
- I
2 I
- O
independent O
growth O
correlated O
with O
the O
acquisition O
of O
a O
constitutively O
activated O
Jak B
- B
STAT I
pathway O
, O
which O
suggests O
that O
this O
pathway O
participates O
in O
HTLV O
- O
I O
- O
mediated O
T O
cell O
transformation O
. O

In O
HTLV O
- O
I O
- O
infected O
cord O
blood O
lymphocytes O
, O
the O
transition O
from O
IL B
- I
2 I
- O
dependent O
to O
IL B
- I
2 I
- O
independent O
growth O
correlated O
with O
the O
acquisition O
of O
a O
constitutively O
activated O
Jak B
- B
STAT I
pathway O
, O
which O
suggests O
that O
this O
pathway O
participates O
in O
HTLV O
- O
I O
- O
mediated O
T O
cell O
transformation O
. O

In O
a O
concentration O
- O
dependent O
manner O
, O
NO O
inhibited O
interleukin B
( I
IL I
) I
- I
1 I
alpha O
- O
stimulated O
VCAM B
- I
1 I
expression O
by O
35 O
- O
55 O
% O
as O
determined O
by O
cell O
surface O
enzyme O
immunoassays O
and O
flow O
cytometry O
. O

Inhibition O
of O
endogenous O
NO O
production O
by O
L O
- O
N O
- O
monomethyl O
- O
arginine O
also O
induced O
the O
expression O
of O
VCAM B
- I
1 I
, O
but O
did O
not O
augment O
cytokine O
- O
induced O
VCAM B
- I
1 I
expression O
. O

Inhibition O
of O
endogenous O
NO O
production O
by O
L O
- O
N O
- O
monomethyl O
- O
arginine O
also O
induced O
the O
expression O
of O
VCAM B
- I
1 I
, O
but O
did O
not O
augment O
cytokine O
- O
induced O
VCAM B
- I
1 I
expression O
. O

One O
member O
, O
ICK B
- I
1A I
, O
behaves O
as O
a O
strong B
negative I
regulator I
. O

One O
member O
, O
ICK B
- I
1A I
, O
behaves O
as O
a O
strong B
negative I
regulator I
. O

The O
signal O
is O
subsequently O
propagated O
through O
the O
activation O
of O
Raf B
- I
1 I
, O
MEK B
, O
and O
MAP B
kinases I
as O
shown O
by O
their O
increased O
autophosphorylation O
in O
vitro O
and O
phosphorylation O
in O
situ O
. O

We O
conclude O
that O
IL B
- I
5 I
induced O
signals O
are O
propagated O
through O
two O
distinct O
pathways O
: O
( O
1 O
) O
Lyn B
- O
- O
> O
Ras B
- O
- O
> O
Raf B
- I
1 I
- O
- O
> O
MEK B
- O
- O
> O
MAP B
kinase I
and O
( O
2 O
) O
Jak2 B
- O
- O
> O
STAT1 B
. O

We O
conclude O
that O
IL B
- I
5 I
induced O
signals O
are O
propagated O
through O
two O
distinct O
pathways O
: O
( O
1 O
) O
Lyn B
- O
- O
> O
Ras B
- O
- O
> O
Raf B
- I
1 I
- O
- O
> O
MEK B
- O
- O
> O
MAP B
kinase I
and O
( O
2 O
) O
Jak2 B
- O
- O
> O
STAT1 B
. O

The O
retinoblastoma B
gene I
product I
negatively O
regulates O
transcriptional O
activation O
mediated O
by O
the O
human B
cytomegalovirus I
IE2 I
protein I
. O

RB O
- O
defective O
tumor O
lines O
are O
non O
- O
inducible O
for O
MHC B
class I
II I
by O
IFN B
- I
gamma I
, O
or O
very O
weakly O
inducible O
, O
but O
transfection O
of O
2 O
different O
lines O
with O
RB B
expression I
vectors I
re O
- O
establishes O
or O
substantially O
enhances O
class O
II O
inducibility O
. O

RB O
- O
defective O
tumor O
lines O
are O
non O
- O
inducible O
for O
MHC B
class I
II I
by O
IFN B
- I
gamma I
, O
or O
very O
weakly O
inducible O
, O
but O
transfection O
of O
2 O
different O
lines O
with O
RB B
expression I
vectors I
re O
- O
establishes O
or O
substantially O
enhances O
class O
II O
inducibility O
. O

RB O
- O
defective O
tumor O
lines O
are O
non O
- O
inducible O
for O
MHC B
class I
II I
by O
IFN B
- I
gamma I
, O
or O
very O
weakly O
inducible O
, O
but O
transfection O
of O
2 O
different O
lines O
with O
RB B
expression I
vectors I
re O
- O
establishes O
or O
substantially O
enhances O
class O
II O
inducibility O
. O

We O
also O
examined O
the O
IFN B
- I
gamma I
induction O
of O
CIITA B
in O
RB B
- O
defective O
lines O
. O

We O
have O
recently O
demonstrated O
that O
stimulation O
of O
human O
T O
and O
natural O
killer O
cells O
with O
IL B
- I
12 I
induces O
tyrosine O
phosphorylation O
of O
the O
Janus B
family I
tyrosine I
kinase I
JAK2 B
and O
Tyk2 B
, O
implicating O
these O
kinases B
in O
the O
immediate O
biochemical O
response O
to O
IL B
- I
12 I
. O

We O
have O
recently O
demonstrated O
that O
stimulation O
of O
human O
T O
and O
natural O
killer O
cells O
with O
IL B
- I
12 I
induces O
tyrosine O
phosphorylation O
of O
the O
Janus B
family I
tyrosine I
kinase I
JAK2 B
and O
Tyk2 B
, O
implicating O
these O
kinases B
in O
the O
immediate O
biochemical O
response O
to O
IL B
- I
12 I
. O

Furthermore O
, O
we O
show O
that O
IL B
- I
12 I
stimulates O
formation O
of O
a O
DNA B
- I
binding I
complex I
that O
recognizes O
a O
DNA O
sequence O
previously O
shown O
to O
bind O
STAT B
proteins I
and O
that O
this O
complex O
contains O
STAT4 B
. O

We O
have O
recently O
found O
a O
novel O
conserved B
motif I
in O
the O
promoters B
of O
several O
T B
- I
cell I
- I
expressed I
cytokines I
[ O
human B
interleukin I
- I
2 I
, I
- I
4 I
, I
- I
5 I
and I
- I
13 I
and O
human B
and I
mouse I
granulocyte I
/ I
macrophage I
- I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
] O
. O

Together O
, O
these O
results O
suggest O
that O
phosphorylation O
of O
I B
kappa I
B I
alpha I
, O
mediated O
through O
both O
the O
TNF B
- I
alpha I
- O
inducible O
and O
the O
PP B
- I
2A I
- I
opposing I
kinases I
, O
may O
serve O
to O
target O
I B
kappa I
B I
alpha I
for O
proteasome B
- O
mediated O
degradation O
. O

The O
5 B
' I
flanking I
region I
of O
the O
human B
alpha I
- I
globin I
gene I
is O
highly O
G O
+ O
C O
rich O
and O
contains O
multiple O
copies O
of O
the O
consensus B
sequence I
for O
the O
Sp1 B
binding I
site I
. O

Finally O
, O
we O
show O
by O
both O
footprint O
analysis O
and O
functional O
assays O
that O
the O
ability O
of O
the O
G B
+ I
C I
- I
rich I
region I
to O
increase O
alpha B
- I
globin I
promoter I
activity O
from O
a O
stably O
integrated O
alpha B
- I
globin I
gene I
is O
mediated O
by O
its O
multiple B
binding I
sites I
for O
the O
transcription B
factor I
Sp1 B
. O

LFA B
- I
3 I
induced O
moderate O
levels O
of O
AP B
- I
1 I
, O
but O
did O
not O
influence O
the O
levels O
of O
NF B
- I
kappa I
B I
, O
while O
B7 B
costimulation O
strongly O
induced O
both O
AP B
- I
1 I
and O
substantially O
enhanced O
NF B
- I
kappa I
B I
binding I
proteins I
. O

LFA B
- I
3 I
induced O
moderate O
levels O
of O
AP B
- I
1 I
, O
but O
did O
not O
influence O
the O
levels O
of O
NF B
- I
kappa I
B I
, O
while O
B7 B
costimulation O
strongly O
induced O
both O
AP B
- I
1 I
and O
substantially O
enhanced O
NF B
- I
kappa I
B I
binding I
proteins I
. O

LFA B
- I
3 I
induced O
moderate O
levels O
of O
AP B
- I
1 I
, O
but O
did O
not O
influence O
the O
levels O
of O
NF B
- I
kappa I
B I
, O
while O
B7 B
costimulation O
strongly O
induced O
both O
AP B
- I
1 I
and O
substantially O
enhanced O
NF B
- I
kappa I
B I
binding I
proteins I
. O

The O
Ah B
receptor I
recognizes O
DNA B
binding I
sites I
for O
the O
B B
cell I
transcription I
factor I
, O
BSAP B
: O
a O
possible O
mechanism O
for O
dioxin O
- O
mediated O
alteration O
of O
CD19 B
gene I
expression O
in O
human O
B O
lymphocytes O
. O

In O
addition O
, O
the O
Ah B
receptor I
complex I
recognized O
a O
DNA B
binding I
site I
for O
B B
cell I
lineage I
- I
specific I
activator I
protein I
( O
BSAP B
) O
in O
the O
promoter B
region I
of O
the O
human O
CD19 B
gene I
which O
is O
similar O
to O
the O
consensus B
Ah I
receptor I
DNA I
binding I
site I
. O

In O
addition O
, O
the O
Ah B
receptor I
complex I
recognized O
a O
DNA B
binding I
site I
for O
B B
cell I
lineage I
- I
specific I
activator I
protein I
( O
BSAP B
) O
in O
the O
promoter B
region I
of O
the O
human O
CD19 B
gene I
which O
is O
similar O
to O
the O
consensus B
Ah I
receptor I
DNA I
binding I
site I
. O

We O
recently O
identified O
a O
differentiation B
inhibitory I
factor I
( O
I B
- I
factor I
) O
in O
mouse O
myeloid O
leukemia O
M1 O
cells O
as O
a O
murine B
homolog I
of O
the O
human B
nm23 I
- I
H2 I
gene I
product I
. O

We O
recently O
identified O
a O
differentiation B
inhibitory I
factor I
( O
I B
- I
factor I
) O
in O
mouse O
myeloid O
leukemia O
M1 O
cells O
as O
a O
murine B
homolog I
of O
the O
human B
nm23 I
- I
H2 I
gene I
product I
. O

GM B
- I
CSF I
and O
IL B
- I
2 I
share O
common O
control O
mechanisms O
in O
response O
to O
costimulatory O
signals O
in O
T O
cells O
. O

GM B
- I
CSF I
and O
IL B
- I
2 I
share O
common O
control O
mechanisms O
in O
response O
to O
costimulatory O
signals O
in O
T O
cells O
. O

Antigen O
complexed O
with O
major B
histocompatibility I
complex I
class I
I I
or I
II I
molecules I
on O
the O
surface O
of O
antigen O
presenting O
cells O
interacts O
with O
the O
T B
cell I
receptor I
( O
TCR B
) O
on O
the O
surface O
of O
T O
cells O
and O
initiates O
an O
activation O
cascade O
. O

Human O
T O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
infects O
T O
cells O
and O
can O
lead O
to O
increase O
GM B
- I
CSF I
expression O
. O

This O
observation O
, O
together O
with O
the O
fact O
that O
both O
GM B
- I
CSF I
and O
IL B
- I
2 I
respond O
to O
TCR B
signals O
via O
NFAT B
, O
implies O
a O
high O
degree O
of O
conservation O
in O
the O
regulation O
of O
cytokine B
gene O
expression O
in O
T O
cells O
. O

This O
observation O
, O
together O
with O
the O
fact O
that O
both O
GM B
- I
CSF I
and O
IL B
- I
2 I
respond O
to O
TCR B
signals O
via O
NFAT B
, O
implies O
a O
high O
degree O
of O
conservation O
in O
the O
regulation O
of O
cytokine B
gene O
expression O
in O
T O
cells O
. O

Formation O
of O
the O
NFAT B
- I
1 I
transcriptional I
complex I
on O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
IL B
- I
2 I
transcription O
. O

WIN O
53071 O
inhibited O
IL B
- I
2 I
production O
induced O
in O
the O
calcium O
- O
dependent O
PMA O
and O
ionomycin O
pathway O
. O

We O
examined O
mRNA B
levels O
of O
various O
V B
- I
ATPase I
subunits O
during O
differentiation O
of O
both O
native O
monocytes O
and O
the O
cell O
line O
THP O
- O
1 O
, O
and O
found O
that O
transcriptional O
and O
post O
- O
transcriptional O
mechanisms O
could O
account O
for O
increases O
in O
cell O
V B
- I
ATPase I
content O
. O

We O
examined O
mRNA B
levels O
of O
various O
V B
- I
ATPase I
subunits O
during O
differentiation O
of O
both O
native O
monocytes O
and O
the O
cell O
line O
THP O
- O
1 O
, O
and O
found O
that O
transcriptional O
and O
post O
- O
transcriptional O
mechanisms O
could O
account O
for O
increases O
in O
cell O
V B
- I
ATPase I
content O
. O

Okadaic O
acid O
augments O
PMA O
- O
as O
well O
as O
calcium O
- O
mediated O
activation O
of O
c B
- I
fos I
, O
and O
has O
little O
or O
no O
effect O
when O
combined O
with O
cAMP O
. O

The O
main O
difference O
between O
Ramos O
( O
B O
cells O
) O
and O
Jurkat O
( O
T O
cells O
) O
in O
the O
regulation O
of O
c B
- I
fos I
is O
that O
cAMP O
plus O
calcium O
is O
strongly O
synergistic O
in O
Jurkat O
and O
is O
without O
effect O
in O
Ramos O
. O

These O
results O
suggest O
that O
cell O
- O
specific O
patterns O
of O
synergy O
are O
an O
essential O
feature O
for O
c B
- I
fos I
induction O
and O
may O
be O
relevant O
for O
c B
- I
fos I
control O
through O
B B
and I
T I
cell I
antigen I
receptors I
. O

These O
results O
suggest O
that O
cell O
- O
specific O
patterns O
of O
synergy O
are O
an O
essential O
feature O
for O
c B
- I
fos I
induction O
and O
may O
be O
relevant O
for O
c B
- I
fos I
control O
through O
B B
and I
T I
cell I
antigen I
receptors I
. O

In O
this O
report O
, O
we O
show O
that O
in O
monocytes O
and O
T O
cells O
IL B
- I
10 I
stimulates O
tyrosine O
phosphorylation O
of O
the O
signal B
transducers I
and O
activators B
of I
transcription I
, O
STAT1 B
alpha I
and O
STAT3 B
, O
in O
a O
differential O
manner O
such O
that O
the O
relative O
formation O
of O
homo B
- I
and I
heterodimers I
varies O
between O
the O
two O
cell O
types O
. O

In O
this O
report O
, O
we O
show O
that O
in O
monocytes O
and O
T O
cells O
IL B
- I
10 I
stimulates O
tyrosine O
phosphorylation O
of O
the O
signal B
transducers I
and O
activators B
of I
transcription I
, O
STAT1 B
alpha I
and O
STAT3 B
, O
in O
a O
differential O
manner O
such O
that O
the O
relative O
formation O
of O
homo B
- I
and I
heterodimers I
varies O
between O
the O
two O
cell O
types O
. O

IL B
- I
10 I
treatment O
of O
both O
T O
cells O
and O
monocytes O
results O
in O
the O
ligand O
- O
induced O
tyrosine O
phosphorylation O
of O
tyk2 B
and O
Jak1 B
, O
but O
not O
Jak2 B
or O
Jak3 B
. O

Selective O
modulation O
of O
immune O
responsiveness O
by O
IL B
- I
10 I
in O
cells O
such O
as O
monocytes O
and O
T O
cells O
may O
result O
in O
part O
from O
the O
differential O
activation O
of O
STAT B
protein I
pairs I
. O

Selective O
modulation O
of O
immune O
responsiveness O
by O
IL B
- I
10 I
in O
cells O
such O
as O
monocytes O
and O
T O
cells O
may O
result O
in O
part O
from O
the O
differential O
activation O
of O
STAT B
protein I
pairs I
. O

Type B
II I
major I
histocompatibility I
complex I
combined O
immune O
deficiency O
( O
type O
II O
MHC B
CID O
or O
bare O
lymphocyte O
syndrome O
) O
is O
a O
congenital O
immunodeficiency O
disease O
characterized O
by O
absent O
MHC B
class I
II I
expression O
. O

These O
results O
demonstrate O
that O
P B
- I
selectin I
, O
through O
its O
ligands O
on O
monocytes O
, O
may O
locally O
regulate O
cytokine B
secretion O
in O
inflamed O
tissues O
. O

In O
vitro O
studies O
using O
pure B
recombinant I
p21ras I
demonstrate O
that O
the O
activation O
is O
direct O
and O
reversible O
. O

In O
the O
present O
study O
we O
analyzed O
the O
control O
of O
IL B
- I
2 I
promoter I
activity O
in O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
- O
transformed O
B O
cell O
clones O
which O
are O
capable O
of O
secreting O
IL B
- I
2 I
at O
a O
low O
level O
after O
stimulation O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
and O
the O
Ca2 O
+ O
ionophore O
ionomycin O
. O

In O
EBV O
- O
transformed O
B O
clones O
, O
the O
chi B
B I
site I
exerted O
the O
strongest O
inducible O
activity O
; O
the O
NF B
- I
AT I
binding I
sites I
showed O
either O
no O
or O
only O
weak O
activity O
compared O
to O
Jurkat O
T O
cells O
. O

In O
seven O
EBV O
- O
B O
cell O
clones O
or O
lines O
differing O
in O
their O
capacity O
to O
secrete O
IL B
- I
2 I
, O
the O
activity O
of O
the O
IL B
- I
2 I
promoter I
correlated O
well O
with O
the O
status O
of O
IL B
- I
2 I
secretion O
. O

In O
seven O
EBV O
- O
B O
cell O
clones O
or O
lines O
differing O
in O
their O
capacity O
to O
secrete O
IL B
- I
2 I
, O
the O
activity O
of O
the O
IL B
- I
2 I
promoter I
correlated O
well O
with O
the O
status O
of O
IL B
- I
2 I
secretion O
. O

Here O
, O
we O
show O
that O
the O
presence O
of O
either O
wild O
- O
type O
EBV O
or O
its O
transforming B
latent I
membrane I
protein I
- I
1 I
( O
LMP B
- I
1 I
) O
results O
in O
the O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
human O
B O
cells O
. O

Transfection O
experiments O
with O
c B
- I
myc I
promoter I
constructs I
in O
both O
DHL O
- O
9 O
and O
Raji O
cells O
revealed O
that O
the O
PuF B
site I
functioned O
as O
a O
positive B
regulatory I
element I
in O
B O
cells O
with O
a O
drop O
in O
activity O
with O
mutation O
of O
this O
site O
. O

These O
results O
indicate O
that O
the O
5 B
' I
- I
UTR I
of O
the O
gamma B
- I
gene I
contains O
sequences O
that O
may O
be O
important O
for O
its O
transcriptional O
and O
developmental O
regulation O
. O

Human O
peripheral O
blood O
monocytes O
responded O
to O
stimulation O
of O
platelet B
- I
activating I
factor I
( O
PAF B
) O
with O
up O
- O
regulation O
of O
the O
transcript O
for O
heparin B
- I
binding I
epidermal I
growth I
factor I
- I
like I
growth I
factor I
( O
HB B
- I
EGF I
) O
, O
a O
potent B
mitogen I
for O
vascular O
smooth O
muscle O
cells O
. O

ZEBRA B
is O
a O
bZIP B
transcriptional I
activator I
which O
binds O
as O
a O
dimer O
to O
7 B
- I
bp I
response I
elements I
within O
EBV B
promoters I
and O
is O
directly O
involved O
in O
the O
stimulation O
of O
virus O
replication O
at O
the O
EBV B
lytic I
origin I
. O

ZEBRA B
is O
a O
bZIP B
transcriptional I
activator I
which O
binds O
as O
a O
dimer O
to O
7 B
- I
bp I
response I
elements I
within O
EBV B
promoters I
and O
is O
directly O
involved O
in O
the O
stimulation O
of O
virus O
replication O
at O
the O
EBV B
lytic I
origin I
. O

Erythroid B
- I
specific I
mRNAs I
encoding O
gamma B
- I
globin I
and O
erythroid B
delta I
- I
aminolevulinate I
synthase I
were O
found O
to O
be O
expressed O
in O
blasts O
from O
most O
of O
these O
cases O
, O
indicating O
that O
majorities O
of O
the O
blasts O
in O
M7 O
and O
TMD O
cases O
have O
erythroid O
and O
megakaryocytic O
phenotypes O
. O

In O
this O
paper O
, O
the O
expression O
of O
this O
gene O
in O
blood O
cells O
was O
first O
investigated O
in O
fractions O
of O
nucleated O
cells O
, O
revealing O
predominant O
expression O
of O
the O
Ah B
receptor I
gene I
in O
the O
monocyte O
fraction O
. O

In O
contrast O
, O
PU B
. I
1 I
is O
expressed O
at O
high O
levels O
not O
only O
in O
monocytes O
and O
macrophages O
but O
also O
in O
neutrophils O
, O
indicating O
that O
PU B
. I
1 I
can O
activate O
gene O
expression O
in O
both O
major O
myeloid O
lineages O
. O

In O
contrast O
, O
PU B
. I
1 I
is O
expressed O
at O
high O
levels O
not O
only O
in O
monocytes O
and O
macrophages O
but O
also O
in O
neutrophils O
, O
indicating O
that O
PU B
. I
1 I
can O
activate O
gene O
expression O
in O
both O
major O
myeloid O
lineages O
. O

When O
transfected O
into O
K562 O
cells O
, O
which O
express O
zeta B
- I
globin I
, O
comparable O
amounts O
of O
activity O
were O
obtained O
from O
the O
- B
557 I
and I
- I
417 I
zeta I
- I
luciferase I
constructs I
and O
the O
alpha B
- I
luciferase I
constructs I
when O
no O
enhancers B
or O
the O
alpha B
- I
globin I
locus I
enhancers I
were O
used O
. O

This O
element O
requires O
GATA B
- I
1 I
and O
additional B
unknown I
factors I
for O
maximal O
activity O
. O

This O
element O
requires O
GATA B
- I
1 I
and O
additional B
unknown I
factors I
for O
maximal O
activity O
. O

Accordingly O
, O
the O
effects O
of O
the O
constitutively B
active I
PKCs I
were O
compared O
to O
the O
effects O
of O
mutationally O
activated O
p21ras B
. O

The O
ability O
of O
PKC B
- I
epsilon I
to O
induce O
transactivation O
of O
NF B
- I
AT I
- I
1 I
and O
AP B
- I
1 I
was O
similar O
to O
the O
stimulatory O
effect O
of O
a O
constitutively B
activated I
p21ras I
. O

The O
ability O
of O
PKC B
- I
epsilon I
to O
induce O
transactivation O
of O
NF B
- I
AT I
- I
1 I
and O
AP B
- I
1 I
was O
similar O
to O
the O
stimulatory O
effect O
of O
a O
constitutively B
activated I
p21ras I
. O

The O
ability O
of O
PKC B
- I
epsilon I
to O
induce O
transactivation O
of O
NF B
- I
AT I
- I
1 I
and O
AP B
- I
1 I
was O
similar O
to O
the O
stimulatory O
effect O
of O
a O
constitutively B
activated I
p21ras I
. O

Moreover O
, O
the O
data O
comparing O
the O
effects O
of O
activated B
Ras I
and O
PKC B
mutants I
suggest O
that O
PKC B
- I
alpha I
, O
p21ras B
, O
and O
PKC B
- I
epsilon I
are O
not O
positioned O
linearly O
on O
a O
single O
signal O
transduction O
pathway O
. O

Moreover O
, O
the O
data O
comparing O
the O
effects O
of O
activated B
Ras I
and O
PKC B
mutants I
suggest O
that O
PKC B
- I
alpha I
, O
p21ras B
, O
and O
PKC B
- I
epsilon I
are O
not O
positioned O
linearly O
on O
a O
single O
signal O
transduction O
pathway O
. O

We O
examined O
the O
ability O
of O
nuclear O
translocated O
glucocorticoid B
receptors I
to O
bind O
to O
their O
DNA B
binding I
sites I
( O
GRE B
) O
using O
electrophoretic O
mobility O
shift O
assays O
in O
PBMC O
from O
patients O
with O
steroid O
- O
sensitive O
and O
steroid O
- O
resistant O
asthma O
. O

Interleukin B
- I
5 I
signaling O
in O
human O
eosinophils O
involves O
JAK2 B
tyrosine I
kinase I
and O
Stat1 B
alpha I
. O

Interleukin B
- I
5 I
signaling O
in O
human O
eosinophils O
involves O
JAK2 B
tyrosine I
kinase I
and O
Stat1 B
alpha I
. O

Here O
we O
show O
that O
the O
lymphoid B
- I
specific I
transcription I
factor I
Oct I
- I
2A I
plays O
a O
critical O
role O
in O
HLA B
- I
DRA I
gene I
expression O
in O
class O
II O
- O
positive O
B O
cell O
lines O
, O
and O
that O
the O
high B
mobility I
group I
protein I
( O
HMG B
) O
I B
/ I
Y I
binds O
to O
multiple O
sites O
within O
the O
DRA B
promoter I
, O
including O
the O
Oct B
- I
2A I
binding I
site I
. O

We O
conclude O
that O
distinct O
sets O
of O
transcription B
factors I
are O
involved O
in O
the O
two O
modes O
of O
HLA B
- I
DRA I
expression O
, O
and O
that O
HMG B
I I
/ I
Y I
may O
be O
important O
for O
B O
cell O
- O
specific O
expression O
, O
and O
is O
essential O
for O
IFN B
- I
gamma I
induction O
. O

We O
conclude O
that O
distinct O
sets O
of O
transcription B
factors I
are O
involved O
in O
the O
two O
modes O
of O
HLA B
- I
DRA I
expression O
, O
and O
that O
HMG B
I I
/ I
Y I
may O
be O
important O
for O
B O
cell O
- O
specific O
expression O
, O
and O
is O
essential O
for O
IFN B
- I
gamma I
induction O
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV B
- I
encoded I
nuclear I
antigens I
( O
EBNA1 B
, I
2 I
, I
3A I
, I
3B I
, I
3C I
, I
- I
LP I
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B B
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

Eosinophils O
were O
purified O
from O
peripheral O
blood O
by O
discontinuous O
Percoll O
gradients O
and O
stimulated O
with O
IL B
- I
5 I
. O

A O
previously O
unrecognized O
element O
, O
located O
downstream O
of O
the O
start B
site I
of I
transcription I
in O
the O
first O
exon B
of O
the O
DR B
alpha I
gene I
, O
has O
been O
defined O
that O
enhances O
promoter O
activity O
up O
to O
eightfold O
in O
a O
position O
- O
dependent O
manner O
. O

The O
nuclear O
factor O
binds O
to O
the O
DR B
alpha I
and I
DP I
alpha I
element I
but O
not O
to O
the O
element O
in O
the O
DQ B
alpha I
gene I
. O

One O
of O
the O
genes O
that O
encodes O
a O
CBF B
alpha I
subunit I
is O
AML1 B
, O
also O
called O
Cbf B
alpha I
2 I
. O

One O
of O
the O
genes O
that O
encodes O
a O
CBF B
alpha I
subunit I
is O
AML1 B
, O
also O
called O
Cbf B
alpha I
2 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Furthermore O
, O
compounds O
such O
as O
tosylphenylalanyl O
chloromethyl O
ketone O
and O
pyrrolidinedithiocar O
that O
are O
known O
to O
selectively O
inhibit O
NF B
kappa I
B I
activation O
block O
cytokine O
gene O
transcription O
in O
LPS O
- O
stimulated O
monocytes O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
inhibition O
of O
NF B
kappa I
B I
activation O
may O
be O
an O
important O
mechanism O
for O
IL B
- I
10 I
suppression O
of O
cytokine O
gene O
transcription O
in O
human O
monocytes O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
inhibition O
of O
NF B
kappa I
B I
activation O
may O
be O
an O
important O
mechanism O
for O
IL B
- I
10 I
suppression O
of O
cytokine O
gene O
transcription O
in O
human O
monocytes O
. O

In O
addition O
, O
this O
TR2RE B
- I
SV40 I
can O
function O
as O
a O
repressor O
to O
suppress O
the O
transcriptional O
activities O
of O
both O
SV40 B
early I
and I
late I
promoters I
. O

Thus O
, O
Mn B
- I
SOD I
RNA O
protein O
levels O
and O
activity O
were O
markedly O
reduced O
in O
the O
presence O
of O
Tat B
. O

EBNA B
- I
2 I
is O
known O
to O
interact O
with O
the O
cellular B
DNA I
- I
binding I
protein I
J B
kappa I
and O
is O
recruited O
to O
promoters B
containing O
the O
GTGGGAA O
J B
kappa I
recognition I
sequence I
. O

The O
minimal B
EBNA I
- I
2 I
- I
responsive I
LMP I
- I
1 I
promoter I
includes O
one O
J B
kappa I
- I
binding I
site I
, O
and O
we O
now O
show O
that O
mutation O
of O
that O
site O
, O
such O
that O
J B
kappa I
can O
not O
bind O
, O
reduces O
EBNA B
- I
2 I
responsiveness O
by O
60 O
% O
. O

Thus O
, O
although O
the O
kappa B
3 I
element I
has O
little O
sequence O
similarity O
to O
other O
NFATp B
- I
binding I
sites I
, O
it O
appears O
to O
function O
as O
a O
cyclosporin B
- I
sensitive I
promoter I
element I
in O
T O
cells O
by O
virtue O
of O
its O
ability O
to O
bind O
NFATp B
. O

By O
contrast O
, O
three O
lymphoblastoid O
cell O
lines O
( O
immortalized O
in O
vitro O
with O
Epstein O
- O
Barr O
virus O
) O
were O
weakly O
positive O
and O
MNDA B
was O
up O
- O
regulated O
by O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
treatment O
. O

By O
contrast O
, O
three O
lymphoblastoid O
cell O
lines O
( O
immortalized O
in O
vitro O
with O
Epstein O
- O
Barr O
virus O
) O
were O
weakly O
positive O
and O
MNDA B
was O
up O
- O
regulated O
by O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
treatment O
. O

EBNA B
- I
2 I
is O
able O
to O
trans O
- O
activate O
the O
expression O
of O
the O
LMP B
gene I
in O
several O
cell O
lines O
. O

Various O
reports O
have O
delineated O
the O
cis B
- I
acting I
elements I
of O
the O
LMP B
promoter I
through O
which O
EBNA B
- I
2 I
mediates O
trans O
- O
activation O
. O

Enhanced O
Ig B
synthesis O
is O
a O
result O
of O
coordinated O
transcriptional O
activation O
of O
Ig B
genes I
without O
promoter O
or O
isotype O
specificity O
, O
and O
differential O
accumulation O
of O
the O
mRNA B
encoding O
the O
secreted O
form O
of O
Ig B
heavy I
chain I
. O

It O
is O
saturable O
and O
subject O
to O
negative O
control O
when O
IL B
- I
6 I
stimulation O
is O
prolonged O
. O

Thus O
, O
differentiation O
of O
B O
cells O
with O
IL B
- I
6 I
in O
vitro O
recapitulates O
the O
hallmarks O
of O
terminal O
B O
differentiation O
in O
vivo O
; O
Oct B
- I
2 I
may O
have O
a O
role O
in O
this O
process O
. O

Thus O
, O
differentiation O
of O
B O
cells O
with O
IL B
- I
6 I
in O
vitro O
recapitulates O
the O
hallmarks O
of O
terminal O
B O
differentiation O
in O
vivo O
; O
Oct B
- I
2 I
may O
have O
a O
role O
in O
this O
process O
. O

TNF O
- O
alpha O
, O
IL O
- O
1 O
beta O
and O
phorbol O
myristate O
acetate O
( O
PMA O
) O
treatment O
increased O
AP B
- I
1 I
and O
NF O
kappa O
B O
DNA O
binding O
by O
up O
to O
200 O
% O
but O
decreased O
CREB B
binding O
( O
38 O
% O
) O
over O
a O
60 O
- O
min O
time O
course O
. O

When O
restimulated O
, O
however O
, O
anergic O
T O
cells O
fail O
to O
up O
- O
regulate O
transcription O
of O
the O
IL B
- I
2 I
gene I
and O
in O
consequence O
do O
not O
produce O
IL B
- I
2 I
. O

Methylation O
studies O
indicated O
that O
the O
tal B
- I
15 I
' I
GC I
- I
rich I
region I
behaves O
like O
a O
CpG B
island I
, O
hypomethylated O
in O
normal O
cells O
, O
and O
methylated O
de O
novo O
on O
transcriptionally B
inactive I
alleles I
in O
established O
cell O
lines O
. O

In O
contrast O
, O
the O
addition O
of O
GM B
- I
CSF I
to O
the O
M O
- O
TAT O
/ O
EPO O
cell O
culture O
decreased O
the O
amount O
of O
hemoglobin O
, O
even O
in O
the O
presence O
of O
EPO B
, O
indicating O
that O
the O
EPO B
signal O
for O
erythroid O
differentiation O
is O
suppressed O
by O
GM B
- I
CSF I
. O

In O
contrast O
, O
the O
addition O
of O
GM B
- I
CSF I
to O
the O
M O
- O
TAT O
/ O
EPO O
cell O
culture O
decreased O
the O
amount O
of O
hemoglobin O
, O
even O
in O
the O
presence O
of O
EPO B
, O
indicating O
that O
the O
EPO B
signal O
for O
erythroid O
differentiation O
is O
suppressed O
by O
GM B
- I
CSF I
. O

Transient O
chloramphenicol B
acetyltransferase I
assay O
revealed O
that O
the O
region O
containing O
E2F B
binding I
site I
had O
a O
strong O
promoter O
activity O
, O
and O
introduction O
of O
the O
mutation O
at O
the O
E2F B
binding I
site I
resulted O
in O
a O
significant O
loss O
of O
the O
activity O
. O

Transient O
chloramphenicol B
acetyltransferase I
assay O
revealed O
that O
the O
region O
containing O
E2F B
binding I
site I
had O
a O
strong O
promoter O
activity O
, O
and O
introduction O
of O
the O
mutation O
at O
the O
E2F B
binding I
site I
resulted O
in O
a O
significant O
loss O
of O
the O
activity O
. O

The O
NFATd B
element I
, O
which O
binds O
the O
transcription B
factor I
NFAT B
- I
1 I
and O
is O
very O
active O
in O
T O
cells O
, O
is O
only O
weakly O
active O
in O
one O
B O
clone O
and O
not O
at O
all O
in O
another O
. O

Transcriptional O
activity O
of O
p105 B
is O
also O
increased O
in O
infected O
cells O
and O
is O
also O
mediated O
by O
NF B
- I
kappa I
B I
through O
a O
specific O
kappa B
B I
motif I
. O

In O
this O
study O
, O
we O
show O
that O
an O
activation B
- I
deficient I
glucocorticoid I
receptor I
mutant I
is O
as O
effective O
as O
the O
wild B
- I
type I
receptor I
in O
repression O
of O
AP B
- I
1 I
activity O
, O
inhibition O
of O
interleukin B
- I
2 I
production O
, O
inhibition O
of O
c B
- I
myc I
expression O
and O
induction O
of O
apoptosis O
. O

In O
this O
study O
, O
we O
show O
that O
an O
activation B
- I
deficient I
glucocorticoid I
receptor I
mutant I
is O
as O
effective O
as O
the O
wild B
- I
type I
receptor I
in O
repression O
of O
AP B
- I
1 I
activity O
, O
inhibition O
of O
interleukin B
- I
2 I
production O
, O
inhibition O
of O
c B
- I
myc I
expression O
and O
induction O
of O
apoptosis O
. O

In O
this O
study O
, O
we O
show O
that O
an O
activation B
- I
deficient I
glucocorticoid I
receptor I
mutant I
is O
as O
effective O
as O
the O
wild B
- I
type I
receptor I
in O
repression O
of O
AP B
- I
1 I
activity O
, O
inhibition O
of O
interleukin B
- I
2 I
production O
, O
inhibition O
of O
c B
- I
myc I
expression O
and O
induction O
of O
apoptosis O
. O

Insertion O
of O
this O
chimeric B
promoter I
( O
ISG15 B
LTR I
) O
upstream O
of O
the O
human B
IFNA2 I
gene I
directed O
high O
levels O
of O
IFN B
synthesis O
in O
Tat O
- O
expressing O
cells O
, O
while O
this O
promoter O
was O
not O
responsive O
to O
tumor B
necrosis I
factor I
alpha I
- O
mediated O
activation O
. O

Selected O
transfected O
clones O
produced O
low O
levels O
of O
IFN B
A I
( O
IFNA B
) O
constitutively O
, O
and O
their O
abilities O
to O
express O
interleukin B
- I
2 I
and O
interleukin B
- I
2 I
receptor I
upon O
stimulation O
with O
phytohemagglutinin B
and O
phorbol O
myristate O
acetate O
were O
retained O
. O

Flow O
cytometric O
analysis O
also O
showed O
that O
at O
72 O
h O
of O
virus O
exposure O
fewer O
T O
cells O
from O
the O
elderly O
produced O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
suggesting O
a O
link O
between O
the O
magnitude O
of O
the O
Fos B
and O
Jun B
and O
IFN B
- I
gamma I
responses O
. O

Flow O
cytometric O
analysis O
also O
showed O
that O
at O
72 O
h O
of O
virus O
exposure O
fewer O
T O
cells O
from O
the O
elderly O
produced O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
suggesting O
a O
link O
between O
the O
magnitude O
of O
the O
Fos B
and O
Jun B
and O
IFN B
- I
gamma I
responses O
. O

Flow O
cytometric O
analysis O
also O
showed O
that O
at O
72 O
h O
of O
virus O
exposure O
fewer O
T O
cells O
from O
the O
elderly O
produced O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
suggesting O
a O
link O
between O
the O
magnitude O
of O
the O
Fos B
and O
Jun B
and O
IFN B
- I
gamma I
responses O
. O

The O
regulation O
of O
HIV O
by O
retinoic O
acid O
correlates O
with O
cellular O
expression O
of O
the O
retinoic B
acid I
receptors I
. O

The O
second O
abnormality O
in O
kappa O
B O
- O
binding O
activity O
in O
T O
cells O
from O
these O
patients O
is O
that O
RelA B
, O
a O
member O
of O
the O
Rel B
homology I
family I
which O
is O
part O
of O
the O
normal O
NF B
- I
kappa I
B I
complex I
, O
was O
not O
induced O
in O
the O
nucleus O
following O
activation O
. O

Protein B
kinase I
C I
is O
not O
a O
downstream O
effector O
of O
p21ras B
in O
activated O
T O
cells O
. O

Data O
is O
presented O
, O
using O
the O
potent O
and O
selective O
PKC B
inhibitor O
Ro O
31 O
- O
8425 O
and O
transient O
expression O
of O
a O
constitutively O
active O
ras O
mutant O
, O
which O
clearly O
shows O
that O
PKC B
is O
not O
downstream O
of O
p21ras B
in O
the O
induction O
of O
NF B
- I
AT I
and O
AP B
- I
1 I
transcriptional O
activity O
and O
in O
the O
expression O
of O
IL B
- I
2 I
in O
human O
Jurkat O
T O
cells O
. O

Data O
is O
presented O
, O
using O
the O
potent O
and O
selective O
PKC B
inhibitor O
Ro O
31 O
- O
8425 O
and O
transient O
expression O
of O
a O
constitutively O
active O
ras O
mutant O
, O
which O
clearly O
shows O
that O
PKC B
is O
not O
downstream O
of O
p21ras B
in O
the O
induction O
of O
NF B
- I
AT I
and O
AP B
- I
1 I
transcriptional O
activity O
and O
in O
the O
expression O
of O
IL B
- I
2 I
in O
human O
Jurkat O
T O
cells O
. O

Data O
is O
presented O
, O
using O
the O
potent O
and O
selective O
PKC B
inhibitor O
Ro O
31 O
- O
8425 O
and O
transient O
expression O
of O
a O
constitutively O
active O
ras O
mutant O
, O
which O
clearly O
shows O
that O
PKC B
is O
not O
downstream O
of O
p21ras B
in O
the O
induction O
of O
NF B
- I
AT I
and O
AP B
- I
1 I
transcriptional O
activity O
and O
in O
the O
expression O
of O
IL B
- I
2 I
in O
human O
Jurkat O
T O
cells O
. O

The O
signaling O
pathways O
involving O
PKC B
activation O
, O
calcium O
mobilization O
and O
ras B
activation O
combine O
to O
provide O
the O
necessary O
components O
for O
production O
of O
IL B
- I
2 I
during O
T O
cell O
activation O
. O

Here O
, O
we O
report O
that O
stimulation O
through O
the O
IL B
- I
2R I
induced O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
, O
a O
newly O
identified O
member O
of O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
family I
of O
proteins O
. O

Apart O
from O
stat3 B
, O
another O
cytoplasmic B
protein I
was O
tyrosine O
phosphorylated O
and O
subsequently O
translocated O
to O
the O
nucleus O
in O
response O
to O
IL B
- I
2 I
. O

Taken O
together O
, O
we O
report O
that O
IL B
- I
2 I
induces O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
and O
an O
as O
yet O
undefined O
84 B
- I
kDa I
protein I
in O
antigen O
- O
specific O
human O
T O
cell O
lines O
. O

Consistent O
with O
the O
activity O
of O
B95 B
- I
8 I
, O
EBNA B
- I
2 I
transcripts I
were O
identified O
within O
infected O
thymocyte O
populations O
. O

These O
results O
indicate O
that O
the O
regulation O
of O
NF B
- I
kappa I
B I
activation O
during O
T O
cell O
activation O
by O
TcR B
/ I
CD3 I
signals O
is O
biphasic O
: O
TcR B
/ I
CD3 I
triggers O
its O
immediate O
translocation O
, O
which O
is O
transient O
if O
no O
TNF B
- I
alpha I
is O
present O
. O

These O
results O
indicate O
that O
the O
regulation O
of O
NF B
- I
kappa I
B I
activation O
during O
T O
cell O
activation O
by O
TcR B
/ I
CD3 I
signals O
is O
biphasic O
: O
TcR B
/ I
CD3 I
triggers O
its O
immediate O
translocation O
, O
which O
is O
transient O
if O
no O
TNF B
- I
alpha I
is O
present O
. O

These O
results O
indicate O
that O
the O
regulation O
of O
NF B
- I
kappa I
B I
activation O
during O
T O
cell O
activation O
by O
TcR B
/ I
CD3 I
signals O
is O
biphasic O
: O
TcR B
/ I
CD3 I
triggers O
its O
immediate O
translocation O
, O
which O
is O
transient O
if O
no O
TNF B
- I
alpha I
is O
present O
. O

The O
cis B
- I
acting I
region I
, O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
( O
positions B
- I
95 I
and O
- B
73 I
) O
, O
within O
the O
murine B
GM I
- I
CSF I
gene I
promoter I
is O
required O
for O
maximal O
induction O
by O
stimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
in O
T O
cells O
. O

We O
report O
here O
that O
three O
copies O
of O
the O
GC B
- I
box I
can O
functionally O
compensate O
for O
the O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
region I
, O
suggesting O
that O
the O
GC O
- O
motif O
can O
function O
independently O
of O
the O
GM B
- I
kappa I
B I
motif I
. O

A O
factor O
that O
regulates O
the O
class B
II I
major I
histocompatibility I
complex I
gene I
DPA B
is O
a O
member O
of O
a O
subfamily O
of O
zinc B
finger I
proteins I
that O
includes O
a O
Drosophila B
developmental I
control I
protein I
. O

It O
encodes O
a O
protein O
predicted O
to O
contain O
688 O
amino O
acid O
residues O
, O
including O
11 O
zinc B
finger I
motifs I
of O
the O
C2H2 B
type I
in O
the O
C B
- I
terminal I
region I
, O
that O
are O
Kruppel O
- O
like O
in O
the O
conservation O
of O
the O
H B
/ I
C I
link I
sequence I
connecting O
them O
. O

One O
of O
the O
Drosophila B
sequences I
, O
ttk B
, O
is O
a O
developmental B
control I
gene I
, O
while O
a O
second O
does O
not O
contain O
a O
zinc B
finger I
region I
but O
encodes O
a O
structure O
important O
in O
oocyte O
development O
. O

One O
of O
the O
Drosophila B
sequences I
, O
ttk B
, O
is O
a O
developmental B
control I
gene I
, O
while O
a O
second O
does O
not O
contain O
a O
zinc B
finger I
region I
but O
encodes O
a O
structure O
important O
in O
oocyte O
development O
. O

This O
Oct B
- I
2 I
- O
dependent O
transactivation O
is O
inhibited O
by O
RA O
. O

We O
also O
show O
that O
both O
Fos B
and O
Jun B
components O
of O
the O
AP B
- I
1 I
factors O
participate O
in O
the O
OAP40 B
complex I
. O

OAP B
confers O
to O
Oct B
- I
2 I
responsivity O
to O
both O
TPA O
/ O
Ca2 O
+ O
and O
RA O
, O
since O
specific O
mutations O
of O
the O
AP B
- I
1 I
/ I
OAP I
- I
binding I
site I
significantly O
reduce O
the O
transactivation O
by O
Oct B
- I
2 I
in O
response O
to O
TPA O
and O
Ca2 O
+ O
and O
abolish O
the O
inhibition O
by O
RA O
. O

OAP B
confers O
to O
Oct B
- I
2 I
responsivity O
to O
both O
TPA O
/ O
Ca2 O
+ O
and O
RA O
, O
since O
specific O
mutations O
of O
the O
AP B
- I
1 I
/ I
OAP I
- I
binding I
site I
significantly O
reduce O
the O
transactivation O
by O
Oct B
- I
2 I
in O
response O
to O
TPA O
and O
Ca2 O
+ O
and O
abolish O
the O
inhibition O
by O
RA O
. O

Therefore O
, O
we O
propose O
that O
the O
TPA O
/ O
calcium O
- O
activated O
AP B
- I
1 I
/ B
OAP I
element O
is O
the O
main O
target O
of O
positive O
or O
negative O
regulatory O
signals O
influencing O
the O
IL B
- I
2 I
octamer I
motif I
, O
through O
synergism O
with O
Oct B
- I
2 I
and O
antagonism O
by O
RAR B
. O

Therefore O
, O
we O
propose O
that O
the O
TPA O
/ O
calcium O
- O
activated O
AP B
- I
1 I
/ B
OAP I
element O
is O
the O
main O
target O
of O
positive O
or O
negative O
regulatory O
signals O
influencing O
the O
IL B
- I
2 I
octamer I
motif I
, O
through O
synergism O
with O
Oct B
- I
2 I
and O
antagonism O
by O
RAR B
. O

Two O
gel B
shift I
complexes I
( O
Mono B
A I
and O
Mono B
B I
) O
were O
formed O
with O
separate O
sequence O
elements O
within O
this O
region O
. O

Increased O
expression O
of O
the O
c B
- I
jun I
protooncogene O
and O
an O
increase O
in O
AP B
- I
1 I
binding O
activity O
in O
PKC O
- O
zeta O
cells O
provides O
a O
potential O
mechanism O
for O
explaining O
the O
altered O
differentiation O
status O
of O
this O
cell O
. O

Increased O
expression O
of O
the O
c B
- I
jun I
protooncogene O
and O
an O
increase O
in O
AP B
- I
1 I
binding O
activity O
in O
PKC O
- O
zeta O
cells O
provides O
a O
potential O
mechanism O
for O
explaining O
the O
altered O
differentiation O
status O
of O
this O
cell O
. O

OBF B
- I
1 I
, O
a O
novel B
B I
cell I
- I
specific I
coactivator I
that O
stimulates O
immunoglobulin B
promoter I
activity O
through O
association O
with O
octamer B
- I
binding I
proteins I
. O

The O
first O
early O
- O
induced O
peak O
was O
transient O
and O
likely O
corresponds O
to O
the O
well O
documented O
typical O
junB B
mRNA I
, O
stimulated O
in O
response O
to O
numerous O
growth B
factors I
, O
including O
IL B
- I
6 I
. O

Erythropoietin B
( O
Epo B
) O
, O
granulocyte B
/ I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
interleukin B
3 I
( O
IL B
- I
3 I
) O
promoted O
the O
growth O
of O
NS O
- O
Meg O
cells O
. O

Erythropoietin B
( O
Epo B
) O
, O
granulocyte B
/ I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
interleukin B
3 I
( O
IL B
- I
3 I
) O
promoted O
the O
growth O
of O
NS O
- O
Meg O
cells O
. O

We O
present O
data O
to O
show O
that O
the O
expression O
of O
TNF B
alpha I
is O
regulated O
by O
the O
transcription B
factor I
C B
/ I
EBP I
beta I
( O
NF B
- I
IL6 I
) O
. O

Induction O
of O
TaxI B
in O
a O
human O
T O
- O
cell O
line O
Jurkat O
carrying O
the O
TaxI B
gene I
under O
the O
metallothionein B
promoter I
led O
to O
increases O
in O
mRNA B
and O
surface O
expression O
of O
ICAM B
- I
I I
. O

Infection O
with O
Theileria O
annulata O
induces O
expression O
of O
matrix B
metalloproteinase I
9 I
and O
transcription B
factor I
AP B
- I
1 I
in O
bovine O
leucocytes O
. O

Infection O
with O
Theileria O
annulata O
induces O
expression O
of O
matrix B
metalloproteinase I
9 I
and O
transcription B
factor I
AP B
- I
1 I
in O
bovine O
leucocytes O
. O

In O
addition O
we O
assayed O
the O
level O
of O
mRNA B
encoding O
c B
- I
Fos I
, O
a O
common O
component O
of O
AP B
- I
1 I
and O
observed O
that O
it O
was O
indeed O
up O
- O
regulated O
in O
infected O
cells O
. O

In O
addition O
we O
assayed O
the O
level O
of O
mRNA B
encoding O
c B
- I
Fos I
, O
a O
common O
component O
of O
AP B
- I
1 I
and O
observed O
that O
it O
was O
indeed O
up O
- O
regulated O
in O
infected O
cells O
. O

We O
generated O
conditional O
EBV O
mutants O
by O
expressing O
EBNA2 B
as O
chimeric B
fusion I
protein I
with O
the O
hormone O
binding O
domain O
of O
the O
estrogen B
receptor I
on O
the O
genetic O
background O
of O
the O
virus O
. O

The O
synergistic O
antigen B
receptor I
initiated O
signals O
are O
mediated O
through O
protein B
kinase I
C I
because O
they O
can O
be O
mimicked O
by O
the O
phorbol O
ester O
, O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
, O
but O
not O
with O
calcium O
ionophores O
; O
and O
are O
staurosporine O
sensitive O
but O
cyclosporine O
resistant O
. O

The O
IL B
- I
1 I
- O
induced O
NF B
- I
kappa I
B I
DNA O
nuclear O
localization O
is O
transient O
and O
can O
be O
prolonged O
either O
by O
an O
antigen O
receptor O
- O
initiated O
signal O
or O
by O
inhibiting O
protein O
synthesis O
. O

A O
synthetic O
oligodeoxyribonucleo O
containing O
an O
SP1 B
- I
box I
( O
5 O
' O
- O
GGGCGG O
) O
could O
compete O
with O
factors O
binding O
to O
the O
12 B
- I
bp I
insert I
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

The O
serum B
response I
element I
( O
SRE B
) O
in O
the O
c B
- I
fos I
regulatory I
region I
participates O
in O
induction O
of O
transcription O
by O
various O
growth B
factors I
and O
by O
phorbol O
esters O
and O
subsequent O
squelching O
of O
transcription O
. O

Band B
A I
contains O
the O
serum B
response I
factor I
plus O
additional O
factor O
( O
s O
) O
. O

Thus O
, O
the O
use O
of O
DNase B
I I
allowed O
us O
, O
for O
the O
first O
time O
, O
to O
correlate O
the O
AIR B
- I
1 I
locus I
defect I
with O
class B
II I
promoter I
occupancy O
alterations O
and O
distinguish O
these O
alterations O
from O
the O
ones O
observed O
in O
phenotypically O
similar O
but O
genetically O
distinct O
MHC O
class O
II O
- O
negative O
cells O
. O

This O
element O
had O
maximal O
activity O
in O
lymphoid O
cells O
, O
paralleling O
the O
cell O
type O
specificity O
of O
Elf B
- I
1 I
expression O
. O

Elf B
- I
1 I
physically O
associated O
with O
HMG B
- I
I I
and O
with O
NF B
- I
kappa I
B I
p50 B
and O
c B
- I
Rel I
in O
vitro O
, O
suggesting O
that O
protein O
- O
protein O
interactions O
might O
functionally O
coordinate O
the O
actions O
of O
the O
upstream B
and I
downstream I
positive I
regulatory I
elements I
. O

Elf B
- I
1 I
physically O
associated O
with O
HMG B
- I
I I
and O
with O
NF B
- I
kappa I
B I
p50 B
and O
c B
- I
Rel I
in O
vitro O
, O
suggesting O
that O
protein O
- O
protein O
interactions O
might O
functionally O
coordinate O
the O
actions O
of O
the O
upstream B
and I
downstream I
positive I
regulatory I
elements I
. O

Elf B
- I
1 I
physically O
associated O
with O
HMG B
- I
I I
and O
with O
NF B
- I
kappa I
B I
p50 B
and O
c B
- I
Rel I
in O
vitro O
, O
suggesting O
that O
protein O
- O
protein O
interactions O
might O
functionally O
coordinate O
the O
actions O
of O
the O
upstream B
and I
downstream I
positive I
regulatory I
elements I
. O

The O
expression O
of O
the O
QR B
gene I
is O
regulated O
by O
the O
transcription B
factor I
AP B
- I
1 I
. O

These O
findings O
suggest O
a O
molecular O
mechanism O
of O
positive O
regulation O
of O
PAFR B
gene O
expression O
by O
PAF B
through O
NF B
- I
kappa I
B I
, O
possibly O
by O
a O
phosphorylation O
reaction O
involving O
protein B
kinase I
C I
by O
PAF B
. O

In O
contrast O
, O
TPCK O
and O
TLCK O
did O
not O
block O
induction O
of O
an O
immediate B
- I
early I
gene I
encoding O
the O
transcription B
factor I
, O
Egr B
- I
1 I
. O

The O
increase O
in O
IL B
- I
2 I
gene O
expression O
triggered O
by O
CD28 B
involves O
a O
kappa B
B I
- I
like I
sequence I
in O
the O
5 B
' I
- I
regulatory I
region I
of O
the O
IL B
- I
2 I
promoter I
, O
called O
CD28 B
- I
responsive I
element I
. O

This O
arrangement O
of O
Ets B
sites I
, O
coupled O
with O
the O
tissue O
- O
and O
developmental O
- O
specific O
expression O
of O
Ets B
members I
, O
likely O
play O
a O
key O
role O
in O
defining O
the O
pattern O
of O
alpha B
4 I
integrin I
. O

Antiandrogens O
result O
in O
protection O
of O
both O
the O
hinge B
region I
and O
C B
- I
terminus I
of O
the O
androgen B
receptor I
agonist O
proteolytic O
attack O
, O
whereas O
other O
studies O
showed O
that O
antiestrogens O
and O
antiprogestagens O
expose O
the O
C B
- I
terminal I
end I
of O
the O
ligand B
binding I
domain I
of O
their O
respective O
receptors O
to O
protease B
. O

Antiandrogens O
result O
in O
protection O
of O
both O
the O
hinge B
region I
and O
C B
- I
terminus I
of O
the O
androgen B
receptor I
agonist O
proteolytic O
attack O
, O
whereas O
other O
studies O
showed O
that O
antiestrogens O
and O
antiprogestagens O
expose O
the O
C B
- I
terminal I
end I
of O
the O
ligand B
binding I
domain I
of O
their O
respective O
receptors O
to O
protease B
. O

However O
, O
reagents O
such O
as O
nerve B
growth I
factor I
( O
NGF B
) O
and O
the O
phorbol O
ester O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
, O
which O
induce O
phenotypical O
differentiation O
of O
the O
SH O
- O
SY5Y O
neuroblastoma O
cell O
line O
, O
activated O
NF B
- I
kappa I
B I
, O
but O
only O
in O
that O
particular O
cell O
line O
. O

Nonpituitary B
human I
prolactin I
gene I
transcription O
is O
independent O
of O
Pit B
- I
1 I
and O
differentially O
controlled O
in O
lymphocytes O
and O
in O
endometrial O
stroma O
. O

T O
lymphocyte O
activation O
and O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
production O
require O
at O
least O
two O
signals O
, O
generated O
by O
phorbol O
ester O
( O
TPA O
) O
and O
Ca2 O
+ O
ionophore O
or O
costimulation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
and O
the O
CD28 B
auxiliary I
receptor I
. O

T O
lymphocyte O
activation O
and O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
production O
require O
at O
least O
two O
signals O
, O
generated O
by O
phorbol O
ester O
( O
TPA O
) O
and O
Ca2 O
+ O
ionophore O
or O
costimulation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
and O
the O
CD28 B
auxiliary I
receptor I
. O

T O
lymphocyte O
activation O
and O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
production O
require O
at O
least O
two O
signals O
, O
generated O
by O
phorbol O
ester O
( O
TPA O
) O
and O
Ca2 O
+ O
ionophore O
or O
costimulation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
and O
the O
CD28 B
auxiliary I
receptor I
. O

T O
lymphocyte O
activation O
and O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
production O
require O
at O
least O
two O
signals O
, O
generated O
by O
phorbol O
ester O
( O
TPA O
) O
and O
Ca2 O
+ O
ionophore O
or O
costimulation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
and O
the O
CD28 B
auxiliary I
receptor I
. O

Full O
activation O
of O
the O
MAP B
kinases I
that O
phosphorylate O
the O
Jun B
activation I
domain I
, O
JNK1 B
and O
JNK2 B
, O
required O
costimulation O
of O
T O
cells O
with O
either O
TPA O
and O
Ca2 O
+ O
ionophore O
or O
antibodies O
to O
TCR B
and O
CD28 B
. O

Addition O
of O
rIL B
- I
2 I
fully O
restored O
the O
proliferative O
response O
and O
partially O
restored O
the O
production O
of O
IL B
- I
4 I
and O
IL B
- I
5 I
, O
but O
not O
that O
of O
other O
cytokines B
. O

Addition O
of O
rIL B
- I
2 I
fully O
restored O
the O
proliferative O
response O
and O
partially O
restored O
the O
production O
of O
IL B
- I
4 I
and O
IL B
- I
5 I
, O
but O
not O
that O
of O
other O
cytokines B
. O

Addition O
of O
rIL B
- I
2 I
fully O
restored O
the O
proliferative O
response O
and O
partially O
restored O
the O
production O
of O
IL B
- I
4 I
and O
IL B
- I
5 I
, O
but O
not O
that O
of O
other O
cytokines B
. O

It O
seems O
therefore O
that O
PGE2 B
, O
by O
elevating O
cAMP O
levels O
, O
interferes O
with O
the O
activation O
pathway O
for O
NF B
- I
kappa I
B I
but O
not O
for O
NF B
- I
AT I
, O
AP B
- I
1 I
or O
CLE0 B
binding I
protein I
. O

It O
seems O
therefore O
that O
PGE2 B
, O
by O
elevating O
cAMP O
levels O
, O
interferes O
with O
the O
activation O
pathway O
for O
NF B
- I
kappa I
B I
but O
not O
for O
NF B
- I
AT I
, O
AP B
- I
1 I
or O
CLE0 B
binding I
protein I
. O

It O
seems O
therefore O
that O
PGE2 B
, O
by O
elevating O
cAMP O
levels O
, O
interferes O
with O
the O
activation O
pathway O
for O
NF B
- I
kappa I
B I
but O
not O
for O
NF B
- I
AT I
, O
AP B
- I
1 I
or O
CLE0 B
binding I
protein I
. O

Moreover O
, O
rapamycin O
, O
an O
inhibitor O
of O
pp70S6K B
activation O
, O
had O
no O
effect O
on O
induction O
of O
EGR B
- I
1 I
expression O
. O

In O
order O
to O
elucidate O
the O
role O
of O
c B
- I
myb I
gene I
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin B
( O
Hm B
) O
and O
erythropoietin B
( O
Epo B
) O
, O
we O
constructed O
recombinant B
plasmid I
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

Fos B
kinase I
may O
play O
a O
role O
in O
transcriptional O
regulation O
through O
its O
capacity O
to O
phosphorylate O
c B
- I
Fos I
at O
a O
site O
required O
for O
expression O
of O
the O
transcriptional O
transrepressive O
activity O
of O
this O
molecule O
. O

Activation O
of O
the O
interleukin B
6 I
gene I
by O
Mycobacterium O
tuberculosis O
or O
lipopolysaccharide O
is O
mediated O
by O
nuclear B
factors I
NF I
- I
IL6 I
and O
NF B
- I
kappa I
B I
[ O
published O
erratum O
appears O
in O
Proc O
Natl O
Acad O
Sci O
U O
S O
A O
1995 O
Apr O
11 O
; O
92 O
( O
8 O
) O
: O
3632 O
] O

In O
this O
regard O
, O
the O
cytokine B
interleukin B
6 I
( O
IL B
- I
6 I
) O
may O
play O
a O
role O
in O
the O
clinical O
manifestations O
and O
pathological O
events O
of O
tuberculosis O
infection O
. O

We O
conclude O
that O
the O
NF B
- I
IL6 I
and I
NF I
- I
kappa I
B I
sites I
mediate O
IL B
- I
6 I
induction O
in O
response O
to O
both O
LPS O
and O
LAM B
, O
acting O
as O
bacterial B
or I
mycobacterial I
response I
elements I
. O

This O
region O
contains O
two O
binding B
sites I
for O
the O
Sp1 B
transcription I
factor I
. O

Human O
immunodeficiency O
virus O
type O
1 O
Nef O
protein O
down O
- O
regulates O
transcription B
factors I
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
in O
human O
T O
cells O
in O
vitro O
after O
T O
- O
cell O
receptor O
stimulation O
. O

Tat B
transactivation O
mediated O
by O
the O
kappa B
B I
domain I
is O
sufficient O
to O
allow O
replication O
of O
TAR B
- O
deleted O
mutant O
HIV O
- O
1 O
in O
astrocytes O
. O

Retinoid B
- I
like I
receptors I
play O
a O
central O
role O
in O
hormonal O
responses O
by O
forming O
heterodimers B
with O
other O
nuclear B
hormone I
receptors I
. O

Several O
human O
myeloid O
leukemia O
cell O
lines O
growing O
in O
vitro O
can O
be O
induced O
to O
differentiate O
to O
more O
mature O
monocyte O
/ O
macrophage O
- O
like O
cells O
by O
treatment O
with O
protein B
kinase I
C I
- O
activating O
phorbol O
esters O
, O
such O
as O
PMA O
. O

Expression O
and O
genomic O
configuration O
of O
GM B
- I
CSF I
, O
IL B
- I
3 I
, O
M B
- I
CSF I
receptor I
( O
C B
- I
FMS I
) O
, O
early B
growth I
response I
gene I
- I
1 I
( O
EGR B
- I
1 I
) O
and O
M B
- I
CSF I
genes I
in O
primary O
myelodysplastic O
syndromes O
. O

Expression O
and O
genomic O
configuration O
of O
GM B
- I
CSF I
, O
IL B
- I
3 I
, O
M B
- I
CSF I
receptor I
( O
C B
- I
FMS I
) O
, O
early B
growth I
response I
gene I
- I
1 I
( O
EGR B
- I
1 I
) O
and O
M B
- I
CSF I
genes I
in O
primary O
myelodysplastic O
syndromes O
. O

Expression O
and O
genomic O
configuration O
of O
GM B
- I
CSF I
, O
IL B
- I
3 I
, O
M B
- I
CSF I
receptor I
( O
C B
- I
FMS I
) O
, O
early B
growth I
response I
gene I
- I
1 I
( O
EGR B
- I
1 I
) O
and O
M B
- I
CSF I
genes I
in O
primary O
myelodysplastic O
syndromes O
. O

Expression O
and O
genomic O
configuration O
of O
GM B
- I
CSF I
, O
IL B
- I
3 I
, O
M B
- I
CSF I
receptor I
( O
C B
- I
FMS I
) O
, O
early B
growth I
response I
gene I
- I
1 I
( O
EGR B
- I
1 I
) O
and O
M B
- I
CSF I
genes I
in O
primary O
myelodysplastic O
syndromes O
. O

The O
observed O
increase O
in O
IL B
- I
2 I
levels O
might O
facilitate O
virus O
spread O
from O
or O
to O
T O
cells O
. O

The O
human B
and I
mouse I
GATA3 I
transcription I
units I
start O
at O
a O
major B
initiation I
site I
. O

CD38 B
is O
a O
leukocyte B
differentiation I
antigen I
that O
has O
been O
thought O
to O
be O
a O
phenotypic O
marker O
of O
different O
subpopulations O
of O
T O
- O
and O
B O
- O
lymphocytes O
. O

Some O
antioxidants O
inhibit O
, O
in O
a O
co O
- O
ordinate O
fashion O
, O
the O
production O
of O
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
beta I
, O
and O
IL B
- I
6 I
by O
human O
peripheral O
blood O
mononuclear O
cells O
. O

Some O
antioxidants O
inhibit O
, O
in O
a O
co O
- O
ordinate O
fashion O
, O
the O
production O
of O
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
beta I
, O
and O
IL B
- I
6 I
by O
human O
peripheral O
blood O
mononuclear O
cells O
. O

Examination O
of O
the O
primary O
amino O
acid O
sequence O
of O
this O
protein O
indicates O
that O
it O
is O
a O
member O
of O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( I
Stat I
) I
family I
of O
DNA B
binding I
proteins I
, O
hereby O
designated O
IL B
- I
4 I
Stat I
. O

The O
magnitude O
and O
time O
kinetics O
of O
the O
LIF B
effects O
were O
similar O
to O
interleukin B
1 I
( O
IL B
- I
1 I
) O
, O
IL B
- I
6 I
, O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
other O
cytokines O
known O
to O
induce O
HIV O
replication O
in O
this O
cell O
line O
. O

The O
magnitude O
and O
time O
kinetics O
of O
the O
LIF B
effects O
were O
similar O
to O
interleukin B
1 I
( O
IL B
- I
1 I
) O
, O
IL B
- I
6 I
, O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
other O
cytokines O
known O
to O
induce O
HIV O
replication O
in O
this O
cell O
line O
. O

The O
magnitude O
and O
time O
kinetics O
of O
the O
LIF B
effects O
were O
similar O
to O
interleukin B
1 I
( O
IL B
- I
1 I
) O
, O
IL B
- I
6 I
, O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
other O
cytokines O
known O
to O
induce O
HIV O
replication O
in O
this O
cell O
line O
. O

In O
both O
cell O
lines O
LIF B
increased O
NF B
- I
kB I
activity O
. O

Induction O
of O
NF B
- I
kB I
and O
HIV O
replication O
by O
cytokines B
are O
at O
least O
in O
part O
dependent O
on O
reactive O
oxygen O
intermediates O
. O

In O
order O
to O
study O
CD14 B
gene I
regulation O
, O
the O
human B
CD14 I
gene I
was O
cloned O
from O
a O
partial O
EcoRI B
digested I
chromosome I
5 I
library I
. O

In O
fertile O
women O
remarkable O
changes O
in O
androgen B
binding I
sites I
were O
seen O
in O
the O
course O
of O
the O
menstrual O
cycle O
, O
with O
a O
significant O
increase O
in O
the O
immediate O
preovulatory O
period O
. O

Stimulation O
of O
the O
CD28 B
cell I
surface I
molecule I
delivers O
costimulatory O
signals O
essential O
for O
lymphokine B
production O
in O
activated O
T O
cells O
via O
a O
conserved B
sequence I
element I
found O
in O
the O
promoter B
of O
several O
lymphokine B
genes I
. O

Wortmannin O
, O
an O
inhibitor O
of O
receptor O
- O
coupled O
PLD B
activation O
, O
blocked O
the O
anti B
- I
CD3 I
- O
induced O
increases O
in O
both O
PLD B
activity O
and O
AP B
- I
1 I
enhancer I
activity O
. O

We O
therefore O
reexamined O
this O
issue O
by O
using O
two O
different O
experimental O
approaches O
that O
allowed O
LMP1 B
- O
induced O
effects O
to O
be O
monitored O
immediately O
following O
expression O
of O
the O
viral O
protein O
and O
in O
the O
absence O
of O
selective O
pressures O
; O
activation O
of O
the O
NF B
- I
kappa I
B I
transcription B
factor I
and O
upregulation O
of O
the O
cell B
adhesion I
molecule I
ICAM B
- I
1 I
were O
used O
as O
early O
indices O
of O
LMP1 B
function O
. O

We O
therefore O
reexamined O
this O
issue O
by O
using O
two O
different O
experimental O
approaches O
that O
allowed O
LMP1 B
- O
induced O
effects O
to O
be O
monitored O
immediately O
following O
expression O
of O
the O
viral O
protein O
and O
in O
the O
absence O
of O
selective O
pressures O
; O
activation O
of O
the O
NF B
- I
kappa I
B I
transcription B
factor I
and O
upregulation O
of O
the O
cell B
adhesion I
molecule I
ICAM B
- I
1 I
were O
used O
as O
early O
indices O
of O
LMP1 B
function O
. O

In O
the O
same O
experiments O
, O
all O
three O
non O
- O
B O
- O
cell O
lines O
showed O
NF B
- I
kappa I
B I
activation O
and O
ICAM B
- I
1 I
upregulation O
but O
never O
any O
effect O
upon O
Bcl B
- I
2 I
. O

In O
the O
same O
experiments O
, O
all O
three O
non O
- O
B O
- O
cell O
lines O
showed O
NF B
- I
kappa I
B I
activation O
and O
ICAM B
- I
1 I
upregulation O
but O
never O
any O
effect O
upon O
Bcl B
- I
2 I
. O

However O
, O
the O
inositol O
phosphate O
response O
was O
stronger O
for O
64 B
. I
1 I
than O
for O
OKT3 B
. O

To O
tie O
these O
events O
to O
gene O
activation O
, O
we O
measured O
NF B
- I
kappa I
B I
and O
NF B
- I
AT I
activity O
in O
the O
nucleus O
after O
anti B
- I
CD3 I
stimulation O
. O

To O
tie O
these O
events O
to O
gene O
activation O
, O
we O
measured O
NF B
- I
kappa I
B I
and O
NF B
- I
AT I
activity O
in O
the O
nucleus O
after O
anti B
- I
CD3 I
stimulation O
. O

Both O
stimuli O
induced O
the O
appearance O
of O
the O
NF B
- I
kappa I
B I
components I
( O
c B
- I
Rel I
, O
p65 B
( O
RelA B
) O
, O
and O
p50 B
( O
NF B
- I
kappa I
B1 I
) O
) O
and O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
in O
the O
nucleus O
. O

From O
a O
consecutive O
series O
of O
350 O
cases O
of O
adult O
de O
novo O
acute O
myeloid O
leukemia O
( O
AML O
) O
, O
we O
identified O
20 O
cases O
( O
6 O
% O
) O
with O
a O
unique O
immunophenotype O
: O
CD33 O
+ O
, O
CD56 O
+ O
, O
CD11a O
+ O
, O
CD13lo O
, O
CD15lo O
, O
CD34 O
+ O
/ O
- O
, O
HLA B
- I
DR I
- O
, O
CD16 B
- O
. O

This O
was O
supported O
by O
the O
observation O
that O
the O
down O
- O
regulatory O
capacity O
of O
IL B
- I
4 I
appeared O
to O
be O
dependent O
on O
de O
novo O
protein O
synthesis O
. O

Although O
these O
data O
suggest O
AP B
- I
1 I
regulated O
cytokine B
mRNA O
expression O
, O
results O
from O
PBMo O
are O
not O
in O
accordance O
with O
this O
notion O
. O

Novel B
membrane I
receptors I
for O
aldosterone O
in O
human O
lymphocytes O
: O
a O
50 B
kDa I
protein I
on O
SDS O
- O
PAGE O
. O

Novel B
membrane I
receptors I
for O
aldosterone O
in O
human O
lymphocytes O
: O
a O
50 B
kDa I
protein I
on O
SDS O
- O
PAGE O
. O

It O
, O
thus O
, O
appears O
as O
an O
integral B
membrane I
protein I
. O

Site B
D I
( O
nt B
4816 I
to I
4851 I
) O
specifically O
bound O
a O
ubiquitously B
expressed I
factor I
. O

Sequence O
analyses O
of O
pCD41 B
indicate O
that O
there O
are O
two O
potential O
open B
reading I
frames I
( O
ORFs B
) O
, O
A B
and O
B B
, O
which O
are O
homologous O
to O
the O
ORFs B
found O
in O
the O
genomic O
clone O
pGD41 B
. O

The O
stimulatory O
effect O
of O
gp160 O
on O
NF B
- I
kappa I
B I
activation O
is O
protein O
synthesis O
independent O
, O
is O
dependent O
upon O
protein O
tyrosine O
phosphorylation O
, O
and O
abrogated O
by O
inhibitors O
of O
protein B
kinase I
C I
. O

Analysis O
of O
Oct2 B
- I
isoform I
expression O
in O
lipopolysaccharide O
- O
stimulated O
B O
lymphocytes O
. O

Oct2 B
- I
isoform I
expression O
in O
splenic O
B O
cells O
stimulated O
with O
lipopolysaccharide O
or O
lipopolysaccharide O
plus O
phorbol O
- O
di O
- O
butyrate O
was O
analysed O
by O
cDNA O
cloning O
. O

Positive O
regulators O
of O
the O
lineage O
- O
specific O
transcription B
factor I
GATA B
- I
1 I
in O
differentiating O
erythroid O
cells O
. O

Analyses O
with O
cultured O
cells O
and O
cell O
- O
free O
systems O
have O
provided O
strong O
evidence O
that O
GATA B
- I
1 I
is O
involved O
in O
control O
of O
globin B
gene I
expression O
during O
erythroid O
differentiation O
. O

The O
response O
of O
mammalian O
cells O
to O
stress O
is O
controlled O
by O
transcriptional B
regulatory I
proteins I
such O
as O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
to O
induce O
a O
wide O
variety O
of O
early B
response I
genes I
. O

The O
response O
of O
mammalian O
cells O
to O
stress O
is O
controlled O
by O
transcriptional B
regulatory I
proteins I
such O
as O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
to O
induce O
a O
wide O
variety O
of O
early B
response I
genes I
. O

In O
comparison O
to O
other O
activators O
of O
NF B
- I
kappa I
B I
such O
as O
phorbol O
myristate O
acetate O
or O
tumor B
necrosis I
factor I
, O
we O
did O
not O
detect O
changes O
in O
the O
tyrosine O
phosphorylation O
status O
of O
I B
kappa I
B I
alpha I
following O
treatment O
with O
either O
of O
these O
agents O
. O

Furthermore O
, O
the O
NFKB2 B
precursor O
is O
physically O
associated O
with O
c B
- I
Rel I
and O
with O
Tax B
in O
HTLV O
- O
I O
infected O
cells O
. O

Electrophoretic O
mobility O
shift O
assays O
indicate O
that O
MS B
- I
2beta I
and O
MS B
- I
2gamma I
interact O
with O
nuclear B
factors I
that O
are O
induced O
during O
U937 O
differentiation O
. O

Electrophoretic O
mobility O
shift O
assays O
indicate O
that O
MS B
- I
2beta I
and O
MS B
- I
2gamma I
interact O
with O
nuclear B
factors I
that O
are O
induced O
during O
U937 O
differentiation O
. O

The O
presence O
of O
multiple O
potential O
binding O
sites O
for O
MS B
- I
2 I
in O
the O
promoter O
regions O
of O
a O
wide O
range O
of O
genes O
expressed O
in O
mature O
myeloid O
cells O
suggests O
this O
factor O
plays O
a O
general O
role O
in O
myeloid O
differentiation O
. O

Acetylsalicylic O
acid O
and O
sodium O
salicylate O
inhibit O
LPS O
- O
induced O
NF B
- I
kappa I
B I
/ I
c I
- I
Rel I
nuclear O
translocation O
, O
and O
synthesis O
of O
tissue B
factor I
( O
TF B
) O
and O
tumor B
necrosis I
factor I
alfa I
( O
TNF B
- I
alpha I
) O
in O
human O
monocytes O
. O

We O
have O
observed O
that O
the O
R24 B
mAb I
stimulates O
GD3 O
+ O
T O
cell O
proliferation O
, O
cytotoxicity O
, O
and O
surface O
marker O
expression O
of O
IL B
- I
2R I
alpha I
- I
chain I
, O
IL B
- I
2R I
beta I
- I
chain I
, O
HLA B
- I
DR I
, O
CD11a B
, O
and O
CD11c B
. O

R24 B
- O
stimulated O
increases O
in O
proliferation O
, O
cytotoxicity O
, O
and O
cell O
surface O
protein O
expression O
could O
be O
blocked O
by O
cyclosporin O
and O
staurosporin O
, O
indicating O
that O
cyclophilin B
/ I
calcineurin I
and O
protein B
kinase I
C I
may O
be O
involved O
in O
the O
R24 B
signaling O
pathway O
. O

R24 B
- O
stimulated O
increases O
in O
proliferation O
, O
cytotoxicity O
, O
and O
cell O
surface O
protein O
expression O
could O
be O
blocked O
by O
cyclosporin O
and O
staurosporin O
, O
indicating O
that O
cyclophilin B
/ I
calcineurin I
and O
protein B
kinase I
C I
may O
be O
involved O
in O
the O
R24 B
signaling O
pathway O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

Although O
no O
proof O
yet O
exists O
of O
a O
role O
for O
these O
lesions O
in O
DLCL O
pathogenesis O
, O
the O
feature O
of O
the O
BCL B
- I
6 I
gene I
product I
, O
its O
specific O
pattern O
of O
expression O
in O
B O
cells O
, O
and O
the O
clustering O
of O
lesions O
disrupting O
its O
regulatory O
domain O
strongly O
suggest O
that O
deregulation O
of O
BCL B
- I
6 I
expression O
may O
contribute O
to O
DLCL O
development O
. O

To O
further O
elucidate O
the O
role O
of O
this O
variant O
octamer B
motif I
in O
the O
regulation O
of O
germline B
transcription O
from O
the O
unrearranged O
kappa B
locus I
, O
we O
have O
quantitated O
the O
relative O
binding O
affinity O
of O
Oct B
- I
1 I
and O
Oct B
- I
2 I
for O
the O
variant O
octamer B
motif I
and O
determined O
the O
functional O
role O
of O
this O
octamer B
motif I
in O
transcriptional O
activation O
. O

To O
further O
elucidate O
the O
role O
of O
this O
variant O
octamer B
motif I
in O
the O
regulation O
of O
germline B
transcription O
from O
the O
unrearranged O
kappa B
locus I
, O
we O
have O
quantitated O
the O
relative O
binding O
affinity O
of O
Oct B
- I
1 I
and O
Oct B
- I
2 I
for O
the O
variant O
octamer B
motif I
and O
determined O
the O
functional O
role O
of O
this O
octamer B
motif I
in O
transcriptional O
activation O
. O

In O
the O
present O
study O
, O
we O
showed O
that O
CD14 O
+ O
adherent O
human O
monocytes O
can O
differentiate O
into O
CD1 O
+ O
relB O
+ O
dendritic O
cells O
( O
DC O
) O
by O
the O
combination O
of O
GM B
- I
CSF I
plus O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
and O
that O
they O
differentiate O
into O
tartrate O
- O
resistant O
acid O
phosphatase O
( O
TRAP O
) O
- O
positive O
osteoclast O
- O
like O
multinucleated O
giant O
cells O
( O
MGC O
) O
by O
the O
combination O
of O
M B
- I
CSF I
plus O
IL B
- I
4 I
. O

In O
the O
present O
study O
, O
we O
showed O
that O
CD14 O
+ O
adherent O
human O
monocytes O
can O
differentiate O
into O
CD1 O
+ O
relB O
+ O
dendritic O
cells O
( O
DC O
) O
by O
the O
combination O
of O
GM B
- I
CSF I
plus O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
and O
that O
they O
differentiate O
into O
tartrate O
- O
resistant O
acid O
phosphatase O
( O
TRAP O
) O
- O
positive O
osteoclast O
- O
like O
multinucleated O
giant O
cells O
( O
MGC O
) O
by O
the O
combination O
of O
M B
- I
CSF I
plus O
IL B
- I
4 I
. O

In O
the O
present O
study O
, O
we O
showed O
that O
CD14 O
+ O
adherent O
human O
monocytes O
can O
differentiate O
into O
CD1 O
+ O
relB O
+ O
dendritic O
cells O
( O
DC O
) O
by O
the O
combination O
of O
GM B
- I
CSF I
plus O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
and O
that O
they O
differentiate O
into O
tartrate O
- O
resistant O
acid O
phosphatase O
( O
TRAP O
) O
- O
positive O
osteoclast O
- O
like O
multinucleated O
giant O
cells O
( O
MGC O
) O
by O
the O
combination O
of O
M B
- I
CSF I
plus O
IL B
- I
4 I
. O

In O
the O
present O
study O
, O
we O
showed O
that O
CD14 O
+ O
adherent O
human O
monocytes O
can O
differentiate O
into O
CD1 O
+ O
relB O
+ O
dendritic O
cells O
( O
DC O
) O
by O
the O
combination O
of O
GM B
- I
CSF I
plus O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
and O
that O
they O
differentiate O
into O
tartrate O
- O
resistant O
acid O
phosphatase O
( O
TRAP O
) O
- O
positive O
osteoclast O
- O
like O
multinucleated O
giant O
cells O
( O
MGC O
) O
by O
the O
combination O
of O
M B
- I
CSF I
plus O
IL B
- I
4 I
. O

In O
the O
present O
study O
, O
we O
showed O
that O
CD14 O
+ O
adherent O
human O
monocytes O
can O
differentiate O
into O
CD1 O
+ O
relB O
+ O
dendritic O
cells O
( O
DC O
) O
by O
the O
combination O
of O
GM B
- I
CSF I
plus O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
and O
that O
they O
differentiate O
into O
tartrate O
- O
resistant O
acid O
phosphatase O
( O
TRAP O
) O
- O
positive O
osteoclast O
- O
like O
multinucleated O
giant O
cells O
( O
MGC O
) O
by O
the O
combination O
of O
M B
- I
CSF I
plus O
IL B
- I
4 I
. O

Flow O
cytometry O
analyses O
on O
cultured O
cells O
that O
were O
treated O
with O
tepoxalin O
or O
antisense O
oligonucleotides O
to O
the O
P65 B
/ I
p50 I
subunit I
of O
NF B
- I
kappa I
B I
, O
and O
then O
stimulated O
with O
PMA O
, O
revealed O
a O
reduced O
expression O
of O
CD11b B
/ I
CD18 I
on O
monocytic O
HL60 O
cells O
, O
and O
endothelial B
adhesion I
molecule I
- I
1 I
( O
CD62E B
) O
and O
vascular B
adhesion I
molecule I
- I
1 I
( O
CD106 B
) O
on O
human O
umbilical O
vein O
endothelial O
cells O
. O

Tepoxalin O
also O
inhibited O
the O
secretion O
of O
a O
NF B
- I
kappa I
B I
regulated I
chemokine I
, O
IL B
- I
8 I
, O
a O
known O
inducer O
of O
CD11b B
/ I
CD18 I
expression O
. O

Tepoxalin O
also O
inhibited O
the O
secretion O
of O
a O
NF B
- I
kappa I
B I
regulated I
chemokine I
, O
IL B
- I
8 I
, O
a O
known O
inducer O
of O
CD11b B
/ I
CD18 I
expression O
. O

Thus O
the O
suppression O
of O
CD11b B
/ I
CD18 I
expression O
by O
tepoxalin O
may O
involve O
IL B
- I
8 I
. O

Thus O
the O
suppression O
of O
CD11b B
/ I
CD18 I
expression O
by O
tepoxalin O
may O
involve O
IL B
- I
8 I
. O

Characterization O
of O
a O
CD43 B
/ I
leukosialin I
- O
mediated O
pathway O
for O
inducing O
apoptosis O
in O
human O
T O
- O
lymphoblastoid O
cells O
. O

NH2 B
- O
terminal O
amino O
acid O
sequence O
analysis O
identified O
the O
140 B
- I
kDa I
surface I
antigen I
for O
mAb B
J393 I
as O
CD43 B
/ I
leukosialin I
, O
the O
major O
sialoglycoprotein B
of O
leukocytes O
. O

While O
Jurkat O
cells O
co O
- O
expressed O
two O
discrete O
cell B
- I
surface I
isoforms I
of O
CD43 B
, O
recognized O
by O
mAb B
J393 I
and O
mAb B
G10 I
- I
2 I
, O
respectively O
, O
only O
J393 B
/ I
CD43 I
signaled O
apoptosis O
. O

Tyrosine B
kinase I
inhibition O
by O
herbimycin O
A O
diminished O
J393 B
/ I
CD43 I
- O
mediated O
apoptosis O
, O
whereas O
inhibition O
of O
phosphotyrosine B
phosphatase I
activity O
by O
bis O
( O
maltolato O
) O
oxovanadium O
- O
IV O
enhanced O
cell O
death O
. O

To O
understand O
the O
mechanism O
by O
which O
PRL B
regulates O
the O
biphasic O
expression O
of O
IRF B
- I
1 I
, O
we O
cloned O
the O
rat B
IRF I
- I
1 I
gene I
and O
functionally O
characterized O
the O
IRF B
- I
1 I
promoter I
. O

Signals O
transduced O
via O
the O
TCR B
activate O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
, O
in O
turn O
, O
is O
critical O
to O
the O
transcriptional O
induction O
of O
many O
genes O
important O
for O
the O
proliferation O
and O
expression O
of O
a O
differentiated O
phenotype O
. O

Here O
we O
identify O
intracellular O
signaling O
components O
involved O
in O
activation O
of O
NF B
- I
kappaB I
following O
TCR B
stimulation O
. O

T O
- O
cell O
- O
directed O
TAL B
- I
1 I
expression O
induces O
T O
- O
cell O
malignancies O
in O
transgenic O
mice O
. O

The O
survival O
rate O
of O
tal B
- I
1 I
transgenic O
animals O
was O
much O
lower O
as O
compared O
with O
control O
mice O
. O

To O
further O
unravel O
the O
tal B
- I
1 I
oncogenic O
potential O
, O
a O
strain O
of O
tal B
- I
1 I
transgenic O
mice O
was O
crossbred O
with O
p53 O
- O
/ O
- O
mice O
; O
the O
survival O
rate O
in O
these O
animals O
was O
reduced O
by O
more O
than O
one O
- O
half O
when O
compared O
with O
that O
of O
tal B
- I
1 I
mice O
, O
and O
histopathological O
analysis O
revealed O
exclusively O
T O
- O
cell O
lymphomas O
. O

To O
further O
unravel O
the O
tal B
- I
1 I
oncogenic O
potential O
, O
a O
strain O
of O
tal B
- I
1 I
transgenic O
mice O
was O
crossbred O
with O
p53 O
- O
/ O
- O
mice O
; O
the O
survival O
rate O
in O
these O
animals O
was O
reduced O
by O
more O
than O
one O
- O
half O
when O
compared O
with O
that O
of O
tal B
- I
1 I
mice O
, O
and O
histopathological O
analysis O
revealed O
exclusively O
T O
- O
cell O
lymphomas O
. O

To O
further O
unravel O
the O
tal B
- I
1 I
oncogenic O
potential O
, O
a O
strain O
of O
tal B
- I
1 I
transgenic O
mice O
was O
crossbred O
with O
p53 O
- O
/ O
- O
mice O
; O
the O
survival O
rate O
in O
these O
animals O
was O
reduced O
by O
more O
than O
one O
- O
half O
when O
compared O
with O
that O
of O
tal B
- I
1 I
mice O
, O
and O
histopathological O
analysis O
revealed O
exclusively O
T O
- O
cell O
lymphomas O
. O

TSC2 B
messenger I
RNA I
was O
widely O
expressed O
in O
various O
cell O
types O
throughout O
the O
body O
, O
including O
epithelia O
, O
lymphocytes O
, O
and O
cells O
with O
endocrine O
functions O
, O
e O
. O
g O
. O
, O
adrenal O
cortex O
and O
anterior O
pituitary O
. O

These O
results O
suggest O
that O
peripheral O
T O
cells O
use O
distinct O
apoptosis O
signaling O
pathways O
with O
differential O
sensitivity O
to O
Bcl B
- I
2 I
and O
interleukin O
- O
1beta O
- O
converting O
enzyme O
family O
protease O
inhibitors O
. O

However O
, O
in O
contrast O
to O
human O
lymphocytes O
, O
IFN B
- I
gamma I
production O
was O
inhibited O
and O
IFN B
- I
gamma I
mRNA I
levels O
were O
unaffected O
at O
24 O
h O
and O
only O
slightly O
upregulated O
at O
48 O
and O
72 O
h O
of O
culture O
in O
murine O
splenocytes O
incubated O
with O
cipro O
( O
20 O
micrograms O
/ O
ml O
) O
. O

Cipro O
did O
not O
affect O
the O
nuclear B
transcription I
factors I
AP B
- I
1 I
or O
NFIL B
- I
2A I
. O

Cipro O
did O
not O
affect O
the O
nuclear B
transcription I
factors I
AP B
- I
1 I
or O
NFIL B
- I
2A I
. O

Cipro O
did O
not O
affect O
the O
nuclear B
transcription I
factors I
AP B
- I
1 I
or O
NFIL B
- I
2A I
. O

Selection O
against O
such O
mutations O
may O
be O
the O
result O
of O
functional O
redundancy O
of O
these O
myogenic B
transcription I
factors I
. O

In O
vertebrates O
, O
five O
distinct O
DNA B
binding I
subunits I
are O
currently O
known O
which O
might O
extensively O
heterodimerize O
, O
thereby O
forming O
complexes O
with O
distinct O
transcriptional O
activity O
, O
DNA O
sequence O
specificity O
, O
and O
cell O
type O
- O
and O
cell O
stage O
- O
specific O
distribution O
. O

The O
intracellular O
events O
that O
lead O
to O
the O
inactivation O
of O
I B
kappa I
B I
, O
i O
. O
e O
. O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
are O
complex O
. O

In O
previous O
studies O
, O
it O
was O
shown O
that O
the O
fusion O
region O
of O
the O
pml B
/ I
RAR I
- I
alpha I
protein I
, O
expressed O
by O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
cells O
, O
can O
be O
specifically O
recognized O
in O
vitro O
by O
donor O
( O
D O
. O
E O
. O
) O
CD4 O
T O
cells O
in O
a O
HLA B
class I
II I
DR11 O
- O
restricted O
fashion O
. O

Interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
is O
produced O
by O
natural O
killer O
cells O
and O
certain O
subsets O
of O
T O
cells O
, O
but O
the O
basis O
for O
its O
selective O
expression O
is O
unknown O
. O

Interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
is O
produced O
by O
natural O
killer O
cells O
and O
certain O
subsets O
of O
T O
cells O
, O
but O
the O
basis O
for O
its O
selective O
expression O
is O
unknown O
. O

The O
proximal O
element O
is O
a O
composite O
site O
that O
binds O
members O
of O
the O
CREB B
/ I
ATF I
, O
AP B
- I
1 I
, O
and O
octamer B
families I
of O
transcription B
factors I
. O

The O
proximal O
element O
is O
a O
composite O
site O
that O
binds O
members O
of O
the O
CREB B
/ I
ATF I
, O
AP B
- I
1 I
, O
and O
octamer B
families I
of O
transcription B
factors I
. O

B O
lymphocyte O
stimulation O
via O
both O
CD40 B
and O
surface B
Ig I
( I
sIg I
) I
receptors I
substantially O
induced O
fra B
- I
1 I
expression O
, O
and O
for O
both O
receptors O
, O
induction O
was O
protein B
kinase I
C I
( O
PKC B
) O
dependent O
. O

B O
lymphocyte O
stimulation O
via O
both O
CD40 B
and O
surface B
Ig I
( I
sIg I
) I
receptors I
substantially O
induced O
fra B
- I
1 I
expression O
, O
and O
for O
both O
receptors O
, O
induction O
was O
protein B
kinase I
C I
( O
PKC B
) O
dependent O
. O

Induction O
of O
fra B
- I
1 I
following O
engagement O
of O
CD40 B
did O
not O
require O
protein O
synthesis O
, O
suggesting O
that O
the O
PKC B
- O
dependent O
linkage O
between O
CD40 B
and O
fra B
- I
1 I
is O
direct O
. O

Induction O
of O
fra B
- I
1 I
following O
engagement O
of O
CD40 B
did O
not O
require O
protein O
synthesis O
, O
suggesting O
that O
the O
PKC B
- O
dependent O
linkage O
between O
CD40 B
and O
fra B
- I
1 I
is O
direct O
. O

Inhibition O
of O
RANTES B
expression O
did O
not O
appear O
to O
be O
secondary O
to O
IL B
- I
2 I
inhibition O
and O
required O
binding O
to O
the O
intracellular O
glucocorticoid B
receptor I
. O

Association O
of O
TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
with O
an O
Epstein B
- I
Barr I
virus I
LMP1 I
domain I
important O
for O
B O
- O
lymphocyte O
transformation O
: O
role O
in O
NF B
- I
kappaB I
activation O
. O

The O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
transforming I
protein I
LMP1 I
appears O
to O
be O
a O
constitutively B
activated I
tumor I
necrosis I
factor I
receptor I
( O
TNFR B
) O
on O
the O
basis O
of O
an O
intrinsic O
ability O
to O
aggregate O
in O
the O
plasma O
membrane O
and O
an O
association O
of O
its O
cytoplasmic B
carboxyl I
terminus I
( O
CT B
) O
with O
TNFR B
- I
associated I
factors I
( O
TRAFs B
) O
. O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

Signaling O
via O
IL B
- I
2 I
and O
IL B
- I
4 I
in O
JAK3 O
- O
deficient O
severe O
combined O
immunodeficiency O
lymphocytes O
: O
JAK3 B
- O
dependent O
and O
independent O
pathways O
. O

Signaling O
via O
IL B
- I
2 I
and O
IL B
- I
4 I
in O
JAK3 O
- O
deficient O
severe O
combined O
immunodeficiency O
lymphocytes O
: O
JAK3 B
- O
dependent O
and O
independent O
pathways O
. O

However O
, O
IL B
- I
4 I
- O
induced O
effects O
were O
clearly O
improved O
following O
JAK3 B
expression O
. O

Interleukin B
2 I
( O
IL B
- I
2 I
) O
stimulates O
IL B
- I
2R I
alpha I
. O

We O
identified O
an O
86 O
- O
nucleotide O
fragment O
that O
is O
90 O
% O
identical O
to O
the O
recently O
characterized O
murine B
IL I
- I
2 I
- I
responsive I
element I
( O
mIL B
- I
2rE I
) O
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Although O
mutation O
of O
either O
Y113 O
and O
Y128 O
has O
a O
minimal O
effect O
on O
SLP B
- I
76 I
function O
, O
mutation O
of O
both O
residues O
decreases O
significantly O
the O
ability O
of O
SLP B
- I
76 I
to O
promote O
T O
cell O
activation O
. O

Although O
mutation O
of O
either O
Y113 O
and O
Y128 O
has O
a O
minimal O
effect O
on O
SLP B
- I
76 I
function O
, O
mutation O
of O
both O
residues O
decreases O
significantly O
the O
ability O
of O
SLP B
- I
76 I
to O
promote O
T O
cell O
activation O
. O

The O
IRF B
- I
2 I
promoter B
region I
contains O
a O
CpG O
island O
, O
with O
several O
GC B
boxes I
, O
a O
putative O
NF B
- I
kappa I
B I
- I
binding I
site I
, O
and O
a O
CAAT B
box I
, O
but O
no O
TATA B
box I
. O

When O
the O
promoter B
region I
was O
linked O
with O
a O
heterologous B
reporter I
gene I
, O
we O
found O
that O
the O
promoter B
region I
is O
inducible O
by O
both O
interferons B
( O
interferon B
- I
alpha I
and I
- I
gamma I
) O
and O
interferon B
regulatory I
factor I
1 I
. O

Binding O
of O
the O
cDNA B
fusion I
protein I
, O
similarly O
to O
the O
results O
obtained O
with O
purified O
Jurkat O
protein O
, O
was O
decreased O
by O
introduction O
of O
site O
- O
specific O
mutations O
in O
the O
DRE B
1 I
regulatory I
sequence I
. O

HIV B
- I
1 I
LTR I
activity O
in O
human O
CD40 O
- O
activated O
B O
lymphocytes O
is O
dependent O
on O
NF B
- I
kappaB I
. O

In O
these O
cells O
, O
nuclear B
factors I
involved O
in O
activation O
of O
the O
HIV B
- I
1 I
LTR I
, O
which O
contains O
the O
transcriptional B
control I
elements I
of O
the O
virus O
, O
are O
unknown O
. O

In O
vitro O
footprinting O
analysis O
within O
this O
part O
of O
the O
promoter B
revealed O
two O
Sp1 B
binding I
sites I
as O
well O
as O
a O
PU B
- I
box I
. O

In O
vitro O
footprinting O
analysis O
within O
this O
part O
of O
the O
promoter B
revealed O
two O
Sp1 B
binding I
sites I
as O
well O
as O
a O
PU B
- I
box I
. O

In O
addition O
Spi B
- I
B I
as O
well O
as O
PU B
. I
1 I
were O
able O
to O
transactivate O
Btk B
expression O
. O

In O
addition O
Spi B
- I
B I
as O
well O
as O
PU B
. I
1 I
were O
able O
to O
transactivate O
Btk B
expression O
. O

They O
also O
demonstrate O
for O
the O
first O
time O
the O
occurrence O
of O
T O
cell O
responses O
against O
EBV B
transactivating I
factors I
, O
which O
might O
be O
central O
in O
the O
control O
of O
virus O
reactivation O
. O

The O
inhibitor O
also O
dramatically O
inhibited O
monocyte O
chemotactic O
activity O
of O
and O
MCP B
- I
1 I
production O
by O
the O
cells O
. O

Thus O
, O
the O
tyrosine B
kinase I
activated O
by O
G B
- I
CSF I
appears O
to O
directly O
transduce O
a O
signal O
to O
a O
protein O
which O
functions O
as O
a O
transcriptional B
regulator I
. O

Moreover O
, O
ZK161422 O
, O
but O
not O
ZK157202 O
, O
showed O
preference O
for O
gene O
activation O
from O
a O
promoter B
carrying O
a O
VD B
response I
element I
with O
a O
palindromic O
arrangement O
of O
two O
hexameric B
receptor I
binding I
sites I
spaced O
by O
9 O
nucleotides O
( O
IP9 O
) O
rather O
than O
for O
activation O
from O
a O
response B
element I
formed O
by O
a O
direct O
repeat O
spaced O
by O
3 O
nucleotides O
( O
DR3 O
) O
. O

The O
process O
of O
activation O
involves O
calcium O
mobilization O
, O
activation O
of O
protein B
kinase I
C I
( O
PKC B
) O
, O
and O
phosphorylation O
of O
tyrosine B
kinases I
. O

The O
involvement O
of O
p21 B
( I
ras I
) I
in O
the O
regulation O
of O
calcium O
- O
dependent O
signals O
has O
been O
suggested O
through O
analysis O
of O
its O
role O
in O
the O
activation O
of O
NF B
- I
AT I
. O

A O
later O
result O
of O
inhibition O
of O
this O
activation O
pathway O
by O
p21 B
( I
ras I
) I
was O
down O
- O
regulation O
of O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
and O
subsequent O
coordinate O
reductions O
in O
IL B
- I
2 I
gene I
expression O
and O
protein O
production O
. O

Inhibition O
of O
membrane O
IL B
- I
2R I
alpha I
and O
IL B
- I
2R I
beta I
expression O
by O
10 O
( O
- O
6 O
) O
M O
DM O
was O
partially O
reversible O
by O
recombinant B
human I
IL I
- I
2 I
( O
rhIL B
- I
2 I
) O
. O

The O
protein B
- I
tyrosine I
kinase I
ZAP B
- I
70 I
is O
implicated O
, O
together O
with O
the O
Src B
kinase I
p56 B
( I
lck I
) I
, O
in O
controlling O
the O
early O
steps O
of O
the O
T O
- O
cell O
antigen O
receptor O
( O
TCR B
) O
signaling O
cascade O
. O

To O
help O
elucidate O
further O
the O
mechanism O
by O
which O
ZAP B
- I
70 I
regulates O
these O
initial O
events O
, O
we O
used O
a O
dominant O
- O
negative O
mutant O
approach O
. O

ZAP B
- I
70 I
will O
then O
be O
able O
to O
effectively O
control O
phosphorylation O
of O
its O
substrates O
and O
lead O
to O
gene O
activation O
. O

Primer O
extension O
and O
nuclease O
S1 O
protection O
analysis O
revealed O
two O
major O
transcription B
initiation I
sites I
. O

The O
- B
326 I
to I
- I
615 I
region I
contained O
positive B
regulatory I
elements I
. O

Furthermore O
, O
overexpression O
and O
constitutive O
nuclear O
localization O
of O
NF B
- I
AT I
, O
but O
not O
Jun B
, I
Fos I
, I
NF I
- I
kappaB I
, I
Oct I
or I
Ets I
family I
members I
, O
renders O
the O
interleukin B
- I
2 I
enhancer I
in O
Jurkat O
T O
lymphocytes O
resistant O
to O
FK506 O
and O
cyclosporin O
A O
. O

The O
expression O
of O
GM B
- I
CSF I
and O
IL B
- I
2 I
is O
inhibited O
by O
immunosuppressive O
drugs O
such O
as O
cyclosporin O
A O
( O
CsA O
) O
and O
FK506 O
. O

The O
expression O
of O
GM B
- I
CSF I
and O
IL B
- I
2 I
is O
inhibited O
by O
immunosuppressive O
drugs O
such O
as O
cyclosporin O
A O
( O
CsA O
) O
and O
FK506 O
. O

The O
constitutively O
active O
type O
of O
the O
CN B
A I
subunit I
, O
which O
lacks O
the O
auto B
- I
inhibitory I
and O
calmodulin B
- I
binding I
domains I
, O
acts O
in O
synergy O
with O
PMA O
to O
activate O
transcription O
from O
the O
GM B
- I
CSF I
promoter I
. O

The O
constitutively O
active O
type O
of O
the O
CN B
A I
subunit I
, O
which O
lacks O
the O
auto B
- I
inhibitory I
and O
calmodulin B
- I
binding I
domains I
, O
acts O
in O
synergy O
with O
PMA O
to O
activate O
transcription O
from O
the O
GM B
- I
CSF I
promoter I
. O

It O
predicts O
for O
two O
open B
reading I
frames I
( O
ORFs B
) O
. O

To O
investigate O
the O
mechanisms O
of O
transcriptional O
activation O
of O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
in O
non O
- O
monocytic O
cells O
, O
we O
constructed O
a O
series O
of O
reporter O
plasmids O
with O
the O
bacterial O
chloramphenicol O
acetyltransferase O
gene O
linked O
to O
various O
parts O
of O
the O
human B
IL I
- I
1beta I
promoter I
and O
performed O
transient O
transfection O
experiments O
. O

To O
investigate O
the O
mechanisms O
of O
transcriptional O
activation O
of O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
in O
non O
- O
monocytic O
cells O
, O
we O
constructed O
a O
series O
of O
reporter O
plasmids O
with O
the O
bacterial O
chloramphenicol O
acetyltransferase O
gene O
linked O
to O
various O
parts O
of O
the O
human B
IL I
- I
1beta I
promoter I
and O
performed O
transient O
transfection O
experiments O
. O

Egr B
- I
1 I
expression O
correlates O
with O
the O
cellular O
phenotype O
and O
the O
specific O
pattern O
of O
viral O
latency O
established O
within O
the O
individual O
cell O
lines O
. O

Several O
forms O
of O
EGR B
- I
1 I
protein I
are O
found O
within O
the O
different O
groups O
of O
cell O
lines O
, O
and O
the O
binding O
activity O
to O
DNA B
consensus I
sequences I
was O
investigated O
. O

In O
all O
cells O
tested O
, O
IL B
- I
10 I
activated O
Stat1 B
and O
Stat3 B
and O
induced O
the O
formation O
of O
three O
distinct O
DNA B
binding I
complexes I
that O
contained O
different O
combinations O
of O
these O
two O
transcription B
factors I
. O

In O
all O
cells O
tested O
, O
IL B
- I
10 I
activated O
Stat1 B
and O
Stat3 B
and O
induced O
the O
formation O
of O
three O
distinct O
DNA B
binding I
complexes I
that O
contained O
different O
combinations O
of O
these O
two O
transcription B
factors I
. O

Using O
a O
structure O
- O
function O
mutagenesis O
approach O
, O
two O
tyrosine O
residues O
( O
Tyr427 O
and O
Tyr477 O
) O
in O
the O
intracellular B
domain I
of O
the O
murine O
IL B
- I
10 I
receptor O
were O
found O
to O
be O
redundantly O
required O
for O
receptor O
function O
and O
for O
activation O
of O
Stat3 B
but O
not O
for O
Stat1 B
or O
Stat5 B
. O

This O
study O
thus O
supports O
the O
concept O
that O
utilization O
of O
distinct O
STAT B
proteins I
by O
different O
cytokine B
receptors I
is O
dependent O
on O
the O
expression O
of O
particular O
ligand O
- O
activatable O
, O
tyrosine B
- I
containing I
STAT I
docking I
sites I
in O
receptor B
intracellular I
domains I
. O

E3 B
transcripts I
were O
RA O
- O
inducible O
in O
HL60 O
cells O
, O
but O
not O
in O
an O
RA O
- O
resistant O
subclone O
, O
HL60R O
, O
that O
harbors O
a O
mutated O
RAR B
alpha I
gene I
. O

The O
molecular O
mechanism O
underlying O
IL B
- I
2 I
transcriptional O
blockade O
in O
anergic O
T O
cell O
clones O
is O
not O
fully O
understood O
. O

Whereas O
AP B
- I
1 I
, O
NF O
- O
kappa O
B O
, O
Oct B
, O
CREB B
and O
SP1 B
displayed O
normal O
binding O
activities O
in O
nuclear O
extracts O
, O
the O
binding O
of O
NF B
- I
AT I
to O
its O
IL B
- I
2 I
promoter O
response O
element O
was O
barely O
detectable O
both O
before O
and O
after O
T O
cell O
stimulation O
. O

Whereas O
AP B
- I
1 I
, O
NF O
- O
kappa O
B O
, O
Oct B
, O
CREB B
and O
SP1 B
displayed O
normal O
binding O
activities O
in O
nuclear O
extracts O
, O
the O
binding O
of O
NF B
- I
AT I
to O
its O
IL B
- I
2 I
promoter O
response O
element O
was O
barely O
detectable O
both O
before O
and O
after O
T O
cell O
stimulation O
. O

Whereas O
AP B
- I
1 I
, O
NF O
- O
kappa O
B O
, O
Oct B
, O
CREB B
and O
SP1 B
displayed O
normal O
binding O
activities O
in O
nuclear O
extracts O
, O
the O
binding O
of O
NF B
- I
AT I
to O
its O
IL B
- I
2 I
promoter O
response O
element O
was O
barely O
detectable O
both O
before O
and O
after O
T O
cell O
stimulation O
. O

Our O
results O
strongly O
suggest O
that O
this O
NF B
- I
AT I
/ O
DNA O
binding O
defect O
is O
responsible O
for O
the O
multiple O
cytokine B
deficiency O
and O
the O
SCID O
phenotype O
observed O
in O
the O
two O
infant O
brothers O
. O

During O
Epstein O
- O
Barr O
virus O
latent O
infection O
of O
B O
lymphocytes O
in O
vitro O
, O
six O
viral B
nuclear I
antigens I
( O
EBNAs B
) O
are O
expressed O
from O
one O
of O
two O
promoters B
, O
Cp B
or O
Wp B
, O
whose O
activities O
are O
mutually O
exclusive O
. O

HIV O
- O
1 O
infection O
resulted O
in O
constitutive O
, O
low O
- O
level O
expression O
of O
type B
1 I
interferon I
( O
IFN B
) O
at O
the O
mRNA O
level O
. O

The O
transcription O
and O
transformation O
activity O
of O
c B
- I
Jun I
is O
governed O
by O
a O
27 B
- I
amino I
acid I
regulatory I
motif I
, O
labeled O
the O
delta B
- I
domain I
, O
which O
is O
deleted O
in O
v B
- I
Jun I
. O

The O
transcription O
and O
transformation O
activity O
of O
c B
- I
Jun I
is O
governed O
by O
a O
27 B
- I
amino I
acid I
regulatory I
motif I
, O
labeled O
the O
delta B
- I
domain I
, O
which O
is O
deleted O
in O
v B
- I
Jun I
. O

The O
transcription O
and O
transformation O
activity O
of O
c B
- I
Jun I
is O
governed O
by O
a O
27 B
- I
amino I
acid I
regulatory I
motif I
, O
labeled O
the O
delta B
- I
domain I
, O
which O
is O
deleted O
in O
v B
- I
Jun I
. O

Therefore O
, O
the O
human B
androgen I
receptor I
assay O
( O
HUMARA O
) O
was O
used O
to O
determine O
granulocyte O
clonality O
. O

Although O
CD40 B
ligand I
( O
CD40L B
) O
triggers O
a O
shift O
from O
dephosphorylated O
to O
phosphorylated O
pRB B
and O
proliferation O
of O
B O
cells O
, O
the O
addition O
of O
exogenous O
IL B
- I
6 I
to O
CD40L B
- O
treated O
B O
cells O
does O
not O
alter O
either O
pRB B
or O
proliferation O
, O
as O
observed O
in O
MM O
cells O
. O

The O
transcriptionally B
regulatory I
regions I
of O
the O
lymphomagenic O
Akv O
and O
SL3 O
- O
3 O
murine O
leukemia O
retroviruses O
( O
MLVs O
) O
contain O
two O
types O
of O
E B
- I
box I
consensus I
motifs I
, O
CAGATG O
. O

We O
have O
examined O
the O
requirements O
of O
the O
individual O
E B
- I
boxes I
in O
MLV O
transcriptional O
regulation O
. O

Moreover O
, O
ectopic B
Id1 I
repressed O
E B
( I
gre I
) I
- O
directed O
but O
not O
EA B
/ I
S I
- O
directed O
MLV O
transcription O
in O
lymphoid O
cell O
lines O
. O

We O
cloned O
human O
nur77 B
beta I
cDNA I
, O
called O
TINUR B
. O

Correlations O
were O
found O
between O
plasma B
IFN I
alpha I
and O
receptor O
Kd O
on O
monocytes O
of O
AIDS O
- O
GR O
( O
r O
= O
0 O
. O
77 O
) O
and O
between O
IFN B
alpha I
and O
plasma O
cortisol O
in O
the O
same O
group O
( O
r O
= O
0 O
. O
74 O
) O
. O

Induction O
of O
bcl B
- I
2 I
expression O
by O
phosphorylated O
CREB O
proteins O
during O
B O
- O
cell O
activation O
and O
rescue O
from O
apoptosis O
. O

It O
is O
possible O
that O
the O
CRE B
site I
is O
responsible O
for O
induction O
of O
bcl B
- I
2 I
expression O
in O
other O
cell O
types O
, O
particularly O
those O
in O
which O
protein B
kinase I
C I
is O
involved O
. O

It O
is O
possible O
that O
the O
CRE B
site I
is O
responsible O
for O
induction O
of O
bcl B
- I
2 I
expression O
in O
other O
cell O
types O
, O
particularly O
those O
in O
which O
protein B
kinase I
C I
is O
involved O
. O

The O
amino B
acid I
sequence I
of O
NFATc B
. I
beta I
differs O
from O
that O
of O
NFATc B
. O

The O
amino B
acid I
sequence I
of O
NFATc B
. I
beta I
differs O
from O
that O
of O
NFATc B
. O

Transient O
expression O
of O
NFATc B
. I
beta I
was O
capable O
of O
activating O
an O
interleukin B
- I
2 I
NFAT I
- I
driven I
reporter I
gene I
in O
stimulated O
Jurkat O
cells O
in O
a O
CsA O
- O
sensitive O
manner O
. O

However O
, O
NFATc B
. I
beta I
neither O
bound O
to O
the O
kappa3 B
element I
( O
an O
NFAT B
- I
binding I
site I
) O
in O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
nor O
activated O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
in O
cotransfection O
assays O
. O

Both O
are O
located O
in O
the O
particulate O
fraction O
following O
platelet O
activation O
and O
are O
also O
able O
to O
bind O
to O
a O
GST B
- I
construct I
containing O
the O
SH2 B
and I
SH3 I
domains I
of O
phospholipase B
C I
gamma I
1 I
. O

Constitutive O
expression O
of O
IFN B
- I
alpha5 I
and O
IFN B
- I
beta I
was O
detected O
in O
different O
lymphoid O
cells O
including O
peripheral O
blood O
mononuclear O
cells O
from O
normal O
individuals O
following O
amplification O
of O
IFN B
mRNA I
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
and O
direct O
sequencing O
of O
the O
amplified B
product I
. O

Constitutive O
expression O
of O
IFN B
- I
alpha5 I
and O
IFN B
- I
beta I
was O
detected O
in O
different O
lymphoid O
cells O
including O
peripheral O
blood O
mononuclear O
cells O
from O
normal O
individuals O
following O
amplification O
of O
IFN B
mRNA I
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
and O
direct O
sequencing O
of O
the O
amplified B
product I
. O

These O
results O
suggest O
that O
IFN B
- I
alpha5 I
and O
IFN B
- I
beta I
are O
produced O
at O
low O
levels O
in O
normal O
tissues O
and O
play O
an O
important O
role O
in O
the O
regulation O
of O
cell O
function O
and O
in O
the O
maintenance O
of O
homeostasis O
. O

These O
results O
suggest O
that O
IFN B
- I
alpha5 I
and O
IFN B
- I
beta I
are O
produced O
at O
low O
levels O
in O
normal O
tissues O
and O
play O
an O
important O
role O
in O
the O
regulation O
of O
cell O
function O
and O
in O
the O
maintenance O
of O
homeostasis O
. O

Thus O
, O
IL B
- I
2 I
- O
induced O
IL B
- I
2R I
alpha I
promoter I
activity O
requires O
a O
complex B
upstream I
element I
, O
which O
appears O
to O
contain O
binding B
sites I
for O
both O
positive B
and I
negative I
regulatory I
factors I
. O

Thus O
, O
IL B
- I
2 I
- O
induced O
IL B
- I
2R I
alpha I
promoter I
activity O
requires O
a O
complex B
upstream I
element I
, O
which O
appears O
to O
contain O
binding B
sites I
for O
both O
positive B
and I
negative I
regulatory I
factors I
. O

Lymphocytes O
from O
CML O
patients O
lack O
a O
47 B
kDa I
factor I
having O
affinity O
for O
a O
genomic B
sterol I
regulatory I
sequence I
. O

We O
report O
here O
on O
the O
identification O
of O
a O
17 B
kDa I
variant I
of O
the O
14 B
kDa I
Id I
- I
3 I
protein O
termed O
Id B
- I
3L I
( O
long O
version O
) O
which O
possesses O
a O
unique O
60 B
amino I
acid I
carboxy I
- I
terminus I
generated O
by O
read O
through O
of O
a O
' O
coding B
intron I
' O
and O
alternative O
splicing O
. O

We O
report O
here O
on O
the O
identification O
of O
a O
17 B
kDa I
variant I
of O
the O
14 B
kDa I
Id I
- I
3 I
protein O
termed O
Id B
- I
3L I
( O
long O
version O
) O
which O
possesses O
a O
unique O
60 B
amino I
acid I
carboxy I
- I
terminus I
generated O
by O
read O
through O
of O
a O
' O
coding B
intron I
' O
and O
alternative O
splicing O
. O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

In O
transient O
transfectin O
experiments O
, O
BCL6 B
can O
repress O
transcription O
from O
promoters B
linked O
to O
its O
DNA B
target I
sequence I
and O
this O
activity O
is O
dependent O
upon O
specific O
DNA O
- O
binding O
and O
the O
presence O
of O
an O
intact O
N B
- I
terminal I
half I
of O
the O
protein O
. O

Three O
subtypes O
of O
retinoic B
acid I
receptors I
( O
RAR B
) O
, O
termed O
RAR B
alpha I
, O
RAR B
beta I
, O
and O
RAR B
gamma I
, O
have O
been O
described O
. O

Our O
findings O
support O
the O
recently O
determined O
calcineurin B
X O
- O
ray O
crystal O
structure O
, O
provide O
evidence O
that O
calcineurin B
is O
the O
only O
CsA B
- I
sensitive I
component I
limiting O
signaling O
from O
the O
T B
cell I
receptor I
to O
the O
nucleus O
, O
and O
suggest O
a O
means O
to O
render O
cells O
and O
tissues O
resistant O
to O
the O
toxic O
side O
effects O
of O
CsA O
and O
FK506 O
. O

PU B
. I
1 I
is O
completely O
absent O
from O
peripheral O
T O
cells O
and O
most O
T O
cell O
lines O
based O
on O
sensitive O
RT O
- O
PCR O
assays O
. O

In O
contrast O
, O
Spi B
- I
B I
is O
expressed O
exclusively O
in O
lymphoid O
cells O
and O
can O
be O
detected O
in O
early O
fetal O
thymus O
and O
spleen O
. O

In O
situ O
hybridization O
and O
Northern O
blot O
analysis O
suggest O
that O
Spi B
- I
B I
gene O
expression O
increases O
during O
B O
cell O
maturation O
and O
decreases O
during O
T O
cell O
maturation O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
differences O
in O
patterns O
of O
expression O
between O
Spi B
- I
B I
and O
PU B
. I
1 I
distinguish O
the O
function O
of O
each O
protein O
during O
development O
of O
the O
immune O
system O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
differences O
in O
patterns O
of O
expression O
between O
Spi B
- I
B I
and O
PU B
. I
1 I
distinguish O
the O
function O
of O
each O
protein O
during O
development O
of O
the O
immune O
system O
. O

Thus O
Oct B
- I
2 I
plays O
an O
important O
role O
in O
the O
regulation O
of O
cellular O
gene O
expression O
in O
both O
B O
cells O
and O
neuronal O
cells O
as O
well O
as O
in O
the O
control O
of O
viral O
latency O
. O

Instead O
, O
ATF B
- I
2 I
and O
Jun B
proteins I
bind O
to O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
and O
NFATp B
binds O
to O
a O
newly O
identified O
second O
NFAT B
site I
centered O
at O
- B
76 I
nucleotides I
relative O
to O
the O
TNF B
- I
alpha I
transcription I
start I
site I
. O

Instead O
, O
ATF B
- I
2 I
and O
Jun B
proteins I
bind O
to O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
and O
NFATp B
binds O
to O
a O
newly O
identified O
second O
NFAT B
site I
centered O
at O
- B
76 I
nucleotides I
relative O
to O
the O
TNF B
- I
alpha I
transcription I
start I
site I
. O

Consistent O
with O
these O
results O
, O
quantitative O
DNase B
footprinting O
of O
the O
TNF B
- I
alpha I
promoter I
using O
increasing O
amounts O
of O
recombinant O
NFATp B
demonstrated O
that O
the O
- B
76 I
site I
binds O
to O
NFATp B
with O
a O
higher O
affinity O
than O
the O
kappa B
3 I
site I
. O

Consistent O
with O
these O
results O
, O
quantitative O
DNase B
footprinting O
of O
the O
TNF B
- I
alpha I
promoter I
using O
increasing O
amounts O
of O
recombinant O
NFATp B
demonstrated O
that O
the O
- B
76 I
site I
binds O
to O
NFATp B
with O
a O
higher O
affinity O
than O
the O
kappa B
3 I
site I
. O

To O
address O
possible O
mechanisms O
that O
could O
explain O
this O
selective O
activity O
of O
c B
- I
ErbB I
, O
we O
analyzed O
the O
ability O
of O
these O
receptors O
to O
activate O
the O
different O
members O
of O
the O
Stat B
transcription I
factor I
family I
. O

Ligand O
activation O
of O
c B
- I
ErbB I
induced O
the O
tyrosine O
phosphorylation O
, O
DNA O
- O
binding O
, O
and O
reporter B
gene I
transcription O
of O
Stat B
5b I
in O
erythroblasts O
. O

In O
contrast O
, O
ligand O
activation O
of O
c B
- I
Kit I
was O
unable O
to O
induce O
any O
of O
these O
effects O
in O
the O
same O
cells O
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
B B
- I
cell I
- I
specific I
coactivator I
OCA B
- I
B I
. O

Precise O
alignment B
of I
sites I
required O
for O
mu B
enhancer I
activation O
in O
B O
cells O
. O

The O
previously O
defined O
minimal B
enhancer I
containing O
the O
muA B
, I
muE3 I
, I
and I
muB I
sites I
is O
transactivated O
by O
a O
combination O
of O
the O
ETS B
- I
domain I
proteins I
PU B
. I
1 I
and O
Ets B
- I
1 I
in O
nonlymphoid O
cells O
. O

The O
previously O
defined O
minimal B
enhancer I
containing O
the O
muA B
, I
muE3 I
, I
and I
muB I
sites I
is O
transactivated O
by O
a O
combination O
of O
the O
ETS B
- I
domain I
proteins I
PU B
. I
1 I
and O
Ets B
- I
1 I
in O
nonlymphoid O
cells O
. O

In O
allergic O
bronchial O
asthma O
, O
inflammation O
seems O
to O
be O
orchestrated O
predominantly O
by O
a O
subset O
of O
T O
lymphocytes O
, O
with O
a O
phenotype O
similar O
to O
the O
Th2 O
subset O
able O
to O
produce O
IL B
- I
4 I
and O
IL B
- I
5 I
. O

In O
allergic O
bronchial O
asthma O
, O
inflammation O
seems O
to O
be O
orchestrated O
predominantly O
by O
a O
subset O
of O
T O
lymphocytes O
, O
with O
a O
phenotype O
similar O
to O
the O
Th2 O
subset O
able O
to O
produce O
IL B
- I
4 I
and O
IL B
- I
5 I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
- I
family I
proteins I
( O
NFAT1 B
/ I
NFATp I
, O
NFATc B
, O
NFAT3 B
, O
and O
NFAT4 B
/ I
NFATx I
/ I
NFATc3 I
) O
play O
a O
key O
role O
in O
the O
transcription O
of O
cytokine B
genes I
and O
other O
genes O
during O
the O
immune O
response O
. O

This O
revealed O
that O
NF B
- I
kappaB I
generation O
was O
sensitive O
to O
chloroquine O
, O
an O
inhibitor O
of O
acidic B
sphingomyelinase I
, O
but O
not O
to O
the O
phosphatidylinositol B
3 I
- I
kinase I
inhibitor O
, O
wortmannin O
. O

In O
contrast O
to O
freshly O
isolated O
T O
cells O
, O
in O
vitro O
- O
cultured O
T O
cells O
did O
not O
require O
costimulation O
for O
cytokine B
secretion O
in O
response O
to O
anti B
- I
CD3 I
alone O
. O

This O
pattern O
of O
STAT B
activation O
was O
seen O
in O
all O
BCP O
- O
ALL O
cases O
that O
respond O
to O
IL B
- I
7 I
in O
proliferation O
assays O
. O

We O
demonstrate O
that O
CaMKIV B
/ I
Gr I
reconstitutes O
the O
capacity O
of O
the O
cytosolic O
component O
of O
NFAT B
to O
direct O
transcription O
from O
NFAT B
sites I
in O
non O
- O
T O
cells O
. O

This O
was O
identified O
as O
the O
mRNA B
encoding O
the O
transcription B
factor I
egr B
- I
1 I
, O
which O
is O
expressed O
with O
fast O
kinetics O
in O
T O
and O
NK O
cells O
upon O
IL B
- I
2 I
, O
but O
not O
IL B
- I
12 I
, O
stimulation O
. O

This O
was O
identified O
as O
the O
mRNA B
encoding O
the O
transcription B
factor I
egr B
- I
1 I
, O
which O
is O
expressed O
with O
fast O
kinetics O
in O
T O
and O
NK O
cells O
upon O
IL B
- I
2 I
, O
but O
not O
IL B
- I
12 I
, O
stimulation O
. O

This O
was O
identified O
as O
the O
mRNA B
encoding O
the O
transcription B
factor I
egr B
- I
1 I
, O
which O
is O
expressed O
with O
fast O
kinetics O
in O
T O
and O
NK O
cells O
upon O
IL B
- I
2 I
, O
but O
not O
IL B
- I
12 I
, O
stimulation O
. O

Increasing O
the O
levels O
of O
BCL B
- I
2 I
retarded O
the O
G0 O
- O
- O
> O
S O
transition O
, O
sustained O
the O
levels O
of O
cyclin B
- I
dependent I
kinase I
inhibitor O
p27Kip1 O
, O
and O
repressed O
postactivation O
death O
. O

However O
, O
the O
transcription O
and O
synthesis O
of O
interleukin B
2 I
and O
other O
delayed O
early O
cytokines B
were O
markedly O
attenuated O
by O
BCL B
- I
2 I
. O

Suppression O
of O
c B
- I
jun I
by O
antisense O
oligonucleotides O
inhibits O
cell O
adhesion O
but O
not O
respiratory O
burst O
during O
phorbol O
ester O
- O
induced O
differentiation O
of O
U937 O
human O
monoblastic O
cells O
. O

GM B
- I
CSF I
gene I
activation O
in O
T O
cells O
is O
known O
to O
involve O
the O
transcription B
factors I
nuclear B
factor I
- I
kappa I
B I
, O
AP B
- I
1 I
, O
NFAT B
, O
and O
Sp1 O
. O

The O
AML1 B
and I
CBF I
beta I
genes I
that O
encode O
CBF B
each O
have O
the O
ability O
to O
influence O
cell O
growth O
and O
differentiation O
and O
have O
been O
implicated O
as O
proto B
- I
oncogenes I
in O
acute O
myeloid O
leukemia O
. O

The O
preferential O
induction O
of O
c B
- I
jun I
by O
H2O2 O
did O
not O
represent O
redox O
stabilization O
of O
mRNA B
transcripts I
, O
and O
oxidative O
signals O
closely O
resembled O
PHA O
/ O
PMA O
stimulation O
by O
effectively O
transactivating O
the O
full O
length O
c B
- I
jun I
promoter O
via O
the O
proximal B
jun1 I
tumor I
promoter I
- I
responsive I
element I
( I
TRE I
) I
- I
like I
promoter I
element I
. O

The O
preferential O
induction O
of O
c B
- I
jun I
by O
H2O2 O
did O
not O
represent O
redox O
stabilization O
of O
mRNA B
transcripts I
, O
and O
oxidative O
signals O
closely O
resembled O
PHA O
/ O
PMA O
stimulation O
by O
effectively O
transactivating O
the O
full O
length O
c B
- I
jun I
promoter O
via O
the O
proximal B
jun1 I
tumor I
promoter I
- I
responsive I
element I
( I
TRE I
) I
- I
like I
promoter I
element I
. O

Furthermore O
, O
sublethal O
levels O
of O
H2O2 O
actively O
suppressed O
the O
transcriptional O
activation O
of O
NF B
- I
AT I
and O
IL B
- I
2 I
reporters I
as O
well O
as O
the O
expression O
of O
IL B
- I
2 I
mRNA I
in O
cells O
stimulated O
with O
PHA O
/ O
PMA O
. O

These O
results O
suggest O
that O
oxidative O
signals O
can O
positively O
and O
negatively O
regulate O
T O
cell O
transcriptional O
events O
and O
that O
changes O
in O
cellular O
redox O
can O
uncouple O
AP B
- I
1 I
regulation O
of O
c B
- I
jun I
from O
transcriptional O
up O
- O
regulation O
of O
IL B
- I
2 I
via O
NF B
- I
AT I
. O

These O
results O
suggest O
that O
oxidative O
signals O
can O
positively O
and O
negatively O
regulate O
T O
cell O
transcriptional O
events O
and O
that O
changes O
in O
cellular O
redox O
can O
uncouple O
AP B
- I
1 I
regulation O
of O
c B
- I
jun I
from O
transcriptional O
up O
- O
regulation O
of O
IL B
- I
2 I
via O
NF B
- I
AT I
. O

These O
results O
suggest O
that O
oxidative O
signals O
can O
positively O
and O
negatively O
regulate O
T O
cell O
transcriptional O
events O
and O
that O
changes O
in O
cellular O
redox O
can O
uncouple O
AP B
- I
1 I
regulation O
of O
c B
- I
jun I
from O
transcriptional O
up O
- O
regulation O
of O
IL B
- I
2 I
via O
NF B
- I
AT I
. O

These O
results O
suggest O
that O
oxidative O
signals O
can O
positively O
and O
negatively O
regulate O
T O
cell O
transcriptional O
events O
and O
that O
changes O
in O
cellular O
redox O
can O
uncouple O
AP B
- I
1 I
regulation O
of O
c B
- I
jun I
from O
transcriptional O
up O
- O
regulation O
of O
IL B
- I
2 I
via O
NF B
- I
AT I
. O

To O
examine O
the O
potential O
effects O
of O
stress O
on O
TH1 O
/ O
TH2 O
balance O
, O
we O
studied O
the O
ability O
of O
three O
prototype O
stress O
hormones O
- O
dexamethasone O
( O
a O
synthetic O
glucocorticoid O
) O
and O
the O
catecholamines O
norepinephrine O
and O
epinephrine O
- O
to O
alter O
the O
production O
of O
IL B
- I
12 I
( O
p70 B
) O
and O
IL B
- I
10 I
induced O
by O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
in O
human O
whole O
blood O
. O

To O
examine O
the O
potential O
effects O
of O
stress O
on O
TH1 O
/ O
TH2 O
balance O
, O
we O
studied O
the O
ability O
of O
three O
prototype O
stress O
hormones O
- O
dexamethasone O
( O
a O
synthetic O
glucocorticoid O
) O
and O
the O
catecholamines O
norepinephrine O
and O
epinephrine O
- O
to O
alter O
the O
production O
of O
IL B
- I
12 I
( O
p70 B
) O
and O
IL B
- I
10 I
induced O
by O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
in O
human O
whole O
blood O
. O

The O
effects O
of O
either O
catecholamine O
on O
IL B
- I
12 I
or O
IL B
- I
10 I
secretion O
were O
blocked O
completely O
by O
propranolol O
, O
a O
beta O
- O
adrenoreceptor O
antagonist O
, O
indicating O
that O
they O
were O
mediated O
by O
the O
beta B
- I
adrenergic I
receptor I
. O

The O
effects O
of O
either O
catecholamine O
on O
IL B
- I
12 I
or O
IL B
- I
10 I
secretion O
were O
blocked O
completely O
by O
propranolol O
, O
a O
beta O
- O
adrenoreceptor O
antagonist O
, O
indicating O
that O
they O
were O
mediated O
by O
the O
beta B
- I
adrenergic I
receptor I
. O

One O
p21ras B
effector O
pathway O
involves O
the O
MAP B
kinase I
ERK B
- I
2 I
, O
and O
we O
have O
examined O
its O
role O
in O
NFAT B
regulation O
. O

Gel O
mobility O
shift O
and O
immunoprecipitation O
analyses O
revealed O
that O
in O
addition O
to O
activating O
STAT3 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
) O
and O
STAT5 B
, O
IL B
- I
2 I
induced O
tyrosine O
and O
serine O
phosphorylation O
of O
STAT1 B
alpha I
, O
which O
formed O
IFN B
- I
gamma I
- I
activated I
sequence I
- I
binding I
complexes I
by O
itself O
and O
with O
STAT3 B
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

STAT1 B
alpha I
activation O
by O
IL B
- I
12 I
correlated O
with O
increased O
phosphorylation O
of O
serine O
, O
but O
not O
tyrosine O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

Therefore O
, O
we O
analyzed O
the O
expression O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
the O
endogenous B
RA I
and I
VitD3 I
receptors I
[ O
retinoic B
acid I
receptors I
( O
RARs B
) O
, O
retinoid B
X I
receptors I
( O
RXRs B
) O
, O
and O
VitD3 B
receptor I
( O
VDR B
) O
] O
in O
the O
U O
- O
937 O
cell O
line O
, O
in O
which O
RA O
and O
VitD3 O
induce O
distinct O
monocytic O
differentiation O
pathways O
. O

Therefore O
, O
we O
analyzed O
the O
expression O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
the O
endogenous B
RA I
and I
VitD3 I
receptors I
[ O
retinoic B
acid I
receptors I
( O
RARs B
) O
, O
retinoid B
X I
receptors I
( O
RXRs B
) O
, O
and O
VitD3 B
receptor I
( O
VDR B
) O
] O
in O
the O
U O
- O
937 O
cell O
line O
, O
in O
which O
RA O
and O
VitD3 O
induce O
distinct O
monocytic O
differentiation O
pathways O
. O

STAT5A B
- I
STAT5A I
homodimers I
and O
STAT5A B
- I
STAT5B I
heterodimers I
formed O
in O
response O
to O
GM B
- I
CSF I
. O

Basal O
total O
white O
blood O
cell O
and O
granulocyte O
counts O
did O
not O
appreciably O
differ O
between O
PML B
/ I
RARalpha I
transgenic O
and O
control O
mice O
. O

As O
expected O
, O
nearly O
all O
control O
mice O
( O
94 O
. O
4 O
% O
) O
survived O
irradiation O
, O
yet O
this O
irradiation O
was O
lethal O
to O
45 O
. O
8 O
% O
of O
PML B
/ I
RARalpha I
transgenic O
mice O
. O

Latent B
membrane I
protein I
1 I
and O
, O
to O
a O
lesser O
extent O
, O
EBV B
nuclear I
antigen I
2 I
mediated O
the O
increase O
in O
p53 B
levels O
via O
activation O
of O
the O
NF B
- I
kappaB I
transcription B
factor I
. O

Tissue O
- O
specific O
expression O
of O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
mediated O
via O
cis B
- I
acting I
elements I
located O
within O
315 O
base O
pairs O
of O
the O
transcription B
start I
. O

Tissue O
- O
specific O
expression O
of O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
mediated O
via O
cis B
- I
acting I
elements I
located O
within O
315 O
base O
pairs O
of O
the O
transcription B
start I
. O

In O
addition O
to O
the O
already O
identified O
NIP B
repressor I
site I
, O
evidence O
is O
presented O
for O
a O
second B
repressor I
region I
that O
restricts O
promoter O
activity O
in O
fibroblasts O
. O

In O
addition O
to O
the O
already O
identified O
NIP B
repressor I
site I
, O
evidence O
is O
presented O
for O
a O
second B
repressor I
region I
that O
restricts O
promoter O
activity O
in O
fibroblasts O
. O

In O
the O
current O
studies O
, O
IL B
- I
2 I
production O
by O
T O
cells O
from O
elderly O
( O
mean O
78 O
years O
) O
and O
young O
( O
mean O
37 O
years O
) O
humans O
was O
measured O
in O
cultures O
stimulated O
with O
PHA B
, O
PHA B
plus O
PMA O
, O
crosslinked O
anti O
- O
CD3 O
mAB O
OKT3 O
plus O
PMA O
, O
or O
PMA O
plus O
ionomycin O
. O

By O
contrast O
, O
T O
cells O
from O
elderly O
subjects O
with O
normal O
levels O
of O
IL B
- I
2 I
production O
exhibited O
normal O
activation O
of O
AP B
- I
1 I
and O
NF B
- I
AT I
. O

By O
contrast O
, O
T O
cells O
from O
elderly O
subjects O
with O
normal O
levels O
of O
IL B
- I
2 I
production O
exhibited O
normal O
activation O
of O
AP B
- I
1 I
and O
NF B
- I
AT I
. O

By O
contrast O
, O
T O
cells O
from O
elderly O
subjects O
with O
normal O
levels O
of O
IL B
- I
2 I
production O
exhibited O
normal O
activation O
of O
AP B
- I
1 I
and O
NF B
- I
AT I
. O

IL B
- I
13 I
caused O
rapid O
phosphorylation O
of O
the O
three O
out O
of O
four O
members O
of O
the O
known O
Janus B
family I
of I
kinases I
( O
JAKs B
) O
. O

IL B
- I
4 I
also O
stimulated O
all O
three O
kinases B
and O
substrates O
, O
but O
unlike O
in O
immune O
cells O
, O
IL B
- I
4 I
did O
not O
involve O
JAK3 B
activation O
for O
its O
signaling O
in O
colon O
cancer O
cell O
lines O
. O

IL B
- I
4 I
also O
stimulated O
all O
three O
kinases B
and O
substrates O
, O
but O
unlike O
in O
immune O
cells O
, O
IL B
- I
4 I
did O
not O
involve O
JAK3 B
activation O
for O
its O
signaling O
in O
colon O
cancer O
cell O
lines O
. O

Furthermore O
, O
JAK2 B
associated O
with O
the O
IL B
- I
4R I
p140 I
before O
and O
after O
stimulation O
with O
IL B
- I
13 I
. O

Differential O
regulation O
of O
IL B
- I
6 I
gene I
transcription O
and O
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
in O
human O
monocytic O
cell O
lines O
. O

Differential O
regulation O
of O
IL B
- I
6 I
gene I
transcription O
and O
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
in O
human O
monocytic O
cell O
lines O
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

In O
chloramphenicol B
acetyltransferase I
assays O
, O
utilizing O
the O
transient O
transfection O
of O
a O
chloramphenicol B
acetyltransferase I
reporter I
plasmid I
containing O
the O
IL B
- I
6 I
gene I
promoter I
, O
IL B
- I
4 I
, O
but O
not O
IL B
- I
10 I
, O
suppressed O
the O
transcriptional O
activity O
of O
the O
IL O
- O
6 O
gene O
promoter O
stimulated O
by O
PMA O
and O
LPS O
. O

In O
chloramphenicol B
acetyltransferase I
assays O
, O
utilizing O
the O
transient O
transfection O
of O
a O
chloramphenicol B
acetyltransferase I
reporter I
plasmid I
containing O
the O
IL B
- I
6 I
gene I
promoter I
, O
IL B
- I
4 I
, O
but O
not O
IL B
- I
10 I
, O
suppressed O
the O
transcriptional O
activity O
of O
the O
IL O
- O
6 O
gene O
promoter O
stimulated O
by O
PMA O
and O
LPS O
. O

On O
the O
other O
hand O
, O
IL B
- I
10 I
enhanced O
the O
degradation O
of O
IL B
- I
6 I
mRNA I
in O
a O
mRNA O
stability O
assay O
. O

These O
results O
suggest O
that O
IL B
- I
4 I
may O
inhibit O
the O
transcription O
of O
the O
IL B
- I
6 I
gene I
by O
affecting O
NF B
- I
kappaB I
binding O
activity O
, O
while O
IL B
- I
10 I
may O
inhibit O
the O
IL B
- I
6 I
mRNA I
levels O
post O
- O
transcriptionally O
, O
without O
suppressing O
promoter O
activity O
. O

These O
results O
suggest O
that O
IL B
- I
4 I
may O
inhibit O
the O
transcription O
of O
the O
IL B
- I
6 I
gene I
by O
affecting O
NF B
- I
kappaB I
binding O
activity O
, O
while O
IL B
- I
10 I
may O
inhibit O
the O
IL B
- I
6 I
mRNA I
levels O
post O
- O
transcriptionally O
, O
without O
suppressing O
promoter O
activity O
. O

These O
results O
suggest O
that O
IL B
- I
4 I
may O
inhibit O
the O
transcription O
of O
the O
IL B
- I
6 I
gene I
by O
affecting O
NF B
- I
kappaB I
binding O
activity O
, O
while O
IL B
- I
10 I
may O
inhibit O
the O
IL B
- I
6 I
mRNA I
levels O
post O
- O
transcriptionally O
, O
without O
suppressing O
promoter O
activity O
. O

IL B
- I
2 I
production O
by O
CsA O
- O
treated O
cells O
is O
therefore O
dramatically O
reduced O
. O

We O
compared O
the O
effects O
of O
the O
deactivating B
cytokine I
interleukin B
10 I
( O
IL B
- I
10 I
) O
on O
human O
peripheral O
blood O
mononuclear O
cell O
( O
PBMC O
) O
responses O
to O
lipopolysaccharide O
( O
LPS O
) O
, O
Cryptococcus O
neoformans O
, O
and O
Candida O
albicans O
. O

To O
determine O
whether O
the O
IL B
- I
10R I
has O
signaling O
functions O
similar O
to O
IL B
- I
6R I
in O
cells O
normally O
expressing O
these O
receptors O
, O
leukocytes O
of O
the O
B O
- O
, O
T O
- O
, O
and O
NK O
- O
cell O
lineages O
were O
treated O
with O
either O
cytokine O
. O

To O
determine O
whether O
the O
IL B
- I
10R I
has O
signaling O
functions O
similar O
to O
IL B
- I
6R I
in O
cells O
normally O
expressing O
these O
receptors O
, O
leukocytes O
of O
the O
B O
- O
, O
T O
- O
, O
and O
NK O
- O
cell O
lineages O
were O
treated O
with O
either O
cytokine O
. O

The O
IL B
- I
10R I
, O
together O
with O
reporter O
gene O
constructs O
containing O
different O
IL B
- I
6 I
- I
responsive I
gene I
elements I
, O
reconstituted O
in O
hepatoma O
cells O
an O
induction O
of O
transcription O
by O
IL B
- I
10 I
that O
was O
comparable O
to O
that O
by O
IL B
- I
6 I
. O

The O
IL B
- I
10R I
, O
together O
with O
reporter O
gene O
constructs O
containing O
different O
IL B
- I
6 I
- I
responsive I
gene I
elements I
, O
reconstituted O
in O
hepatoma O
cells O
an O
induction O
of O
transcription O
by O
IL B
- I
10 I
that O
was O
comparable O
to O
that O
by O
IL B
- I
6 I
. O

The O
IL B
- I
10R I
, O
together O
with O
reporter O
gene O
constructs O
containing O
different O
IL B
- I
6 I
- I
responsive I
gene I
elements I
, O
reconstituted O
in O
hepatoma O
cells O
an O
induction O
of O
transcription O
by O
IL B
- I
10 I
that O
was O
comparable O
to O
that O
by O
IL B
- I
6 I
. O

These O
receptor O
functions O
required O
the O
presence O
of O
the O
box B
3 I
motifs I
, O
as O
shown O
by O
the O
analysis O
of O
the O
mouse O
IL B
- I
10R I
constructs O
containing O
progressively B
truncated I
cytoplasmic I
domains I
. O

These O
receptor O
functions O
required O
the O
presence O
of O
the O
box B
3 I
motifs I
, O
as O
shown O
by O
the O
analysis O
of O
the O
mouse O
IL B
- I
10R I
constructs O
containing O
progressively B
truncated I
cytoplasmic I
domains I
. O

These O
results O
suggest O
that O
both O
common O
mechanisms O
, O
such O
as O
the O
one O
mediated O
by O
the O
CIITA B
trans I
- I
activator I
, O
and O
distinct O
tissue O
- O
specific O
constraints O
contribute O
to O
the O
transcriptional O
control O
of O
constitutive O
and O
IFN B
- I
gamma I
- O
induced O
MHC B
class I
II I
gene I
expression O
. O

We O
have O
demonstrated O
that O
the O
level O
of O
CRE B
binding I
protein I
( O
CREB B
) O
was O
the O
same O
in O
all O
cell O
lines O
and O
that O
the O
putative O
AR B
- I
CRE I
forms O
specific O
and O
compatible O
protein O
interactions O
with O
CREB B
. O

We O
have O
demonstrated O
that O
the O
level O
of O
CRE B
binding I
protein I
( O
CREB B
) O
was O
the O
same O
in O
all O
cell O
lines O
and O
that O
the O
putative O
AR B
- I
CRE I
forms O
specific O
and O
compatible O
protein O
interactions O
with O
CREB B
. O

Biochemical O
analysis O
of O
the O
region O
- B
158 I
/ I
- I
90 I
revealed O
a O
binding O
site O
for O
transcription B
factors I
of O
the O
polyomavirus B
enhancer I
- I
binding I
protein I
2 I
/ I
core I
- I
binding I
factor I
( I
PEBP2 I
/ I
CBF I
) I
family I
at O
position B
- I
103 I
. O

Neutralizing O
antiserum O
against O
IFN B
- I
gamma I
, O
but O
not O
other O
cytokines B
tested O
, O
blocked O
activation O
of O
the O
factor O
almost O
completely O
, O
and O
IFN B
- I
gamma I
was O
found O
in O
the O
culture O
supernatants O
of O
stimulated O
cells O
at O
levels O
at O
which O
recombinant O
IFN B
- I
gamma I
could O
activate O
the O
factor O
in O
naive O
cells O
. O

Neutralizing O
antiserum O
against O
IFN B
- I
gamma I
, O
but O
not O
other O
cytokines B
tested O
, O
blocked O
activation O
of O
the O
factor O
almost O
completely O
, O
and O
IFN B
- I
gamma I
was O
found O
in O
the O
culture O
supernatants O
of O
stimulated O
cells O
at O
levels O
at O
which O
recombinant O
IFN B
- I
gamma I
could O
activate O
the O
factor O
in O
naive O
cells O
. O

Neutralizing O
antiserum O
against O
IFN B
- I
gamma I
, O
but O
not O
other O
cytokines B
tested O
, O
blocked O
activation O
of O
the O
factor O
almost O
completely O
, O
and O
IFN B
- I
gamma I
was O
found O
in O
the O
culture O
supernatants O
of O
stimulated O
cells O
at O
levels O
at O
which O
recombinant O
IFN B
- I
gamma I
could O
activate O
the O
factor O
in O
naive O
cells O
. O

Therefore O
, O
a O
STAT1 B
transcription B
factor I
is O
activated O
by O
IFN B
- I
gamma I
synthesized O
and O
released O
upon O
stimulation O
of O
T O
lymphocyte O
populations O
. O

While O
Jurkat O
cells O
both O
secrete O
and O
respond O
to O
IFN B
- I
gamma I
in O
an O
autocrine O
loop O
, O
it O
seems O
likely O
that O
the O
responding O
cells O
may O
differ O
from O
those O
synthesizing O
this O
cytokine B
in O
the O
mononuclear O
cell O
cultures O
in O
the O
light O
of O
the O
recent O
report O
that O
Th1 O
cells O
lack O
the O
IFN B
- I
gamma I
receptor O
chain O
necessary O
for O
activation O
of O
STAT1 B
( O
Pernis O
, O
A O
. O
, O
Gupta O
, O
S O
. O
, O
Gollob O
, O
K O
. O
J O
. O
, O
Garfein O
, O
E O
. O
, O
Coffman O
, O
R O
. O
L O
. O
, O
Schindler O
, O
C O
. O
, O
and O
Rothman O

While O
Jurkat O
cells O
both O
secrete O
and O
respond O
to O
IFN B
- I
gamma I
in O
an O
autocrine O
loop O
, O
it O
seems O
likely O
that O
the O
responding O
cells O
may O
differ O
from O
those O
synthesizing O
this O
cytokine B
in O
the O
mononuclear O
cell O
cultures O
in O
the O
light O
of O
the O
recent O
report O
that O
Th1 O
cells O
lack O
the O
IFN B
- I
gamma I
receptor O
chain O
necessary O
for O
activation O
of O
STAT1 B
( O
Pernis O
, O
A O
. O
, O
Gupta O
, O
S O
. O
, O
Gollob O
, O
K O
. O
J O
. O
, O
Garfein O
, O
E O
. O
, O
Coffman O
, O
R O
. O
L O
. O
, O
Schindler O
, O
C O
. O
, O
and O
Rothman O

Expression O
of O
the O
MAP B
kinase I
- I
specific I
phosphatase I
, O
MKP B
- I
1 I
, O
which O
blocks O
ERK B
activation O
, O
inhibited O
IL B
- I
2 I
promoter I
and O
NF B
- I
AT I
- O
driven O
transcription O
stimulated O
by O
a O
calcium O
ionophore O
and O
PMA O
, O
and O
in O
addition O
, O
MKP B
- I
1 I
neutralized O
the O
transcriptional O
enhancement O
caused O
by O
active O
Raf O
- O
1 O
and O
MEK1 O
expression O
. O

Expression O
of O
the O
MAP B
kinase I
- I
specific I
phosphatase I
, O
MKP B
- I
1 I
, O
which O
blocks O
ERK B
activation O
, O
inhibited O
IL B
- I
2 I
promoter I
and O
NF B
- I
AT I
- O
driven O
transcription O
stimulated O
by O
a O
calcium O
ionophore O
and O
PMA O
, O
and O
in O
addition O
, O
MKP B
- I
1 I
neutralized O
the O
transcriptional O
enhancement O
caused O
by O
active O
Raf O
- O
1 O
and O
MEK1 O
expression O
. O

Expression O
of O
the O
MAP B
kinase I
- I
specific I
phosphatase I
, O
MKP B
- I
1 I
, O
which O
blocks O
ERK B
activation O
, O
inhibited O
IL B
- I
2 I
promoter I
and O
NF B
- I
AT I
- O
driven O
transcription O
stimulated O
by O
a O
calcium O
ionophore O
and O
PMA O
, O
and O
in O
addition O
, O
MKP B
- I
1 I
neutralized O
the O
transcriptional O
enhancement O
caused O
by O
active O
Raf O
- O
1 O
and O
MEK1 O
expression O
. O

Although O
GM B
- I
CSF I
does O
not O
appear O
to O
be O
essential O
for O
normal O
hemopoiesis O
, O
overexpression O
of O
GM O
- O
CSF O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
some O
diseases O
such O
as O
myeloid O
leukemia O
and O
chronic O
inflammation O
. O

We O
investigated O
oligonucleotide O
- O
directed O
triple O
helix O
formation O
across O
this O
regulatory B
sequence I
as O
a O
potential O
tool O
to O
inhibit O
GM B
- I
CSF I
gene O
transcription O
. O

Finally O
, O
GM3 O
greatly O
reduced O
the O
concentration O
of O
endogenous O
GM B
- I
CSF I
mRNA I
induced O
by O
different O
stimuli O
in O
Jurkat O
T O
cells O
but O
did O
not O
affect O
interleukin B
3 I
mRNA I
levels O
in O
the O
same O
cells O
. O

Costimulation O
of O
U1 O
cells O
with O
LPS O
plus O
GM B
- I
CSF I
resulted O
in O
the O
accumulation O
of O
steady O
- O
state O
levels O
of O
HIV B
RNA I
; O
however O
, O
only O
a O
weak O
induction O
of O
HIV B
long I
terminal I
repeat I
- O
driven O
transcription O
, O
which O
was O
not O
associated O
with O
the O
activation O
of O
the O
cellular B
transcription I
factor I
nuclear B
factor I
- I
kappa I
B I
, O
was O
noted O
. O

Costimulation O
of O
U1 O
cells O
with O
LPS O
plus O
GM B
- I
CSF I
resulted O
in O
the O
accumulation O
of O
steady O
- O
state O
levels O
of O
HIV B
RNA I
; O
however O
, O
only O
a O
weak O
induction O
of O
HIV B
long I
terminal I
repeat I
- O
driven O
transcription O
, O
which O
was O
not O
associated O
with O
the O
activation O
of O
the O
cellular B
transcription I
factor I
nuclear B
factor I
- I
kappa I
B I
, O
was O
noted O
. O

IL B
- I
12 I
is O
a O
novel O
heterodimeric B
cytokine I
important O
for O
the O
regulation O
and O
differentiation O
of O
lymphocytes O
and O
NK O
cells O
. O

Using O
these O
T O
cells O
as O
a O
model O
of O
IL B
- I
12 I
signal O
transduction O
, O
we O
confirmed O
that O
these O
events O
involve O
members O
of O
the O
Janus B
kinase I
family I
of O
nonreceptor B
tyrosine I
kinases I
JAK2 B
, O
TYK2 B
, O
and O
signal B
transducer I
and I
activator I
of I
transcription I
4 I
. O

Using O
these O
T O
cells O
as O
a O
model O
of O
IL B
- I
12 I
signal O
transduction O
, O
we O
confirmed O
that O
these O
events O
involve O
members O
of O
the O
Janus B
kinase I
family I
of O
nonreceptor B
tyrosine I
kinases I
JAK2 B
, O
TYK2 B
, O
and O
signal B
transducer I
and I
activator I
of I
transcription I
4 I
. O

Using O
these O
T O
cells O
as O
a O
model O
of O
IL B
- I
12 I
signal O
transduction O
, O
we O
confirmed O
that O
these O
events O
involve O
members O
of O
the O
Janus B
kinase I
family I
of O
nonreceptor B
tyrosine I
kinases I
JAK2 B
, O
TYK2 B
, O
and O
signal B
transducer I
and I
activator I
of I
transcription I
4 I
. O

Nuclei O
of O
unstimulated O
PBL O
from O
different O
donors O
expressed O
p62c B
- I
fos I
and O
p39c B
- I
jun I
, O
but O
AP B
- I
1 I
was O
not O
detected O
in O
the O
majority O
of O
samples O
. O

Nuclei O
of O
unstimulated O
PBL O
from O
different O
donors O
expressed O
p62c B
- I
fos I
and O
p39c B
- I
jun I
, O
but O
AP B
- I
1 I
was O
not O
detected O
in O
the O
majority O
of O
samples O
. O

Nuclei O
of O
unstimulated O
PBL O
from O
different O
donors O
expressed O
p62c B
- I
fos I
and O
p39c B
- I
jun I
, O
but O
AP B
- I
1 I
was O
not O
detected O
in O
the O
majority O
of O
samples O
. O

Following O
PHA B
stimulation O
of O
PBL O
, O
the O
increase O
in O
AP B
- I
1 I
activity O
was O
delayed O
with O
respect O
to O
the O
augmentation O
of O
p39c B
- I
jun I
expression O
. O

Following O
PHA B
stimulation O
of O
PBL O
, O
the O
increase O
in O
AP B
- I
1 I
activity O
was O
delayed O
with O
respect O
to O
the O
augmentation O
of O
p39c B
- I
jun I
expression O
. O

r B
- I
hTBP I
- I
1 I
and O
rhu B
TNFR I
: I
Fc I
also O
decreased O
p24 B
antigen I
synthesized O
by O
U1 O
cells O
in O
response O
to O
other O
stimuli O
, O
including O
phytohemagglutinin B
( I
PHA I
) I
- I
induced I
supernatant I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
interleukin B
- I
6 I
, O
and O
TNF B
. O

The O
viral B
protein I
Tax I
was O
likely O
responsible O
for O
this O
higher O
level O
of O
class B
II I
gene I
transcription O
, O
as O
purified B
Tax I
was O
found O
to O
stimulate O
both O
genes O
when O
added O
to O
the O
uninfected O
cell O
extract O
or O
in O
reconstituted O
systems O
. O

The O
viral B
protein I
Tax I
was O
likely O
responsible O
for O
this O
higher O
level O
of O
class B
II I
gene I
transcription O
, O
as O
purified B
Tax I
was O
found O
to O
stimulate O
both O
genes O
when O
added O
to O
the O
uninfected O
cell O
extract O
or O
in O
reconstituted O
systems O
. O

Efficient O
gene O
activation O
requires O
the O
heterodimerization O
of O
VDR B
with O
Retinoid B
X I
Receptors I
( O
RXR B
) O
. O

A O
variety O
of O
cytokines B
and O
growth B
factors I
act O
through O
an O
induction O
of O
gene O
expression O
mediated O
by O
a O
family O
of O
latent B
transcription I
factors I
called O
STAT B
( I
signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

The O
effects O
of O
IFN B
- I
gamma I
on O
the O
transcription B
factors I
were O
specific O
, O
since O
no O
change O
was O
observed O
in O
the O
expression O
of O
NF B
- I
IL I
- I
6 I
or O
I B
kappa I
B I
alpha I
, O
the O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

We O
conclude O
that O
the O
effects O
of O
IFN B
- I
gamma I
on O
the O
expression O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
may O
be O
important O
for O
the O
modulatory O
effects O
of O
IFN B
- I
gamma I
on O
the O
cytokine B
expression O
in O
activated O
human O
monocytes O
. O

We O
conclude O
that O
the O
effects O
of O
IFN B
- I
gamma I
on O
the O
expression O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
may O
be O
important O
for O
the O
modulatory O
effects O
of O
IFN B
- I
gamma I
on O
the O
cytokine B
expression O
in O
activated O
human O
monocytes O
. O

We O
conclude O
that O
the O
effects O
of O
IFN B
- I
gamma I
on O
the O
expression O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
may O
be O
important O
for O
the O
modulatory O
effects O
of O
IFN B
- I
gamma I
on O
the O
cytokine B
expression O
in O
activated O
human O
monocytes O
. O

We O
have O
previously O
identified O
a O
new O
transcription B
factor I
family I
( O
the O
MNP B
family I
) O
whose O
expression O
is O
crucial O
for O
the O
induction O
of O
MIP B
- I
1 I
alpha I
transcription O
during O
cellular O
activation O
and O
in O
transformed O
B O
cells O
. O

In O
this O
report O
we O
show O
induction O
of O
MNP B
- I
1 I
in O
Jurkat O
T O
- O
cells O
expressing O
HIV B
- I
1 I
tat I
. O

The O
EGR1 B
binding I
motif I
was O
shown O
to O
be O
necessary O
for O
stimulus O
- O
induced O
expression O
of O
a O
CD44 B
promoter B
- I
chloramphenicol I
acetyltransferase I
reporter I
construct I
in O
nontransformed O
B O
lymphocytes O
and O
was O
required O
for O
transactivation O
by O
an O
EGR1 B
expression I
vector I
in O
a O
B O
- O
cell O
line O
. O

The O
EGR1 B
binding I
motif I
was O
shown O
to O
be O
necessary O
for O
stimulus O
- O
induced O
expression O
of O
a O
CD44 B
promoter B
- I
chloramphenicol I
acetyltransferase I
reporter I
construct I
in O
nontransformed O
B O
lymphocytes O
and O
was O
required O
for O
transactivation O
by O
an O
EGR1 B
expression I
vector I
in O
a O
B O
- O
cell O
line O
. O

In O
Jurkat O
cells O
that O
are O
not O
sensitive O
to O
H2O2 O
- O
induced O
NF B
- I
kappaB I
activation O
, O
H2O2 O
potentiated O
NF B
- I
kappaB I
activation O
in O
the O
presence O
of O
sustained O
high O
[ O
Ca2 O
+ O
] O
i O
following O
thapsigargin O
treatment O
. O

In O
Jurkat O
cells O
that O
are O
not O
sensitive O
to O
H2O2 O
- O
induced O
NF B
- I
kappaB I
activation O
, O
H2O2 O
potentiated O
NF B
- I
kappaB I
activation O
in O
the O
presence O
of O
sustained O
high O
[ O
Ca2 O
+ O
] O
i O
following O
thapsigargin O
treatment O
. O

A O
mutant O
Tax B
protein I
deficient O
in O
transactivation O
of O
genes O
by O
the O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
pathway O
was O
unable O
to O
induce O
transcriptional O
activity O
of O
IL B
- I
1alpha I
promoter I
- I
CAT I
constructs I
, O
but O
was O
rescued O
by O
exogenous O
provision O
of O
p65 B
/ I
p50 I
NF B
- I
kappaB I
. O

A O
mutant O
Tax B
protein I
deficient O
in O
transactivation O
of O
genes O
by O
the O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
pathway O
was O
unable O
to O
induce O
transcriptional O
activity O
of O
IL B
- I
1alpha I
promoter I
- I
CAT I
constructs I
, O
but O
was O
rescued O
by O
exogenous O
provision O
of O
p65 B
/ I
p50 I
NF B
- I
kappaB I
. O

Electrophoretic O
mobility O
shift O
analyses O
demonstrated O
that O
the O
151 B
- I
bp I
region I
contains O
nuclear B
protein I
binding I
sites I
for O
Sp1 B
, O
PU B
. I
1 I
, O
and O
/ O
or O
Elf B
- I
1 I
, O
and O
a O
novel B
factor I
. O

Electrophoretic O
mobility O
shift O
analyses O
demonstrated O
that O
the O
151 B
- I
bp I
region I
contains O
nuclear B
protein I
binding I
sites I
for O
Sp1 B
, O
PU B
. I
1 I
, O
and O
/ O
or O
Elf B
- I
1 I
, O
and O
a O
novel B
factor I
. O

IL B
- I
10 I
markedly O
reduces O
nuclear O
factor O
( B
NF I
) I
- I
kappa I
B I
/ I
Rel I
nuclear O
activity O
induced O
in O
PBMC O
by O
stimulation O
with O
the O
anti B
- I
CD3 I
mAb I
OKT3 B
. O

As O
judged O
by O
supershifting O
the O
DNA B
- I
protein I
complexes I
with O
Abs B
recognizing O
specific O
components O
of O
the O
NF B
- I
kappa I
B I
/ I
Rel I
protein I
family I
, O
the O
p50 B
/ I
p65 I
( O
Rel B
A I
) O
heterodimeric O
form O
of O
NF B
- I
kappa I
B I
is O
primarily O
affected O
. O

The O
maximal O
effect O
is O
observed O
at O
the O
IL B
- I
10 I
concentration O
of O
20 O
U O
/ O
ml O
. O

Our O
results O
demonstrate O
that O
IL B
- I
10 I
can O
inhibit O
the O
induction O
of O
NF B
- I
kappa I
B I
/ I
Rel I
nuclear O
activity O
in O
CD3 O
- O
stimulated O
T O
lymphocytes O
. O

In O
a O
panel O
of O
32 O
B O
- O
cell O
lines O
, O
A B
- I
myb I
was O
very O
strongly O
expressed O
in O
most O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
cell O
lines O
, O
but O
weak O
or O
negative O
in O
2 O
pre O
- O
B O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
4 O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
NHL O
) O
, O
6 O
Epstein O
- O
Barr O
virus O
- O
immortalized O
lymphoblastoid O
cell O
lines O
, O
and O
6 O
myeloma O
lines O
. O

C O
- O
myb O
and O
B B
- I
myb I
were O
expressed O
in O
all O
neoplastic O
groups O
, O
except O
in O
CLL O
cells O
. O

Thus O
, O
A B
- I
myb I
expression O
, O
unlike O
that O
of O
c B
- I
myb I
and O
B B
- I
myb I
, O
is O
restricted O
to O
a O
subset O
of O
B O
- O
cell O
neoplasias O
( O
in O
particular O
BL O
and O
slg O
+ O
B O
- O
ALL O
) O
representative O
of O
a O
specific O
stage O
of O
B O
- O
cell O
differentiation O
. O

Thus O
, O
A B
- I
myb I
expression O
, O
unlike O
that O
of O
c B
- I
myb I
and O
B B
- I
myb I
, O
is O
restricted O
to O
a O
subset O
of O
B O
- O
cell O
neoplasias O
( O
in O
particular O
BL O
and O
slg O
+ O
B O
- O
ALL O
) O
representative O
of O
a O
specific O
stage O
of O
B O
- O
cell O
differentiation O
. O

Thus O
, O
A B
- I
myb I
expression O
, O
unlike O
that O
of O
c B
- I
myb I
and O
B B
- I
myb I
, O
is O
restricted O
to O
a O
subset O
of O
B O
- O
cell O
neoplasias O
( O
in O
particular O
BL O
and O
slg O
+ O
B O
- O
ALL O
) O
representative O
of O
a O
specific O
stage O
of O
B O
- O
cell O
differentiation O
. O

Here O
we O
provide O
evidence O
that O
this O
transformation O
is O
the O
result O
of O
double O
infection O
of O
a O
cell O
with O
two O
virions O
, O
the O
P3HR1 B
virus I
genome I
and O
a O
mini B
- I
EBV I
plasmid I
carrying O
the O
chimeric O
EBNA2 B
gene I
. O

Expression O
of O
ATF B
- I
2 I
in O
S O
. O
cerevisiae O
did O
not O
activate O
TRE B
- I
1 I
in O
the O
presence O
of O
Tax B
. O

Expression O
of O
ATF B
- I
2 I
in O
S O
. O
cerevisiae O
did O
not O
activate O
TRE B
- I
1 I
in O
the O
presence O
of O
Tax B
. O

This O
shows O
that O
in O
a O
eukaryotic O
nucleus O
, O
Tax B
specifically O
interacts O
with O
the O
basic B
domain I
- I
leucine I
zipper I
region I
of O
ATF B
- I
1 I
, O
CREB B
, O
and O
CREM B
. O

Phorbol O
ester O
treatment O
of O
monocytes O
inhibited O
IFN O
alpha O
- O
stimulated O
tyrosine O
phosphorylation O
of O
the O
transcription B
factors I
Stat1alpha B
, O
Stat2 B
, O
and O
Stat3 B
and O
of O
the O
tyrosine B
kinase I
Tyk2 B
but O
had O
no O
effect O
on O
IFN B
- I
gamma I
activation O
of O
Stat1alpha B
. O

Interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
- B
reporter I
gene I
behavior O
closely O
parallels O
the O
endogenous B
gene I
in O
response O
to O
T B
cell I
receptor I
and O
costimulatory O
signals O
. O

Interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
- B
reporter I
gene I
behavior O
closely O
parallels O
the O
endogenous B
gene I
in O
response O
to O
T B
cell I
receptor I
and O
costimulatory O
signals O
. O

The O
RAR B
- I
RXR I
as O
well O
as O
the O
RXR B
- I
RXR I
pathway O
is O
involved O
in O
signaling O
growth O
inhibition O
of O
human O
CD34 O
+ O
erythroid O
progenitor O
cells O
. O

The O
RAR B
- I
RXR I
as O
well O
as O
the O
RXR B
- I
RXR I
pathway O
is O
involved O
in O
signaling O
growth O
inhibition O
of O
human O
CD34 O
+ O
erythroid O
progenitor O
cells O
. O

Previous O
studies O
have O
shown O
that O
retinoic O
acid O
( O
RA O
) O
, O
similar O
to O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
can O
act O
as O
a O
bifunctional O
regulator O
of O
the O
growth O
of O
bone O
marrow O
progenitors O
, O
in O
that O
it O
can O
stimulate O
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
( O
GM O
- O
CSF O
) O
- O
or O
interleukin O
- O
3 O
( O
IL O
- O
3 O
) O
- O
induced O
GM O
colony O
formation O
, O
but O
potently O
inhibit O
G B
- I
CSF I
- O
induced O
growth O
. O

Previous O
studies O
have O
shown O
that O
retinoic O
acid O
( O
RA O
) O
, O
similar O
to O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
can O
act O
as O
a O
bifunctional O
regulator O
of O
the O
growth O
of O
bone O
marrow O
progenitors O
, O
in O
that O
it O
can O
stimulate O
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
( O
GM O
- O
CSF O
) O
- O
or O
interleukin O
- O
3 O
( O
IL O
- O
3 O
) O
- O
induced O
GM O
colony O
formation O
, O
but O
potently O
inhibit O
G B
- I
CSF I
- O
induced O
growth O
. O

At O
this O
concentration O
, O
Ro O
13 O
- O
7410 O
potently O
inhibited O
G B
- I
CSF I
- O
stimulated O
myeloid O
as O
well O
as O
SCF B
+ O
Epo B
- O
induced O
erythroid O
colony O
growth O
. O

At O
the O
same O
concentration O
, O
Ro O
25 O
- O
6603 O
and O
Ro O
25 O
- O
7386 O
had O
little O
or O
no O
effect O
on O
G B
- I
CSF I
- O
induced O
colony O
formation O
, O
whereas O
they O
inhibited O
75 O
% O
and O
53 O
% O
, O
respectively O
, O
of O
SCF B
+ O
Epo B
- O
stimulated O
BFU O
- O
E O
colony O
growth O
. O

Thus O
, O
the O
RAR B
- I
RXR I
response O
pathway O
can O
signal O
growth O
inhibition O
of O
normal O
bone O
marrow O
myeloid O
and O
erythroid O
progenitor O
cells O
. O

After O
treatment O
of O
APL O
cells O
with O
AM580 O
either O
alone O
or O
in O
combination O
with O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
, O
the O
compound O
induces O
granulocytic O
maturation O
, O
as O
assessed O
by O
determination O
of O
the O
levels O
of O
leukocyte B
alkaline I
phosphatase I
, I
CD11b I
, I
CD33 I
, I
and I
G I
- I
CSF I
receptor I
mRNA I
, O
at O
concentrations O
that O
are O
10 O
- O
to O
100 O
- O
fold O
lower O
than O
those O
of O
ATRA O
necessary O
to O
produce O
similar O
effects O
. O

These O
results O
show O
that O
AM580 O
is O
more O
powerful O
than O
ATRA O
in O
modulating O
the O
expression O
of O
differentiation O
antigens O
only O
in O
cells O
in O
which O
PML B
- I
RAR I
is O
present O
. O

Binding O
experiments O
, O
using O
COS O
- O
7 O
cells O
transiently O
transfected O
with O
PML B
- I
RAR I
and O
the O
normal O
RAR B
alpha I
, O
show O
that O
AM580 O
has O
a O
lower O
affinity O
than O
ATRA O
for O
both O
receptors O
. O

We O
conclude O
that O
a O
VDRE B
- I
binding I
protein I
( O
s O
) O
, O
distinct O
from O
IDBP B
and O
present O
in O
nuclear O
extract O
of O
cells O
from O
a O
prototypical O
vitamin O
D O
- O
resistant O
NWP O
, O
is O
capable O
of O
inhibiting O
normal O
VDR B
- I
RXR I
heterodimer O
binding O
to O
the O
VDRE B
. O

Although O
a O
role O
of O
p16 B
in O
this O
regulation O
has O
been O
presumed O
, O
there O
is O
no O
proof O
so O
far O
that O
loss O
of O
this O
tumor B
suppressor I
gene I
really O
affects O
E2F B
- O
mediated O
regulations O
. O

We O
have O
isolated O
a O
novel B
cDNA I
clone I
encoding O
interferon B
( I
IFN I
) I
consensus I
sequence I
- I
binding I
protein I
in O
adult O
T O
- O
cell O
leukemia O
cell O
line O
or O
activated O
T O
cells O
( O
ICSAT B
) O
; O
this O
protein O
is O
the O
human O
homolog O
of O
the O
recently O
cloned O
Pip B
/ I
LSIRF I
. O

We O
have O
isolated O
a O
novel B
cDNA I
clone I
encoding O
interferon B
( I
IFN I
) I
consensus I
sequence I
- I
binding I
protein I
in O
adult O
T O
- O
cell O
leukemia O
cell O
line O
or O
activated O
T O
cells O
( O
ICSAT B
) O
; O
this O
protein O
is O
the O
human O
homolog O
of O
the O
recently O
cloned O
Pip B
/ I
LSIRF I
. O

Here O
, O
we O
describe O
the O
effect O
of O
383 B
- I
bp I
( I
delta383 I
) I
and I
99 I
- I
bp I
( I
delta99 I
) I
sequences I
containing O
the O
PYBF B
- I
binding I
site I
on O
transcription O
from O
various O
globin O
and O
non O
- O
globin O
promoters O
, O
using O
a O
transient O
assay O
with O
the O
cat B
reporter I
gene I
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
, O
a O
cell O
line O
with O
abundant O
PYBF B
activity O
. O

DeltaSpi B
- I
B I
product O
was O
not O
able O
to O
bind O
DNA O
and O
was O
recovered O
in O
cytoplasmic O
cellular O
extracts O
. O

Both O
CIITA B
and O
Bob1 B
increase O
the O
expression O
from O
the O
DRA B
promoter I
, O
which O
is O
a O
prototypic O
class B
II I
promoter I
. O

The O
chromosome B
17 I
breakpoint I
was O
localized O
to O
intron B
2 I
of O
RARA B
by O
Southern O
blotting O
, O
and O
there O
was O
no O
evidence O
at O
the O
molecular O
level O
for O
rearrangement O
at O
PML B
locus I
. O

Cyclic O
AMP O
- B
responsive I
element I
- O
dependent O
activation O
of O
Epstein O
- O
Barr O
virus O
zebra B
promoter I
by O
human O
herpesvirus O
6 O
. O

Antibodies O
against O
CRE B
- I
binding I
( I
CREB I
) I
protein I
but O
not O
against O
c B
- I
Fos I
or O
c B
- I
Jun I
were O
able O
to O
supershift O
the O
DNA B
- I
protein I
complex I
, O
identifying O
the O
nature O
of O
the O
transcription B
factor I
which O
binds O
to O
ZII B
as O
a O
member O
of O
the O
CREB B
family I
of I
proteins I
. O

Antibodies O
against O
CRE B
- I
binding I
( I
CREB I
) I
protein I
but O
not O
against O
c B
- I
Fos I
or O
c B
- I
Jun I
were O
able O
to O
supershift O
the O
DNA B
- I
protein I
complex I
, O
identifying O
the O
nature O
of O
the O
transcription B
factor I
which O
binds O
to O
ZII B
as O
a O
member O
of O
the O
CREB B
family I
of I
proteins I
. O

The O
lymphoid B
- I
specific I
transcription I
factor I
Oct B
- I
2a I
is O
implicated O
in O
B O
cell O
- O
specific O
transcriptional O
activity O
via O
the O
octamer O
motif O
. O

Structure O
/ O
function O
analysis O
of O
various O
Oct B
- I
2a I
effector I
regions I
in O
the O
context O
of O
the O
GAL4 B
DNA I
- I
binding I
domain I
revealed O
that O
Oct B
- I
2a I
contains O
two O
functionally O
different O
activation B
domains I
at O
the O
N B
and I
the I
C I
termini I
. O

In O
this O
study O
we O
present O
a O
deletion O
analysis O
of O
the O
N B
- I
terminal I
region I
of O
Oct B
- I
2a I
to O
determine O
the O
minimal B
repression I
domain I
. O

In O
this O
study O
we O
present O
a O
deletion O
analysis O
of O
the O
N B
- I
terminal I
region I
of O
Oct B
- I
2a I
to O
determine O
the O
minimal B
repression I
domain I
. O

The O
possibility O
that O
Oct B
- I
2a I
can O
act O
as O
an O
activator O
and O
/ O
or O
a O
repressor O
may O
have O
important O
consequences O
for O
the O
function O
of O
Oct B
- I
2a I
in O
B O
cell O
differentiation O
and O
other O
developmental O
processes O
. O

The O
possibility O
that O
Oct B
- I
2a I
can O
act O
as O
an O
activator O
and O
/ O
or O
a O
repressor O
may O
have O
important O
consequences O
for O
the O
function O
of O
Oct B
- I
2a I
in O
B O
cell O
differentiation O
and O
other O
developmental O
processes O
. O

The O
first O
was O
to O
abruptly O
terminate O
tumor O
necrosis O
factor O
- O
induced O
NF B
- I
kappaB I
binding O
to O
the O
enhancer O
sequences O
in O
U1 O
monocytic O
cells O
, O
using O
a O
short O
pulse O
of O
exogenous B
tumor I
necrosis I
factor I
. O

Together O
, O
our O
results O
indicate O
that O
occupancy O
of O
the O
viral B
enhancer I
by O
NF B
- I
kappaB I
( I
p50 I
/ I
p65 I
) I
heterodimers I
is O
required O
for O
ongoing O
transcription O
of O
integrated O
HIV O
provirus O
in O
monocytes O
, O
even O
in O
cells O
chronically O
infected O
and O
permanently O
producing O
functional O
HIV B
Tat I
protein I
. O

Exogenous O
IL B
- I
2 I
, O
which O
restitutes O
the O
proliferative O
response O
of O
the O
anti O
- O
CD3 O
- O
and O
anti O
- O
CD28 O
- O
treated O
Rel O
- O
/ O
- O
T O
cells O
, O
restores O
production O
of O
IL O
- O
5 O
, O
TNF B
- I
alpha I
, O
and O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
3 I
and O
GM B
- I
CSF I
expression O
to O
approximately O
normal O
levels O
. O

Exogenous O
IL B
- I
2 I
, O
which O
restitutes O
the O
proliferative O
response O
of O
the O
anti O
- O
CD3 O
- O
and O
anti O
- O
CD28 O
- O
treated O
Rel O
- O
/ O
- O
T O
cells O
, O
restores O
production O
of O
IL O
- O
5 O
, O
TNF B
- I
alpha I
, O
and O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
3 I
and O
GM B
- I
CSF I
expression O
to O
approximately O
normal O
levels O
. O

Exogenous O
IL B
- I
2 I
, O
which O
restitutes O
the O
proliferative O
response O
of O
the O
anti O
- O
CD3 O
- O
and O
anti O
- O
CD28 O
- O
treated O
Rel O
- O
/ O
- O
T O
cells O
, O
restores O
production O
of O
IL O
- O
5 O
, O
TNF B
- I
alpha I
, O
and O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
3 I
and O
GM B
- I
CSF I
expression O
to O
approximately O
normal O
levels O
. O

Exogenous O
IL B
- I
2 I
, O
which O
restitutes O
the O
proliferative O
response O
of O
the O
anti O
- O
CD3 O
- O
and O
anti O
- O
CD28 O
- O
treated O
Rel O
- O
/ O
- O
T O
cells O
, O
restores O
production O
of O
IL O
- O
5 O
, O
TNF B
- I
alpha I
, O
and O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
3 I
and O
GM B
- I
CSF I
expression O
to O
approximately O
normal O
levels O
. O

Exogenous O
IL B
- I
2 I
, O
which O
restitutes O
the O
proliferative O
response O
of O
the O
anti O
- O
CD3 O
- O
and O
anti O
- O
CD28 O
- O
treated O
Rel O
- O
/ O
- O
T O
cells O
, O
restores O
production O
of O
IL O
- O
5 O
, O
TNF B
- I
alpha I
, O
and O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
3 I
and O
GM B
- I
CSF I
expression O
to O
approximately O
normal O
levels O
. O

These O
findings O
establish O
that O
Rel B
can O
function O
as O
an O
activator O
or O
repressor O
of O
gene O
expression O
and O
is O
required O
by O
T O
lymphocytes O
for O
production O
of O
IL B
- I
3 I
and O
GM B
- I
CSF I
. O

These O
findings O
establish O
that O
Rel B
can O
function O
as O
an O
activator O
or O
repressor O
of O
gene O
expression O
and O
is O
required O
by O
T O
lymphocytes O
for O
production O
of O
IL B
- I
3 I
and O
GM B
- I
CSF I
. O

Nuclear O
appearance O
of O
a O
factor O
that O
binds O
the O
CD28 B
response I
element I
within O
the O
interleukin B
- I
2 I
enhancer I
correlates O
with O
interleukin B
- I
2 I
production O
. O

Nuclear O
appearance O
of O
a O
factor O
that O
binds O
the O
CD28 B
response I
element I
within O
the O
interleukin B
- I
2 I
enhancer I
correlates O
with O
interleukin B
- I
2 I
production O
. O

These O
results O
indicate O
that O
mitogenic O
combinations O
of O
T O
cell O
activation O
signals O
are O
integrated O
at O
the O
level O
of O
NF B
- I
MATp35 I
induction O
. O

Two O
explanations O
for O
hyporesponsiveness O
of O
the O
human B
iNOS I
promoter I
to O
LPS O
+ O
/ O
- O
IFN B
- I
gamma I
were O
found O
: O
( O
1 O
) O
multiple O
inactivating O
nucleotide O
substitutions O
in O
the O
human O
counterpart O
of O
the O
enhancer B
element I
that O
has O
been O
shown O
to O
regulate O
LPS O
/ O
IFN B
- I
gamma I
induced O
expression O
of O
the O
mouse B
iNOS I
gene I
; O
and O
( O
2 O
) O
and O
absence O
of O
one O
or O
more O
nuclear B
factors I
in O
human O
macrophages O
( O
e O
. O
g O
. O
, O
an O
LPS B
- I
inducible I
nuclear I
factor I
- I
kappa I
B I
/ I
Rel I
complex I
) O
, O
that O
is O
( O
are O
) O
required O
for O

Two O
explanations O
for O
hyporesponsiveness O
of O
the O
human B
iNOS I
promoter I
to O
LPS O
+ O
/ O
- O
IFN B
- I
gamma I
were O
found O
: O
( O
1 O
) O
multiple O
inactivating O
nucleotide O
substitutions O
in O
the O
human O
counterpart O
of O
the O
enhancer B
element I
that O
has O
been O
shown O
to O
regulate O
LPS O
/ O
IFN B
- I
gamma I
induced O
expression O
of O
the O
mouse B
iNOS I
gene I
; O
and O
( O
2 O
) O
and O
absence O
of O
one O
or O
more O
nuclear B
factors I
in O
human O
macrophages O
( O
e O
. O
g O
. O
, O
an O
LPS B
- I
inducible I
nuclear I
factor I
- I
kappa I
B I
/ I
Rel I
complex I
) O
, O
that O
is O
( O
are O
) O
required O
for O

Two O
explanations O
for O
hyporesponsiveness O
of O
the O
human B
iNOS I
promoter I
to O
LPS O
+ O
/ O
- O
IFN B
- I
gamma I
were O
found O
: O
( O
1 O
) O
multiple O
inactivating O
nucleotide O
substitutions O
in O
the O
human O
counterpart O
of O
the O
enhancer B
element I
that O
has O
been O
shown O
to O
regulate O
LPS O
/ O
IFN B
- I
gamma I
induced O
expression O
of O
the O
mouse B
iNOS I
gene I
; O
and O
( O
2 O
) O
and O
absence O
of O
one O
or O
more O
nuclear B
factors I
in O
human O
macrophages O
( O
e O
. O
g O
. O
, O
an O
LPS B
- I
inducible I
nuclear I
factor I
- I
kappa I
B I
/ I
Rel I
complex I
) O
, O
that O
is O
( O
are O
) O
required O
for O

Two O
explanations O
for O
hyporesponsiveness O
of O
the O
human B
iNOS I
promoter I
to O
LPS O
+ O
/ O
- O
IFN B
- I
gamma I
were O
found O
: O
( O
1 O
) O
multiple O
inactivating O
nucleotide O
substitutions O
in O
the O
human O
counterpart O
of O
the O
enhancer B
element I
that O
has O
been O
shown O
to O
regulate O
LPS O
/ O
IFN B
- I
gamma I
induced O
expression O
of O
the O
mouse B
iNOS I
gene I
; O
and O
( O
2 O
) O
and O
absence O
of O
one O
or O
more O
nuclear B
factors I
in O
human O
macrophages O
( O
e O
. O
g O
. O
, O
an O
LPS B
- I
inducible I
nuclear I
factor I
- I
kappa I
B I
/ I
Rel I
complex I
) O
, O
that O
is O
( O
are O
) O
required O
for O

Large O
amounts O
of O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
and O
significant O
quantities O
of O
NF B
- I
AT I
were O
induced O
in O
SEA O
- O
activated O
CD4 O
+ O
spleen O
T O
cells O
, O
whereas O
Oct O
- O
1 O
and O
Oct O
- O
2 O
DNA O
binding O
activity O
was O
similar O
in O
both O
resting O
and O
activated O
T O
cells O
. O

Large O
amounts O
of O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
and O
significant O
quantities O
of O
NF B
- I
AT I
were O
induced O
in O
SEA O
- O
activated O
CD4 O
+ O
spleen O
T O
cells O
, O
whereas O
Oct O
- O
1 O
and O
Oct O
- O
2 O
DNA O
binding O
activity O
was O
similar O
in O
both O
resting O
and O
activated O
T O
cells O
. O

Although O
prior O
studies O
suggest O
a O
role O
for O
protein B
tyrosine I
kinases I
and O
phosphatases O
in O
Fas B
signaling O
, O
we O
report O
here O
that O
Fas O
ligation O
induces O
apoptosis O
in O
T O
cells O
deficient O
in O
either O
CD45 B
or O
Lck B
. O

These O
data O
indicate O
that O
, O
in O
contrast O
to O
most O
LPS O
effects O
, O
AP B
- I
1 I
, O
but O
not O
nuclear B
factor I
- I
kappaB I
, O
mediates O
LPS O
induction O
of O
collagenase B
transcription O
in O
macrophagelike O
cells O
. O

These O
results O
suggest O
that O
LPS O
activation O
of O
JNK B
in O
monocyte O
/ O
macrophage O
cells O
is O
a O
CD14 O
- O
and O
protein O
tyrosine O
phosphorylation O
- O
dependent O
event O
that O
may O
mediate O
the O
early O
activation O
of O
AP B
- I
1 I
in O
regulating O
LPS O
- O
triggered O
gene O
induction O
. O

A O
cell B
type I
- I
specific I
enhancer I
in O
the O
human B
B7 I
. I
1 I
gene I
regulated O
by O
NF B
- I
kappaB I
. O

This O
183 B
- I
bp I
region I
was O
both O
cell O
type O
specific O
and O
responsive O
to O
two O
distinct O
stimuli O
, O
lipopolysaccharide O
and O
dibutyryl O
cAMP O
, O
known O
to O
regulate O
B7 B
. I
1 I
expression O
. O

This O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
regulatory B
elements I
that O
control O
expression O
of O
a O
gene O
encoding O
a O
B7 B
costimulatory I
molecule I
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin B
carrier I
enzymes I
E214K B
, O
E220K B
, O
or O
E232K B
in O
the O
presence O
of O
the O
ubiquitin B
- I
activating I
enzyme I
, O
E1 B
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin B
carrier I
enzymes I
E214K B
, O
E220K B
, O
or O
E232K B
in O
the O
presence O
of O
the O
ubiquitin B
- I
activating I
enzyme I
, O
E1 B
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin B
carrier I
enzymes I
E214K B
, O
E220K B
, O
or O
E232K B
in O
the O
presence O
of O
the O
ubiquitin B
- I
activating I
enzyme I
, O
E1 B
. O

We O
have O
also O
characterized O
the O
genomic B
mBob1 I
clone I
. O

mBob1 B
interacts O
with O
the O
octamer B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
stimulates O
transcription O
mediated O
by O
these O
factors O
. O

mBob1 B
interacts O
with O
the O
octamer B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
stimulates O
transcription O
mediated O
by O
these O
factors O
. O

mBob1 B
interacts O
with O
the O
octamer B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
stimulates O
transcription O
mediated O
by O
these O
factors O
. O

Northern O
blot O
analysis O
as O
well O
as O
Ab O
blocking O
and O
cytokine B
secretion O
studies O
indicated O
that O
the O
induction O
of O
either O
endogenous B
TNF I
- I
alpha I
or O
IL B
- I
10 I
was O
not O
involved O
in O
the O
cooperativity O
, O
nor O
was O
an O
up O
- O
regulation O
of O
TNF B
- I
alpha I
receptors I
. O

This O
raises O
the O
intriguing O
possibility O
that O
physical O
association O
of O
the O
HsN3 B
proteasome I
subunit I
with O
HTLV B
- I
I I
Tax I
coupled O
with O
the O
independent O
interaction O
of O
Tax B
with O
either O
p100 O
or O
p65 O
- O
I B
kappa I
B I
alpha I
targets O
these O
cytoplasmic B
NF I
- I
kappa I
B I
/ I
Rel I
complexes I
to O
the O
proteasome B
for O
processing O
. O

Basement O
membrane O
immunoreactivity O
for O
type B
IV I
collagen I
and O
laminin B
was O
discontinuous O
in O
most O
examples O
of O
IDC O
regardless O
of O
type O
, O
with O
a O
trend O
toward O
more O
intense O
staining O
in O
comedo O
than O
in O
noncomedo O
carcinomas O
. O

Paclitaxel O
and O
other O
drugs O
that O
disturb O
microtubule B
dynamics O
kill O
cells O
in O
a O
Fas B
/ B
Fas I
ligand I
( O
FasL B
) O
- O
dependent O
manner O
; O
antibody O
to O
FasL B
inhibits O
paclitaxel O
- O
induced O
apoptosis O
. O

The O
effects O
of O
Bcl B
- I
2 I
can O
be O
overcome O
, O
at O
least O
partially O
, O
through O
phosphorylation O
of O
Bcl B
- I
2 I
. O

The O
effects O
of O
Bcl B
- I
2 I
can O
be O
overcome O
, O
at O
least O
partially O
, O
through O
phosphorylation O
of O
Bcl B
- I
2 I
. O

Regulatory O
effects O
of O
interleukin B
- I
11 I
during O
acute O
lung O
inflammatory O
injury O
. O

Recently O
, O
we O
and O
others O
have O
shown O
that O
thrombopoietin B
induces O
rapid O
tyrosine O
phosphorylation O
of O
Jak2 B
and O
other O
proteins O
in O
human O
platelets O
and O
BaF3 O
cells O
, O
genetically O
engineered O
to O
express O
c B
- I
Mpl I
, O
a O
receptor O
for O
thrombopoietin B
. O

Thus O
, O
our O
data O
indicate O
that O
Stat3 B
and O
Stat5 B
may O
be O
involved O
in O
signal O
transduction O
after O
ligand O
binding O
to O
c B
- I
Mpl I
and O
that O
this O
event O
may O
have O
a O
role O
in O
megakaryopoiesis O
/ O
thrombopoiesis O
or O
possibly O
a O
mature O
platelet O
function O
such O
as O
aggregation O
. O

IL B
- I
4 I
activates O
gene O
expression O
by O
inducing O
tyrosine O
phosphorylation O
, O
homodimerization O
, O
and O
nuclear O
translocation O
of O
the O
latent B
transcription I
factor I
, O
STAT6 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
6 I
) O
. O

IL B
- I
4 I
activates O
gene O
expression O
by O
inducing O
tyrosine O
phosphorylation O
, O
homodimerization O
, O
and O
nuclear O
translocation O
of O
the O
latent B
transcription I
factor I
, O
STAT6 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
6 I
) O
. O

Because O
STAT6 B
activation O
is O
essential O
for O
IL B
- I
4 I
- O
induced O
gene O
expression O
, O
we O
examined O
the O
ability O
of O
type O
I O
and O
type O
II O
IFNs B
to O
regulate O
activation O
of O
STAT6 B
by O
IL B
- I
4 I
in O
primary O
human O
monocytes O
. O

Because O
STAT6 B
activation O
is O
essential O
for O
IL B
- I
4 I
- O
induced O
gene O
expression O
, O
we O
examined O
the O
ability O
of O
type O
I O
and O
type O
II O
IFNs B
to O
regulate O
activation O
of O
STAT6 B
by O
IL B
- I
4 I
in O
primary O
human O
monocytes O
. O

One O
- O
hybrid O
assays O
in O
yeast B
isolated I
NF I
- I
ATp I
as O
an O
E1 B
binding I
protein I
, O
and O
transfection O
of O
NF B
- I
ATp I
into O
T O
and O
B O
cell O
lines O
strongly O
enhanced O
the O
activation B
- I
dependent I
SCM I
- I
1 I
promoter O
activity O
. O

One O
- O
hybrid O
assays O
in O
yeast B
isolated I
NF I
- I
ATp I
as O
an O
E1 B
binding I
protein I
, O
and O
transfection O
of O
NF B
- I
ATp I
into O
T O
and O
B O
cell O
lines O
strongly O
enhanced O
the O
activation B
- I
dependent I
SCM I
- I
1 I
promoter O
activity O
. O

Consistent O
with O
the O
role O
of O
NF B
- I
kappaB I
in O
mediating O
dopamine O
responsiveness O
, O
the O
proteasome O
inhibitor O
MG132 O
abolished O
dopamine O
- O
induced O
transcriptional O
activation O
. O

This O
may O
explain O
the O
difference O
between O
IL B
- I
10 I
and O
IFN B
- I
gamma I
in O
biological O
activity O
, O
and O
the O
inhibitory O
effect O
of O
IL B
- I
10 I
on O
IFN B
- I
gamma I
activities O
. O

This O
may O
explain O
the O
difference O
between O
IL B
- I
10 I
and O
IFN B
- I
gamma I
in O
biological O
activity O
, O
and O
the O
inhibitory O
effect O
of O
IL B
- I
10 I
on O
IFN B
- I
gamma I
activities O
. O

This O
may O
explain O
the O
difference O
between O
IL B
- I
10 I
and O
IFN B
- I
gamma I
in O
biological O
activity O
, O
and O
the O
inhibitory O
effect O
of O
IL B
- I
10 I
on O
IFN B
- I
gamma I
activities O
. O

This O
may O
explain O
the O
difference O
between O
IL B
- I
10 I
and O
IFN B
- I
gamma I
in O
biological O
activity O
, O
and O
the O
inhibitory O
effect O
of O
IL B
- I
10 I
on O
IFN B
- I
gamma I
activities O
. O

To O
investigate O
a O
potential O
role O
of O
E2F B
- I
1 I
in O
differentiation O
, O
we O
assayed O
the O
ability O
of O
megakaryocytes O
to O
form O
platelets O
in O
an O
in O
vivo O
transgenic O
model O
. O

A O
recent O
sib O
- O
pair O
analysis O
revealed O
a O
tight O
linkage O
between O
markers O
on O
5q31 B
. I
1 I
and O
a O
major B
susceptibility I
gene I
controlling O
total O
serum O
IgE B
levels O
. O

A O
recent O
sib O
- O
pair O
analysis O
revealed O
a O
tight O
linkage O
between O
markers O
on O
5q31 B
. I
1 I
and O
a O
major B
susceptibility I
gene I
controlling O
total O
serum O
IgE B
levels O
. O

The O
mineralocorticoid O
aldosterone O
exerted O
a O
significant O
decrease O
in O
LPS O
- O
induced O
monocyte O
IL B
- I
1ra I
secretion O
in O
vitro O
, O
which O
was O
blocked O
by O
coincubation O
with O
spironolactone O
. O

Moreover O
, O
we O
provide O
evidence O
that O
, O
in O
addition O
to O
a O
glucocorticoid B
receptor I
- O
mediated O
effect O
, O
the O
mineralocorticoid B
receptor I
is O
involved O
in O
the O
inhibition O
of O
monocyte O
IL B
- I
1ra I
secretion O
by O
cortisol O
. O

Here O
, O
we O
have O
readdressed O
the O
issue O
of O
CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
the O
72 B
- I
kDa I
major I
immediate I
- I
early I
protein I
( O
IE B
- I
1 I
) O
, O
which O
is O
nonstructural O
but O
is O
found O
very O
early O
and O
throughout O
the O
replicative O
cycle O
. O

In O
summary O
, O
our O
results O
suggest O
that O
IE B
- I
1 I
is O
far O
more O
important O
as O
a O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
target O
than O
current O
opinion O
suggests O
. O

They O
also O
indicate O
that O
abundant O
TCL1 B
expression O
in O
quiescent O
mantle O
zone O
B O
cells O
is O
down O
- O
regulated O
in O
activated O
germinal O
center O
follicular O
B O
cells O
in O
parallel O
to O
the O
known O
expression O
pattern O
of O
BCL B
- I
2 I
. O

Here O
, O
we O
report O
a O
model O
of O
CD28 B
costimulation O
using O
PMA O
plus O
the O
natural B
ligand I
CD80 I
that O
resulted O
in O
very O
limited O
stimulation O
of O
IL B
- I
2 I
, O
as O
evidenced O
by O
both O
cytokine B
production O
and O
IL B
- I
2 I
promoter I
stimulation O
. O

Here O
, O
we O
report O
a O
model O
of O
CD28 B
costimulation O
using O
PMA O
plus O
the O
natural B
ligand I
CD80 I
that O
resulted O
in O
very O
limited O
stimulation O
of O
IL B
- I
2 I
, O
as O
evidenced O
by O
both O
cytokine B
production O
and O
IL B
- I
2 I
promoter I
stimulation O
. O

In O
transient O
- O
transfection O
assays O
, O
a O
Qp B
- I
CAT I
reporter I
was O
activated O
by O
cotransfected O
JAK B
- I
1 I
and O
by O
treatment O
of O
cells O
with O
the O
cytokine B
IL B
- I
6 I
. O

In O
transient O
- O
transfection O
assays O
, O
a O
Qp B
- I
CAT I
reporter I
was O
activated O
by O
cotransfected O
JAK B
- I
1 I
and O
by O
treatment O
of O
cells O
with O
the O
cytokine B
IL B
- I
6 I
. O

Reactive O
oxygen O
intermediate O
- O
release O
of O
fibre O
- O
exposed O
monocytes O
increases O
inflammatory O
cytokine B
- I
mRNA I
level O
, O
protein B
tyrosine I
kinase I
and O
NF B
- I
kappaB I
activity O
in O
co O
- O
cultured O
bronchial O
epithelial O
cells O
( O
BEAS O
- O
2B O
) O
. O

Reactive O
oxygen O
intermediate O
- O
release O
of O
fibre O
- O
exposed O
monocytes O
increases O
inflammatory O
cytokine B
- I
mRNA I
level O
, O
protein B
tyrosine I
kinase I
and O
NF B
- I
kappaB I
activity O
in O
co O
- O
cultured O
bronchial O
epithelial O
cells O
( O
BEAS O
- O
2B O
) O
. O

Reactive O
oxygen O
intermediate O
- O
release O
of O
fibre O
- O
exposed O
monocytes O
increases O
inflammatory O
cytokine B
- I
mRNA I
level O
, O
protein B
tyrosine I
kinase I
and O
NF B
- I
kappaB I
activity O
in O
co O
- O
cultured O
bronchial O
epithelial O
cells O
( O
BEAS O
- O
2B O
) O
. O

Taken O
together O
, O
these O
observations O
suggest O
that O
mitogenic O
activation O
, O
mediated O
primarily O
through O
the O
NF B
kappa I
B I
enhancer I
, O
is O
susceptible O
to O
CD8 B
- O
mediated O
inhibition O
, O
however O
, O
inhibition O
of O
Tat B
- O
mediated O
activation O
may O
rely O
upon O
a O
different O
pathway O
that O
is O
NFAT B
- I
1 I
dependent O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl B
- I
xs I
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl B
- I
xs I
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl B
- I
xs I
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl B
- I
xs I
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

We O
find O
that O
recruitment O
of O
EKLF B
to O
5 B
' I
HS2 I
requires O
the O
TATA B
box I
, O
but O
recruitment O
to O
5 B
' I
HS3 I
depends O
on O
the O
CACCC O
and O
TATA B
boxes I
of O
the O
beta B
- I
globin I
promoter I
. O

We O
find O
that O
recruitment O
of O
EKLF B
to O
5 B
' I
HS2 I
requires O
the O
TATA B
box I
, O
but O
recruitment O
to O
5 B
' I
HS3 I
depends O
on O
the O
CACCC O
and O
TATA B
boxes I
of O
the O
beta B
- I
globin I
promoter I
. O

We O
have O
found O
that O
the O
recruitment O
of O
EKLF B
to O
5 B
' I
HS3 I
depends O
on O
the O
presence O
of O
5 B
' I
HS2 I
in O
cis O
, O
but O
the O
recruitment O
to O
5 B
' I
HS2 I
does O
not O
depend O
on O
5 B
' I
HS3 I
. O

We O
have O
found O
that O
the O
recruitment O
of O
EKLF B
to O
5 B
' I
HS3 I
depends O
on O
the O
presence O
of O
5 B
' I
HS2 I
in O
cis O
, O
but O
the O
recruitment O
to O
5 B
' I
HS2 I
does O
not O
depend O
on O
5 B
' I
HS3 I
. O

We O
have O
found O
that O
the O
recruitment O
of O
EKLF B
to O
5 B
' I
HS3 I
depends O
on O
the O
presence O
of O
5 B
' I
HS2 I
in O
cis O
, O
but O
the O
recruitment O
to O
5 B
' I
HS2 I
does O
not O
depend O
on O
5 B
' I
HS3 I
. O

We O
have O
found O
that O
the O
recruitment O
of O
EKLF B
to O
5 B
' I
HS3 I
depends O
on O
the O
presence O
of O
5 B
' I
HS2 I
in O
cis O
, O
but O
the O
recruitment O
to O
5 B
' I
HS2 I
does O
not O
depend O
on O
5 B
' I
HS3 I
. O

The O
resulting O
diminished O
phosphorylation O
of O
c B
- I
Jun I
and O
JunD B
at O
their O
NH B
( I
2 I
) I
- I
termini I
decreases O
the O
ability O
of O
these O
nuclear O
proteins O
to O
autostimulate O
the O
expression O
of O
the O
c B
- I
Jun I
and I
JunD I
genes I
, O
thus O
leading O
to O
lower O
production O
of O
c B
- I
Jun I
and O
JunD B
. O

The O
resulting O
diminished O
phosphorylation O
of O
c B
- I
Jun I
and O
JunD B
at O
their O
NH B
( I
2 I
) I
- I
termini I
decreases O
the O
ability O
of O
these O
nuclear O
proteins O
to O
autostimulate O
the O
expression O
of O
the O
c B
- I
Jun I
and I
JunD I
genes I
, O
thus O
leading O
to O
lower O
production O
of O
c B
- I
Jun I
and O
JunD B
. O

Recent O
data O
show O
that O
TCR B
/ I
CD3 I
stimulation O
induces O
activation O
of O
Stat5 B
in O
murine O
T O
cells O
. O

CD40 B
signaling O
activates O
downstream B
effectors I
, O
including O
the O
tyrosine B
protein I
kinase I
, O
Lyn B
, O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( O
PI B
- I
3 I
kinase I
) O
, O
and O
the O
transcription O
factor O
, O
NF B
- I
kappa I
B I
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

Induced O
MIP B
- I
1alpha I
expression O
and O
secretion O
in O
PMA O
/ O
PHA O
stimulated O
tax O
transfected O
cells O
correlate O
with O
the O
noninduction O
of O
MNP B
- I
1 I
transcription B
factor I
, O
which O
is O
intimately O
involved O
in O
downmodulating O
the O
MIP B
- I
1alpha I
gene I
. O

Induced O
MIP B
- I
1alpha I
expression O
and O
secretion O
in O
PMA O
/ O
PHA O
stimulated O
tax O
transfected O
cells O
correlate O
with O
the O
noninduction O
of O
MNP B
- I
1 I
transcription B
factor I
, O
which O
is O
intimately O
involved O
in O
downmodulating O
the O
MIP B
- I
1alpha I
gene I
. O

The O
other O
major O
subpopulation O
expressing O
the O
CD4 B
receptor I
, O
namely O
, O
the O
double O
- O
positive O
( O
DP O
) O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
CD3 O
( O
+ O
/ O
- O
) O
thymocytes O
, O
despite O
the O
entry O
of O
the O
virus O
, O
do O
not O
produce O
a O
significant O
level O
of O
virus O
, O
presumably O
because O
they O
are O
unresponsive O
to O
TNF B
and O
IL B
- I
7 I
. O

MBP B
over O
the O
concentration O
range O
of O
0 O
. O
1 O
to O
10 O
microM O
stimulated O
the O
release O
of O
up O
to O
approximately O
8 O
ng O
/ O
ml O
IL B
- I
8 I
. O

MBP B
also O
induced O
transient O
increases O
in O
mRNA B
for O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
- I
1alpha I
and O
MIP B
- I
1beta I
, O
but O
did O
not O
stimulate O
the O
release O
of O
either O
chemokine B
. O

A O
high O
- O
affinity O
calcineurin B
- O
binding O
peptide O
was O
selected O
from O
combinatorial O
peptide O
libraries O
based O
on O
the O
calcineurin B
docking I
motif I
of O
NFAT B
. O

Substitution O
of O
the O
optimized O
peptide O
sequence O
into O
the O
natural O
calcineurin B
docking I
site I
increased O
the O
calcineurin B
responsiveness O
of O
NFAT B
. O

We O
have O
investigated O
mechanisms O
and O
consequences O
of O
STAT5 B
activation O
through O
the O
human B
IL I
- I
4 I
receptor I
( O
IL B
- I
4R I
) O
. O

By O
functionally O
expressing O
receptor B
mutants I
in O
the O
murine O
pro O
- O
B O
cell O
line O
Ba O
/ O
F3 O
, O
we O
could O
show O
that O
phosphorylated O
tyrosine O
residues O
within O
the O
IL B
- I
4R I
alpha I
chain I
are O
dispensable O
for O
IL B
- I
4 I
- O
induced O
STAT5 B
activity O
. O

Immunoprecipitation O
of O
epitope B
- I
labeled I
BKO I
demonstrated O
for O
the O
formation O
of O
a O
tight O
complex O
with O
endogenous B
B I
subunit I
in O
Jurkat O
cells O
, O
consistent O
with O
an O
inhibitory O
mechanism O
that O
involves O
the O
sequestration O
of O
the O
B B
subunit I
. O

RNA B
was O
extracted O
by O
phenol O
/ O
chloroform O
and O
c B
- I
fos I
expression O
was O
analyzed O
by O
PCR O
assisted O
mRNA O
assay O
. O

A O
significant O
2 O
- O
4 O
fold O
increase O
of O
c B
- I
fos I
expression O
was O
observed O
within O
30 O
min O
of O
stimulation O
with O
IL B
- I
10 I
( O
p O
< O
0 O
. O
01 O
) O
. O

A O
significant O
2 O
- O
4 O
fold O
increase O
of O
c B
- I
fos I
expression O
was O
observed O
within O
30 O
min O
of O
stimulation O
with O
IL B
- I
10 I
( O
p O
< O
0 O
. O
01 O
) O
. O

Since O
this O
is O
the O
first O
report O
on O
IL B
- I
10 I
induced O
signal O
transduction O
, O
these O
data O
may O
help O
to O
identify O
the O
intracellular O
mechanisms O
by O
which O
IL B
- I
10 I
stimulates O
human O
B O
- O
cells O
. O

Since O
this O
is O
the O
first O
report O
on O
IL B
- I
10 I
induced O
signal O
transduction O
, O
these O
data O
may O
help O
to O
identify O
the O
intracellular O
mechanisms O
by O
which O
IL B
- I
10 I
stimulates O
human O
B O
- O
cells O
. O

Peroxisome B
proliferator I
- I
activated I
receptors I
( O
PPARs B
) O
, O
members O
of O
the O
nuclear B
receptor I
superfamily I
of O
transcription B
factors I
, O
are O
activated O
by O
fatty O
acid O
metabolites O
, O
peroxisome O
proliferators O
, O
and O
thiazolidinediones O
and O
are O
now O
recognized O
as O
important O
mediators O
in O
the O
inflammatory O
response O
. O

Expression O
of O
wild B
- I
type I
SHP1 I
had O
a O
very O
small O
effect O
on O
the O
TCR O
- O
induced O
tyrosine O
phosphorylation O
of O
ZAP B
- I
70 I
and O
Syk B
, O
even O
when O
SHP1 B
was O
overexpressed O
20 O
- O
100 O
- O
fold O
over O
endogenous B
SHP1 I
. O

However O
, O
the O
two O
SH2 B
domains I
of O
SHP1 B
did O
not O
facilitate O
its O
recognition O
of O
ZAP B
- I
70 I
and O
Syk B
as O
substrates O
in O
intact O
cells O
. O

In O
the O
cell O
line O
HT93A O
, O
which O
is O
capable O
of O
differentiating O
towards O
both O
the O
eosinophil O
and O
neutrophil O
lineages O
in O
response O
to O
retinoic O
acid O
( O
RA O
) O
, O
C B
/ I
EBPalpha I
mRNA I
expression O
decreased O
significantly O
concomitant O
with O
eosinophilic O
and O
neutrophilic O
differentiation O
, O
whereas O
C B
/ I
EBPbeta I
expression O
was O
markedly O
increased O
. O

Furthermore O
, O
we O
have O
demonstrated O
that O
both O
C B
/ I
EBPbeta I
and O
GATA B
- I
1 I
can O
bind O
simultaneously O
to O
the O
C O
/ O
EBP O
- O
and O
GATA B
- I
binding I
sites I
in O
the O
MBP B
promoter I
. O

Furthermore O
, O
we O
have O
demonstrated O
that O
both O
C B
/ I
EBPbeta I
and O
GATA B
- I
1 I
can O
bind O
simultaneously O
to O
the O
C O
/ O
EBP O
- O
and O
GATA B
- I
binding I
sites I
in O
the O
MBP B
promoter I
. O

Role O
of O
the O
camp B
response I
element I
site I
in O
mediating O
repression O
by O
the O
upstream B
regulatory I
region I
. O

DNase B
I I
footprinting O
identified O
several O
protected O
areas O
including O
Sp1 B
, I
Sp1 I
/ I
AP I
- I
2 I
, I
and I
cAMP I
response I
element I
( I
CRE I
) I
binding I
sites I
within O
the O
201 O
- O
bp O
core O
promoter O
region O
and O
Sp1 B
, I
NRE I
- I
2a I
, I
TCF I
- I
1 I
/ I
LEF I
- I
1 I
, I
and I
Sp1 I
/ I
NF I
- I
AT I
binding I
sites I
in O
the O
upstream B
regulatory I
region I
. O

Electrophoretic O
mobility O
shift O
assay O
analysis O
of O
proteins O
binding O
to O
the O
CRE B
site I
identified O
both O
ATF B
- I
1 I
and O
ATF B
- I
2 I
in O
Jurkat O
cells O
. O

Electrophoretic O
mobility O
shift O
assay O
analysis O
of O
proteins O
binding O
to O
the O
CRE B
site I
identified O
both O
ATF B
- I
1 I
and O
ATF B
- I
2 I
in O
Jurkat O
cells O
. O

These O
foci O
, O
which O
were O
preferentially O
found O
adjacent O
to O
nucleoli O
or O
at O
the O
nuclear O
periphery O
, O
did O
not O
represent O
sites O
of O
active O
transcription O
or O
binding O
of O
GATA B
- I
1 I
to O
consensus B
sites I
in O
the O
beta B
- I
globin I
loci I
. O

Putative B
steroid I
binding I
domain I
of O
the O
human B
mineralocorticoid I
receptor I
, O
expressed O
in O
E O
. O
coli O
in O
the O
presence O
of O
heat B
shock I
proteins I
shows O
typical O
native O
receptor O
characteristics O
. O

Putative B
steroid I
binding I
domain I
of O
the O
human B
mineralocorticoid I
receptor I
, O
expressed O
in O
E O
. O
coli O
in O
the O
presence O
of O
heat B
shock I
proteins I
shows O
typical O
native O
receptor O
characteristics O
. O

In O
this O
study O
, O
we O
investigate O
the O
role O
of O
TNFalpha B
- O
inducible O
reactive O
oxygen O
species O
( O
ROS O
) O
in O
IL B
- I
8 I
expression O
by O
` O
` O
monocyte O
- O
like O
' O
' O
U937 O
histiocytic O
lymphoma O
cells O
. O

These O
data O
indicate O
that O
TNFalpha B
induces O
a O
delayed O
ROS O
- O
dependent O
signalling O
pathway O
that O
is O
required O
for O
NF B
- I
kappaB I
transcriptional O
activation O
and O
is O
separable O
from O
that O
required O
for O
its O
nuclear O
translocation O
. O

Protein B
kinase I
C I
and O
calcineurin B
synergize O
to O
activate O
IkappaB B
kinase I
and O
NF B
- I
kappaB I
in O
T O
lymphocytes O
. O

Protein B
kinase I
C I
and O
calcineurin B
synergize O
to O
activate O
IkappaB B
kinase I
and O
NF B
- I
kappaB I
in O
T O
lymphocytes O
. O

These O
findings O
indicate O
that O
B29 B
gene I
expression O
is O
controlled O
by O
the O
complex O
interplay O
of O
positive O
and O
negative B
regulatory I
elements I
. O

A O
factor O
in O
bovine O
colostrum O
( O
colostrum B
inhibitory I
factor I
, O
CIF B
) O
inhibits O
interleukin B
2 I
( O
IL2 B
) O
production O
in O
activated O
T O
helper O
cells O
by O
blocking O
the O
accumulation O
of O
IL2 B
mRNA I
. O

The O
NFAT B
- I
controlled I
luciferase I
gene I
system I
distinguishes O
CIF B
from O
other O
T O
cell O
inhibitory O
activities O
present O
in O
colostrum O
, O
in O
particular O
, O
TGF B
beta I
1 I
and O
TGF B
beta I
2 I
and O
the O
glucocorticoids O
. O

The O
NFAT B
- I
controlled I
luciferase I
gene I
system I
distinguishes O
CIF B
from O
other O
T O
cell O
inhibitory O
activities O
present O
in O
colostrum O
, O
in O
particular O
, O
TGF B
beta I
1 I
and O
TGF B
beta I
2 I
and O
the O
glucocorticoids O
. O

Using O
a O
combination O
of O
bacterial O
motility O
assays O
in O
platelet O
extracts O
with O
Escherichia O
coli O
expressing O
the O
Shigella B
IcsA I
protein I
and O
in O
vitro O
analysis O
of O
reconstituted O
systems O
from O
purified B
proteins I
, O
we O
show O
here O
that O
the O
bacterial B
protein I
IcsA I
binds O
N B
- I
WASP I
and O
activates O
it O
in O
a O
Cdc42 B
- O
like O
fashion O
. O

Using O
a O
combination O
of O
bacterial O
motility O
assays O
in O
platelet O
extracts O
with O
Escherichia O
coli O
expressing O
the O
Shigella B
IcsA I
protein I
and O
in O
vitro O
analysis O
of O
reconstituted O
systems O
from O
purified B
proteins I
, O
we O
show O
here O
that O
the O
bacterial B
protein I
IcsA I
binds O
N B
- I
WASP I
and O
activates O
it O
in O
a O
Cdc42 B
- O
like O
fashion O
. O

Using O
a O
combination O
of O
bacterial O
motility O
assays O
in O
platelet O
extracts O
with O
Escherichia O
coli O
expressing O
the O
Shigella B
IcsA I
protein I
and O
in O
vitro O
analysis O
of O
reconstituted O
systems O
from O
purified B
proteins I
, O
we O
show O
here O
that O
the O
bacterial B
protein I
IcsA I
binds O
N B
- I
WASP I
and O
activates O
it O
in O
a O
Cdc42 B
- O
like O
fashion O
. O

c B
- I
Maf I
induces O
monocytic O
differentiation O
and O
apoptosis O
in O
bipotent O
myeloid O
progenitors O
. O

We O
have O
shown O
that O
the O
c B
- I
Maf I
and O
c B
- I
Myb I
transcription I
factors I
physically O
interact O
in O
myeloid O
cells O
to O
form O
inhibitory O
complexes O
that O
hinder O
transactivation O
of O
c B
- I
Myb I
target I
genes I
through O
direct O
binding O
to O
Myb B
consensus I
sites I
. O

We O
have O
shown O
that O
the O
c B
- I
Maf I
and O
c B
- I
Myb I
transcription I
factors I
physically O
interact O
in O
myeloid O
cells O
to O
form O
inhibitory O
complexes O
that O
hinder O
transactivation O
of O
c B
- I
Myb I
target I
genes I
through O
direct O
binding O
to O
Myb B
consensus I
sites I
. O

Analysis O
of O
targets O
that O
could O
mediate O
these O
phenotypic O
changes O
indicated O
that O
c B
- I
Maf I
likely O
plays O
a O
key O
role O
in O
myeloid O
cell O
development O
through O
dual O
mechanisms O
; O
inhibition O
of O
a O
select O
set O
of O
c B
- I
Myb I
regulated O
targets O
, O
such O
as O
Bcl B
- I
2 I
and O
CD13 B
/ I
APN I
, O
coupled O
with O
the O
activation O
of O
as O
yet O
undefined O
differentiation B
- I
promoting I
genes I
. O

Analysis O
of O
targets O
that O
could O
mediate O
these O
phenotypic O
changes O
indicated O
that O
c B
- I
Maf I
likely O
plays O
a O
key O
role O
in O
myeloid O
cell O
development O
through O
dual O
mechanisms O
; O
inhibition O
of O
a O
select O
set O
of O
c B
- I
Myb I
regulated O
targets O
, O
such O
as O
Bcl B
- I
2 I
and O
CD13 B
/ I
APN I
, O
coupled O
with O
the O
activation O
of O
as O
yet O
undefined O
differentiation B
- I
promoting I
genes I
. O

Analysis O
of O
targets O
that O
could O
mediate O
these O
phenotypic O
changes O
indicated O
that O
c B
- I
Maf I
likely O
plays O
a O
key O
role O
in O
myeloid O
cell O
development O
through O
dual O
mechanisms O
; O
inhibition O
of O
a O
select O
set O
of O
c B
- I
Myb I
regulated O
targets O
, O
such O
as O
Bcl B
- I
2 I
and O
CD13 B
/ I
APN I
, O
coupled O
with O
the O
activation O
of O
as O
yet O
undefined O
differentiation B
- I
promoting I
genes I
. O

Analysis O
of O
targets O
that O
could O
mediate O
these O
phenotypic O
changes O
indicated O
that O
c B
- I
Maf I
likely O
plays O
a O
key O
role O
in O
myeloid O
cell O
development O
through O
dual O
mechanisms O
; O
inhibition O
of O
a O
select O
set O
of O
c B
- I
Myb I
regulated O
targets O
, O
such O
as O
Bcl B
- I
2 I
and O
CD13 B
/ I
APN I
, O
coupled O
with O
the O
activation O
of O
as O
yet O
undefined O
differentiation B
- I
promoting I
genes I
. O

We O
have O
examined O
the O
effect O
of O
Rb B
expression O
on O
the O
activation O
of O
the O
promoter O
for O
HLA B
- I
DRA I
, O
the O
prototype B
class I
II I
gene I
. O

These O
findings O
suggest O
that O
BCL B
- I
6 I
may O
play O
a O
role O
in O
regulating O
differentiation O
of O
normal O
germinal O
center O
B O
cells O
and O
that O
its O
deregulated O
expression O
caused O
by O
rearrangements O
may O
contribute O
to O
lymphomagenesis O
. O

Since O
NF O
- O
kappaB O
/ O
IkappaB B
system O
regulates O
the O
transcription O
of O
proinflammatory B
genes I
, O
including O
those O
responsible O
for O
ROS O
generation O
, O
we O
tested O
the O
hypothesis O
that O
hydrocortisone O
may O
stimulate O
IkappaB B
production O
thus O
inhibiting O
NF B
- I
kappaB I
translocation O
from O
the O
cytosol O
into O
the O
nucleus O
in O
MNC O
, O
in O
vivo O
. O

Our O
data O
demonstrate O
that O
hydrocortisone O
induces O
IkappaB B
and O
suppresses O
NF B
- I
kappaB I
expression O
in O
MNC O
in O
parallel O
. O

Proinflammatory B
cytokines I
such O
as O
IL B
- I
1beta I
and O
TNF B
- I
alpha I
were O
down O
- O
regulated O
by O
GC O
treatment O
. O

Proinflammatory B
cytokines I
such O
as O
IL B
- I
1beta I
and O
TNF B
- I
alpha I
were O
down O
- O
regulated O
by O
GC O
treatment O
. O

Continuous O
treatment O
of O
monocytes O
with O
IL B
- I
1beta I
, O
but O
not O
with O
TNF B
- I
alpha I
, O
could O
almost O
completely O
prevent O
GC O
- O
induced O
cell O
death O
. O

Continuous O
treatment O
of O
monocytes O
with O
IL B
- I
1beta I
, O
but O
not O
with O
TNF B
- I
alpha I
, O
could O
almost O
completely O
prevent O
GC O
- O
induced O
cell O
death O
. O

The O
addition O
of O
mifepristone O
or O
caspase O
- O
3 O
inhibitor O
could O
partially O
abrogate O
GC O
- O
induced O
apoptosis O
as O
well O
as O
GC O
- O
induced O
inhibition O
of O
IL B
- I
1beta I
. O

The O
inflammatory O
mediators O
lipopolysaccharide O
( O
LPS O
) O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
are O
potent O
activators O
of O
NF B
- I
kappaB I
. O

The O
inflammatory O
mediators O
lipopolysaccharide O
( O
LPS O
) O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
are O
potent O
activators O
of O
NF B
- I
kappaB I
. O

Kinase O
assays O
showed O
that O
TNF B
elicited O
a O
rapid O
but O
short O
- O
lived O
induction O
of O
IKK B
activity O
with O
a O
3 O
- O
fold O
greater O
effect O
on O
IKK B
- I
alpha I
than O
on O
IKK B
- I
beta I
, O
peaking O
at O
5 O
min O
. O

Kinase O
assays O
showed O
that O
TNF B
elicited O
a O
rapid O
but O
short O
- O
lived O
induction O
of O
IKK B
activity O
with O
a O
3 O
- O
fold O
greater O
effect O
on O
IKK B
- I
alpha I
than O
on O
IKK B
- I
beta I
, O
peaking O
at O
5 O
min O
. O

Furthermore O
, O
our O
studies O
showed O
association O
of O
the O
IKK B
- I
alpha I
/ I
beta I
heterodimer I
with O
NIK B
, O
IkappaB B
- I
alpha I
and O
- B
epsilon I
in O
unstimulated O
cells O
. O

TNFalpha B
decreased O
( O
P O
< O
0 O
. O
001 O
) O
, O
while O
IL B
- I
10 I
increased O
( O
P O
< O
0 O
. O
001 O
) O
, O
the O
concentration O
of O
dexamethasone O
binding O
sites O
in O
these O
cells O
, O
with O
no O
discernible O
effect O
on O
their O
binding O
affinity O
. O

We O
conclude O
that O
glucocorticoids O
differentially O
modulate O
TNFalpha B
and O
IL B
- I
10 I
secretion O
by O
human O
monocytes O
in O
a O
LPS O
dose O
- O
dependent O
fashion O
and O
that O
the O
sensitivity O
of O
these O
cells O
to O
glucocorticoids O
is O
altered O
by O
TNFalpha B
or O
IL B
- I
10 I
pretreatment O
; O
TNFalpha B
blocks O
their O
effects O
, O
whereas O
IL B
- I
10 I
acts O
synergistically O
with O
glucocorticoids O
. O

We O
conclude O
that O
glucocorticoids O
differentially O
modulate O
TNFalpha B
and O
IL B
- I
10 I
secretion O
by O
human O
monocytes O
in O
a O
LPS O
dose O
- O
dependent O
fashion O
and O
that O
the O
sensitivity O
of O
these O
cells O
to O
glucocorticoids O
is O
altered O
by O
TNFalpha B
or O
IL B
- I
10 I
pretreatment O
; O
TNFalpha B
blocks O
their O
effects O
, O
whereas O
IL B
- I
10 I
acts O
synergistically O
with O
glucocorticoids O
. O

We O
conclude O
that O
glucocorticoids O
differentially O
modulate O
TNFalpha B
and O
IL B
- I
10 I
secretion O
by O
human O
monocytes O
in O
a O
LPS O
dose O
- O
dependent O
fashion O
and O
that O
the O
sensitivity O
of O
these O
cells O
to O
glucocorticoids O
is O
altered O
by O
TNFalpha B
or O
IL B
- I
10 I
pretreatment O
; O
TNFalpha B
blocks O
their O
effects O
, O
whereas O
IL B
- I
10 I
acts O
synergistically O
with O
glucocorticoids O
. O

AG O
- O
490 O
also O
inhibited O
IL B
- I
2 I
- O
mediated O
proliferative O
growth O
in O
human O
T O
cells O
with O
an O
IC50 O
) O
= O
25 O
microM O
that O
was O
partially O
recoverable O
. O

PU B
. I
1 I
is O
a O
hematopoietic B
- I
specific I
Ets I
family I
transcription I
factor I
that O
is O
required O
for O
development O
of O
some O
lymphoid O
and O
myeloid O
lineages O
. O

We O
find O
that O
PU B
. I
1 I
interacts O
directly O
with O
GATA B
- I
1 I
, O
a O
zinc B
finger I
transcription I
factor I
required O
for O
erythroid O
differentiation O
. O

We O
find O
that O
PU B
. I
1 I
interacts O
directly O
with O
GATA B
- I
1 I
, O
a O
zinc B
finger I
transcription I
factor I
required O
for O
erythroid O
differentiation O
. O

Both O
the O
DNA B
binding I
and O
transactivation B
domains I
of O
PU B
. I
1 I
are O
required O
for O
repression O
and O
both O
domains O
are O
also O
needed O
to O
block O
terminal O
differentiation O
in O
MEL O
cells O
. O

To O
better O
clarify O
the O
molecular O
basis O
of O
IL B
- I
12 I
action O
, O
we O
set O
out O
to O
characterize O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
first O
by O
contrasting O
IL B
- I
12 I
- O
and O
IFN B
- I
alpha I
- I
inducible I
genes I
. O

To O
better O
clarify O
the O
molecular O
basis O
of O
IL B
- I
12 I
action O
, O
we O
set O
out O
to O
characterize O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
first O
by O
contrasting O
IL B
- I
12 I
- O
and O
IFN B
- I
alpha I
- I
inducible I
genes I
. O

To O
better O
clarify O
the O
molecular O
basis O
of O
IL B
- I
12 I
action O
, O
we O
set O
out O
to O
characterize O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
first O
by O
contrasting O
IL B
- I
12 I
- O
and O
IFN B
- I
alpha I
- I
inducible I
genes I
. O

We O
identified O
several O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
namely O
, O
MIP B
- I
1alpha I
, O
MIP B
- I
1beta I
, O
IL B
- I
1RA I
, O
and O
IFN B
regulatory I
factor I
- I
1 I
( I
IRF I
- I
1 I
) I
. O

We O
identified O
several O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
namely O
, O
MIP B
- I
1alpha I
, O
MIP B
- I
1beta I
, O
IL B
- I
1RA I
, O
and O
IFN B
regulatory I
factor I
- I
1 I
( I
IRF I
- I
1 I
) I
. O

We O
identified O
several O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
namely O
, O
MIP B
- I
1alpha I
, O
MIP B
- I
1beta I
, O
IL B
- I
1RA I
, O
and O
IFN B
regulatory I
factor I
- I
1 I
( I
IRF I
- I
1 I
) I
. O

We O
identified O
several O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
namely O
, O
MIP B
- I
1alpha I
, O
MIP B
- I
1beta I
, O
IL B
- I
1RA I
, O
and O
IFN B
regulatory I
factor I
- I
1 I
( I
IRF I
- I
1 I
) I
. O

Therefore O
, O
IRF B
- I
1 I
may O
be O
an O
important O
contributor O
to O
IL B
- I
12 I
signaling O
, O
and O
we O
speculate O
that O
the O
defective O
IL B
- I
12 I
responses O
seen O
in O
IRF B
- O
1 O
- O
/ O
- O
mice O
might O
be O
attributable O
, O
in O
part O
, O
to O
the O
absence O
of O
this O
transcription B
factor I
. O

Therefore O
, O
IRF B
- I
1 I
may O
be O
an O
important O
contributor O
to O
IL B
- I
12 I
signaling O
, O
and O
we O
speculate O
that O
the O
defective O
IL B
- I
12 I
responses O
seen O
in O
IRF B
- O
1 O
- O
/ O
- O
mice O
might O
be O
attributable O
, O
in O
part O
, O
to O
the O
absence O
of O
this O
transcription B
factor I
. O

Therefore O
, O
IRF B
- I
1 I
may O
be O
an O
important O
contributor O
to O
IL B
- I
12 I
signaling O
, O
and O
we O
speculate O
that O
the O
defective O
IL B
- I
12 I
responses O
seen O
in O
IRF B
- O
1 O
- O
/ O
- O
mice O
might O
be O
attributable O
, O
in O
part O
, O
to O
the O
absence O
of O
this O
transcription B
factor I
. O

Regulation O
of O
low O
shear O
flow O
- O
induced O
HAEC O
VCAM B
- I
1 I
expression O
and O
monocyte O
adhesion O
. O

Here O
we O
investigate O
the O
hypothesis O
that O
low O
shear O
- O
induced O
activation O
of O
NF B
- I
kappaB I
is O
responsible O
for O
enhanced O
expression O
of O
vascular B
cell I
adhesion I
molecule I
( O
VCAM B
- I
1 I
) O
resulting O
in O
augmented O
endothelial O
cell O
- O
monocyte O
( O
EC O
- O
Mn O
) O
adhesion O
and O
that O
this O
activation O
is O
dependent O
on O
intracellular O
oxidant O
activity O
. O

Here O
we O
investigate O
the O
hypothesis O
that O
low O
shear O
- O
induced O
activation O
of O
NF B
- I
kappaB I
is O
responsible O
for O
enhanced O
expression O
of O
vascular B
cell I
adhesion I
molecule I
( O
VCAM B
- I
1 I
) O
resulting O
in O
augmented O
endothelial O
cell O
- O
monocyte O
( O
EC O
- O
Mn O
) O
adhesion O
and O
that O
this O
activation O
is O
dependent O
on O
intracellular O
oxidant O
activity O
. O

These O
data O
suggest O
that O
NF B
- I
kappaB I
plays O
a O
key O
role O
in O
low O
shear O
- O
induced O
VCAM B
- I
1 I
expression O
and O
that O
pathways O
mediating O
low O
shear O
- O
and O
cytokine O
- O
induced O
EC O
- O
Mn O
adhesion O
may O
be O
differentially O
regulated O
. O

These O
data O
suggest O
that O
NF B
- I
kappaB I
plays O
a O
key O
role O
in O
low O
shear O
- O
induced O
VCAM B
- I
1 I
expression O
and O
that O
pathways O
mediating O
low O
shear O
- O
and O
cytokine O
- O
induced O
EC O
- O
Mn O
adhesion O
may O
be O
differentially O
regulated O
. O

Pertussis O
toxin O
, O
which O
ADP O
- O
ribosylates O
the O
Gi B
proteins I
known O
to O
couple O
to O
the O
C5a B
receptor I
, O
produced O
minimal O
inhibition O
of O
C5a O
- O
induced O
IL B
- I
8 I
expression O
and O
had O
little O
effect O
on O
C5a O
- O
induced O
calcium O
mobilization O
in O
RAW264 O
. O
7 O
cells O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Interestingly O
, O
when O
we O
fused O
HT O
- O
2 O
cells O
expressing O
the O
EPOR B
with O
Ba O
/ O
F3 O
cells O
in O
a O
complementation O
assay O
, O
the O
resulting O
hybridomas O
proliferated O
and O
potently O
activated O
STAT B
- I
5 I
and O
MAPK B
in O
response O
to O
EPO B
. O

When O
a O
drug O
appears O
to O
be O
less O
effective O
than O
preclinical O
models O
suggest O
, O
can O
failures O
in O
effectiveness O
from O
delivery O
or O
dosing O
be O
differentiated O
? O
The O
disappointing O
results O
of O
clinical O
trials O
with O
IL B
- I
10 I
- O
- O
so O
at O
odds O
with O
the O
prediction O
of O
benefit O
from O
animal O
models O
- O
- O
bring O
into O
question O
the O
validity O
of O
those O
models O
as O
well O
as O
the O
soundness O
of O
design O
of O
the O
clinical O
trials O
on O
which O
efficacy O
of O
IL B
- I
10 I
is O
judged O
. O

When O
a O
drug O
appears O
to O
be O
less O
effective O
than O
preclinical O
models O
suggest O
, O
can O
failures O
in O
effectiveness O
from O
delivery O
or O
dosing O
be O
differentiated O
? O
The O
disappointing O
results O
of O
clinical O
trials O
with O
IL B
- I
10 I
- O
- O
so O
at O
odds O
with O
the O
prediction O
of O
benefit O
from O
animal O
models O
- O
- O
bring O
into O
question O
the O
validity O
of O
those O
models O
as O
well O
as O
the O
soundness O
of O
design O
of O
the O
clinical O
trials O
on O
which O
efficacy O
of O
IL B
- I
10 I
is O
judged O
. O

Potent O
and O
stable O
attenuation O
of O
live O
- O
HIV O
- O
1 O
by O
gain O
of O
a O
proteolysis B
- I
resistant I
inhibitor I
of O
NF B
- I
kappaB I
( O
IkappaB B
- I
alphaS32 I
/ I
36A I
) O
and O
the O
implications O
for O
vaccine O
development O
. O

The O
transcription B
factor I
NF B
- I
ATc I
that O
controls O
gene O
expression O
in O
T O
lymphocytes O
and O
embryonic O
cardiac O
cells O
is O
expressed O
in O
three O
prominent O
isoforms O
. O

Various O
stimuli O
of O
T O
cells O
that O
induce O
the O
activity O
of O
TAD B
- I
A I
also O
enhance O
the O
activity O
of O
TAD B
- I
B I
, O
but O
, O
unlike O
TAD B
- I
A I
, O
TAD B
- I
B I
remains O
unphosphorylated O
by O
protein O
from O
12 O
- O
O O
- O
tetradecanoyl O
12 O
- O
phorbol O
13 O
- O
acetate O
- O
stimulated O
T O
cells O
. O

Various O
stimuli O
of O
T O
cells O
that O
induce O
the O
activity O
of O
TAD B
- I
A I
also O
enhance O
the O
activity O
of O
TAD B
- I
B I
, O
but O
, O
unlike O
TAD B
- I
A I
, O
TAD B
- I
B I
remains O
unphosphorylated O
by O
protein O
from O
12 O
- O
O O
- O
tetradecanoyl O
12 O
- O
phorbol O
13 O
- O
acetate O
- O
stimulated O
T O
cells O
. O

Various O
stimuli O
of O
T O
cells O
that O
induce O
the O
activity O
of O
TAD B
- I
A I
also O
enhance O
the O
activity O
of O
TAD B
- I
B I
, O
but O
, O
unlike O
TAD B
- I
A I
, O
TAD B
- I
B I
remains O
unphosphorylated O
by O
protein O
from O
12 O
- O
O O
- O
tetradecanoyl O
12 O
- O
phorbol O
13 O
- O
acetate O
- O
stimulated O
T O
cells O
. O

Various O
stimuli O
of O
T O
cells O
that O
induce O
the O
activity O
of O
TAD B
- I
A I
also O
enhance O
the O
activity O
of O
TAD B
- I
B I
, O
but O
, O
unlike O
TAD B
- I
A I
, O
TAD B
- I
B I
remains O
unphosphorylated O
by O
protein O
from O
12 O
- O
O O
- O
tetradecanoyl O
12 O
- O
phorbol O
13 O
- O
acetate O
- O
stimulated O
T O
cells O
. O

These O
results O
indicate O
that O
ALG B
- I
4 I
is O
necessary O
and O
sufficient O
for O
FasL B
expression O
. O

Among O
upstream B
signaling I
molecules I
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

Among O
upstream B
signaling I
molecules I
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

Among O
upstream B
signaling I
molecules I
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

Among O
upstream B
signaling I
molecules I
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

Transcriptional O
control O
of O
the O
IL B
- I
5 I
gene O
by O
human O
helper O
T O
cells O
: O
IL B
- I
5 I
synthesis O
is O
regulated O
independently O
from O
IL B
- I
2 I
or O
IL B
- I
4 I
synthesis O
. O

Transcriptional O
control O
of O
the O
IL B
- I
5 I
gene O
by O
human O
helper O
T O
cells O
: O
IL B
- I
5 I
synthesis O
is O
regulated O
independently O
from O
IL B
- I
2 I
or O
IL B
- I
4 I
synthesis O
. O

Transcriptional O
control O
of O
the O
IL B
- I
5 I
gene O
by O
human O
helper O
T O
cells O
: O
IL B
- I
5 I
synthesis O
is O
regulated O
independently O
from O
IL B
- I
2 I
or O
IL B
- I
4 I
synthesis O
. O

Transcriptional O
control O
of O
the O
IL B
- I
5 I
gene O
by O
human O
helper O
T O
cells O
: O
IL B
- I
5 I
synthesis O
is O
regulated O
independently O
from O
IL B
- I
2 I
or O
IL B
- I
4 I
synthesis O
. O

CONCLUSION O
: O
IL B
- I
5 I
synthesis O
by O
human O
helper O
T O
cells O
is O
regulated O
at O
the O
transcriptional O
level O
. O

We O
used O
an O
adenoviral O
technique O
of O
blocking O
NF B
- I
kappaB I
through O
overexpression O
of O
the O
inhibitory B
subunit I
IkappaBalpha B
, O
which O
has O
the O
advantage O
that O
it O
can O
be O
used O
in O
the O
diseased O
tissue O
itself O
, O
with O
> O
90 O
% O
of O
the O
synovial O
macrophages O
, O
fibroblasts O
, O
and O
T O
cells O
infected O
. O

Clonality O
analysis O
utilizing O
X B
- I
chromosome I
inactivation O
has O
been O
used O
in O
the O
study O
of O
various O
diseases O
, O
including O
hematological O
malignancies O
. O

However O
, O
activation O
of O
STAT6 B
, O
CD23 B
expression O
, O
and O
IgE B
synthesis O
induced O
by O
IL B
- I
4 I
were O
not O
affected O
in O
p47phox O
- O
deficient O
patients O
, O
which O
raises O
the O
possibility O
that O
p47phox O
may O
be O
important O
in O
other O
signaling O
activities O
as O
well O
in O
B O
cells O
. O

On O
the O
contrary O
, O
the O
release O
of O
MCP B
- I
1 I
was O
significantly O
inhibited O
, O
also O
in O
a O
dose O
- O
dependent O
manner O
. O

Messenger B
RNA I
production O
coding O
for O
IL B
- I
8 I
, O
RANTES B
, O
and O
MCP B
- I
1 I
showed O
parallel O
variations O
to O
the O
production O
of O
the O
correspondent B
proteins I
. O

Messenger B
RNA I
production O
coding O
for O
IL B
- I
8 I
, O
RANTES B
, O
and O
MCP B
- I
1 I
showed O
parallel O
variations O
to O
the O
production O
of O
the O
correspondent B
proteins I
. O

Furthermore O
, O
SLP B
- I
76 I
and O
Vav B
have O
a O
synergistic O
effect O
on O
interleukin B
( I
IL I
) I
- I
2 I
promoter I
activity O
in O
T O
cells O
. O

Surprisingly O
, O
we O
find O
also O
that O
the O
interaction O
between O
SLP B
- I
76 I
and O
Vav B
is O
not O
required O
for O
their O
cooperation O
in O
augmenting O
IL B
- I
2 I
promoter I
activity O
, O
as O
the O
two O
molecules O
appear O
to O
function O
in O
different O
signaling O
pathways O
upstream O
of O
IL B
- I
2 I
gene I
expression O
. O

In O
contrast O
, O
overexpression O
of O
Vav B
leads O
to O
enhanced O
nuclear B
factor I
of I
activated I
T I
cells I
activity O
without O
affecting O
AP B
- I
1 I
. O

Additionally O
, O
overexpression O
of O
Vav B
, O
but O
not O
SLP B
- I
76 I
, O
augments O
CD28 O
- O
induced O
IL B
- I
2 I
promoter I
activity O
. O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

inhibited O
by O
dominant O
negative O
c B
- I
Fos I
; O
and O
( O
iv O
) O
PGN O
- O
induced O
activation O
of O
CREB B
/ I
ATF I
and O
AP B
- I
1 I
was O
mediated O
through O
CD14 B
. O

inhibited O
by O
dominant O
negative O
c B
- I
Fos I
; O
and O
( O
iv O
) O
PGN O
- O
induced O
activation O
of O
CREB B
/ I
ATF I
and O
AP B
- I
1 I
was O
mediated O
through O
CD14 B
. O

inhibited O
by O
dominant O
negative O
c B
- I
Fos I
; O
and O
( O
iv O
) O
PGN O
- O
induced O
activation O
of O
CREB B
/ I
ATF I
and O
AP B
- I
1 I
was O
mediated O
through O
CD14 B
. O

Our O
findings O
offer O
important O
insights O
into O
parasite O
survival O
strategies O
and O
demonstrate O
that O
parasite O
- O
induced O
constitutive O
NF B
- I
kappaB I
activation O
is O
an O
essential O
step O
in O
maintaining O
the O
transformed O
phenotype O
of O
the O
infected O
cells O
. O

A O
polymorphism O
that O
affects O
OCT B
- I
1 I
binding O
to O
the O
TNF B
promoter I
region I
is O
associated O
with O
severe O
malaria O
[ O
see O
comments O
] O

A O
polymorphism O
that O
affects O
OCT B
- I
1 I
binding O
to O
the O
TNF B
promoter I
region I
is O
associated O
with O
severe O
malaria O
[ O
see O
comments O
] O

Repression O
by O
Ikaros B
and O
Aiolos B
is O
mediated O
through O
histone B
deacetylase I
complexes I
. O

HIV O
- O
1 O
reactivation O
in O
resting O
peripheral O
blood O
mononuclear O
cells O
of O
infected O
adults O
upon O
in O
vitro O
CD4 B
cross O
- O
linking O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
extracellular B
domain I
1 I
. O

HIV O
- O
1 O
reactivation O
in O
resting O
peripheral O
blood O
mononuclear O
cells O
of O
infected O
adults O
upon O
in O
vitro O
CD4 B
cross O
- O
linking O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
extracellular B
domain I
1 I
. O

Additionally O
, O
virus O
reactivation O
in O
resting O
PBMCs O
infected O
in O
vitro O
with O
HIV O
- O
1 O
was O
found O
to O
be O
specifically O
induced O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
domain B
1 I
( O
D1 B
) O
of O
CD4 B
( O
virus B
envelope I
and I
anti I
- I
CD4 I
monoclonal I
antibodies I
) O
. O

Given O
the O
critical O
role O
that O
LT B
- I
alpha1beta2 I
plays O
in O
lymphoid O
architecture O
, O
we O
speculate O
that O
LT B
- I
alpha1beta2 I
may O
be O
involved O
in O
HIV O
- O
associated O
abnormalities O
of O
the O
lymphoid O
organs O
. O

Given O
the O
critical O
role O
that O
LT B
- I
alpha1beta2 I
plays O
in O
lymphoid O
architecture O
, O
we O
speculate O
that O
LT B
- I
alpha1beta2 I
may O
be O
involved O
in O
HIV O
- O
associated O
abnormalities O
of O
the O
lymphoid O
organs O
. O

The O
secretion O
levels O
of O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
and O
von O
Willebrand O
factor O
( O
vWF O
) O
were O
determined O
, O
to O
serve O
as O
markers O
for O
EC O
activation O
. O

The O
secretion O
levels O
of O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
and O
von O
Willebrand O
factor O
( O
vWF O
) O
were O
determined O
, O
to O
serve O
as O
markers O
for O
EC O
activation O
. O

In O
addition O
, O
nuclear O
extracts O
of O
the O
mAECA O
- O
treated O
EC O
were O
analyzed O
for O
the O
induction O
of O
translocation O
of O
nuclear B
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
using O
a O
specific O
NF B
- I
kappaB I
oligoprobe O
in O
an O
electrophoretic O
mobility O
shift O
assay O
. O

In O
addition O
, O
nuclear O
extracts O
of O
the O
mAECA O
- O
treated O
EC O
were O
analyzed O
for O
the O
induction O
of O
translocation O
of O
nuclear B
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
using O
a O
specific O
NF B
- I
kappaB I
oligoprobe O
in O
an O
electrophoretic O
mobility O
shift O
assay O
. O

In O
addition O
, O
nuclear O
extracts O
of O
the O
mAECA O
- O
treated O
EC O
were O
analyzed O
for O
the O
induction O
of O
translocation O
of O
nuclear B
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
using O
a O
specific O
NF B
- I
kappaB I
oligoprobe O
in O
an O
electrophoretic O
mobility O
shift O
assay O
. O

The O
mAECA B
, O
but O
not O
normal B
human I
IgG I
, O
had O
anti O
- O
human O
aortic O
EC O
activity O
. O

Four O
of O
the O
6 O
mAECA B
activated O
EC O
, O
manifested O
by O
increased O
IL B
- I
6 I
and O
vWF O
secretion O
. O

However O
NF B
- I
ATs I
appear O
in O
the O
nuclei O
of O
IL O
- O
4 O
- O
, O
IL O
- O
5 O
- O
, O
or O
ionomycin O
- O
stimulated O
eosinophils O
. O

Both O
PPARalpha B
activators O
decreased O
cytokine O
- O
induced O
VCAM B
- I
1 I
mRNA O
expression O
without O
altering O
its O
mRNA O
half O
- O
life O
. O

CBP B
/ I
p300 I
integrates O
Raf B
/ O
Rac B
- O
signaling O
pathways O
in O
the O
transcriptional O
induction O
of O
NF B
- I
ATc I
during O
T O
cell O
activation O
. O

CBP B
/ I
p300 I
integrates O
Raf B
/ O
Rac B
- O
signaling O
pathways O
in O
the O
transcriptional O
induction O
of O
NF B
- I
ATc I
during O
T O
cell O
activation O
. O

Inhibition O
of O
NF B
- I
kappaB I
has O
been O
achieved O
by O
pharmacological O
and O
genetic O
approaches O
; O
however O
, O
monocyte O
interactions O
with O
activated O
endothelium O
in O
shear O
flow O
following O
gene O
transfer O
of O
the O
NF B
- I
kappaB I
inhibitor O
IkappaB B
- I
alpha I
have O
not O
been O
studied O
. O

Inhibition O
of O
NF B
- I
kappaB I
has O
been O
achieved O
by O
pharmacological O
and O
genetic O
approaches O
; O
however O
, O
monocyte O
interactions O
with O
activated O
endothelium O
in O
shear O
flow O
following O
gene O
transfer O
of O
the O
NF B
- I
kappaB I
inhibitor O
IkappaB B
- I
alpha I
have O
not O
been O
studied O
. O

Inhibition O
of O
NF B
- I
kappaB I
has O
been O
achieved O
by O
pharmacological O
and O
genetic O
approaches O
; O
however O
, O
monocyte O
interactions O
with O
activated O
endothelium O
in O
shear O
flow O
following O
gene O
transfer O
of O
the O
NF B
- I
kappaB I
inhibitor O
IkappaB B
- I
alpha I
have O
not O
been O
studied O
. O

This O
was O
associated O
with O
a O
reduction O
in O
endothelial O
MCP B
- I
1 I
secretion O
and O
GRO B
- I
alpha I
immobilization O
. O

This O
was O
associated O
with O
a O
reduction O
in O
endothelial O
MCP B
- I
1 I
secretion O
and O
GRO B
- I
alpha I
immobilization O
. O

Adhesion O
assays O
under O
physiological O
shear O
flow O
conditions O
showed O
that O
firm O
arrest O
, O
spreading O
, O
and O
transmigration O
of O
monocytes O
on O
TNF B
- I
alpha I
- O
activated O
endothelium O
was O
markedly O
inhibited O
by O
IkappaB B
- I
alpha I
overexpression O
. O

Adhesion O
assays O
under O
physiological O
shear O
flow O
conditions O
showed O
that O
firm O
arrest O
, O
spreading O
, O
and O
transmigration O
of O
monocytes O
on O
TNF B
- I
alpha I
- O
activated O
endothelium O
was O
markedly O
inhibited O
by O
IkappaB B
- I
alpha I
overexpression O
. O

In O
contrast O
, O
rolling O
of O
monocytes O
was O
increased O
by O
IkappaB B
- I
alpha I
transfer O
and O
was O
partly O
mediated O
by O
P B
- I
selectin I
; O
however O
, O
it O
appeared O
to O
be O
unaffected O
by O
the O
inhibition O
of O
E B
- I
selectin I
induction O
. O

In O
contrast O
, O
rolling O
of O
monocytes O
was O
increased O
by O
IkappaB B
- I
alpha I
transfer O
and O
was O
partly O
mediated O
by O
P B
- I
selectin I
; O
however O
, O
it O
appeared O
to O
be O
unaffected O
by O
the O
inhibition O
of O
E B
- I
selectin I
induction O
. O

In O
contrast O
, O
rolling O
of O
monocytes O
was O
increased O
by O
IkappaB B
- I
alpha I
transfer O
and O
was O
partly O
mediated O
by O
P B
- I
selectin I
; O
however O
, O
it O
appeared O
to O
be O
unaffected O
by O
the O
inhibition O
of O
E B
- I
selectin I
induction O
. O

We O
have O
identified O
an O
E B
box I
around O
- B
260 I
and O
a O
YY1 B
binding I
site I
around O
- B
300 I
relative O
to O
the O
transcription B
start I
site I
. O

We O
have O
identified O
an O
E B
box I
around O
- B
260 I
and O
a O
YY1 B
binding I
site I
around O
- B
300 I
relative O
to O
the O
transcription B
start I
site I
. O

RCC O
- O
S O
did O
not O
alter O
the O
cytoplasmic O
levels O
of O
RelA B
and O
NF B
- I
kappaB1 I
but O
did O
suppress O
their O
nuclear O
localization O
and O
inhibited O
the O
activation O
of O
RelA B
/ I
NF I
- I
kappaB1 I
binding I
complexes I
. O

These O
results O
show O
that O
RCC O
- O
S O
can O
induce O
in O
normal O
T O
cells O
the O
same O
phenotype O
of O
impaired O
NF B
- I
kappaB I
activation O
that O
is O
detected O
in O
T O
cells O
of O
RCC O
patient O
. O

STAT1 B
activity O
was O
evident O
on O
the O
STAT B
binding I
sequences I
( O
SBE B
) O
present O
in O
the O
promoters B
of O
genes O
which O
are O
up O
- O
regulated O
during O
monocyte O
to O
macrophage O
maturation O
such O
as O
FcgammaRI B
and O
ICAM B
- I
1 I
, O
and O
in O
the O
promoter O
of O
the O
transcription B
factor I
IFN I
regulatory I
factor I
- I
1 I
. O

STAT1 B
activity O
was O
evident O
on O
the O
STAT B
binding I
sequences I
( O
SBE B
) O
present O
in O
the O
promoters B
of O
genes O
which O
are O
up O
- O
regulated O
during O
monocyte O
to O
macrophage O
maturation O
such O
as O
FcgammaRI B
and O
ICAM B
- I
1 I
, O
and O
in O
the O
promoter O
of O
the O
transcription B
factor I
IFN I
regulatory I
factor I
- I
1 I
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic B
genes I
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic B
genes I
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic B
genes I
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic B
genes I
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic B
genes I
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic B
genes I
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

Fibroblast B
growth I
factors I
( O
FGFs B
) O
are O
heparin B
- I
binding I
proteins I
crucial O
to O
embryogenesis O
, O
angiogenesis O
, O
and O
wound O
healing O
. O

FGF B
- I
1 I
is O
abundantly O
expressed O
in O
the O
synovium O
in O
rheumatoid O
arthritis O
and O
in O
rejecting O
allografts O
, O
sites O
of O
chronic O
immune O
- O
mediated O
inflammation O
. O

In O
this O
paper O
, O
we O
show O
that O
HCMV O
down O
regulates O
gamma O
interferon O
( O
IFN B
- I
gamma I
) O
- O
induced O
HLA B
- I
DR I
expression O
in O
U373 O
MG O
astrocytoma O
cells O
due O
to O
a O
defect O
downstream O
of O
STAT1 B
phosphorylation O
and O
nuclear O
translocation O
. O

In O
this O
paper O
, O
we O
show O
that O
HCMV O
down O
regulates O
gamma O
interferon O
( O
IFN B
- I
gamma I
) O
- O
induced O
HLA B
- I
DR I
expression O
in O
U373 O
MG O
astrocytoma O
cells O
due O
to O
a O
defect O
downstream O
of O
STAT1 B
phosphorylation O
and O
nuclear O
translocation O
. O

Inhibition O
of O
NF B
- I
kappaB I
transcriptional O
activity O
and O
promotion O
of O
IkappaBalpha B
degradation O
. O

DZA O
inhibits O
the O
transcriptional O
activity O
of O
NF B
- I
kappaB I
through O
the O
hindrance O
of O
p65 B
( O
Rel B
- I
A I
) O
phosphorylation O
without O
reduction O
of O
its O
nuclear O
translocation O
and O
DNA O
binding O
activity O
. O

DZA O
inhibits O
the O
transcriptional O
activity O
of O
NF B
- I
kappaB I
through O
the O
hindrance O
of O
p65 B
( O
Rel B
- I
A I
) O
phosphorylation O
without O
reduction O
of O
its O
nuclear O
translocation O
and O
DNA O
binding O
activity O
. O

The O
inhibitory O
effect O
of O
DZA O
on O
NF B
- I
kappaB I
transcriptional O
activity O
is O
potentiated O
by O
the O
addition O
of O
homocysteine O
. O

Here O
, O
we O
investigate O
the O
role O
of O
Rho B
in O
regulating O
the O
distribution O
of O
the O
monocyte B
- I
binding I
receptors I
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
in O
human O
endothelial O
cells O
. O

Here O
, O
we O
investigate O
the O
role O
of O
Rho B
in O
regulating O
the O
distribution O
of O
the O
monocyte B
- I
binding I
receptors I
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
in O
human O
endothelial O
cells O
. O

Here O
, O
we O
investigate O
the O
role O
of O
Rho B
in O
regulating O
the O
distribution O
of O
the O
monocyte B
- I
binding I
receptors I
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
in O
human O
endothelial O
cells O
. O

C3 O
transferase O
and O
cytochalasin O
D O
did O
not O
alter O
the O
expression O
levels O
of O
monocyte B
- I
binding I
receptors I
on O
endothelial O
cells O
, O
but O
did O
inhibit O
clustering O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
on O
the O
cell O
surface O
induced O
by O
monocyte O
adhesion O
or O
cross B
- I
linking I
antibodies I
. O

C3 O
transferase O
and O
cytochalasin O
D O
did O
not O
alter O
the O
expression O
levels O
of O
monocyte B
- I
binding I
receptors I
on O
endothelial O
cells O
, O
but O
did O
inhibit O
clustering O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
on O
the O
cell O
surface O
induced O
by O
monocyte O
adhesion O
or O
cross B
- I
linking I
antibodies I
. O

C3 O
transferase O
and O
cytochalasin O
D O
did O
not O
alter O
the O
expression O
levels O
of O
monocyte B
- I
binding I
receptors I
on O
endothelial O
cells O
, O
but O
did O
inhibit O
clustering O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
on O
the O
cell O
surface O
induced O
by O
monocyte O
adhesion O
or O
cross B
- I
linking I
antibodies I
. O

CD28 B
costimulation O
augments O
IL B
- I
2 I
secretion O
of O
activated O
lamina O
propria O
T O
cells O
by O
increasing O
mRNA O
stability O
without O
enhancing O
IL B
- I
2 I
gene O
transactivation O
. O

CD28 B
costimulation O
augments O
IL B
- I
2 I
secretion O
of O
activated O
lamina O
propria O
T O
cells O
by O
increasing O
mRNA O
stability O
without O
enhancing O
IL B
- I
2 I
gene O
transactivation O
. O

Previous O
studies O
have O
characterized O
the O
CD28 B
augmentation O
of O
TCR B
- O
mediated O
signaling O
in O
peripheral O
blood O
T O
cells O
through O
transcriptional O
activation O
of O
an O
IL B
- I
2 I
promoter O
CD28 B
response I
element I
( O
CD28RE B
) O
, O
along O
with O
enhanced O
mRNA O
stability O
. O

Previous O
studies O
have O
characterized O
the O
CD28 B
augmentation O
of O
TCR B
- O
mediated O
signaling O
in O
peripheral O
blood O
T O
cells O
through O
transcriptional O
activation O
of O
an O
IL B
- I
2 I
promoter O
CD28 B
response I
element I
( O
CD28RE B
) O
, O
along O
with O
enhanced O
mRNA O
stability O
. O

LPMC O
exhibited O
increased O
IL B
- I
2 I
production O
in O
response O
to O
CD28 B
costimulation O
, O
compared O
with O
cells O
activated O
through O
CD2 B
alone O
. O

In O
conclusion O
, O
production O
of O
a O
Th1 B
cytokine I
, O
IFN B
- I
gamma I
, O
by O
HBsAg B
- O
reactive O
cells O
was O
associated O
with O
hepatocyte O
damage O
in O
chronic O
hepatitis O
B O
, O
while O
no O
counteracting O
effect O
of O
Th2 B
cytokines I
produced O
by O
those O
cells O
was O
observed O
. O

Caspase B
- I
3 I
activation O
, O
usually O
resulting O
from O
delta O
psi O
( O
m O
) O
collapse O
, O
was O
not O
always O
associated O
with O
As2O3 O
- O
induced O
apoptosis O
. O

As2O3 O
induced O
PML O
( O
promyelocytic O
leukemia O
) O
protein O
degradation O
but O
did O
not O
modulate O
expression O
of O
cell B
cycle I
- I
related I
proteins I
, O
including O
c B
- I
myc I
, O
retinoblastoma B
protein I
, O
cyclin B
- I
dependent I
kinase I
4 I
, O
cyclin B
D1 I
, O
and O
p53 B
, O
or O
expression O
of O
differentiation B
- I
related I
antigens I
. O

A20 O
can O
be O
regulated O
by O
the O
NF B
- I
kappaB I
transcription B
factor I
, O
which O
is O
known O
to O
be O
activated O
by O
the O
EBV B
LMP I
- I
1 I
protein I
. O

CTLA B
- I
4 I
ligation O
inhibited O
CD3 O
/ O
CD28 B
- O
induced O
IL B
- I
2 I
mRNA I
accumulation O
by O
inhibiting O
IL B
- I
2 I
transcription O
, O
which O
appears O
to O
be O
mediated O
in O
part O
through O
decreasing O
NF B
- I
AT I
accumulation O
in O
the O
nuclei O
. O

CTLA B
- I
4 I
ligation O
inhibited O
CD3 O
/ O
CD28 B
- O
induced O
IL B
- I
2 I
mRNA I
accumulation O
by O
inhibiting O
IL B
- I
2 I
transcription O
, O
which O
appears O
to O
be O
mediated O
in O
part O
through O
decreasing O
NF B
- I
AT I
accumulation O
in O
the O
nuclei O
. O

CTLA B
- I
4 I
ligation O
inhibited O
CD3 O
/ O
CD28 B
- O
induced O
IL B
- I
2 I
mRNA I
accumulation O
by O
inhibiting O
IL B
- I
2 I
transcription O
, O
which O
appears O
to O
be O
mediated O
in O
part O
through O
decreasing O
NF B
- I
AT I
accumulation O
in O
the O
nuclei O
. O

Further O
, O
CTLA B
- I
4 I
engagement O
inhibited O
progression O
through O
the O
cell O
cycle O
by O
inhibiting O
the O
production O
of O
cyclin B
D3 I
, O
cyclin B
- I
dependent I
kinase I
( B
cdk I
) I
4 I
, O
and O
cdk6 B
when O
the O
T O
cells O
were O
stimulated O
with O
anti B
- I
CD3 I
/ I
CD28 I
and O
with O
anti B
- I
CD3 I
alone O
. O

Further O
, O
CTLA B
- I
4 I
engagement O
inhibited O
progression O
through O
the O
cell O
cycle O
by O
inhibiting O
the O
production O
of O
cyclin B
D3 I
, O
cyclin B
- I
dependent I
kinase I
( B
cdk I
) I
4 I
, O
and O
cdk6 B
when O
the O
T O
cells O
were O
stimulated O
with O
anti B
- I
CD3 I
/ I
CD28 I
and O
with O
anti B
- I
CD3 I
alone O
. O

Dexamethasone O
( O
Dex O
) O
, O
a O
synthetic O
glucocorticoid O
hormone O
, O
cooperated O
with O
Epo B
and O
stem B
cell I
factor I
to O
induce O
erythroid O
progenitors O
to O
undergo O
15 O
to O
22 O
cell O
divisions O
, O
corresponding O
to O
a O
10 O
( O
5 O
) O
- O
to O
10 O
( O
6 O
) O
- O
fold O
amplification O
of O
erythroid O
cells O
. O

We O
conclude O
that O
NF B
- I
kappaB I
is O
a O
context O
- O
dependent O
apoptosis O
regulator O
. O

SOCS B
- I
3 I
protein O
was O
detectable O
as O
early O
as O
30 O
min O
following O
IL B
- I
2 I
stimulation O
, O
while O
CIS B
was O
seen O
only O
at O
low O
levels O
after O
2 O
h O
. O

SOCS B
- I
3 I
protein O
was O
detectable O
as O
early O
as O
30 O
min O
following O
IL B
- I
2 I
stimulation O
, O
while O
CIS B
was O
seen O
only O
at O
low O
levels O
after O
2 O
h O
. O

Tyrosine O
phosphorylation O
of O
SOCS B
- I
3 I
was O
observed O
upon O
coexpression O
with O
Jak1 B
and O
Jak2 B
but O
only O
weakly O
with O
Jak3 B
. O

Finally O
, O
proliferation O
induced O
by O
both O
IL B
- I
2 I
- O
and O
IL B
- I
3 I
was O
significantly O
inhibited O
in O
the O
presence O
of O
SOCS B
- I
3 I
. O

Finally O
, O
proliferation O
induced O
by O
both O
IL B
- I
2 I
- O
and O
IL B
- I
3 I
was O
significantly O
inhibited O
in O
the O
presence O
of O
SOCS B
- I
3 I
. O

Finally O
, O
proliferation O
induced O
by O
both O
IL B
- I
2 I
- O
and O
IL B
- I
3 I
was O
significantly O
inhibited O
in O
the O
presence O
of O
SOCS B
- I
3 I
. O

There O
was O
, O
however O
, O
a O
significant O
difference O
in O
the O
amounts O
of O
the O
nuclear B
protein I
, O
REF B
- I
1 I
( O
which O
regulates O
AP B
- I
1 I
DNA O
binding O
by O
altering O
the O
redox O
status O
of O
FOS B
and O
JUN B
proteins I
) O
, O
in O
alveolar O
macrophages O
compared O
with O
monocytes O
. O

There O
was O
, O
however O
, O
a O
significant O
difference O
in O
the O
amounts O
of O
the O
nuclear B
protein I
, O
REF B
- I
1 I
( O
which O
regulates O
AP B
- I
1 I
DNA O
binding O
by O
altering O
the O
redox O
status O
of O
FOS B
and O
JUN B
proteins I
) O
, O
in O
alveolar O
macrophages O
compared O
with O
monocytes O
. O

Finally O
, O
addition O
of O
REF B
- I
1 I
from O
activated O
monocytes O
to O
alveolar O
macrophage O
nuclear O
proteins O
resulted O
in O
a O
marked O
increase O
in O
AP B
- I
1 I
DNA O
binding O
. O

Finally O
, O
addition O
of O
REF B
- I
1 I
from O
activated O
monocytes O
to O
alveolar O
macrophage O
nuclear O
proteins O
resulted O
in O
a O
marked O
increase O
in O
AP B
- I
1 I
DNA O
binding O
. O

A O
role O
for O
RanBP1 B
in O
the O
release O
of O
CRM1 B
from O
the O
nuclear B
pore I
complex I
in O
a O
terminal O
step O
of O
nuclear O
export O
. O

In O
a O
model O
where O
foreign O
cells O
( O
rat O
fibroblasts O
) O
were O
cocultured O
with O
human O
IL O
- O
2 O
activated O
NK O
cells O
, O
we O
observed O
that O
NK O
cells O
were O
capable O
of O
efficiently O
killing O
their O
targets O
only O
if O
the O
cells O
overexpressed O
the O
oncogene O
c B
- I
Myc I
or O
E1A B
. O

These O
results O
provided O
evidence O
that O
c B
- I
Myc I
and O
E1A B
activated O
the O
NK O
cell O
induced O
cytolysis O
at O
a O
post O
- O
triggering O
stage O
of O
NK O
cell O
- O
target O
cell O
interaction O
. O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

However O
, O
stimulation O
with O
IL B
- I
2 I
resulted O
in O
Jak3 B
and O
STAT5 B
phosphorylation O
in O
both O
leukemic O
ATLL O
cells O
and O
IL O
- O
2 O
- O
dependent O
lines O
. O

Here O
we O
report O
that O
in O
erythroid O
cells O
, O
GATA B
- I
1 I
strongly O
induces O
the O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
bcl B
- I
xL I
, O
but O
not O
the O
related O
proteins O
bcl B
- I
2 I
and O
mcl B
- I
1 I
. O

Here O
we O
report O
that O
in O
erythroid O
cells O
, O
GATA B
- I
1 I
strongly O
induces O
the O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
bcl B
- I
xL I
, O
but O
not O
the O
related O
proteins O
bcl B
- I
2 I
and O
mcl B
- I
1 I
. O

Here O
we O
report O
that O
in O
erythroid O
cells O
, O
GATA B
- I
1 I
strongly O
induces O
the O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
bcl B
- I
xL I
, O
but O
not O
the O
related O
proteins O
bcl B
- I
2 I
and O
mcl B
- I
1 I
. O

Here O
we O
report O
that O
in O
erythroid O
cells O
, O
GATA B
- I
1 I
strongly O
induces O
the O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
bcl B
- I
xL I
, O
but O
not O
the O
related O
proteins O
bcl B
- I
2 I
and O
mcl B
- I
1 I
. O

In O
T O
lymphocytes O
, O
the O
hematopoietic B
cytokine I
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
uses O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
- O
induced O
signaling O
pathways O
to O
regulate O
E2F B
transcriptional O
activity O
, O
a O
critical O
cell O
cycle O
checkpoint O
. O

In O
T O
lymphocytes O
, O
the O
hematopoietic B
cytokine I
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
uses O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
- O
induced O
signaling O
pathways O
to O
regulate O
E2F B
transcriptional O
activity O
, O
a O
critical O
cell O
cycle O
checkpoint O
. O

Moreover O
, O
the O
effects O
of O
rapamycin O
on O
, O
and O
the O
role O
of O
p70 B
( I
s6k I
) I
in O
, O
IL B
- I
2 I
and O
PI B
3 I
- I
kinase I
activation O
of O
E2Fs B
have O
not O
been O
characterized O
. O

Our O
present O
results O
show O
that O
IL B
- I
2 I
- O
and O
PI B
3 I
- I
kinase I
- O
induced O
pathways O
for O
the O
regulation O
of O
E2F B
transcriptional O
activity O
include O
both O
rapamycin O
- O
resistant O
and O
rapamycin O
- O
sensitive O
components O
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

Paradoxical O
priming O
effects O
of O
IL B
- I
10 I
on O
cytokine B
production O
. O

Interestingly O
, O
an O
enhanced O
frequency O
of O
CD16 B
and O
CD68 O
( O
+ O
) O
cells O
among O
the O
CD14 O
( O
+ O
) O
cells O
was O
observed O
in O
the O
presence O
of O
IL B
- I
10 I
, O
independently O
of O
the O
pre O
- O
culture O
conditions O
of O
the O
PBMC O
. O

Transcription B
factors I
Sp1 B
and O
AP B
- I
2 I
mediate O
induction O
of O
acid B
sphingomyelinase I
during O
monocytic O
differentiation O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
319 I
and I
- I
219 I
bp I
upstream I
of O
the O
initiation O
codon O
and O
co O
- O
transfections O
with O
transcription B
factor I
expression I
plasmids I
for O
AP B
- I
2 I
and O
Sp1 B
resulted O
in O
augmented O
ASM O
promoter O
activity O
, O
which O
was O
abolished O
when O
the O
binding B
sites I
for O
these O
two O
factors O
were O
deleted O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
319 I
and I
- I
219 I
bp I
upstream I
of O
the O
initiation O
codon O
and O
co O
- O
transfections O
with O
transcription B
factor I
expression I
plasmids I
for O
AP B
- I
2 I
and O
Sp1 B
resulted O
in O
augmented O
ASM O
promoter O
activity O
, O
which O
was O
abolished O
when O
the O
binding B
sites I
for O
these O
two O
factors O
were O
deleted O
. O

NF B
- I
kappaB I
DNA O
binding O
was O
evaluated O
by O
electrophoretic O
mobility O
shift O
assay O
. O

Direct O
activation O
of O
PKC B
with O
PMA O
induced O
both O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
production O
by O
human O
monocytes O
. O

Direct O
activation O
of O
PKC B
with O
PMA O
induced O
both O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
production O
by O
human O
monocytes O
. O

Furthermore O
, O
our O
results O
provide O
evidence O
that O
PTK B
plays O
a O
role O
in O
LPS O
- O
induced O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
release O
in O
human O
monocytes O
and O
thus O
could O
be O
a O
potential O
therapeutic O
target O
in O
inflammatory O
states O
. O

Furthermore O
, O
our O
results O
provide O
evidence O
that O
PTK B
plays O
a O
role O
in O
LPS O
- O
induced O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
release O
in O
human O
monocytes O
and O
thus O
could O
be O
a O
potential O
therapeutic O
target O
in O
inflammatory O
states O
. O

The O
effects O
of O
GDSP O
on O
pancreatic O
weight O
, O
serum B
amylase I
and I
lipase I
, O
morphologic O
changes O
in O
the O
pancreas O
, O
neutrophil O
infiltration O
, O
and O
nuclear B
factor I
KB I
( O
NF B
- I
KB I
) O
activation O
were O
measured O
in O
rats O
infused O
with O
supramaximal O
dose O
of O
cerulein O
( O
5 O
( O
g O
/ O
kg O
/ O
h O
) O
for O
6 O
h O
. O

The O
effects O
of O
GDSP O
on O
pancreatic O
weight O
, O
serum B
amylase I
and I
lipase I
, O
morphologic O
changes O
in O
the O
pancreas O
, O
neutrophil O
infiltration O
, O
and O
nuclear B
factor I
KB I
( O
NF B
- I
KB I
) O
activation O
were O
measured O
in O
rats O
infused O
with O
supramaximal O
dose O
of O
cerulein O
( O
5 O
( O
g O
/ O
kg O
/ O
h O
) O
for O
6 O
h O
. O

The O
nature O
of O
the O
nuclear B
factor I
( O
s O
) O
that O
control O
TNF B
- I
alpha I
gene O
transcription O
in O
humans O
remains O
obscure O
, O
although O
NF B
- I
kappaB I
has O
been O
suggested O
. O

The O
nature O
of O
the O
nuclear B
factor I
( O
s O
) O
that O
control O
TNF B
- I
alpha I
gene O
transcription O
in O
humans O
remains O
obscure O
, O
although O
NF B
- I
kappaB I
has O
been O
suggested O
. O

Our O
previous O
studies O
pertaining O
to O
macrophage O
response O
to O
LPS O
identified O
a O
novel O
DNA B
- I
binding I
domain I
located O
from O
- O
550 O
to O
- O
487 O
in O
the O
human B
TNF I
- I
alpha I
promoter I
that O
contains O
transcriptional O
activity O
, O
but O
lacks O
any O
known O
NF B
- I
kappaB I
- B
binding I
sites I
. O

Our O
previous O
studies O
pertaining O
to O
macrophage O
response O
to O
LPS O
identified O
a O
novel O
DNA B
- I
binding I
domain I
located O
from O
- O
550 O
to O
- O
487 O
in O
the O
human B
TNF I
- I
alpha I
promoter I
that O
contains O
transcriptional O
activity O
, O
but O
lacks O
any O
known O
NF B
- I
kappaB I
- B
binding I
sites I
. O

Inhibition O
of O
LITAF B
mRNA I
expression O
in O
THP O
- O
1 O
cells O
resulted O
in O
a O
reduction O
of O
TNF B
- I
alpha I
transcripts O
. O

Capacitance O
would O
simply O
involve O
expression O
of O
IL B
- I
12R I
beta I
1 I
and I
beta I
2 I
subunits I
, O
regulated O
by O
TCR O
, O
IL B
- I
4 I
and O
IFNs B
. O

The O
transcription B
factor I
NF B
- I
ATc I
is O
synthesized O
in O
three O
prominent O
isoforms B
. O

Together O
, O
these O
results O
demonstrate O
that O
ER B
and O
PR B
can O
be O
activated O
by O
endogenous O
or O
exogenous O
ligands O
to O
induce O
a O
genetic O
response O
that O
impairs O
TNF B
- I
alpha I
- O
induced O
apoptosis O
in O
U937 O
cells O
. O

However O
, O
p38 B
MAPK I
is O
activated O
strongly O
and O
synergistically O
by O
either O
CD3 B
/ I
CD28 I
coligation O
or O
PMA O
/ O
Ca2 O
+ O
ionophore O
stimulation O
, O
which O
mimics O
TCR B
- O
CD3 B
/ I
CD28 I
- O
mediated O
signaling O
. O

However O
, O
p38 B
MAPK I
is O
activated O
strongly O
and O
synergistically O
by O
either O
CD3 B
/ I
CD28 I
coligation O
or O
PMA O
/ O
Ca2 O
+ O
ionophore O
stimulation O
, O
which O
mimics O
TCR B
- O
CD3 B
/ I
CD28 I
- O
mediated O
signaling O
. O

These O
data O
suggest O
that O
, O
in O
this O
inflammatory O
model O
, O
initial O
activation O
of O
NF B
- I
kappaB I
occurs O
in O
alveolar O
macrophages O
and O
the O
ensuing O
production O
of O
TNF B
- I
alpha I
may O
propagate O
NF B
- I
kappaB I
activation O
to O
other O
cell O
types O
in O
the O
lung O
. O

These O
data O
suggest O
that O
, O
in O
this O
inflammatory O
model O
, O
initial O
activation O
of O
NF B
- I
kappaB I
occurs O
in O
alveolar O
macrophages O
and O
the O
ensuing O
production O
of O
TNF B
- I
alpha I
may O
propagate O
NF B
- I
kappaB I
activation O
to O
other O
cell O
types O
in O
the O
lung O
. O

These O
data O
suggest O
that O
, O
in O
this O
inflammatory O
model O
, O
initial O
activation O
of O
NF B
- I
kappaB I
occurs O
in O
alveolar O
macrophages O
and O
the O
ensuing O
production O
of O
TNF B
- I
alpha I
may O
propagate O
NF B
- I
kappaB I
activation O
to O
other O
cell O
types O
in O
the O
lung O
. O

Interferon B
- I
beta I
mediates O
stromal O
cell O
rescue O
of O
T O
cells O
from O
apoptosis O
. O

Interferon B
- I
alpha I
and I
- I
beta I
promote O
the O
reversion O
of O
blast O
Tcells O
to O
a O
resting O
G0 O
/ O
G1 O
configuration O
with O
all O
the O
characteristic O
features O
of O
stromal O
cell O
rescue O
; O
such O
as O
high O
Bcl B
- I
XL I
expression O
and O
low O
Bcl B
- I
2 I
. O

Interferon B
- I
alpha I
and I
- I
beta I
promote O
the O
reversion O
of O
blast O
Tcells O
to O
a O
resting O
G0 O
/ O
G1 O
configuration O
with O
all O
the O
characteristic O
features O
of O
stromal O
cell O
rescue O
; O
such O
as O
high O
Bcl B
- I
XL I
expression O
and O
low O
Bcl B
- I
2 I
. O

We O
also O
show O
that O
DFX O
treatment O
limits O
the O
in O
vivo O
activation O
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
involved O
in O
both O
TNF B
- I
alpha I
gene O
transcription O
and O
TNF B
- I
alpha I
signalling O
( O
P O
< O
0 O
. O
005 O
) O
. O

We O
also O
show O
that O
DFX O
treatment O
limits O
the O
in O
vivo O
activation O
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
involved O
in O
both O
TNF B
- I
alpha I
gene O
transcription O
and O
TNF B
- I
alpha I
signalling O
( O
P O
< O
0 O
. O
005 O
) O
. O

We O
also O
show O
that O
DFX O
treatment O
limits O
the O
in O
vivo O
activation O
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
involved O
in O
both O
TNF B
- I
alpha I
gene O
transcription O
and O
TNF B
- I
alpha I
signalling O
( O
P O
< O
0 O
. O
005 O
) O
. O

N O
- O
acetyl O
- O
L O
- O
cysteine O
inhibits O
primary O
human O
T O
cell O
responses O
at O
the O
dendritic O
cell O
level O
: O
association O
with O
NF B
- I
kappaB I
inhibition O
. O

Thrombin B
receptor O
activation O
peptide O
, O
a O
14 O
- O
amino O
- O
acid O
peptide O
representing O
the O
new O
NH2 B
terminus I
of O
proteolytically O
activated O
receptor B
- I
1 I
, O
mimicked O
thrombin B
' O
s O
action O
in O
inducing O
ICAM B
- I
1 I
expression O
. O

Thrombin B
receptor O
activation O
peptide O
, O
a O
14 O
- O
amino O
- O
acid O
peptide O
representing O
the O
new O
NH2 B
terminus I
of O
proteolytically O
activated O
receptor B
- I
1 I
, O
mimicked O
thrombin B
' O
s O
action O
in O
inducing O
ICAM B
- I
1 I
expression O
. O

These O
data O
indicate O
that O
thrombin B
activates O
endothelial O
ICAM B
- I
1 I
expression O
and O
polymorphonuclear O
leukocyte O
adhesion O
by O
NF B
- I
kappa I
Bp65 I
binding O
to O
the O
downstream O
NF B
- I
kappa I
B I
site I
of O
ICAM B
- I
1 I
promoter I
after O
proteolytically O
activated O
receptor O
- O
1 O
activation O
. O

Here O
we O
demonstrate O
that O
both O
Smad6 B
and O
Smad7 B
are O
human B
bone I
morphogenetic I
protein I
- I
2 I
( O
hBMP B
- I
2 I
) O
- O
inducible O
antagonists O
of O
hBMP B
- I
2 I
- O
induced O
growth O
arrest O
and O
apoptosis O
in O
mouse O
B O
cell O
hybridoma O
HS O
- O
72 O
cells O
. O

Here O
we O
demonstrate O
that O
both O
Smad6 B
and O
Smad7 B
are O
human B
bone I
morphogenetic I
protein I
- I
2 I
( O
hBMP B
- I
2 I
) O
- O
inducible O
antagonists O
of O
hBMP B
- I
2 I
- O
induced O
growth O
arrest O
and O
apoptosis O
in O
mouse O
B O
cell O
hybridoma O
HS O
- O
72 O
cells O
. O

Interestingly O
, O
CyA O
and O
indomethacin O
did O
not O
suppress O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
- O
induced O
adhesion O
molecule O
expression O
on O
HUVECs O
, O
whereas O
aspirin O
had O
an O
inhibitory O
effect O
. O

50 O
% O
HCS O
downregulates O
the O
alpha B
- I
chain I
and O
slightly O
upregulates O
the O
beta B
- I
chain I
. O

50 O
% O
HCS O
downregulates O
the O
alpha B
- I
chain I
and O
slightly O
upregulates O
the O
beta B
- I
chain I
. O

Inhibition O
of O
IL B
- I
4 I
- O
inducible O
gene O
expression O
in O
human O
monocytes O
by O
type B
I I
and I
type I
II I
interferons I
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

A O
cdk2 O
inhibitor O
, O
Olomoucine O
, O
as O
well O
as O
a O
dominant B
- I
negative I
cdk2 I
construct I
prevented O
HLA B
class I
I I
- O
mediated O
inactivation O
of O
Rb B
; O
in O
contrast O
, O
dominant B
- I
negative I
cdk4 I
and I
cdk6 I
constructs I
had O
no O
effect O
. O

In O
Jurkat O
T O
- O
cells O
, O
PG490 O
inhibits O
PMA O
/ O
Iono O
- O
stimulated O
IL B
- I
2 I
transcription O
. O

PG490 O
also O
inhibits O
PMA O
- O
stimulated O
activation O
of O
a O
chimeric B
transcription I
factor I
in O
which O
the O
C B
- I
terminal I
TA1 I
transactivation I
domain I
of O
NF B
- I
kappaB I
p65 I
is O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL4 B
. O

PG490 O
also O
inhibits O
PMA O
- O
stimulated O
activation O
of O
a O
chimeric B
transcription I
factor I
in O
which O
the O
C B
- I
terminal I
TA1 I
transactivation I
domain I
of O
NF B
- I
kappaB I
p65 I
is O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL4 B
. O

Unexpected O
and O
coordinated O
expression O
of O
Spi B
- I
1 I
, O
Fli B
- I
1 I
, O
and O
megakaryocytic B
genes I
in O
four O
Epo O
- O
dependent O
cell O
lines O
established O
from O
transgenic O
mice O
displaying O
erythroid O
- O
specific O
expression O
of O
a O
thermosensitive B
SV40 I
T I
antigen I
. O

Unexpected O
and O
coordinated O
expression O
of O
Spi B
- I
1 I
, O
Fli B
- I
1 I
, O
and O
megakaryocytic B
genes I
in O
four O
Epo O
- O
dependent O
cell O
lines O
established O
from O
transgenic O
mice O
displaying O
erythroid O
- O
specific O
expression O
of O
a O
thermosensitive B
SV40 I
T I
antigen I
. O

Most O
erythroleukemic O
cell O
lines O
established O
in O
vitro O
coexpress O
erythrocytic B
and I
megakaryocytic I
markers I
that O
often O
are O
associated O
with O
expression O
of O
Spi B
- I
1 I
and O
/ O
or O
Fli B
- I
1 I
transcription I
factors I
known O
as O
transactivators B
of I
megakaryocyte I
- I
specific I
promoters I
. O

However O
, O
like O
normal O
Ter O
119 O
erythroid O
cells O
, O
these O
Ter O
119 O
positive O
cells O
from O
transgenic O
mice O
still O
expressed O
high O
levels O
of O
beta B
- I
globin I
and O
very O
low O
or O
undetectable O
glycoprotein B
IIb I
and O
platelet B
factor I
4 I
megakaryocytic I
transcripts I
. O

Spi B
- I
C I
, O
a O
novel O
Ets B
protein I
that O
is O
temporally O
regulated O
during O
B O
lymphocyte O
development O
. O

Spi B
- I
C I
interacted O
with O
DNA O
similarly O
to O
PU B
. I
1 I
as O
judged O
by O
methylation O
interference O
, O
band O
- O
shift O
and O
site O
selection O
analysis O
, O
and O
activated O
transcription O
of O
a O
kappaY B
element I
reporter I
gene I
upon O
co O
- O
transfection O
of O
HeLa O
cells O
. O

Spi B
- I
C I
interacted O
with O
DNA O
similarly O
to O
PU B
. I
1 I
as O
judged O
by O
methylation O
interference O
, O
band O
- O
shift O
and O
site O
selection O
analysis O
, O
and O
activated O
transcription O
of O
a O
kappaY B
element I
reporter I
gene I
upon O
co O
- O
transfection O
of O
HeLa O
cells O
. O

The O
viral B
protein I
Tax B
induces O
the O
activation O
and O
nuclear O
translocalization O
of O
transcription B
factor I
NF B
- I
kappaB I
, O
which O
is O
proposed O
to O
play O
a O
crucial O
role O
in O
the O
transformation O
of O
T O
cells O
by O
HTLV O
- O
I O
. O

We O
found O
that O
leukemic O
cells O
from O
ATL O
patients O
, O
like O
HTLV O
- O
I O
- O
infected O
T O
- O
cell O
lines O
, O
display O
constitutive O
NF B
- I
kappaB I
DNA O
binding O
activity O
and O
increased O
degradation O
of O
IkappaBalpha B
( O
an O
inhibitor O
of O
NF B
- I
kappaB I
) O
. O

We O
found O
that O
leukemic O
cells O
from O
ATL O
patients O
, O
like O
HTLV O
- O
I O
- O
infected O
T O
- O
cell O
lines O
, O
display O
constitutive O
NF B
- I
kappaB I
DNA O
binding O
activity O
and O
increased O
degradation O
of O
IkappaBalpha B
( O
an O
inhibitor O
of O
NF B
- I
kappaB I
) O
. O

One O
T O
- O
cell O
line O
derived O
from O
ATL O
leukemic O
cells O
, O
TL O
- O
Om1 O
, O
displayed O
constitutive O
NF B
- I
kappaB I
activity O
, O
as O
well O
as O
enhanced O
degradation O
of O
IkappaBalpha B
, O
despite O
the O
lack O
of O
detectable O
Tax B
expression O
. O

Interestingly O
, O
the O
NF B
- I
kappaB I
in O
TL O
- O
Om1 O
consists O
of O
p50 B
/ I
p50 I
and O
p50 B
/ I
p65 I
like O
that O
in O
fresh O
primary O
leukemic O
cells O
. O

Interestingly O
, O
the O
NF B
- I
kappaB I
in O
TL O
- O
Om1 O
consists O
of O
p50 B
/ I
p50 I
and O
p50 B
/ I
p65 I
like O
that O
in O
fresh O
primary O
leukemic O
cells O
. O

Interestingly O
, O
the O
NF B
- I
kappaB I
in O
TL O
- O
Om1 O
consists O
of O
p50 B
/ I
p50 I
and O
p50 B
/ I
p65 I
like O
that O
in O
fresh O
primary O
leukemic O
cells O
. O

Therefore O
, O
this O
study O
was O
designed O
to O
analyze O
the O
role O
of O
Lck B
in O
IFN B
- I
alpha I
signaling O
by O
using O
the O
Jurkat O
, O
JCam O
( O
an O
Lck O
- O
defective O
cell O
line O
derived O
from O
Jurkat O
) O
, O
and O
JCam O
/ O
Lck O
( O
JCam O
cells O
with O
Lck B
restored O
) O
. O

Finally O
, O
the O
results O
demonstrate O
that O
IFN B
- I
alpha I
exerts O
an O
antiproliferative O
effect O
in O
all O
three O
cell O
lines O
. O

We O
investigated O
the O
MAPk B
kinase I
( O
MKK B
) O
that O
activates O
p38 B
MAPk I
in O
response O
to O
LPS O
, O
the O
p38 B
MAPk I
isoforms I
that O
are O
activated O
as O
part O
of O
this O
pathway O
, O
and O
the O
functional O
responses O
affected O
by O
p38 B
MAPk I
activation O
. O

The O
I B
gamma I
3 I
ECS B
lies O
upstream O
of O
the O
major B
I I
gamma I
3 I
transcription I
initiation I
site I
and O
displays O
more O
than O
90 O
% O
identity O
with O
the O
corresponding O
human B
I I
gamma I
1 I
, O
I B
gamma I
2 I
, O
and O
I B
gamma I
4 I
regions O
. O

The O
I B
gamma I
3 I
ECS B
lies O
upstream O
of O
the O
major B
I I
gamma I
3 I
transcription I
initiation I
site I
and O
displays O
more O
than O
90 O
% O
identity O
with O
the O
corresponding O
human B
I I
gamma I
1 I
, O
I B
gamma I
2 I
, O
and O
I B
gamma I
4 I
regions O
. O

The O
I B
gamma I
3 I
ECS B
lies O
upstream O
of O
the O
major B
I I
gamma I
3 I
transcription I
initiation I
site I
and O
displays O
more O
than O
90 O
% O
identity O
with O
the O
corresponding O
human B
I I
gamma I
1 I
, O
I B
gamma I
2 I
, O
and O
I B
gamma I
4 I
regions O
. O

In O
these O
transfected O
CL O
- O
01 O
cells O
, O
CD40 O
: O
CD40L B
engagement O
and O
exposure O
to O
IL B
- I
4 I
synergistically O
induced O
gamma O
3 O
ECS O
- O
dependent O
luciferase B
reporter I
gene I
activation O
. O

In O
these O
transfected O
CL O
- O
01 O
cells O
, O
CD40 O
: O
CD40L B
engagement O
and O
exposure O
to O
IL B
- I
4 I
synergistically O
induced O
gamma O
3 O
ECS O
- O
dependent O
luciferase B
reporter I
gene I
activation O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
p50 B
/ I
p65 I
/ I
c I
- I
Rel I
and O
STAT B
- I
6 I
are O
effectively O
induced O
by O
CD40L B
and O
IL B
- I
4 I
, O
respectively O
, O
and O
bind O
to O
specific O
DNA B
motifs I
within O
the O
ECS B
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
p50 B
/ I
p65 I
/ I
c I
- I
Rel I
and O
STAT B
- I
6 I
are O
effectively O
induced O
by O
CD40L B
and O
IL B
- I
4 I
, O
respectively O
, O
and O
bind O
to O
specific O
DNA B
motifs I
within O
the O
ECS B
. O

Activation O
of O
MHC B
class I
II I
promoters I
requires O
binding O
of O
at O
least O
three O
distinct O
multi B
- I
protein I
complexes I
( O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
) O
. O

We O
show O
, O
however O
, O
that O
the O
presence O
of O
CIITA B
does O
not O
affect O
the O
stability O
of O
the O
higher O
- O
order O
protein O
complex O
formed O
on O
DNA O
by O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
. O

SH2 B
domain I
- I
containing I
protein I
76 I
( O
SLP B
- I
76 I
) O
interacts O
with O
the O
guanine B
nucleotide I
exchange I
factor I
Vav B
to O
activate O
the O
nuclear B
factor I
of I
activated I
cells I
( O
NF B
- I
AT I
) O
, O
and O
its O
expression O
is O
required O
for O
normal O
T O
cell O
development O
. O

SH2 B
domain I
- I
containing I
protein I
76 I
( O
SLP B
- I
76 I
) O
interacts O
with O
the O
guanine B
nucleotide I
exchange I
factor I
Vav B
to O
activate O
the O
nuclear B
factor I
of I
activated I
cells I
( O
NF B
- I
AT I
) O
, O
and O
its O
expression O
is O
required O
for O
normal O
T O
cell O
development O
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC B
chemokine I
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma B
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

Role O
of O
cellular B
tumor I
necrosis I
factor I
receptor I
- I
associated I
factors I
in O
NF B
- I
kappaB I
activation O
and O
lymphocyte O
transformation O
by O
herpesvirus O
Saimiri O
STP B
. O

In O
addition O
, O
a O
somewhat O
divergent O
region O
of O
STP B
- I
C488 I
is O
critical O
for O
TRAF B
association O
. O

MDS1 B
/ I
EVI1 I
is O
inappropriately O
activated O
in O
myeloid O
leukemias O
following O
chromosomal O
rearrangements O
involving O
band B
3q26 I
. O

This O
fusion O
protein O
contains O
the O
DNA B
- I
binding I
domain I
of O
the O
transcription B
factor I
AML1 B
fused O
in O
- O
frame O
to O
the O
entire O
MDS1 B
/ I
EVI1 I
with O
the O
exclusion O
of O
its O
first O
12 O
amino O
acids O
. O

By O
using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
also O
show O
that O
EVI1 B
( O
contained O
in O
its O
entirety O
in O
MDS1 B
/ I
EVI1 I
and O
AML1 B
/ I
MDS1 I
/ I
EVI1 I
) O
physically O
interacts O
with O
SMAD3 B
, O
which O
is O
an O
intracellular O
mediator O
of O
TGF B
- I
beta1 I
signaling O
. O

By O
using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
also O
show O
that O
EVI1 B
( O
contained O
in O
its O
entirety O
in O
MDS1 B
/ I
EVI1 I
and O
AML1 B
/ I
MDS1 I
/ I
EVI1 I
) O
physically O
interacts O
with O
SMAD3 B
, O
which O
is O
an O
intracellular O
mediator O
of O
TGF B
- I
beta1 I
signaling O
. O

Tcf B
- I
1 I
- O
mediated O
transcription O
in O
T O
lymphocytes O
: O
differential O
role O
for O
glycogen B
synthase I
kinase I
- I
3 I
in O
fibroblasts O
and O
T O
cells O
. O

Recently O
, O
members O
of O
the O
Lef B
/ I
Tcf I
transcription I
factor I
family I
have O
been O
identified O
as O
protein O
partners O
of O
beta B
- I
catenin I
, O
explaining O
how O
beta B
- I
catenin I
alters O
gene O
expression O
. O

Recently O
, O
members O
of O
the O
Lef B
/ I
Tcf I
transcription I
factor I
family I
have O
been O
identified O
as O
protein O
partners O
of O
beta B
- I
catenin I
, O
explaining O
how O
beta B
- I
catenin I
alters O
gene O
expression O
. O

In O
contrast O
, O
in O
C57MG O
fibroblast O
cells O
, O
lithium O
inactivates O
GSK B
- I
3beta I
and O
induces O
Tcf O
- O
controlled O
transcription O
. O

Overexpression O
of O
SIT B
in O
Jurkat O
cells O
downmodulates O
T O
cell O
receptor O
- O
and O
phytohemagglutinin O
- O
mediated O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
by O
interfering O
with O
signaling O
processes O
that O
are O
probably O
located O
upstream O
of O
activation O
of O
phospholipase B
C I
. O

However O
, O
binding O
of O
SHP2 B
to O
SIT B
is O
not O
required O
for O
inhibition O
of O
NF B
- I
AT I
induction O
, O
suggesting O
that O
SIT B
not O
only O
regulates O
NF B
- I
AT I
activity O
but O
also O
controls O
NF B
- I
AT I
unrelated O
pathways O
of O
T O
cell O
activation O
involving O
SHP2 B
. O

However O
, O
binding O
of O
SHP2 B
to O
SIT B
is O
not O
required O
for O
inhibition O
of O
NF B
- I
AT I
induction O
, O
suggesting O
that O
SIT B
not O
only O
regulates O
NF B
- I
AT I
activity O
but O
also O
controls O
NF B
- I
AT I
unrelated O
pathways O
of O
T O
cell O
activation O
involving O
SHP2 B
. O

However O
, O
binding O
of O
SHP2 B
to O
SIT B
is O
not O
required O
for O
inhibition O
of O
NF B
- I
AT I
induction O
, O
suggesting O
that O
SIT B
not O
only O
regulates O
NF B
- I
AT I
activity O
but O
also O
controls O
NF B
- I
AT I
unrelated O
pathways O
of O
T O
cell O
activation O
involving O
SHP2 B
. O

Angiotensin B
II I
activates O
the O
proinflammatory B
transcription I
factor I
nuclear B
factor I
- I
kappaB I
in O
human O
monocytes O
. O

ANG B
II I
, O
like O
TNFalpha B
, O
caused O
rapid O
activation O
of O
NF B
- I
kappaB I
in O
human O
mononuclear O
cells O
isolated O
from O
peripheral O
blood O
by O
Ficoll O
density O
gradient O
. O

Increased O
mRNA B
and O
surface O
expression O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
were O
noted O
within O
hours O
. O

Increased O
mRNA B
and O
surface O
expression O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
were O
noted O
within O
hours O
. O

Increased O
mRNA B
and O
surface O
expression O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
were O
noted O
within O
hours O
. O

Transient O
pseudo O
- O
hypoaldosteronism O
following O
resection O
of O
the O
ileum O
: O
normal O
level O
of O
lymphocytic B
aldosterone I
receptors I
outside O
the O
acute O
phase O
. O

In O
contrast O
, O
treatment O
of O
HL O
- O
60 O
cells O
with O
retinoic O
acid O
or O
DMSO O
, O
which O
results O
in O
a O
granulocytic O
differentiation O
of O
these O
cells O
, O
decreases O
4E B
- I
BP1 I
amount O
without O
affecting O
its O
phosphorylation O
and O
strongly O
increases O
4E B
- I
BP2 I
amount O
. O

In O
contrast O
, O
treatment O
of O
HL O
- O
60 O
cells O
with O
retinoic O
acid O
or O
DMSO O
, O
which O
results O
in O
a O
granulocytic O
differentiation O
of O
these O
cells O
, O
decreases O
4E B
- I
BP1 I
amount O
without O
affecting O
its O
phosphorylation O
and O
strongly O
increases O
4E B
- I
BP2 I
amount O
. O

In O
typical O
AITL O
, O
some O
neoplastic O
cells O
were O
positive O
for O
Bcl B
- I
6 I
, O
showing O
variable O
degrees O
of O
staining O
. O

( O
2 O
) O
Intrafollicular O
CD3 O
+ O
T O
cells O
, O
many O
of O
which O
were O
also O
positive O
for O
Bcl B
- I
6 I
, O
were O
markedly O
depleted O
in O
AITL O
/ O
GC O
, O
with O
increased O
interfollicular O
Bcl O
- O
6 O
+ O
/ O
CD3 O
+ O
cells O
, O
suggesting O
an O
outward O
migration O
of O
intrafollicular O
T O
cells O
in O
this O
condition O
. O

( O
5 O
) O
Some O
neoplastic O
cells O
in O
AITL O
stained O
for O
Bcl B
- I
6 I
, O
suggesting O
up O
- O
regulation O
of O
Bcl B
- I
6 I
expression O
in O
this O
tumor O
. O

( O
5 O
) O
Some O
neoplastic O
cells O
in O
AITL O
stained O
for O
Bcl B
- I
6 I
, O
suggesting O
up O
- O
regulation O
of O
Bcl B
- I
6 I
expression O
in O
this O
tumor O
. O

Because O
these O
induced O
gene O
products O
have O
NF B
- I
kappaB I
sites I
in O
their O
promoter B
regions I
, O
we O
next O
examined O
whether O
there O
was O
an O
up O
- O
regulation O
of O
nuclear O
NF B
- I
kappaB I
levels O
. O

Glycoprotein B
( I
GP I
) I
IX I
is O
a O
subunit O
of O
the O
von B
Willebrand I
receptor I
, O
GPIb B
- I
V I
- I
IX I
, O
which O
mediates O
adhesion O
of O
platelets O
to O
the O
subendothelium O
of O
damaged O
blood O
vessels O
. O

These O
results O
suggest O
that O
Fli B
- I
1 I
is O
likely O
to O
regulate O
lineage B
- I
specific I
genes I
during O
megakaryocytopoiesis O
. O

Immunoprecipitation O
experiments O
failed O
to O
demonstrate O
an O
association O
between O
nuclear O
I B
( I
kappa I
) I
B I
( I
alpha I
) I
and O
NF B
- I
kappaB I
proteins O
. O

Additionally O
, O
CoCl2 O
caused O
a O
two O
- O
to O
threefold O
increase O
in O
the O
rate O
of O
transendothelial O
migration O
of O
monocyte O
- O
like O
HL O
- O
60 O
cells O
and O
a O
twentyfold O
increase O
in O
phosphorylation O
of O
platelet B
endothelial I
cell I
adhesion I
molecules I
( O
PECAM B
- I
1 I
) O
. O

Activation O
of O
NF B
- I
kappaB I
is O
thought O
to O
be O
required O
for O
cytokine O
release O
from O
LPS O
- O
responsive O
cells O
, O
a O
critical O
step O
for O
endotoxic O
effects O
. O

LPS O
- O
induced O
NF B
- I
kappaB I
activation O
was O
not O
inhibited O
by O
a O
dominant O
negative O
mutant O
of O
TRAF2 B
that O
is O
involved O
in O
TNF B
signaling O
. O

Tyrosine O
phosphorylation O
of O
IFN B
- I
gammaR I
, O
Jak1 B
, O
Jak2 B
, O
and O
Stat1alpha B
was O
examined O
by O
immunoblotting O
. O

In O
addition O
, O
IFN B
- I
gamma I
enhanced O
the O
DNA O
- O
binding O
activity O
of O
Stat1alpha B
. O

Moreover O
, O
several O
transgenic O
mice O
developed O
acute O
leukemia O
, O
classified O
as O
T O
- O
ALL O
based O
on O
the O
surface O
marker O
analysis O
and O
DNA O
rearrangements O
, O
suggesting O
that O
an O
additional O
event O
is O
required O
for O
malignant O
transformation O
of O
lymphoid O
cells O
expressing O
E2A B
- I
HLF I
. O

Our O
findings O
provide O
insight O
into O
the O
biological O
function O
of O
E2A B
- I
HLF I
in O
lymphoid O
development O
and O
also O
its O
role O
in O
leukemogenesis O
. O

We O
found O
IL B
- I
2Ralpha I
expression O
to O
be O
increased O
in O
BAL O
cells O
from O
involved O
sites O
of O
active O
pulmonary O
tuberculosis O
. O

Expression O
of O
the O
alpha B
- I
chain I
of O
IL B
- I
2Ralpha I
on O
peripheral O
blood O
monocytes O
( O
PBM O
) O
was O
induced O
by O
M O
. O
tuberculosis O
by O
flow O
cytometry O
evaluation O
. O

Expression O
of O
the O
alpha B
- I
chain I
of O
IL B
- I
2Ralpha I
on O
peripheral O
blood O
monocytes O
( O
PBM O
) O
was O
induced O
by O
M O
. O
tuberculosis O
by O
flow O
cytometry O
evaluation O
. O

The O
IL B
- I
2 I
growth O
hormone O
is O
the O
major O
growth O
factor O
of O
activated O
T O
lymphocytes O
during O
a O
developing O
immune O
response O
. O

In O
several O
cell O
types O
, O
activation O
of O
NF B
- I
kappa I
B I
and O
/ O
or O
activating B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
has O
been O
demonstrated O
to O
be O
extremely O
important O
in O
blocking O
apoptosis O
. O

Similarly O
, O
IL B
- I
2 I
neither O
activates O
JNK B
nor O
increases O
AP B
- I
1 I
binding O
activity O
to O
a O
consensus O
o B
- I
tetradecanoylphorbol I
13 I
- I
acetate I
( I
TPA I
) I
response I
element I
. O

Similarly O
, O
IL B
- I
2 I
neither O
activates O
JNK B
nor O
increases O
AP B
- I
1 I
binding O
activity O
to O
a O
consensus O
o B
- I
tetradecanoylphorbol I
13 I
- I
acetate I
( I
TPA I
) I
response I
element I
. O

Unlike O
the O
proposed O
role O
of O
Cbl B
as O
a O
negative O
regulator O
, O
our O
results O
suggest O
that O
the O
Cbl B
homologue O
Cbl B
- I
b I
has O
a O
positive O
role O
in O
T O
- O
cell O
signaling O
, O
most O
likely O
via O
a O
direct O
interaction O
with O
the O
upstream B
kinase I
Zap B
- I
70 I
. O

Unlike O
the O
proposed O
role O
of O
Cbl B
as O
a O
negative O
regulator O
, O
our O
results O
suggest O
that O
the O
Cbl B
homologue O
Cbl B
- I
b I
has O
a O
positive O
role O
in O
T O
- O
cell O
signaling O
, O
most O
likely O
via O
a O
direct O
interaction O
with O
the O
upstream B
kinase I
Zap B
- I
70 I
. O

Grf40 B
, O
A O
novel O
Grb2 B
family I
member I
, O
is O
involved O
in O
T O
cell O
signaling O
through O
interaction O
with O
SLP B
- I
76 I
and O
LAT B
. O

Grf40 B
, O
A O
novel O
Grb2 B
family I
member I
, O
is O
involved O
in O
T O
cell O
signaling O
through O
interaction O
with O
SLP B
- I
76 I
and O
LAT B
. O

The O
therapeutic O
potential O
of O
drugs O
that O
block O
the O
induction O
of O
cyclooxygenase B
- I
2 I
has O
been O
emphasized O
. O

When O
two O
4 O
- O
trifluoromethyl O
salicylate O
derivatives O
[ O
2 O
- O
acetoxy O
- O
4 O
- O
trifluoromethyl O
- O
benzoic O
acid O
( O
triflusal O
) O
and O
its O
deacetylated O
metabolite O
2 O
- O
hydroxy O
- O
4 O
- O
trifluoromethylbenzo O
acid O
( O
HTB O
) O
] O
were O
compared O
with O
aspirin O
and O
sodium O
salicylate O
as O
cyclooxygenase B
- I
2 I
( O
COX O
- O
2 O
) O
inhibitors O
, O
we O
observed O
that O
in O
bacterial O
lipopolysaccharide O
- O
activated O
human O
blood O
, O

The O
CD34 O
+ O
myelomonocytic O
cell O
line O
KG1 O
differentiates O
into O
dendritic O
- O
like O
cells O
in O
response O
to O
granulocyte B
- I
macrophage I
CSF I
plus O
TNF B
- I
alpha I
, O
or O
PMA O
( O
with O
or O
without O
the O
calcium O
ionophore O
ionomycin O
, O
or O
TNF B
- I
alpha I
) O
, O
with O
different O
stimuli O
mediating O
different O
aspects O
of O
the O
process O
. O

The O
CD34 O
+ O
myelomonocytic O
cell O
line O
KG1 O
differentiates O
into O
dendritic O
- O
like O
cells O
in O
response O
to O
granulocyte B
- I
macrophage I
CSF I
plus O
TNF B
- I
alpha I
, O
or O
PMA O
( O
with O
or O
without O
the O
calcium O
ionophore O
ionomycin O
, O
or O
TNF B
- I
alpha I
) O
, O
with O
different O
stimuli O
mediating O
different O
aspects O
of O
the O
process O
. O

In O
this O
study O
, O
we O
examined O
whether O
gp41 B
- O
induced O
IL B
- I
10 I
up O
- O
regulation O
is O
mediated O
by O
the O
previously O
described O
synergistic O
activation O
of O
cAMP O
and O
NF B
- I
kappaB I
pathways O
. O

In O
this O
study O
, O
we O
examined O
whether O
gp41 B
- O
induced O
IL B
- I
10 I
up O
- O
regulation O
is O
mediated O
by O
the O
previously O
described O
synergistic O
activation O
of O
cAMP O
and O
NF B
- I
kappaB I
pathways O
. O

The O
transcription B
factors I
PU B
. I
1 I
and O
C B
/ I
EBPalpha I
are O
responsible O
for O
normal O
myeloid O
differentiation O
from O
stem O
cells O
to O
monocytes O
or O
granulocytes O
. O

The O
transcription B
factors I
PU B
. I
1 I
and O
C B
/ I
EBPalpha I
are O
responsible O
for O
normal O
myeloid O
differentiation O
from O
stem O
cells O
to O
monocytes O
or O
granulocytes O
. O

However O
, O
the O
phenotypic O
analysis O
of O
NF B
- I
AT I
- O
deficient O
mice O
supports O
the O
idea O
that O
there O
are O
tissue O
- O
and O
gene O
- O
specific O
functions O
as O
well O
. O

RFLAT B
- I
1 I
: O
a O
new O
zinc B
finger I
transcription I
factor I
that O
activates O
RANTES B
gene I
expression O
in O
T O
lymphocytes O
. O

In O
addition O
, O
the O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
and O
enhanced O
tyrosine O
phosphorylation O
of O
phospholipase O
Cgamma O
were O
seen O
after O
anti O
- O
CD28 O
mAb O
and O
CHO O
- O
CD80 O
stimulation O
but O
to O
a O
much O
lesser O
extent O
after O
CHO B
- I
CD86 I
stimulation O
. O

If O
there O
is O
a O
reciprocal O
elevation O
of O
gamma B
- I
globin I
expression O
upon O
repression O
, O
this O
approach O
could O
be O
useful O
in O
additional O
hemoglobinopathies O
. O

The O
master O
switch O
for O
the O
expression O
of O
these O
genes O
is O
the O
class B
II I
transactivator I
( O
CIITA B
) O
. O

In O
order O
to O
elucidate O
the O
role O
of O
NF B
- I
ATp I
, O
one O
of O
the O
most O
prominent O
members O
of O
family O
of O
NF B
- I
AT I
transcription I
factors I
in O
peripheral O
T O
lymphocytes O
, O
in O
T O
cell O
activation O
and O
differentiation O
we O
created O
NF B
- I
ATp I
- O
deficient O
mice O
by O
gene O
targeting O
. O

In O
order O
to O
elucidate O
the O
role O
of O
NF B
- I
ATp I
, O
one O
of O
the O
most O
prominent O
members O
of O
family O
of O
NF B
- I
AT I
transcription I
factors I
in O
peripheral O
T O
lymphocytes O
, O
in O
T O
cell O
activation O
and O
differentiation O
we O
created O
NF B
- I
ATp I
- O
deficient O
mice O
by O
gene O
targeting O
. O

Apart O
from O
clear O
- O
cut O
defects O
in O
the O
synthesis O
of O
mRNAs B
for O
Th2 B
- I
type I
lymphokines I
, O
such O
as O
IL B
- I
4 I
, O
IL B
- I
5 I
, O
IL B
- I
10 I
and O
IL B
- I
13 I
, O
in O
primary O
and O
secondary O
stimulations O
of O
spleen O
cells O
in O
vitro O
, O
of O
a O
distinct O
impaired O
deletion O
of O
V O
beta O
11 O
+ O
/ O
CD4 O
+ O
T O
lymphocytes O
from O
these O
mice O
was O
detected O
after O
superantigen O
injection O
. O

Apart O
from O
clear O
- O
cut O
defects O
in O
the O
synthesis O
of O
mRNAs B
for O
Th2 B
- I
type I
lymphokines I
, O
such O
as O
IL B
- I
4 I
, O
IL B
- I
5 I
, O
IL B
- I
10 I
and O
IL B
- I
13 I
, O
in O
primary O
and O
secondary O
stimulations O
of O
spleen O
cells O
in O
vitro O
, O
of O
a O
distinct O
impaired O
deletion O
of O
V O
beta O
11 O
+ O
/ O
CD4 O
+ O
T O
lymphocytes O
from O
these O
mice O
was O
detected O
after O
superantigen O
injection O
. O

Apart O
from O
clear O
- O
cut O
defects O
in O
the O
synthesis O
of O
mRNAs B
for O
Th2 B
- I
type I
lymphokines I
, O
such O
as O
IL B
- I
4 I
, O
IL B
- I
5 I
, O
IL B
- I
10 I
and O
IL B
- I
13 I
, O
in O
primary O
and O
secondary O
stimulations O
of O
spleen O
cells O
in O
vitro O
, O
of O
a O
distinct O
impaired O
deletion O
of O
V O
beta O
11 O
+ O
/ O
CD4 O
+ O
T O
lymphocytes O
from O
these O
mice O
was O
detected O
after O
superantigen O
injection O
. O

Apart O
from O
clear O
- O
cut O
defects O
in O
the O
synthesis O
of O
mRNAs B
for O
Th2 B
- I
type I
lymphokines I
, O
such O
as O
IL B
- I
4 I
, O
IL B
- I
5 I
, O
IL B
- I
10 I
and O
IL B
- I
13 I
, O
in O
primary O
and O
secondary O
stimulations O
of O
spleen O
cells O
in O
vitro O
, O
of O
a O
distinct O
impaired O
deletion O
of O
V O
beta O
11 O
+ O
/ O
CD4 O
+ O
T O
lymphocytes O
from O
these O
mice O
was O
detected O
after O
superantigen O
injection O
. O

Moreover O
, O
NF B
- I
ATp I
- O
/ O
- O
mice O
older O
than O
6 O
weeks O
show O
an O
2 O
- O
5 O
fold O
increase O
in O
number O
of O
lymphocytes O
. O

Our O
data O
constitute O
a O
starting O
point O
for O
studies O
to O
elucidate O
the O
molecular O
mechanism O
by O
which O
TGF B
- I
beta I
regulates O
IgA B
production O
. O

Using O
synovial O
cells O
from O
rheumatoid O
arthritis O
( O
RA O
) O
patients O
, O
we O
demonstrated O
that O
CD44 O
cross O
- O
linking O
and O
binding O
to O
hyaluronan O
augmented O
VCAM B
- I
1 I
expression O
and O
subsequently O
VCAM B
- I
1 I
- O
mediated O
cell O
adhesion O
. O

Using O
synovial O
cells O
from O
rheumatoid O
arthritis O
( O
RA O
) O
patients O
, O
we O
demonstrated O
that O
CD44 O
cross O
- O
linking O
and O
binding O
to O
hyaluronan O
augmented O
VCAM B
- I
1 I
expression O
and O
subsequently O
VCAM B
- I
1 I
- O
mediated O
cell O
adhesion O
. O

In O
neutrophils O
, O
TNF B
- I
alpha I
caused O
a O
gliotoxin O
- O
inhibitable O
activation O
of O
an O
inducible O
form O
of O
NF B
- I
kappaB I
, O
a O
response O
that O
may O
underlie O
the O
ability O
of O
TNF B
- I
alpha I
to O
delay O
apoptosis O
at O
later O
times O
( O
12 O
- O
24 O
h O
) O
and O
limit O
its O
early O
killing O
effect O
. O

In O
neutrophils O
, O
TNF B
- I
alpha I
caused O
a O
gliotoxin O
- O
inhibitable O
activation O
of O
an O
inducible O
form O
of O
NF B
- I
kappaB I
, O
a O
response O
that O
may O
underlie O
the O
ability O
of O
TNF B
- I
alpha I
to O
delay O
apoptosis O
at O
later O
times O
( O
12 O
- O
24 O
h O
) O
and O
limit O
its O
early O
killing O
effect O
. O

In O
neutrophils O
, O
TNF B
- I
alpha I
caused O
a O
gliotoxin O
- O
inhibitable O
activation O
of O
an O
inducible O
form O
of O
NF B
- I
kappaB I
, O
a O
response O
that O
may O
underlie O
the O
ability O
of O
TNF B
- I
alpha I
to O
delay O
apoptosis O
at O
later O
times O
( O
12 O
- O
24 O
h O
) O
and O
limit O
its O
early O
killing O
effect O
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

The O
aberrant O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
from O
lpr O
/ O
lpr O
and O
gld O
/ O
gld O
mice O
, O
which O
have O
mutations O
in O
the O
genes O
encoding O
Fas B
and O
FasL B
, O
respectively O
, O
have O
an O
activated O
phenotype O
and O
constitutively O
express O
high O
levels O
of O
fasL B
mRNA I
, O
prompting O
us O
to O
ask O
what O
role O
if O
any O
the O
FLRE B
and O
Egr B
family I
proteins I
have O
in O
this O
aberrant O
expression O
of O
fasL B
. O

Although O
overexpressed O
Egr B
- I
1 I
was O
ineffective O
, O
overexpressed O
Egr B
- I
2 I
was O
as O
potent O
as O
Egr B
- I
3 I
in O
inducing O
fasL B
promoter I
- I
dependent I
reporter I
constructs I
in O
T O
cell O
hybridomas O
and O
HeLa O
cells O
, O
and O
both O
up O
- O
regulated O
endogenous O
fasL B
mRNA I
in O
HeLa O
cells O
. O

Although O
overexpressed O
Egr B
- I
1 I
was O
ineffective O
, O
overexpressed O
Egr B
- I
2 I
was O
as O
potent O
as O
Egr B
- I
3 I
in O
inducing O
fasL B
promoter I
- I
dependent I
reporter I
constructs I
in O
T O
cell O
hybridomas O
and O
HeLa O
cells O
, O
and O
both O
up O
- O
regulated O
endogenous O
fasL B
mRNA I
in O
HeLa O
cells O
. O

Although O
overexpressed O
Egr B
- I
1 I
was O
ineffective O
, O
overexpressed O
Egr B
- I
2 I
was O
as O
potent O
as O
Egr B
- I
3 I
in O
inducing O
fasL B
promoter I
- I
dependent I
reporter I
constructs I
in O
T O
cell O
hybridomas O
and O
HeLa O
cells O
, O
and O
both O
up O
- O
regulated O
endogenous O
fasL B
mRNA I
in O
HeLa O
cells O
. O

Recent O
studies O
have O
suggested O
that O
Y319 O
also O
positively O
regulate O
ZAP B
- I
70 I
function O
. O

Deletion O
of O
interdomain B
B I
did O
not O
affect O
the O
ability O
of O
ZAP B
- I
70 I
to O
bind O
to O
the O
receptor O
. O

The O
B B
cell I
- I
specific I
cell I
surface I
molecule I
CD19 B
is O
expressed O
at O
all O
stages O
of O
B O
cell O
development O
, O
including O
normal O
plasma O
cells O
, O
and O
mediates O
signal O
transduction O
via O
interaction O
with O
cytoplasmic B
effector I
proteins I
. O

The O
regulatory B
regions I
of O
several O
genes O
specifically O
expressed O
in O
B O
cells O
contain O
functional B
binding I
sites I
for O
Oct2 B
. O

Binding O
of O
c B
- I
Rel I
to O
STAT5 B
target I
sequences I
in O
HTLV O
- O
I O
- O
transformed O
T O
cells O
. O

Binding O
of O
c B
- I
Rel I
to O
STAT5 B
target I
sequences I
in O
HTLV O
- O
I O
- O
transformed O
T O
cells O
. O

The O
functional O
contribution O
of O
the O
kappaB B
- I
Sp1 I
composite I
site I
in O
P B
/ I
I I
- I
inducible I
fas I
promoter I
activation O
was O
verified O
by O
using O
kappaB O
- O
Sp1 B
concatamers O
( O
- B
295 I
to I
- I
286 I
) O
in O
a O
thymidine B
kinase I
promoter I
- I
driven I
reporter I
construct I
and O
native B
promoter I
constructs I
in O
Jurkat O
cells O
overexpressing O
IkappaB B
- I
alpha I
. O

The O
functional O
contribution O
of O
the O
kappaB B
- I
Sp1 I
composite I
site I
in O
P B
/ I
I I
- I
inducible I
fas I
promoter I
activation O
was O
verified O
by O
using O
kappaB O
- O
Sp1 B
concatamers O
( O
- B
295 I
to I
- I
286 I
) O
in O
a O
thymidine B
kinase I
promoter I
- I
driven I
reporter I
construct I
and O
native B
promoter I
constructs I
in O
Jurkat O
cells O
overexpressing O
IkappaB B
- I
alpha I
. O

The O
induction O
of O
clonal O
anergy O
in O
a O
T O
cell O
inhibits O
IL B
- I
2 I
secretion O
because O
of O
the O
development O
of O
a O
proximal O
signal O
transduction O
defect O
. O

Members O
of O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
binding I
( I
CREB I
) I
/ I
activating I
transcription I
factor I
1 I
( I
ATF I
- I
1 I
) I
family I
of O
transcription B
factors I
bind O
three O
21 B
- I
bp I
repeats I
( O
Tax B
- I
responsive I
element I
- I
1 I
, O
or O
TRE B
- I
1 I
) O
within O
the O
viral B
promoter I
and O
are O
important O
for O
basal O
and O
Tax O
- O
mediated O
transcription O
. O

The O
inhibition O
of O
IL B
- I
2 I
production O
was O
observed O
in O
the O
CD3 B
( O
+ O
) O
T O
- O
lymphocyte O
cytoplasm O
as O
early O
as O
4 O
h O
after O
activation O
by O
PMA O
+ O
ionomycin O
. O

Delta O
- O
opioid O
receptors O
expressed O
by O
Jurkat O
T O
cells O
enhance O
IL B
- I
2 I
secretion O
by O
increasing O
AP B
- I
1 I
complexes I
and O
activity O
of O
the O
NF B
- I
AT I
/ I
AP I
- I
1 I
- I
binding I
promoter I
element I
. O

These O
cells O
, O
stimulated O
by O
an O
agonistic O
monoclonal O
antibody O
against O
CD40 B
or O
by O
transfection O
with O
a O
CD40L B
expression I
vector I
, O
secreted O
p40 B
and O
showed O
enhanced O
p40 B
mRNA I
expression O
. O

HS B
I I
- I
III I
, O
located O
5 O
' O
from O
the O
transcriptional B
initiation I
site I
, O
were O
found O
in O
hematopoietic O
and O
non O
- O
hematopoietic O
cells O
, O
whereas O
HS B
IV I
- I
VII I
, O
located O
3 O
' O
from O
the O
transcriptional B
start I
site I
, O
were O
exclusively O
observed O
in O
T O
- O
cells O
. O

HS B
I I
- I
III I
, O
located O
5 O
' O
from O
the O
transcriptional B
initiation I
site I
, O
were O
found O
in O
hematopoietic O
and O
non O
- O
hematopoietic O
cells O
, O
whereas O
HS B
IV I
- I
VII I
, O
located O
3 O
' O
from O
the O
transcriptional B
start I
site I
, O
were O
exclusively O
observed O
in O
T O
- O
cells O
. O

Among O
these O
hypersensitive B
sites I
, O
two O
transcriptional B
control I
elements I
were O
found O
, O
one O
in O
the O
first B
intron I
of O
the O
GATA B
- I
3 I
gene I
and O
the O
other O
between B
8 I
. I
3 I
and I
5 I
. I
9 I
kilobases I
5 O
' O
from O
the O
GATA B
- I
3 I
transcriptional I
initiation I
site I
. O

Reactive O
oxygen O
intermediate O
- O
dependent O
NF B
- I
kappaB I
activation O
by O
interleukin B
- I
1beta I
requires O
5 B
- I
lipoxygenase I
or O
NADPH O
oxidase O
activity O
. O

Reactive O
oxygen O
intermediate O
- O
dependent O
NF B
- I
kappaB I
activation O
by O
interleukin B
- I
1beta I
requires O
5 B
- I
lipoxygenase I
or O
NADPH O
oxidase O
activity O
. O

Reactive O
oxygen O
intermediate O
- O
dependent O
NF B
- I
kappaB I
activation O
by O
interleukin B
- I
1beta I
requires O
5 B
- I
lipoxygenase I
or O
NADPH O
oxidase O
activity O
. O

However O
, O
the O
sources O
for O
ROIs O
in O
various O
cell O
types O
are O
yet O
to O
be O
determined O
and O
might O
include O
5 B
- I
lipoxygenase I
( O
5 B
- I
LOX I
) O
and O
NADPH O
oxidase O
. O

However O
, O
the O
sources O
for O
ROIs O
in O
various O
cell O
types O
are O
yet O
to O
be O
determined O
and O
might O
include O
5 B
- I
lipoxygenase I
( O
5 B
- I
LOX I
) O
and O
NADPH O
oxidase O
. O

Stimulation O
of O
lymphoid O
cells O
with O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
led O
to O
ROI O
production O
and O
NF B
- I
kappaB I
activation O
, O
which O
could O
both O
be O
blocked O
by O
antioxidants O
or O
FLAP B
inhibitors O
, O
confirming O
that O
5 B
- I
LOX I
was O
the O
source O
of O
ROIs O
and O
was O
required O
for O
NF B
- I
kappaB I
activation O
in O
these O
cells O
. O

Stimulation O
of O
lymphoid O
cells O
with O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
led O
to O
ROI O
production O
and O
NF B
- I
kappaB I
activation O
, O
which O
could O
both O
be O
blocked O
by O
antioxidants O
or O
FLAP B
inhibitors O
, O
confirming O
that O
5 B
- I
LOX I
was O
the O
source O
of O
ROIs O
and O
was O
required O
for O
NF B
- I
kappaB I
activation O
in O
these O
cells O
. O

Stimulation O
of O
lymphoid O
cells O
with O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
led O
to O
ROI O
production O
and O
NF B
- I
kappaB I
activation O
, O
which O
could O
both O
be O
blocked O
by O
antioxidants O
or O
FLAP B
inhibitors O
, O
confirming O
that O
5 B
- I
LOX I
was O
the O
source O
of O
ROIs O
and O
was O
required O
for O
NF B
- I
kappaB I
activation O
in O
these O
cells O
. O

Stimulation O
of O
lymphoid O
cells O
with O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
led O
to O
ROI O
production O
and O
NF B
- I
kappaB I
activation O
, O
which O
could O
both O
be O
blocked O
by O
antioxidants O
or O
FLAP B
inhibitors O
, O
confirming O
that O
5 B
- I
LOX I
was O
the O
source O
of O
ROIs O
and O
was O
required O
for O
NF B
- I
kappaB I
activation O
in O
these O
cells O
. O

Stimulation O
of O
lymphoid O
cells O
with O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
led O
to O
ROI O
production O
and O
NF B
- I
kappaB I
activation O
, O
which O
could O
both O
be O
blocked O
by O
antioxidants O
or O
FLAP B
inhibitors O
, O
confirming O
that O
5 B
- I
LOX I
was O
the O
source O
of O
ROIs O
and O
was O
required O
for O
NF B
- I
kappaB I
activation O
in O
these O
cells O
. O

Constitutive O
expression O
of O
human B
colony I
- I
stimulating I
factor I
- I
1 I
receptor I
( O
CSF B
- I
1R I
) O
confers O
long O
- O
lasting O
CSF B
- I
1 I
- O
dependent O
proliferation O
to O
mouse O
myeloid O
cell O
lines O
. O

Constitutive O
expression O
of O
human B
colony I
- I
stimulating I
factor I
- I
1 I
receptor I
( O
CSF B
- I
1R I
) O
confers O
long O
- O
lasting O
CSF B
- I
1 I
- O
dependent O
proliferation O
to O
mouse O
myeloid O
cell O
lines O
. O

In O
agar O
cultures O
, O
47 O
. O
10 O
cells O
form O
7 O
- O
and O
14 O
- O
day O
colonies O
in O
response O
to O
a O
cocktail O
of O
granulocyte B
/ I
macrophage I
colony I
- I
stimulating I
factor I
( O
2 O
. O
5 O
ng O
/ O
mL O
) O
, O
interleukin B
- I
3 I
( O
1 O
ng O
/ O
mL O
) O
, O
and O
mouse O
CSF B
- I
1 I
( O
10 O
ng O
/ O
mL O
) O
. O

In O
agar O
cultures O
, O
47 O
. O
10 O
cells O
form O
7 O
- O
and O
14 O
- O
day O
colonies O
in O
response O
to O
a O
cocktail O
of O
granulocyte B
/ I
macrophage I
colony I
- I
stimulating I
factor I
( O
2 O
. O
5 O
ng O
/ O
mL O
) O
, O
interleukin B
- I
3 I
( O
1 O
ng O
/ O
mL O
) O
, O
and O
mouse O
CSF B
- I
1 I
( O
10 O
ng O
/ O
mL O
) O
. O

Regulation O
of O
IL B
- I
4 I
expression O
by O
the O
transcription B
factor I
JunB B
during O
T O
helper O
cell O
differentiation O
. O

Here O
we O
show O
that O
JunB B
, O
but O
not O
the O
other O
Jun B
family I
members I
, O
was O
selectively O
induced O
in O
Th2 O
cells O
and O
not O
in O
Th1 O
cells O
during O
differentiation O
. O

The O
finding O
of O
Tax B
mutants O
segregating O
these O
two O
pathways O
suggested O
that O
the O
NF B
- I
kappaB I
pathway O
was O
essential O
for O
IL B
- I
2 I
- O
independent O
growth O
of O
CTLL O
- O
2 O
cells O
while O
the O
CRE B
pathway O
was O
unnecessary O
. O

The O
finding O
of O
Tax B
mutants O
segregating O
these O
two O
pathways O
suggested O
that O
the O
NF B
- I
kappaB I
pathway O
was O
essential O
for O
IL B
- I
2 I
- O
independent O
growth O
of O
CTLL O
- O
2 O
cells O
while O
the O
CRE B
pathway O
was O
unnecessary O
. O

Our O
results O
show O
that O
Tax B
has O
at O
least O
two O
distinct O
activities O
on O
T O
cells O
, O
and O
suggest O
that O
Tax B
plays O
a O
crucial O
role O
in O
IL B
- I
2 I
- O
independent O
T O
- O
cell O
transformation O
induced O
by O
HTLV O
- O
1 O
, O
in O
addition O
to O
its O
well O
- O
known O
IL B
- I
2 I
- O
dependent O
cell O
transformation O
. O

Our O
results O
show O
that O
Tax B
has O
at O
least O
two O
distinct O
activities O
on O
T O
cells O
, O
and O
suggest O
that O
Tax B
plays O
a O
crucial O
role O
in O
IL B
- I
2 I
- O
independent O
T O
- O
cell O
transformation O
induced O
by O
HTLV O
- O
1 O
, O
in O
addition O
to O
its O
well O
- O
known O
IL B
- I
2 I
- O
dependent O
cell O
transformation O
. O

First O
, O
it O
gives O
no O
information O
on O
memory O
to O
lytic B
cycle I
antigens I
; O
second O
, O
it O
preferentially O
amplifies O
the O
dominant O
components O
of O
latent O
antigen O
- O
specific O
memory O
at O
the O
expense O
of O
key O
subdominant O
reactivities O
. O

Extinction O
of O
immunoglobulin B
gene I
expression O
in O
B O
cells O
upon O
fusion O
with O
HeLa O
cells O
is O
preceded O
by O
rapid O
nuclear O
depletion O
of O
essential B
transcription I
factors I
and O
is O
accompanied O
by O
widespread O
inactivation O
of O
genes O
expressed O
in O
a O
B O
cell O
- O
specific O
manner O
. O

Evidence O
for O
suppressed O
activity O
of O
the O
transcription B
factor I
NFAT1 B
at O
its O
proximal B
binding I
element I
P0 B
in O
the O
IL B
- I
4 I
promoter I
associated O
with O
enhanced O
IL B
- I
4 I
gene I
transcription O
in O
T O
cells O
of O
atopic O
patients O
. O

These O
findings O
suggest O
that O
high O
- O
level O
IL B
- I
4 I
production O
in O
atopic O
Th2 O
cells O
is O
associated O
with O
selective O
reduction O
of O
suppressive O
NFAT1 B
activity O
at O
the O
IL B
- I
4 I
P0 I
element I
and O
that O
some O
patients O
with O
this O
multifactorial O
disease O
may O
have O
a O
putative O
systemic O
disorder O
at O
this O
level O
. O

NF B
- I
kappaB I
activity O
is O
tightly O
correlated O
with O
the O
transcriptional O
activity O
of O
a O
long B
terminal I
repeat I
( O
LTR B
) O
of O
HIV O
- O
1 O
transfected O
in O
thymocytes O
. O

NF B
- I
kappaB I
activity O
is O
tightly O
correlated O
with O
the O
transcriptional O
activity O
of O
a O
long B
terminal I
repeat I
( O
LTR B
) O
of O
HIV O
- O
1 O
transfected O
in O
thymocytes O
. O

Serial O
sectioning O
of O
6 O
micrometer O
was O
performed O
using O
a O
cryostat O
, O
and O
samples O
were O
immunohistochemicall O
stained O
using O
the O
streptoavidin B
- B
biotin I
peroxidase I
method O
and O
a O
monoclonal O
antibody O
against O
c O
- O
fos O
. O

The O
allele O
- O
specific O
expression O
profiles O
of O
other O
imprinted B
genes I
, O
IGF2 B
and O
H19 B
, O
on O
human B
chromosome I
11 I
were O
constant O
and O
consistent O
with O
those O
in O
other O
tissues O
. O

Specific O
staining O
as O
well O
as O
electron O
microscopic O
examinations O
revealed O
the O
accumulation O
of O
metal O
gold O
in O
the O
cells O
, O
supporting O
our O
previous O
hypothesis O
that O
gold O
ions O
could O
block O
NF B
- I
kappaB I
- O
DNA O
binding O
by O
a O
redox O
mechanism O
. O

The O
5 B
' I
sequences I
up O
to O
nucleotide O
- O
120 O
of O
the O
human O
and O
murine O
IL B
- I
16 I
genes O
share O
> O
84 O
% O
sequence O
homology O
and O
harbor B
promoter I
elements I
for O
constitutive O
and O
inducible O
transcription O
in O
T O
cells O
. O

The O
5 B
' I
sequences I
up O
to O
nucleotide O
- O
120 O
of O
the O
human O
and O
murine O
IL B
- I
16 I
genes O
share O
> O
84 O
% O
sequence O
homology O
and O
harbor B
promoter I
elements I
for O
constitutive O
and O
inducible O
transcription O
in O
T O
cells O
. O

The O
5 B
' I
sequences I
up O
to O
nucleotide O
- O
120 O
of O
the O
human O
and O
murine O
IL B
- I
16 I
genes O
share O
> O
84 O
% O
sequence O
homology O
and O
harbor B
promoter I
elements I
for O
constitutive O
and O
inducible O
transcription O
in O
T O
cells O
. O

A O
Taq B
I I
polymorphism I
was O
identified O
which O
enabled O
chicken O
IL2 B
to O
be O
mapped O
to O
chromosome B
4 I
, O
linked O
to O
ANX5 B
, O
with O
synteny O
with O
mouse B
chromosome I
3 I
and O
human B
chromosome I
4 I
. O

A O
Taq B
I I
polymorphism I
was O
identified O
which O
enabled O
chicken O
IL2 B
to O
be O
mapped O
to O
chromosome B
4 I
, O
linked O
to O
ANX5 B
, O
with O
synteny O
with O
mouse B
chromosome I
3 I
and O
human B
chromosome I
4 I
. O

A O
Taq B
I I
polymorphism I
was O
identified O
which O
enabled O
chicken O
IL2 B
to O
be O
mapped O
to O
chromosome B
4 I
, O
linked O
to O
ANX5 B
, O
with O
synteny O
with O
mouse B
chromosome I
3 I
and O
human B
chromosome I
4 I
. O

There O
is O
increasing O
evidence O
that O
IFN B
- I
alpha I
has O
an O
important O
role O
in O
T O
- O
cell O
biology O
. O

The O
induction O
of O
these O
genes O
is O
associated O
with O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
- O
induced O
T O
- O
cell O
proliferation O
. O

The O
induction O
of O
these O
genes O
is O
associated O
with O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
- O
induced O
T O
- O
cell O
proliferation O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
IFN B
- I
alpha I
, O
IL B
- I
2 I
, O
IL B
- I
12 I
, O
and O
IL B
- I
15 I
have O
overlapping O
activities O
on O
human O
T O
cells O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
IFN B
- I
alpha I
, O
IL B
- I
2 I
, O
IL B
- I
12 I
, O
and O
IL B
- I
15 I
have O
overlapping O
activities O
on O
human O
T O
cells O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
IFN B
- I
alpha I
, O
IL B
- I
2 I
, O
IL B
- I
12 I
, O
and O
IL B
- I
15 I
have O
overlapping O
activities O
on O
human O
T O
cells O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
IFN B
- I
alpha I
, O
IL B
- I
2 I
, O
IL B
- I
12 I
, O
and O
IL B
- I
15 I
have O
overlapping O
activities O
on O
human O
T O
cells O
. O

The O
Megakaryocyte B
/ I
Platelet I
- I
specific I
enhancer I
of O
the O
alpha2beta1 B
integrin I
gene I
: O
two O
tandem O
AP1 B
sites I
and O
the O
mitogen B
- I
activated I
protein I
kinase I
signaling O
cascade O
. O

Transcriptional O
regulation O
of O
the O
alpha2 B
integrin I
gene I
in O
cells O
undergoing O
megakaryocytic O
differentiation O
requires O
a O
core B
promoter I
between O
bp O
- O
30 O
and O
- O
92 O
, O
a O
silencer B
between O
bp O
- O
92 O
and O
- O
351 O
, O
and O
megakaryocytic B
enhancers I
in O
the O
distal B
5 I
' I
flank I
. O

These O
findings O
suggest O
the O
presence O
in O
vaginal O
fluid O
of O
agent O
( O
s O
) O
derived O
from O
indigenous O
bacteria O
that O
can O
activate O
the O
HIV B
- I
1 I
LTR I
, O
cytokine B
production O
, O
and O
NF B
- I
kappaB I
in O
cells O
of O
macrophage O
lineage O
, O
with O
possible O
influence O
on O
vaginal O
physiology O
and O
host O
defense O
. O

Activated O
primed O
CD4 O
T O
cells O
contain O
more O
NFAT1 B
and O
support O
greater O
NFAT B
- O
directed O
transcription O
than O
unprimed O
CD4 O
T O
cells O
, O
while O
activator B
protein I
1 I
binding O
and O
activator B
protein I
1 I
- O
mediated O
transcription O
by O
both O
cell O
types O
is O
similar O
. O

Activated O
primed O
CD4 O
T O
cells O
contain O
more O
NFAT1 B
and O
support O
greater O
NFAT B
- O
directed O
transcription O
than O
unprimed O
CD4 O
T O
cells O
, O
while O
activator B
protein I
1 I
binding O
and O
activator B
protein I
1 I
- O
mediated O
transcription O
by O
both O
cell O
types O
is O
similar O
. O

TNF B
stimulated O
expression O
of O
both O
intercellular B
adhesion I
molecule I
- I
1 I
and O
E B
- I
selectin I
in O
HUVECs O
, O
but O
in O
HUAECs O
, O
only O
intercellular B
adhesion I
molecule I
- I
1 I
was O
increased O
. O

By O
contrast O
, O
the O
cell B
surface I
receptors I
for O
testosterone O
are O
in O
a O
functionally O
active O
state O
, O
enabling O
T O
cells O
a O
nongenomic O
response O
to O
testosterone O
. O

Highly O
purified O
monocytes O
were O
incubated O
with O
IL B
- I
10 I
for O
60 O
to O
90 O
minutes O
before O
the O
addition O
of O
IFNgamma B
or O
IFNalpha B
. O

IL B
- I
10 I
preincubation O
resulted O
in O
the O
inhibition O
of O
gene O
expression O
for O
several O
IFN B
- I
induced I
genes I
, O
such O
as O
IP B
- I
10 I
, O
ISG54 B
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

IL B
- I
10 I
preincubation O
resulted O
in O
the O
inhibition O
of O
gene O
expression O
for O
several O
IFN B
- I
induced I
genes I
, O
such O
as O
IP B
- I
10 I
, O
ISG54 B
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

IL B
- I
10 I
treatment O
prevented O
the O
downregulation O
of O
p27 B
( I
Kip1 I
) O
, O
an O
inhibitory B
protein I
that O
controls O
progression O
out O
of O
the O
G0 O
phase O
of O
the O
cell O
cycle O
. O

IL B
- I
10 I
treatment O
prevented O
the O
downregulation O
of O
p27 B
( I
Kip1 I
) O
, O
an O
inhibitory B
protein I
that O
controls O
progression O
out O
of O
the O
G0 O
phase O
of O
the O
cell O
cycle O
. O

Associated O
with O
the O
inhibition O
of O
the O
cell O
cycle O
, O
IL B
- I
10 I
suppressed O
SEB B
induction O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

Associated O
with O
the O
inhibition O
of O
the O
cell O
cycle O
, O
IL B
- I
10 I
suppressed O
SEB B
induction O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

Associated O
with O
the O
inhibition O
of O
the O
cell O
cycle O
, O
IL B
- I
10 I
suppressed O
SEB B
induction O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

Although O
this O
reversal O
by O
IL B
- I
2 I
was O
pronounced O
, O
it O
was O
not O
complete O
, O
suggesting O
that O
IL B
- I
10 I
may O
have O
some O
effects O
not O
directly O
related O
to O
the O
suppression O
of O
IL B
- I
2 I
production O
. O

Although O
this O
reversal O
by O
IL B
- I
2 I
was O
pronounced O
, O
it O
was O
not O
complete O
, O
suggesting O
that O
IL B
- I
10 I
may O
have O
some O
effects O
not O
directly O
related O
to O
the O
suppression O
of O
IL B
- I
2 I
production O
. O

Although O
this O
reversal O
by O
IL B
- I
2 I
was O
pronounced O
, O
it O
was O
not O
complete O
, O
suggesting O
that O
IL B
- I
10 I
may O
have O
some O
effects O
not O
directly O
related O
to O
the O
suppression O
of O
IL B
- I
2 I
production O
. O

IL B
- I
4 I
and O
IL B
- I
13 I
induced O
dose O
- O
and O
time O
- O
dependent O
increases O
in O
IL O
- O
1RI O
and O
IL O
- O
1RII O
mRNA O
levels O
. O

IL B
- I
4 I
and O
IL B
- I
13 I
induced O
dose O
- O
and O
time O
- O
dependent O
increases O
in O
IL O
- O
1RI O
and O
IL O
- O
1RII O
mRNA O
levels O
. O

IFN B
- I
gamma I
decreased O
basal O
expression O
as O
well O
as O
the O
induction O
of O
these O
genes O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
. O

IFN B
- I
gamma I
decreased O
basal O
expression O
as O
well O
as O
the O
induction O
of O
these O
genes O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
. O

IFN B
- I
gamma I
decreased O
basal O
expression O
as O
well O
as O
the O
induction O
of O
these O
genes O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
. O

Inhibition O
of O
IL B
- I
1RI I
and O
IL O
- O
1RII O
mRNA O
levels O
by O
IFN B
- I
gamma I
was O
transcriptionally O
mediated O
, O
and O
correlated O
directly O
with O
decreased O
production O
of O
soluble O
IL B
- I
1RII I
. O

Inhibition O
of O
IL B
- I
1RI I
and O
IL O
- O
1RII O
mRNA O
levels O
by O
IFN B
- I
gamma I
was O
transcriptionally O
mediated O
, O
and O
correlated O
directly O
with O
decreased O
production O
of O
soluble O
IL B
- I
1RII I
. O

Inhibition O
of O
IL B
- I
1RI I
and O
IL O
- O
1RII O
mRNA O
levels O
by O
IFN B
- I
gamma I
was O
transcriptionally O
mediated O
, O
and O
correlated O
directly O
with O
decreased O
production O
of O
soluble O
IL B
- I
1RII I
. O

In O
conclusion O
, O
the O
long O
- O
term O
regulation O
of O
transcription B
factor I
gene O
expression O
in O
non O
- O
proliferating O
cells O
seems O
to O
be O
of O
minor O
importance O
after O
influenza O
infection O
since O
in O
apoptosisprone O
cells O
an O
immediate O
availability O
of O
transcription B
factor I
proteins I
is O
required O
. O

Patients O
with O
diabetic O
nephropathy O
showed O
higher O
NF B
- I
kappaB I
binding O
activity O
in O
Electrophoretic O
Mobility O
Shift O
Assays O
and O
stronger O
immunohistological O
staining O
for O
activated O
NF B
- I
kappaBp65 I
than O
patients O
without O
renal O
complications O
. O

Patients O
with O
diabetic O
nephropathy O
showed O
higher O
NF B
- I
kappaB I
binding O
activity O
in O
Electrophoretic O
Mobility O
Shift O
Assays O
and O
stronger O
immunohistological O
staining O
for O
activated O
NF B
- I
kappaBp65 I
than O
patients O
without O
renal O
complications O
. O

We O
incubated O
sodium O
oleate O
with O
human O
umbilical O
vein O
endothelial O
cells O
for O
0 O
to O
72 O
hours O
, O
followed O
by O
coincubation O
of O
oleate O
with O
human B
recombinant I
tumor I
necrosis I
factor I
, O
interleukin B
( I
IL I
) I
- I
1alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
4 I
, O
Escherichia O
coli O
lipopolysaccharide O
( O
LPS O
) O
, O
or O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
for O
a O
further O
6 O
to O
24 O
hours O
. O

We O
incubated O
sodium O
oleate O
with O
human O
umbilical O
vein O
endothelial O
cells O
for O
0 O
to O
72 O
hours O
, O
followed O
by O
coincubation O
of O
oleate O
with O
human B
recombinant I
tumor I
necrosis I
factor I
, O
interleukin B
( I
IL I
) I
- I
1alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
4 I
, O
Escherichia O
coli O
lipopolysaccharide O
( O
LPS O
) O
, O
or O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
for O
a O
further O
6 O
to O
24 O
hours O
. O

The O
endothelial O
expression O
of O
vascular B
cell I
adhesion I
molecule I
- I
1 I
( O
VCAM B
- I
1 I
) O
, O
E B
- I
selectin I
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
monitored O
by O
cell O
surface O
enzyme O
immunoassays O
or O
flow O
cytometry O
, O
and O
steady O
- O
state O
levels O
of O
VCAM B
- I
1 I
mRNA I
were O
assessed O
by O
Northern O
blot O
analysis O
. O

The O
endothelial O
expression O
of O
vascular B
cell I
adhesion I
molecule I
- I
1 I
( O
VCAM B
- I
1 I
) O
, O
E B
- I
selectin I
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
monitored O
by O
cell O
surface O
enzyme O
immunoassays O
or O
flow O
cytometry O
, O
and O
steady O
- O
state O
levels O
of O
VCAM B
- I
1 I
mRNA I
were O
assessed O
by O
Northern O
blot O
analysis O
. O

The O
importance O
of O
BCL2 B
and O
Stat3 B
on O
IL B
- I
6 I
- O
induced O
macrophage O
- O
differentiation O
and O
apoptosis O
was O
studied O
with O
1A9 O
- O
M O
cells O
expressing O
human B
BCL2 I
or O
a O
dominant O
- O
negative O
form O
of O
Stat3 B
, O
respectively O
. O

IL B
- I
6 I
- O
induced O
apoptosis O
, O
but O
not O
macrophage O
- O
differentiation O
, O
was O
blocked O
by O
continuously O
expressed O
BCL2 B
. O

Interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
is O
a O
chemokine B
that O
belongs O
to O
the O
alpha B
- I
chemokine I
or O
CXC B
subfamily I
and O
is O
produced O
by O
a O
wide O
variety O
of O
human O
cells O
, O
including O
monocytes O
and O
polymorphonuclear O
cells O
( O
PMN O
) O
. O

Interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
is O
a O
chemokine B
that O
belongs O
to O
the O
alpha B
- I
chemokine I
or O
CXC B
subfamily I
and O
is O
produced O
by O
a O
wide O
variety O
of O
human O
cells O
, O
including O
monocytes O
and O
polymorphonuclear O
cells O
( O
PMN O
) O
. O

Interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
is O
a O
chemokine B
that O
belongs O
to O
the O
alpha B
- I
chemokine I
or O
CXC B
subfamily I
and O
is O
produced O
by O
a O
wide O
variety O
of O
human O
cells O
, O
including O
monocytes O
and O
polymorphonuclear O
cells O
( O
PMN O
) O
. O

IL B
- I
8 I
is O
secreted O
in O
response O
to O
inflammatory O
stimuli O
, O
notably O
bacterial O
products O
such O
as O
lipopolysaccharide O
( O
LPS O
) O
, O
but O
little O
is O
known O
about O
the O
mechanisms O
by O
which O
these O
agents O
mediate O
IL B
- I
8 I
induction O
. O

IL B
- I
8 I
is O
secreted O
in O
response O
to O
inflammatory O
stimuli O
, O
notably O
bacterial O
products O
such O
as O
lipopolysaccharide O
( O
LPS O
) O
, O
but O
little O
is O
known O
about O
the O
mechanisms O
by O
which O
these O
agents O
mediate O
IL B
- I
8 I
induction O
. O

In O
this O
report O
, O
we O
show O
that O
Mycoplasma B
fermentans I
lipid I
- I
associated I
membrane I
proteins I
( O
LAMPf B
) O
induce O
the O
production O
of O
high O
levels O
of O
IL B
- I
8 I
by O
THP O
- O
1 O
( O
human O
monocyte O
) O
cells O
and O
PMN O
at O
the O
same O
extent O
as O
LPS O
. O

In O
this O
study O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
gene O
expression O
and O
protein O
secretion O
of O
IL B
- I
6 I
in O
human O
PBMCs O
, O
either O
alone O
or O
in O
combination O
with O
LPS O
or O
IL B
- I
1beta I
. O

In O
this O
study O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
gene O
expression O
and O
protein O
secretion O
of O
IL B
- I
6 I
in O
human O
PBMCs O
, O
either O
alone O
or O
in O
combination O
with O
LPS O
or O
IL B
- I
1beta I
. O

Furthermore O
, O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
induction O
of O
NF B
- I
kappaB I
and O
activating B
protein I
- I
1 I
binding O
. O

The O
suggested O
roles O
of O
the O
downstream B
3 I
' I
regions I
acting O
as O
a O
Locus B
Control I
Region I
( O
LCR B
) O
, O
have O
allowed O
comparisons O
to O
be O
made O
between O
the O
regulation O
of O
the O
IgH B
locus I
with O
other O
model O
systems O
whose O
gene O
expression O
is O
governed O
by O
LCR B
activity O
. O

T O
lymphocytes O
recognize O
antigens O
in O
the O
form O
of O
peptides O
bound O
to O
HLA B
- I
molecules I
. O

MATERIALS O
AND O
METHODS O
: O
Peptides O
derived O
from O
oncogenic B
proteins I
were O
screened O
for O
the O
presence O
of O
HLA B
binding I
motifs I
; O
actual O
binding O
were O
evaluated O
by O
HLA O
stabilization O
experiments O
using O
transfectants O
and O
specific O
anti B
- I
HLA I
antibodies I
. O

RESULTS O
: O
We O
identified O
peptides O
derived O
from O
EWS B
/ I
FLI I
- I
1 I
fusion I
protein I
and O
from O
mutated B
K I
- I
RAS I
protein I
( O
encompassing O
respectively O
the O
fusion B
point I
and O
the O
mutation O
at O
position B
12 I
) O
that O
showed O
binding B
motif I
for O
HLA B
- I
Cw I
* I
0702 I
and O
HLA B
- I
A3 I
respectively O
. O

OCA B
- I
B I
is O
a O
functional O
analog O
of O
VP16 B
but O
targets O
a O
separate O
surface O
of O
the O
Oct B
- I
1 I
POU I
domain I
[ O
published O
erratum O
appears O
in O
Mol O
Cell O
Biol O
1998 O
Apr O
; O
18 O
( O
4 O
) O
: O
2430 O
] O

Here O
, O
we O
show O
that O
OCA B
- I
B I
alters O
the O
activity O
of O
Oct B
- I
1 I
in O
two O
ways O
. O

Here O
, O
we O
show O
that O
OCA B
- I
B I
alters O
the O
activity O
of O
Oct B
- I
1 I
in O
two O
ways O
. O

Phosphatidylinositol B
3 I
- I
kinase I
couples O
the O
interleukin B
- I
2 I
receptor I
to O
the O
cell B
cycle I
regulator I
E2F B
. O

In O
transfection O
assays O
, O
TRADD B
and O
TES2 B
synergistically O
mediated O
high O
- O
level O
NF B
- I
kappaB I
activation O
. O

From O
these O
observations O
we O
conclude O
that O
free O
thiols O
in O
the O
IL B
- I
1RI I
complex I
are O
essential O
for O
the O
activation O
of O
the O
IL B
- I
1RI I
- I
associated I
protein I
kinase I
and O
that O
this O
process O
is O
mandatory O
for O
IL B
- I
1 I
signaling O
leading O
to O
NF B
- I
kappa I
B I
activation O
. O

Its O
normal O
cellular O
equivalent O
c B
- I
myb I
, O
has O
been O
shown O
to O
promote O
the O
proliferation O
and O
block O
the O
differentiation O
of O
haematopoietic O
cells O
in O
several O
experimental O
models O
and O
is O
required O
for O
fetal O
haematopoiesis O
. O

These O
studies O
indicate O
that O
A B
- I
myb I
plays O
a O
role O
during O
a O
narrow O
window O
of O
normal O
B O
cell O
differentiation O
. O

Furthermore O
, O
compared O
with O
wild B
- I
type I
Id3 I
, O
an O
Id3 B
Asp5 I
mutant I
( O
mimicking O
phosphorylation O
) O
is O
unable O
to O
promote O
cell O
cycle O
S O
phase O
entry O
in O
transfected O
fibroblasts O
, O
whereas O
an O
Id3 B
Ala5 I
mutant I
( O
ablating O
phosphorylation O
) O
displays O
an O
activity O
significantly O
greater O
than O
that O
of O
wild B
- I
type I
Id3 I
protein I
. O

Furthermore O
, O
compared O
with O
wild B
- I
type I
Id3 I
, O
an O
Id3 B
Asp5 I
mutant I
( O
mimicking O
phosphorylation O
) O
is O
unable O
to O
promote O
cell O
cycle O
S O
phase O
entry O
in O
transfected O
fibroblasts O
, O
whereas O
an O
Id3 B
Ala5 I
mutant I
( O
ablating O
phosphorylation O
) O
displays O
an O
activity O
significantly O
greater O
than O
that O
of O
wild B
- I
type I
Id3 I
protein I
. O

Here O
we O
describe O
cloning O
and O
characterization O
of O
full O
- O
length O
cDNA B
encoding I
murine I
( I
m I
) I
NFATc I
which O
predicts O
that O
the O
protein O
has O
all O
the O
conserved B
structural I
motifs I
of O
NFAT B
family I
members I
, O
including O
the O
rel O
homology O
domain O
, O
the O
NFAT B
homology I
domain I
and O
the O
nuclear O
translocation O
signals O
. O

Here O
we O
describe O
cloning O
and O
characterization O
of O
full O
- O
length O
cDNA B
encoding I
murine I
( I
m I
) I
NFATc I
which O
predicts O
that O
the O
protein O
has O
all O
the O
conserved B
structural I
motifs I
of O
NFAT B
family I
members I
, O
including O
the O
rel O
homology O
domain O
, O
the O
NFAT B
homology I
domain I
and O
the O
nuclear O
translocation O
signals O
. O

Here O
we O
describe O
cloning O
and O
characterization O
of O
full O
- O
length O
cDNA B
encoding I
murine I
( I
m I
) I
NFATc I
which O
predicts O
that O
the O
protein O
has O
all O
the O
conserved B
structural I
motifs I
of O
NFAT B
family I
members I
, O
including O
the O
rel O
homology O
domain O
, O
the O
NFAT B
homology I
domain I
and O
the O
nuclear O
translocation O
signals O
. O

Cooperation O
of O
binding B
sites I
for O
STAT6 B
and O
NF B
kappa I
B I
/ I
rel I
in O
the O
IL B
- I
4 I
- O
induced O
up O
- O
regulation O
of O
the O
human B
IgE I
germline I
promoter I
. O

YY1 B
, O
a O
widely O
distributed O
human B
transcription I
factor I
, O
is O
known O
to O
inhibit O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
transcription O
and O
virus O
production O
. O

LSF B
( O
also O
known O
as O
LBP B
- I
1 I
, O
UBP B
, O
and O
CP B
- I
2 I
) O
has O
been O
shown O
to O
repress O
LTR O
transcription O
in O
vitro O
, O
but O
transient O
expression O
of O
LSF B
has O
no O
effect O
on O
LTR B
activity O
in O
vivo O
. O

LSF B
( O
also O
known O
as O
LBP B
- I
1 I
, O
UBP B
, O
and O
CP B
- I
2 I
) O
has O
been O
shown O
to O
repress O
LTR O
transcription O
in O
vitro O
, O
but O
transient O
expression O
of O
LSF B
has O
no O
effect O
on O
LTR B
activity O
in O
vivo O
. O

Relative O
affinities O
of O
transcriptional B
regulatory I
elements I
for O
their O
respective O
factor O
have O
been O
essentially O
studied O
by O
bandshift O
analysis O
. O

Stable O
transfection O
of O
U937 O
cells O
with O
sense O
or O
antisense B
RXR I
- I
alpha I
cDNA I
suggests O
a O
role O
for O
RXR B
- I
alpha I
in O
the O
control O
of O
monoblastic O
differentiation O
induced O
by O
retinoic O
acid O
and O
vitamin O
D O
. O

The O
role O
of O
the O
viral B
trans I
- I
activator I
Tax I
protein I
in O
the O
induction O
of O
VCAM B
- I
1 I
was O
first O
indicated O
by O
the O
detection O
of O
this O
adhesion B
molecule I
on O
Jurkat O
T O
- O
cell O
clones O
stably O
expressing O
the O
tax O
gene O
. O

The O
effect O
of O
Tax B
on O
VCAM B
- I
1 I
gene O
transcription O
was O
next O
confirmed O
in O
JPX O
- O
9 O
cells O
, O
a O
subclone O
of O
Jurkat O
cells O
, O
carrying O
the O
tax B
sequences I
under O
the O
control O
of O
an O
inducible B
promoter I
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

Interleukin B
2 I
( O
IL B
- I
2 I
) O
induces O
tyrosine O
phosphorylation O
of O
STATs B
3 I
and I
5 I
( O
signal O
transducer O
and O
activator O
of O
transcription O
) O
. O

IL B
- I
2 I
and O
T B
cell I
antigen I
receptor I
complex I
induction O
of O
STAT3alpha B
serine O
727 O
phosphorylation O
is O
dependent O
on O
the O
activity O
of O
the O
MEK B
/ B
ERK I
pathway O
. O

In O
addition O
, O
both O
RelA B
and O
c B
- I
Rel I
, O
but O
not O
NF B
- I
kappa I
B1 I
, O
were O
shown O
to O
transactivate O
an O
ICAM B
- I
1 I
kappa I
B I
- I
reporter I
construct I
. O

Competent O
transcription O
initiation O
by O
RNA B
polymerase I
II I
in O
cell O
- O
free O
extracts O
from O
xeroderma O
pigmentosum O
groups O
B O
and O
D O
in O
an O
optimized O
RNA O
transcription O
assay O
. O

The O
generality O
of O
this O
finding O
was O
confirmed O
by O
the O
induction O
of O
Bcl B
- I
xL I
in O
human O
myeloid O
U O
- O
937 O
cells O
, O
human O
peripheral O
blood O
monocytes O
exposed O
to O
phorbol O
ester O
, O
and O
mouse O
thioglycollate O
- O
activated O
and O
resident O
peritoneal O
macrophages O
. O

Furthermore O
, O
the O
degree O
of O
CN B
inhibition O
was O
reflected O
by O
a O
similar O
degree O
of O
reduction O
in O
lymphocyte O
proliferation O
and O
IFN B
- I
gamma I
production O
in O
the O
allogeneic O
mixed O
lymphocyte O
cultures O
. O

Increased O
CRH B
promoter O
activity O
following O
phorbol O
ester O
treatment O
was O
inhibited O
by O
a O
dominant O
negative O
NF B
- I
IL6 I
mutant I
, O
showing O
that O
the O
effects O
of O
phorbol O
ester O
were O
principally O
mediated O
by O
C B
/ I
EBP I
. O

Interleukin B
- I
7 I
upregulates O
the O
interleukin B
- I
2 I
- I
gene I
expression O
in O
activated O
human O
T O
lymphocytes O
at O
the O
transcriptional O
level O
by O
enhancing O
the O
DNA O
binding O
activities O
of O
both O
nuclear O
factor O
of O
activated O
T O
cells O
and O
activator B
protein I
- I
1 I
. O

Production O
of O
IL B
- I
2 I
requires O
the O
formation O
of O
transcription B
factors I
involved O
in O
the O
IL B
- I
2 I
- I
gene I
regulation O
. O

We O
have O
therefore O
investigated O
the O
transcriptional O
activity O
of O
A B
- I
MYB I
and O
its O
regulation O
in O
several O
human O
lymphoid O
cell O
lines O
using O
co O
- O
transfection O
assays O
and O
show O
that O
A B
- I
MYB I
is O
transcriptionally O
active O
in O
all O
the O
B O
cell O
lines O
studied O
, O
but O
not O
in O
T O
cells O
. O

We O
have O
therefore O
investigated O
the O
transcriptional O
activity O
of O
A B
- I
MYB I
and O
its O
regulation O
in O
several O
human O
lymphoid O
cell O
lines O
using O
co O
- O
transfection O
assays O
and O
show O
that O
A B
- I
MYB I
is O
transcriptionally O
active O
in O
all O
the O
B O
cell O
lines O
studied O
, O
but O
not O
in O
T O
cells O
. O

Transcription O
factor O
Egr B
- I
1 I
activity O
down O
- O
regulates O
Fas O
and O
CD23 O
expression O
in O
B O
cells O
. O

Transcription B
factor I
NF B
- I
kappa I
B I
must O
be O
released O
from O
cytoplasmic B
inhibitory I
molecules I
( O
I B
kappa I
Bs I
) O
in O
order O
to O
move O
to O
the O
nucleus O
and O
to O
activate O
its O
target B
genes I
. O

Transcription B
factor I
NF B
- I
kappa I
B I
must O
be O
released O
from O
cytoplasmic B
inhibitory I
molecules I
( O
I B
kappa I
Bs I
) O
in O
order O
to O
move O
to O
the O
nucleus O
and O
to O
activate O
its O
target B
genes I
. O

CD40 B
ligation O
leads O
to O
B O
cell O
activation O
events O
such O
as O
proliferation O
, O
Ig O
secretion O
, O
isotype O
switching O
, O
and O
up O
- O
regulation O
of O
cell B
surface I
molecules I
, O
as O
well O
as O
the O
generation O
of O
memory O
B O
cells O
. O

NF B
- I
kappa I
B I
activation O
correlated O
with O
the O
ability O
of O
CD40 B
to O
induce O
Ab O
secretion O
and O
the O
up O
- O
regulation O
of O
ICAM B
- I
1 I
and O
LFA B
- I
1 I
. O

NF B
- I
kappa I
B I
activation O
correlated O
with O
the O
ability O
of O
CD40 B
to O
induce O
Ab O
secretion O
and O
the O
up O
- O
regulation O
of O
ICAM B
- I
1 I
and O
LFA B
- I
1 I
. O

Addition O
of O
GM B
- I
CSF I
to O
this O
basic O
cocktail O
consistently O
increased O
the O
clonogenic O
capacity O
of O
single O
CD34 O
+ O
Thy O
- O
1 O
+ O
cells O
, O
and O
this O
effect O
was O
further O
enhanced O
( O
up O
to O
72 O
. O
3 O
+ O
/ O
- O
4 O
. O
3 O
% O
on O
day O
7 O
) O
by O
the O
inclusion O
of O
TNF B
- I
alpha I
. O

Addition O
of O
GM B
- I
CSF I
to O
this O
basic O
cocktail O
consistently O
increased O
the O
clonogenic O
capacity O
of O
single O
CD34 O
+ O
Thy O
- O
1 O
+ O
cells O
, O
and O
this O
effect O
was O
further O
enhanced O
( O
up O
to O
72 O
. O
3 O
+ O
/ O
- O
4 O
. O
3 O
% O
on O
day O
7 O
) O
by O
the O
inclusion O
of O
TNF B
- I
alpha I
. O

Induction O
of O
endothelial B
cell I
surface I
adhesion I
molecules I
by O
tumor B
necrosis I
factor I
is O
blocked O
by O
protein O
tyrosine O
phosphatase O
inhibitors O
: O
role O
of O
the O
nuclear B
transcription I
factor I
NF I
- I
kappa I
B I
. O

The O
induction O
of O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
, O
and O
ELAM B
- I
1 I
by O
TNF B
in O
MVEC O
occurred O
within O
6 O
h O
and O
was O
also O
completely O
down O
- O
regulated O
by O
PAO O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
induction O
of O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
, O
and O
ELAM B
- I
1 I
by O
TNF B
in O
MVEC O
occurred O
within O
6 O
h O
and O
was O
also O
completely O
down O
- O
regulated O
by O
PAO O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
induction O
of O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
, O
and O
ELAM B
- I
1 I
by O
TNF B
in O
MVEC O
occurred O
within O
6 O
h O
and O
was O
also O
completely O
down O
- O
regulated O
by O
PAO O
in O
a O
dose O
- O
dependent O
manner O
. O

Further O
, O
M O
. O
tuberculosis O
and O
its O
tuberculin B
, O
purified B
protein I
derivative I
, O
induced O
the O
degradation O
of O
I B
kappa I
B I
- I
alpha I
and O
the O
expression O
of O
I B
kappa I
B I
- I
alpha I
mRNA I
, O
and O
purified O
protein O
derivative O
induced O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
monocytes O
. O

These O
results O
show O
that O
Spi O
- O
1 O
/ O
PU B
. I
1 I
requires O
signals O
emanating O
from O
specific O
cytokine O
and O
growth O
factor O
receptors O
to O
affect O
the O
survival O
, O
proliferation O
and O
differentiation O
control O
of O
primary O
erythroblasts O
. O

Inhibition O
of O
TF B
induction O
in O
the O
presence O
of O
high O
CsA O
blood O
concentrations O
was O
also O
observed O
when O
stimulation O
of O
cells O
was O
performed O
with O
interferon B
- I
gamma I
or O
interleukin B
- I
1beta I
. O

Inhibition O
of O
TF B
induction O
in O
the O
presence O
of O
high O
CsA O
blood O
concentrations O
was O
also O
observed O
when O
stimulation O
of O
cells O
was O
performed O
with O
interferon B
- I
gamma I
or O
interleukin B
- I
1beta I
. O

Inhibition O
of O
monocyte O
TF B
induction O
by O
CsA O
may O
contribute O
to O
its O
successful O
use O
in O
cardiac O
transplant O
medicine O
and O
might O
be O
useful O
in O
managing O
further O
settings O
of O
vascular O
pathology O
also O
known O
to O
involve O
TF B
expression O
and O
NF B
- I
kappaB I
activation O
. O

IL B
- I
2 I
and O
IL B
- I
7 I
were O
equivalent O
in O
their O
ability O
to O
induce O
tyrosine O
phosphorylation O
of O
STAT5A B
and O
STAT5B B
and O
to O
facilitate O
binding O
of O
these O
STATs B
to O
an O
immobilized B
GAS I
element I
. O

IL B
- I
2 I
and O
IL B
- I
7 I
were O
equivalent O
in O
their O
ability O
to O
induce O
tyrosine O
phosphorylation O
of O
STAT5A B
and O
STAT5B B
and O
to O
facilitate O
binding O
of O
these O
STATs B
to O
an O
immobilized B
GAS I
element I
. O

IL B
- I
2 I
and O
IL B
- I
7 I
were O
equivalent O
in O
their O
ability O
to O
induce O
tyrosine O
phosphorylation O
of O
STAT5A B
and O
STAT5B B
and O
to O
facilitate O
binding O
of O
these O
STATs B
to O
an O
immobilized B
GAS I
element I
. O

These O
data O
suggest O
that O
IL B
- I
2 I
and O
IL B
- I
7 I
induce O
assembly O
of O
STAT B
heterodimers I
in O
a O
similar O
manner O
and O
that O
subsequent O
cellular O
responses O
may O
be O
driven O
by O
induction O
of O
similar O
sets O
of O
genes B
. O

These O
data O
suggest O
that O
IL B
- I
2 I
and O
IL B
- I
7 I
induce O
assembly O
of O
STAT B
heterodimers I
in O
a O
similar O
manner O
and O
that O
subsequent O
cellular O
responses O
may O
be O
driven O
by O
induction O
of O
similar O
sets O
of O
genes B
. O

The O
POU B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
regulate O
the O
activity O
of O
octamer B
- I
dependent I
promoters I
, O
including O
those O
that O
direct O
transcription O
from O
rearranged O
immunoglobulin B
genes I
. O

The O
POU B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
regulate O
the O
activity O
of O
octamer B
- I
dependent I
promoters I
, O
including O
those O
that O
direct O
transcription O
from O
rearranged O
immunoglobulin B
genes I
. O

The O
POU B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
regulate O
the O
activity O
of O
octamer B
- I
dependent I
promoters I
, O
including O
those O
that O
direct O
transcription O
from O
rearranged O
immunoglobulin B
genes I
. O

Transient O
transfection O
of O
a O
B O
lymphoma O
line O
resulted O
in O
up O
to O
89 O
% O
reduction O
of O
constitutive O
MHC B
class I
II I
expression O
within O
5 O
days O
and O
suppression O
of O
HLA B
- I
DRA I
mRNA I
synthesis O
. O

We O
show O
here O
that O
helenalin O
, O
and O
, O
to O
a O
much O
lesser O
degree O
, O
11alpha O
, O
13 O
- O
dihydrohelenalin O
and O
chamissonolid O
, O
inhibit O
activation O
of O
transcription B
factor I
NF B
- I
kappaB I
. O

NF B
- I
AT I
activation O
induced O
by O
a O
CAML B
- O
interacting O
member O
of O
the O
tumor B
necrosis I
factor I
receptor I
superfamily I
. O

The O
CAML B
( I
calcium I
- I
modulator I
and I
cyclophilin I
ligand I
) I
protein I
is O
a O
coinducer O
of O
NF B
- I
AT I
activation O
when O
overexpressed O
in O
Jurkat O
T O
cells O
. O

These O
results O
suggest O
that O
coordination O
of O
NF B
- I
kappaB I
and O
STAT6 B
may O
be O
required O
for O
induction O
of O
germline B
Cepsilon O
transcription O
by O
IL B
- I
4 I
, O
and O
that O
CD40 B
- O
mediated O
NF B
- I
kappaB I
activation O
may O
be O
important O
in O
regulating O
both O
enhancement O
of O
germline B
Cepsilon O
transcription O
and O
class O
switching O
to O
IgE B
. O

These O
results O
suggest O
that O
coordination O
of O
NF B
- I
kappaB I
and O
STAT6 B
may O
be O
required O
for O
induction O
of O
germline B
Cepsilon O
transcription O
by O
IL B
- I
4 I
, O
and O
that O
CD40 B
- O
mediated O
NF B
- I
kappaB I
activation O
may O
be O
important O
in O
regulating O
both O
enhancement O
of O
germline B
Cepsilon O
transcription O
and O
class O
switching O
to O
IgE B
. O

These O
results O
suggest O
that O
coordination O
of O
NF B
- I
kappaB I
and O
STAT6 B
may O
be O
required O
for O
induction O
of O
germline B
Cepsilon O
transcription O
by O
IL B
- I
4 I
, O
and O
that O
CD40 B
- O
mediated O
NF B
- I
kappaB I
activation O
may O
be O
important O
in O
regulating O
both O
enhancement O
of O
germline B
Cepsilon O
transcription O
and O
class O
switching O
to O
IgE B
. O

Thus O
, O
our O
data O
establish O
that O
ATF B
/ I
CREB I
factors I
functionally O
modulate O
histone B
H4 I
gene I
transcription O
at O
distal B
and I
proximal I
promoter I
elements I
. O

A O
nuclear B
membrane I
protein I
related O
to O
yeast B
sterol I
isomerase I
. O

A O
nuclear B
membrane I
protein I
related O
to O
yeast B
sterol I
isomerase I
. O

Using O
a O
radiolabeled O
chemical O
probe O
, O
we O
here O
purified O
a O
target O
of O
SR O
31747A O
and O
called O
it O
SR B
31747A I
- I
binding I
protein I
( O
SR B
- I
BP I
) O
. O

Northern O
blot O
analysis O
of O
SR B
- I
BP I
gene O
expression O
revealed O
a O
single O
transcript O
of O
2 B
kilobases I
which O
was O
widely O
expressed O
among O
organs O
, O
with O
the O
highest O
abundance O
in O
liver O
and O
the O
lowest O
abundance O
in O
brain O
. O

Here O
we O
report O
the O
induction O
of O
the O
synthesis O
and O
of O
the O
hydrolytic O
activity O
of O
phospholipase B
C I
gamma I
1 I
( O
PLC B
gamma I
1 I
) O
in O
human O
T O
lymphocytes O
by O
IFN B
- I
beta I
. O

Here O
we O
report O
the O
induction O
of O
the O
synthesis O
and O
of O
the O
hydrolytic O
activity O
of O
phospholipase B
C I
gamma I
1 I
( O
PLC B
gamma I
1 I
) O
in O
human O
T O
lymphocytes O
by O
IFN B
- I
beta I
. O

The O
increased O
level O
of O
PLC B
gamma I
1 I
becomes O
evident O
after O
90 O
min O
of O
IFN B
- I
beta I
treatment O
and O
is O
still O
detectable O
after O
24 O
h O
. O

The O
increased O
level O
of O
PLC B
gamma I
1 I
becomes O
evident O
after O
90 O
min O
of O
IFN B
- I
beta I
treatment O
and O
is O
still O
detectable O
after O
24 O
h O
. O

Neither O
the O
PLC B
gamma I
1 I
overexpression O
induced O
by O
IFN B
nor O
the O
increased O
hydrolytic O
activity O
of O
the O
enzyme B
appear O
to O
be O
affected O
by O
pretreatment O
of O
the O
cells O
with O
the O
protein O
tyrosine B
kinase I
inhibitor O
genistein O
, O
which O
is O
known O
to O
prevent O
the O
association O
of O
ISGF3 B
components O
. O

These O
results O
suggest O
that O
in O
human O
T O
lymphocytes O
IFN B
- I
beta I
can O
activate O
other O
transcription B
factor I
( O
s O
) O
distinct O
from O
ISGF3 B
to O
regulate O
PLC B
gamma I
1 I
expression O
. O

These O
results O
suggest O
that O
in O
human O
T O
lymphocytes O
IFN B
- I
beta I
can O
activate O
other O
transcription B
factor I
( O
s O
) O
distinct O
from O
ISGF3 B
to O
regulate O
PLC B
gamma I
1 I
expression O
. O

Our O
results O
support O
an O
important O
role O
for O
autocrine O
TNF B
- I
alpha I
secretion O
in O
controlling O
HIV O
replication O
in O
primary O
T O
cells O
because O
of O
its O
ability O
to O
maintain O
NF B
- I
kappa I
B I
elevated O
in O
the O
nucleus O
of O
T O
cells O
. O

Intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
is O
an O
important O
molecule O
in O
promotion O
of O
polymorphonuclear O
neutrophil O
transendothelial O
migration O
during O
inflammation O
. O

These O
results O
indicate O
that O
JAK2 B
/ B
STAT5 I
activation O
is O
a O
common O
JAK B
/ B
STAT I
pathway O
for O
hIL B
- I
5 I
- O
mediated O
signal O
in O
these O
cells O
. O

The O
transcriptional B
start I
sites I
were O
identified O
by O
an O
RNase B
protection O
assay O
. O

Genomic O
organization O
, O
sequence O
, O
and O
transcriptional O
regulation O
of O
the O
human B
eotaxin I
gene I
. O

The O
pp52 B
promoter I
contains O
an O
initiator O
specifying O
the O
unique O
5 B
' I
terminus I
of O
pp52 B
mRNA I
, O
tandem O
pairs O
of O
Ets B
and I
SP1 I
motifs I
, O
and O
a O
lone B
C I
/ I
EBP I
motif I
. O

The O
immediate O
- O
early O
gene O
product O
Egr B
- I
1 I
regulates O
the O
human B
interleukin I
- I
2 I
receptor I
beta I
- I
chain I
promoter I
through O
noncanonical B
Egr I
and I
Sp1 I
binding I
sites I
. O

In O
Jurkat O
cells O
, O
both O
sites O
were O
required O
for O
maximal O
IL B
- I
2Rbeta I
promoter O
activity O
, O
and O
in O
HeLaS3 O
cells O
, O
transfection O
of O
Egr B
- I
1 I
could O
drive O
activity O
of O
a O
reporter O
construct O
containing O
both O
sites O
. O

In O
Jurkat O
cells O
, O
both O
sites O
were O
required O
for O
maximal O
IL B
- I
2Rbeta I
promoter O
activity O
, O
and O
in O
HeLaS3 O
cells O
, O
transfection O
of O
Egr B
- I
1 I
could O
drive O
activity O
of O
a O
reporter O
construct O
containing O
both O
sites O
. O

Acquisition O
of O
heat O
shock O
factor O
2 O
( O
HSF2 O
) O
DNA O
binding O
activity O
is O
accompanied O
by O
induced O
transcription O
of O
heat B
shock I
genes I
in O
hemin O
- O
treated O
K562 O
cells O
undergoing O
erythroid O
differentiation O
. O

These O
defects O
are O
paralleled O
by O
an O
impaired O
ability O
to O
produce O
Th1 B
cytokines I
( O
IL B
- I
2 I
and O
IFN B
- I
gamma I
) O
. O

These O
defects O
are O
paralleled O
by O
an O
impaired O
ability O
to O
produce O
Th1 B
cytokines I
( O
IL B
- I
2 I
and O
IFN B
- I
gamma I
) O
. O

Like O
the O
class B
II I
genes I
, O
the O
HLA B
- I
DM I
genes I
contain O
upstream O
regulatory O
sequences O
similar O
to O
the O
S B
- I
X I
- I
Y I
regulatory I
region I
as O
well O
as O
additional O
putative O
regulatory O
sites O
. O

In O
a O
previous O
study O
, O
we O
demonstrated O
that O
bufalin O
, O
which O
is O
an O
active O
principle O
of O
Chinese O
medicine O
, O
chan O
' O
su O
, O
caused O
apoptosis O
in O
human O
leukemia O
U937 O
cells O
by O
anomalous O
activation O
of O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
via O
the O
signaling O
pathway O
of O
Ras B
, O
Raf B
- I
1 I
, O
and O
MAPK B
kinase I
- I
1 I
. O

Here O
, O
we O
report O
the O
effect O
of O
overexpression O
of O
bcl B
- I
2 I
in O
U937 O
cells O
on O
the O
signaling O
pathway O
of O
apoptosis O
that O
is O
induced O
by O
bufalin O
. O

The O
genes O
encoding O
the O
functionally O
related O
hepatocyte B
nuclear I
factors I
HNF B
- I
1alpha I
and O
HNF B
- I
4alpha I
play O
a O
critical O
role O
in O
normal O
pancreatic O
beta O
- O
cell O
function O
. O

The O
genes O
encoding O
the O
functionally O
related O
hepatocyte B
nuclear I
factors I
HNF B
- I
1alpha I
and O
HNF B
- I
4alpha I
play O
a O
critical O
role O
in O
normal O
pancreatic O
beta O
- O
cell O
function O
. O

The O
genes O
encoding O
the O
functionally O
related O
hepatocyte B
nuclear I
factors I
HNF B
- I
1alpha I
and O
HNF B
- I
4alpha I
play O
a O
critical O
role O
in O
normal O
pancreatic O
beta O
- O
cell O
function O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

Anti B
- I
E I
. I
chaffeensis I
antibody I
complexed O
with O
E O
. O
chaffeensis O
significantly O
enhanced O
mRNA O
expression O
of O
IL B
- I
1beta I
in O
THP O
- O
1 O
cells O
. O

Molecular O
cloning O
of O
SLAP B
- I
130 I
, O
an O
SLP B
- I
76 I
- I
associated I
substrate I
of O
the O
T B
cell I
antigen I
receptor I
- I
stimulated I
protein I
tyrosine I
kinases I
. O

These O
data O
suggest O
that O
SLP B
- I
76 I
recruits O
a O
negative O
regulator O
, O
SLAP B
- I
130 I
, O
as O
well O
as O
positive O
regulators O
of O
signal O
transduction O
in O
T O
cells O
. O

These O
data O
suggest O
that O
SLP B
- I
76 I
recruits O
a O
negative O
regulator O
, O
SLAP B
- I
130 I
, O
as O
well O
as O
positive O
regulators O
of O
signal O
transduction O
in O
T O
cells O
. O

From O
analyses O
of O
mice O
deficient O
in O
transcription B
factor I
genes I
and O
from O
the O
characterizations O
of O
chromosome B
breakpoints I
in O
human O
leukemias O
, O
it O
has O
become O
evident O
that O
transcription B
factors I
are O
important O
regulators O
of O
hematopoiesis O
. O

In O
THP O
- O
1 O
cells O
transfected O
with O
HIV B
plasmid I
constructs I
, O
both O
organisms O
induced O
transcription O
from O
the O
HIV B
long I
terminal I
repeat I
that O
was O
dependent O
on O
intact O
NF B
- I
kappaB I
binding I
sequences I
. O

c B
- I
Myb I
and O
Ets B
proteins I
synergize O
to O
overcome O
transcriptional O
repression O
by O
ZEB B
. O

IL B
- I
4 I
- O
dependent O
activation O
of O
Stat6 B
was O
also O
observed O
in O
HC11 O
mammary O
epithelial O
cells O
. O

In O
pre O
- O
B O
cells O
( O
Ba O
/ O
F3 O
) O
, O
the O
transactivation O
domain O
of O
Stat6 B
was O
IL B
- I
4 I
regulated O
, O
independently O
from O
its O
DNA O
binding O
function O
. O

Granulocyte B
- I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
is O
one O
such O
cytokine B
, O
whose O
increased O
expression O
results O
mostly O
from O
increases O
in O
transcription O
. O

We O
have O
previously O
shown O
that O
ETS1 B
can O
transactivate O
GM B
- I
CSF I
in O
Jurkat O
T O
cells O
, O
but O
only O
after O
the O
cells O
have O
been O
stimulated O
by O
treatment O
with O
PMA O
and O
ionomycin O
, O
agents O
that O
mimic O
T O
cell O
activation O
. O

Signaling O
through O
CD40 B
with O
soluble O
CD40 B
ligand O
stimulated O
fibroblast O
activation O
, O
as O
evidenced O
by O
mobilization O
of O
nuclear O
factor O
- O
kappaB O
and O
by O
induction O
of O
the O
proinflammatory O
and O
chemoattractant O
cytokines B
IL B
- I
6 I
and O
IL B
- I
8 I
. O

Signaling O
through O
CD40 B
with O
soluble O
CD40 B
ligand O
stimulated O
fibroblast O
activation O
, O
as O
evidenced O
by O
mobilization O
of O
nuclear O
factor O
- O
kappaB O
and O
by O
induction O
of O
the O
proinflammatory O
and O
chemoattractant O
cytokines B
IL B
- I
6 I
and O
IL B
- I
8 I
. O

In O
contrast O
, O
it O
was O
found O
to O
be O
TNF B
- I
alpha I
independent O
in O
the O
early O
time O
point O
. O

In O
fact O
, O
mAb B
L243 I
but O
not O
the O
staphylococcal B
superantigens I
, O
staphylococcal B
exotoxin I
toxic I
shock I
syndrome I
toxin I
- I
I I
or O
staphylococcal B
enterotoxin I
B I
, O
regulate O
the O
NF B
- I
kappa I
B I
binding O
activity O
. O

Fusion O
proteins O
involving O
the O
retinoic O
acid O
receptor B
alpha I
( O
RAR B
alpha I
) O
and O
the O
PML B
or O
PLZF B
nuclear I
protein I
are O
the O
genetic O
markers O
of O
acute O
promyelocytic O
leukemias O
( O
APLs O
) O
. O

Cytomegalovirus O
( O
CMV O
) O
infection O
induced O
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
gene O
transcription O
in O
a O
human O
monocytic O
cell O
line O
, O
THP O
- O
1 O
cells O
, O
leading O
to O
IL B
- I
8 I
secretion O
. O

Cytomegalovirus O
( O
CMV O
) O
infection O
induced O
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
gene O
transcription O
in O
a O
human O
monocytic O
cell O
line O
, O
THP O
- O
1 O
cells O
, O
leading O
to O
IL B
- I
8 I
secretion O
. O

Cytomegalovirus O
( O
CMV O
) O
infection O
induced O
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
gene O
transcription O
in O
a O
human O
monocytic O
cell O
line O
, O
THP O
- O
1 O
cells O
, O
leading O
to O
IL B
- I
8 I
secretion O
. O

Moreover O
, O
electrophoretic O
mobility O
shift O
assays O
demonstrated O
that O
CMV O
induced O
the O
formation O
of O
NF B
- I
kappaB I
and O
AP B
- I
1 I
complexes I
. O

Interleukin B
- I
12 I
( O
IL B
- I
12 I
) O
is O
a O
cytokine B
that O
exhibits O
pleiotropic O
effects O
on O
lymphocytes O
and O
natural O
killer O
cells O
and O
has O
been O
shown O
to O
have O
promise O
for O
the O
immunotherapy O
of O
cancer O
. O

Interleukin B
- I
12 I
( O
IL B
- I
12 I
) O
is O
a O
cytokine B
that O
exhibits O
pleiotropic O
effects O
on O
lymphocytes O
and O
natural O
killer O
cells O
and O
has O
been O
shown O
to O
have O
promise O
for O
the O
immunotherapy O
of O
cancer O
. O

There O
was O
, O
however O
, O
a O
significant O
decrease O
in O
the O
plasma B
sialyltransferase I
: I
cortisol O
ratio O
in O
the O
depressed O
group O
suggesting O
an O
inability O
of O
the O
raised O
cortisol O
levels O
to O
induce O
enzyme O
expression O
and O
this O
ratio O
may O
provide O
a O
useful O
biochemical O
marker O
of O
cortisol O
receptor O
function O
. O

Using O
a O
previously O
described O
mutant O
of O
the O
Jurkat O
T O
cell O
line O
, O
we O
show O
that O
proximal O
signaling O
events O
dependent O
on O
the O
presence O
of O
the O
CD45 B
tyrosine I
phosphatase I
are O
required O
for O
TCR B
- O
stimulated O
CD95 B
ligand I
expression O
. O

TCP O
succinate O
( O
200 O
microM O
, O
24 O
h O
) O
reduced O
TNF B
- I
induced I
VCAM I
- I
1 I
and O
E B
- I
selectin I
expression O
from O
a O
specific O
mean O
fluorescence O
intensity O
of O
151 O
+ O
/ O
- O
28 O
to O
12 O
+ O
/ O
- O
4 O
channels O
and O
from O
225 O
+ O
/ O
- O
38 O
to O
79 O
+ O
/ O
- O
21 O
channels O
, O
respectively O
. O

When O
macrophages O
were O
pretreated O
with O
low O
doses O
of O
IFN B
- I
gamma I
and O
then O
stimulated O
with O
IFN B
- I
alpha I
, O
clearly O
enhanced O
formation O
of O
specific O
transcription B
factor I
complexes O
was O
detected O
. O

When O
macrophages O
were O
pretreated O
with O
low O
doses O
of O
IFN B
- I
gamma I
and O
then O
stimulated O
with O
IFN B
- I
alpha I
, O
clearly O
enhanced O
formation O
of O
specific O
transcription B
factor I
complexes O
was O
detected O
. O

Activation O
and O
regulation O
of O
NF B
- I
kappa I
B I
are O
tightly O
controlled O
by O
a O
group O
of O
inhibitory B
proteins I
( O
I B
kappa I
B I
) O
that O
sequester O
NF B
- I
kappa I
B I
in O
the O
cytoplasm O
of O
immune O
/ O
inflammatory O
effector O
cells O
. O

Liberated O
NF B
- I
kappa I
B I
migrates O
to O
the O
nucleus O
, O
where O
it O
binds O
to O
specific B
promoter I
sites I
and O
activates O
gene O
transcription O
. O

Constitutive O
expression O
of O
E2a B
- I
Pbx1 I
did O
not O
induce O
apoptosis O
or O
continued O
cycling O
of O
Rat O
- O
1 O
fibroblasts O
in O
low O
serum O
conditions O
. O

Thus O
, O
C B
/ I
EBPepsilon I
is O
regulated O
in O
a O
complex O
fashion O
and O
may O
play O
a O
role O
in O
the O
regulation O
of O
genes O
involved O
in O
myeloid O
differentiation O
. O

We O
now O
report O
that O
PO B
- I
B I
DNA O
- O
binding O
in O
HL O
- O
60 O
cells O
is O
similarly O
induced O
during O
differentiation O
to O
the O
granulocytic O
lineage O
( O
with O
either O
retinoic O
acid O
or O
dimethylsulfoxide O
) O
. O

Oct B
- I
2 I
expressed O
in O
this O
tester O
strain O
represses O
the O
expression O
of O
the O
reporter O
gene O
and O
changes O
the O
phenotype O
of O
the O
cell O
from O
Lac O
+ O
to O
Lac O
- O
. O

One O
of O
them O
, O
hT86 O
, O
encoding O
a O
putative B
zinc I
finger I
protein I
was O
found O
to O
derepress O
beta B
- I
galactosidase I
activity O
in O
the O
Oct B
- I
2 I
- O
harboring O
tester O
strain O
at O
the O
transcriptional O
level O
. O

One O
of O
them O
, O
hT86 O
, O
encoding O
a O
putative B
zinc I
finger I
protein I
was O
found O
to O
derepress O
beta B
- I
galactosidase I
activity O
in O
the O
Oct B
- I
2 I
- O
harboring O
tester O
strain O
at O
the O
transcriptional O
level O
. O

Furthermore O
, O
increasing O
the O
spacing O
between O
the O
CRE B
and I
the I
kappaB3 I
sites I
completely O
abolished O
LPS O
induction O
, O
suggesting O
a O
cooperative O
interaction O
between O
c B
- I
Jun I
complexes I
and O
p50 B
/ I
p65 I
. O

IL B
- I
10 I
inhibition O
of O
IFN B
- I
gamma I
- O
induced O
ICAM B
- I
1 I
expression O
was O
apparent O
as O
early O
as O
3 O
hours O
and O
was O
blocked O
by O
an O
anti B
- I
IL I
- I
10 I
antibody I
but O
not O
by O
an O
isotype B
- I
matched I
control I
antibody I
. O

IL B
- I
10 I
inhibition O
of O
IFN B
- I
gamma I
- O
induced O
ICAM B
- I
1 I
expression O
was O
apparent O
as O
early O
as O
3 O
hours O
and O
was O
blocked O
by O
an O
anti B
- I
IL I
- I
10 I
antibody I
but O
not O
by O
an O
isotype B
- I
matched I
control I
antibody I
. O

IL B
- I
10 I
inhibition O
of O
IFN B
- I
gamma I
- O
induced O
ICAM B
- I
1 I
expression O
was O
apparent O
as O
early O
as O
3 O
hours O
and O
was O
blocked O
by O
an O
anti B
- I
IL I
- I
10 I
antibody I
but O
not O
by O
an O
isotype B
- I
matched I
control I
antibody I
. O

Phosphatidylinositol B
3 I
- I
kinase I
( O
PI3 B
- I
K I
) O
has O
been O
implicated O
in O
the O
regulation O
of O
cell O
proliferation O
in O
many O
cell O
types O
. O

The O
resulting O
fusion B
genes I
encode O
the O
two O
structurally O
unique O
PML B
/ I
RARalpha I
and O
RARalpha B
/ I
PML I
fusion I
proteins I
as O
well O
as O
aberrant B
PML I
gene I
products I
, O
the O
respective O
pathogenetic O
roles O
of O
which O
have O
not O
been O
elucidated O
. O

Interferon O
- O
gamma O
( O
IFN B
- I
gamma I
) O
is O
a O
key O
cytokine O
of O
T O
lymphocytes O
with O
major O
regulatory O
functions O
in O
the O
immune O
system O
. O

This O
novel B
target I
site I
, O
denoted O
the O
C B
- I
site I
, O
was O
shown O
by O
several O
criteria O
, O
including O
cell O
distribution O
studies O
, O
stimulation O
experiments O
, O
supershift O
assays O
, O
and O
cross O
- O
competition O
electrophoretic O
mobility O
shift O
assays O
to O
bind O
the O
transcription B
factor I
AP I
- I
1 I
. O

This O
novel B
target I
site I
, O
denoted O
the O
C B
- I
site I
, O
was O
shown O
by O
several O
criteria O
, O
including O
cell O
distribution O
studies O
, O
stimulation O
experiments O
, O
supershift O
assays O
, O
and O
cross O
- O
competition O
electrophoretic O
mobility O
shift O
assays O
to O
bind O
the O
transcription B
factor I
AP I
- I
1 I
. O

Mutation O
of O
the O
C B
- I
site I
that O
prevented O
AP B
- I
1 I
binding O
to O
this O
site O
was O
sufficient O
strikingly O
to O
reduce O
inducible O
promoter O
activity O
in O
primary O
CD45R0 O
T O
cells O
. O

Mutation O
of O
the O
C B
- I
site I
that O
prevented O
AP B
- I
1 I
binding O
to O
this O
site O
was O
sufficient O
strikingly O
to O
reduce O
inducible O
promoter O
activity O
in O
primary O
CD45R0 O
T O
cells O
. O

Latent O
infection O
of O
B O
lymphocytes O
by O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
can O
be O
disrupted O
by O
expression O
of O
the O
EBV B
ZEBRA I
protein I
. O

To O
better O
understand O
the O
AP B
- I
1 I
- O
dependent O
luciferase B
expression O
in O
Jurkat O
T O
cells O
, O
we O
tested O
two O
specific O
inhibitors O
of O
serine B
/ I
threonine I
phosphatases I
- I
1 I
and I
- I
2A I
: O
okadaic O
acid O
and O
calyculin O
A O
. O

While O
the O
activation O
of O
JAK2 B
, O
Shc B
, O
Erk B
, O
and O
STAT5 B
proteins I
correlated O
with O
hGM B
- I
CSF I
- O
mediated O
cell O
growth O
, O
cellular O
differentiation O
occurred O
in O
the O
absence O
of O
activation O
of O
these O
signal O
transduction O
pathways O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA B
, O
CHEMR1 B
, O
encoding O
a O
chemokine B
receptor I
with O
a O
homology O
to O
the O
human B
C I
- I
C I
chemokine I
receptor I
, O
CCR B
- I
4 I
. O

This O
suggests O
that O
CHEMR1 B
may O
be O
a O
receptor O
for O
unidentified O
C B
- I
C I
chemokine I
or O
a O
low O
- O
affinity O
receptor O
for O
MIP B
- I
1alpha I
. O

Its O
N B
- I
terminal I
region I
is O
capable O
of O
activating O
transcription O
from O
a O
reporter O
gene O
when O
fused O
to O
a O
DNA B
binding I
domain I
. O

Human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Tat I
, O
an O
early O
regulatory B
protein I
that O
is O
critical O
for O
viral O
gene O
expression O
and O
replication O
, O
transactivates O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
via O
its O
binding O
to O
the O
transactivation B
response I
element I
( O
TAR B
) O
and O
, O
along O
with O
other O
cellular O
factors O
, O
increases O
viral O
transcription O
initiation O
and O
elongation O
. O

The O
combined O
treatment O
resulted O
in O
more O
durable O
inhibition O
of O
HIV O
- O
1 O
replication O
than O
was O
seen O
with O
the O
NF B
- I
kappa I
B I
inhibitors O
alone O
or O
the O
anti O
- O
Tat B
sFv I
intrabodies I
alone O
. O

The O
methodology O
employed O
transient O
transfection O
of O
HEK O
293 O
cells O
with O
a O
cDNA O
for O
the O
52 O
- O
kDa O
form O
of O
G B
( I
S I
) I
alpha I
under O
regulation O
by O
inducible B
metallothionein I
promoters I
. O

Patients O
with O
one O
type O
of O
major B
histocompatibility I
complex I
class I
II I
combined O
immunodeficiency O
have O
mutations O
in O
a O
gene O
termed O
class B
II I
transactivator I
( O
CIITA B
) O
, O
which O
coordinately O
controls O
the O
transcription O
of O
the O
three O
major O
human B
class I
II I
genes I
, O
HLA B
- I
DR I
, I
- I
DQ I
, I
and I
- I
DP I
. O

We O
report O
here O
that O
ectopic O
expression O
of O
CIITA B
cDNAs I
derived O
by O
reverse O
transcriptase O
polymerase O
chain O
reaction O
from O
clone O
13 O
do O
not O
restore O
expression O
of O
HLA B
- I
DQ I
in O
another O
CIITA O
- O
deficient O
cell O
line O
, O
RJ2 O
. O
2 O
. O
5 O
. O

In O
contrast O
, O
somatic O
cell O
fusion O
between O
clone O
13 O
and O
RJ2 O
. O
2 O
. O
5 O
restored O
expression O
of O
the O
HLA B
- I
DQ I
haplotype O
encoded O
by O
the O
RJ2 B
. I
2 I
. I
5 I
DQB I
gene I
. O

The O
cytokines B
interleukin B
( I
IL I
) I
- I
4 I
and O
IL B
- I
13 I
play O
a O
critical O
role O
in O
inducing O
Cepsilon B
germline I
transcripts I
and O
IgE B
isotype I
switching O
in O
human O
B O
cells O
. O

The O
cytokines B
interleukin B
( I
IL I
) I
- I
4 I
and O
IL B
- I
13 I
play O
a O
critical O
role O
in O
inducing O
Cepsilon B
germline I
transcripts I
and O
IgE B
isotype I
switching O
in O
human O
B O
cells O
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

Analysis O
of O
these O
PBLs O
revealed O
that O
activation O
of O
the O
NF B
- I
kappaB I
pathway O
is O
sufficient O
to O
promote O
the O
growth O
response O
to O
IL B
- I
2 I
. O

Analysis O
of O
these O
PBLs O
revealed O
that O
activation O
of O
the O
NF B
- I
kappaB I
pathway O
is O
sufficient O
to O
promote O
the O
growth O
response O
to O
IL B
- I
2 I
. O

Treatment O
of O
cells O
expressing O
the O
chimeric B
receptor I
kit B
/ I
IL I
- I
4R I
alpha I
with O
SCF B
induces O
activation O
of O
the O
IL B
- I
4R I
alpha I
- I
associated I
kinase I
JAK B
- I
1 I
and O
the O
transcription B
factor I
STAT6 B
. O

Dose O
- O
dependence O
studies O
using O
histamine O
and O
dimaprit O
showed O
that O
the O
EC50 O
values O
for O
cAMP O
production O
and O
c B
- I
fos I
increase O
were O
similar O
, O
suggesting O
that O
cAMP O
might O
be O
involved O
in O
c B
- I
fos I
induction O
via O
H2 B
receptors I
. O

Dose O
- O
dependence O
studies O
using O
histamine O
and O
dimaprit O
showed O
that O
the O
EC50 O
values O
for O
cAMP O
production O
and O
c B
- I
fos I
increase O
were O
similar O
, O
suggesting O
that O
cAMP O
might O
be O
involved O
in O
c B
- I
fos I
induction O
via O
H2 B
receptors I
. O

After O
4 O
hours O
, O
IL B
- I
1 I
beta I
and O
IL B
- I
8 I
concentration O
of O
the O
cell O
- O
free O
supernatant O
had O
increased O
by O
268 O
+ O
/ O
- O
36 O
% O
and O
210 O
+ O
/ O
- O
7 O
% O
, O
respectively O
, O
and O
cellular O
MCP B
- I
1 I
content O
had O
increased O
by O
170 O
+ O
/ O
- O
8 O
% O
. O

After O
4 O
hours O
, O
IL B
- I
1 I
beta I
and O
IL B
- I
8 I
concentration O
of O
the O
cell O
- O
free O
supernatant O
had O
increased O
by O
268 O
+ O
/ O
- O
36 O
% O
and O
210 O
+ O
/ O
- O
7 O
% O
, O
respectively O
, O
and O
cellular O
MCP B
- I
1 I
content O
had O
increased O
by O
170 O
+ O
/ O
- O
8 O
% O
. O

Clonal O
analysis O
revealed O
individual O
responses O
to O
the O
two O
immediate B
early I
proteins I
BZLF1 B
and O
BRLF1 B
, O
and O
to O
three O
( O
BMLF1 B
, O
BMRF1 B
, O
and O
BALF2 B
) O
of O
the O
six O
early B
proteins I
tested O
. O

Triggering O
of O
HLA B
class I
II I
antigens I
by O
the O
anti B
- I
HLA I
- I
DR I
monoclonal I
antibody I
( I
mAb I
) I
L243 I
significantly O
( O
P O
< O
0 O
. O
05 O
) O
and O
differentially O
enhanced O
the O
release O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
by O
the O
non O
- O
Hodgkin O
' O
s O
lymphoma O
cells O
Ri O
- O
I O
, O
Ci O
- O
I O
, O
and O
Sc O
- O
I O
, O
which O
are O
at O
a O
distinct O
stage O
of O
B O
- O
cell O
differentiation O
, O
and O
by O
the O
more O
mature O
Burkitt O
lymphoma O
cell O
Raji O
; O
in O
contrast O
, O
it O
did O
not O
induce O
TNF B
- I

Altogether O
, O
our O
data O
demonstrate O
that O
: O
( O
a O
) O
the O
ability O
of O
B O
cells O
to O
release O
TNF B
- I
alpha I
after O
triggering O
of O
HLA B
- I
DR I
antigens I
depends O
on O
their O
stage O
of O
differentiation O
; O
( O
b O
) O
levels O
of O
released O
TNF B
- I
alpha I
seem O
to O
correlate O
with O
the O
stage O
of O
B O
- O
cell O
maturation O
but O
do O
not O
correlate O
with O
the O
amounts O
of O
cell B
surface I
HLA I
- I
DR I
antigens I
; O
( O
c O
) O
secreted O
TNF B
- I
alpha I
regulates O
the O
levels O
of O
expression O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
by O
an O
autocrine O
loop O
; O
and O
( O
d O
) O
intracellular O
signals O
mediating O

Altogether O
, O
our O
data O
demonstrate O
that O
: O
( O
a O
) O
the O
ability O
of O
B O
cells O
to O
release O
TNF B
- I
alpha I
after O
triggering O
of O
HLA B
- I
DR I
antigens I
depends O
on O
their O
stage O
of O
differentiation O
; O
( O
b O
) O
levels O
of O
released O
TNF B
- I
alpha I
seem O
to O
correlate O
with O
the O
stage O
of O
B O
- O
cell O
maturation O
but O
do O
not O
correlate O
with O
the O
amounts O
of O
cell B
surface I
HLA I
- I
DR I
antigens I
; O
( O
c O
) O
secreted O
TNF B
- I
alpha I
regulates O
the O
levels O
of O
expression O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
by O
an O
autocrine O
loop O
; O
and O
( O
d O
) O
intracellular O
signals O
mediating O

Altogether O
, O
our O
data O
demonstrate O
that O
: O
( O
a O
) O
the O
ability O
of O
B O
cells O
to O
release O
TNF B
- I
alpha I
after O
triggering O
of O
HLA B
- I
DR I
antigens I
depends O
on O
their O
stage O
of O
differentiation O
; O
( O
b O
) O
levels O
of O
released O
TNF B
- I
alpha I
seem O
to O
correlate O
with O
the O
stage O
of O
B O
- O
cell O
maturation O
but O
do O
not O
correlate O
with O
the O
amounts O
of O
cell B
surface I
HLA I
- I
DR I
antigens I
; O
( O
c O
) O
secreted O
TNF B
- I
alpha I
regulates O
the O
levels O
of O
expression O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
by O
an O
autocrine O
loop O
; O
and O
( O
d O
) O
intracellular O
signals O
mediating O

TNF B
- I
alpha I
release O
by O
B O
cells O
are O
distinct O
from O
those O
regulating O
homotypic O
aggregation O
and O
proliferation O
. O

Bacterially O
expressed O
RP1 B
protein I
revealed O
specific O
binding O
to O
wild B
- I
type I
but O
not O
to O
mutated B
APC I
protein I
. O

Bacterially O
expressed O
RP1 B
protein I
revealed O
specific O
binding O
to O
wild B
- I
type I
but O
not O
to O
mutated B
APC I
protein I
. O

We O
show O
for O
human O
Jurkat O
T O
leukemia O
cells O
, O
as O
well O
as O
human O
and O
mouse O
primary O
T O
lymphocytes O
, O
that O
this O
inhibitory O
effect O
is O
accompanied O
by O
an O
impaired O
nuclear O
translocation O
of O
the O
Rel B
proteins I
c B
- I
Rel I
, O
RelA B
/ I
p65 I
and O
NF B
- I
kappa I
B1 I
/ I
p50 I
, O
whereas O
the O
nuclear O
appearance O
of O
RelB B
remains O
unaffected O
. O

We O
show O
for O
human O
Jurkat O
T O
leukemia O
cells O
, O
as O
well O
as O
human O
and O
mouse O
primary O
T O
lymphocytes O
, O
that O
this O
inhibitory O
effect O
is O
accompanied O
by O
an O
impaired O
nuclear O
translocation O
of O
the O
Rel B
proteins I
c B
- I
Rel I
, O
RelA B
/ I
p65 I
and O
NF B
- I
kappa I
B1 I
/ I
p50 I
, O
whereas O
the O
nuclear O
appearance O
of O
RelB B
remains O
unaffected O
. O

Accordingly O
, O
immunoblot O
experiments O
showed O
that O
amongst O
NF B
- I
kappa I
B I
/ B
Rel I
proteins I
, O
RelA B
and O
p50 B
are O
mobilized O
to O
the O
nucleus O
following O
microglial O
cell O
stimulation O
with O
A O
beta O
( O
25 O
- O
35 O
) O
plus O
IFN B
gamma I
. O

As O
expected O
, O
LPS O
strongly O
induced O
the O
formation O
of O
two O
NF B
- I
kappa I
B I
DNA O
- O
binding O
activities O
, O
one O
of O
which O
was O
identified O
as O
RelA B
/ I
p50 I
. O

We O
have O
generated O
transgenic O
mice O
that O
express O
a O
catalytically B
inactive I
form I
of O
Ca2 B
+ I
/ I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
specifically O
in O
thymic O
T O
cells O
. O

Transcriptional O
induction O
of O
collagenase B
- I
1 I
in O
differentiated O
monocyte O
- O
like O
( O
U937 O
) O
cells O
is O
regulated O
by O
AP B
- I
1 I
and O
an O
upstream B
C I
/ I
EBP I
- I
beta I
site I
. O

Transcriptional O
induction O
of O
collagenase B
- I
1 I
in O
differentiated O
monocyte O
- O
like O
( O
U937 O
) O
cells O
is O
regulated O
by O
AP B
- I
1 I
and O
an O
upstream B
C I
/ I
EBP I
- I
beta I
site I
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter O
deletion O
analyses O
suggested O
a O
role O
for O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
- I
beta I
( I
C I
/ I
EBP I
- I
beta I
) I
binding I
site I
between O
- B
2010 I
and I
- I
1954 I
in O
regulating O
transcription O
of O
collagenase B
- I
1 I
in O
monocytic O
cells O
. O

It O
has O
been O
recently O
claimed O
that O
polymorphism O
for O
the O
vitamin B
D I
receptor I
( O
VDR B
) O
influences O
several O
aspects O
of O
calcium O
and O
bone O
metabolism O
. O

Unexpectedly O
, O
a O
second O
, O
stronger O
RBP B
- I
Jkappa I
- I
binding I
site I
, O
which O
lies O
within O
the O
intracellular B
domain I
close O
to O
the O
transmembrane O
region O
and O
significantly O
augments O
association O
with O
RBP B
- I
Jkappa I
, O
was O
not O
needed O
for O
oncogenesis O
or O
for O
transcriptional O
activation O
. O

In O
support O
of O
this O
interpretation O
, O
mutation O
of O
putative O
nuclear B
localization I
sequences I
decreased O
nuclear O
localization O
and O
increased O
transcriptional O
activation O
by O
membrane B
- I
bound I
DeltaE I
. O

EMS O
analyses O
utilizing O
a O
series O
of O
mutated B
pp I
repeat I
elements I
demonstrate O
that O
the O
nucleotide O
sequence O
requirements O
for O
U1 B
( O
U1A B
/ I
U1B I
) O
and O
U2 B
formation O
are O
separable O
from O
those O
required O
for O
C1 B
- I
C3 I
formation O
. O

EMS O
analyses O
utilizing O
a O
series O
of O
mutated B
pp I
repeat I
elements I
demonstrate O
that O
the O
nucleotide O
sequence O
requirements O
for O
U1 B
( O
U1A B
/ I
U1B I
) O
and O
U2 B
formation O
are O
separable O
from O
those O
required O
for O
C1 B
- I
C3 I
formation O
. O

Cytokine B
and O
growth B
factor I
receptor I
engagement O
leads O
to O
the O
rapid O
phosphorylation O
and O
activation O
of O
latent O
, O
cytosolic B
signal I
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
proteins I
, O
which O
then O
translocate O
to O
the O
nucleus O
where O
they O
regulate O
transcriptional O
events O
from O
specific B
promoter I
sequences I
. O

Cytokine B
and O
growth B
factor I
receptor I
engagement O
leads O
to O
the O
rapid O
phosphorylation O
and O
activation O
of O
latent O
, O
cytosolic B
signal I
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
proteins I
, O
which O
then O
translocate O
to O
the O
nucleus O
where O
they O
regulate O
transcriptional O
events O
from O
specific B
promoter I
sequences I
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

c B
- I
Fos I
protein O
was O
shown O
essential O
for O
an O
optimal O
transactivation O
of O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
by O
Tat B
: O
incubation O
of O
Jurkat O
cells O
with O
antisense O
, O
but O
not O
sense O
, O
c O
- O
fos O
oligonucleotides O
significantly O
reduced O
either O
the O
Tat B
- O
enhanced O
expression O
of O
an O
LTR B
- I
CAT I
reporter I
construct I
or O
the O
levels O
of O
gag B
p24 I
in O
the O
culture O
supernatants O
of O
Jurkat O
cells O
and O
PBMC O
acutely O
infected O
with O
HIV O
- O
1 O
. O

c B
- I
Fos I
protein O
was O
shown O
essential O
for O
an O
optimal O
transactivation O
of O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
by O
Tat B
: O
incubation O
of O
Jurkat O
cells O
with O
antisense O
, O
but O
not O
sense O
, O
c O
- O
fos O
oligonucleotides O
significantly O
reduced O
either O
the O
Tat B
- O
enhanced O
expression O
of O
an O
LTR B
- I
CAT I
reporter I
construct I
or O
the O
levels O
of O
gag B
p24 I
in O
the O
culture O
supernatants O
of O
Jurkat O
cells O
and O
PBMC O
acutely O
infected O
with O
HIV O
- O
1 O
. O

Regulation O
of O
the O
tissue B
factor I
gene I
in O
human O
monocytic O
cells O
. O

Role O
of O
AP B
- I
1 I
, O
NF B
- I
kappa I
B I
/ I
Rel I
, O
and O
Sp1 B
proteins O
in O
uninduced O
and O
lipopolysaccharide O
- O
induced O
expression O
. O

The O
human B
TF I
promoter I
contains O
binding O
sites O
for O
the O
transcription O
factors O
AP B
- I
1 I
, O
c B
- I
Rel I
/ I
p65 I
, O
Egr B
- I
1 I
, O
and O
Sp1 B
. O

The O
human B
TF I
promoter I
contains O
binding O
sites O
for O
the O
transcription O
factors O
AP B
- I
1 I
, O
c B
- I
Rel I
/ I
p65 I
, O
Egr B
- I
1 I
, O
and O
Sp1 B
. O

The O
human B
TF I
promoter I
contains O
binding O
sites O
for O
the O
transcription O
factors O
AP B
- I
1 I
, O
c B
- I
Rel I
/ I
p65 I
, O
Egr B
- I
1 I
, O
and O
Sp1 B
. O

Inhibitory O
effect O
of O
growth O
hormone O
on O
TNF B
- I
alpha I
secretion O
and O
nuclear B
factor I
- I
kappaB I
translocation O
in O
lipopolysaccharide O
- O
stimulated O
human O
monocytes O
. O

The O
present O
study O
demonstrates O
that O
human O
THP O
- O
1 O
promonocytic O
cells O
, O
engineered O
by O
gene O
transfer O
to O
constitutively O
produce O
human O
growth O
hormone O
( O
hGH O
) O
, O
secreted O
depressed O
amounts O
of O
TNF B
- I
alpha I
in O
response O
to O
challenge O
by O
LPS O
. O

Furthermore O
, O
we O
show O
that O
exogenous O
PGE2 O
mimics O
the O
NF B
- I
kappaB I
inhibitory O
effect O
of O
FCM O
. O

Two O
main O
pieces O
of O
data O
prompted O
us O
to O
focus O
on O
the O
activation O
of O
the O
platelet B
fibrinogen I
receptor I
, O
the O
alphaIIbbeta3 B
integrin I
. O

Treatment O
by O
NE B
of O
ATP O
- O
depleted O
platelets O
or O
Chinese O
hamster O
ovary O
cells O
expressing O
human B
recombinant I
alphaIIbbeta3 I
clearly O
established O
that O
activation O
of O
the O
integrin B
was O
independent O
of O
signal O
transduction O
events O
and O
was O
concomitant O
with O
the O
proteolysis O
of O
alphaIIbH B
. O

To O
test O
the O
hypothesis O
that O
the O
chimera B
PMLRAR I
alpha I
plays O
a O
role O
in O
leukemogenesis O
, O
we O
expressed O
a O
PMLRAR B
alpha I
cDNA I
in O
myeloid O
cells O
of O
transgenic O
mice O
. O

To O
test O
the O
hypothesis O
that O
the O
chimera B
PMLRAR I
alpha I
plays O
a O
role O
in O
leukemogenesis O
, O
we O
expressed O
a O
PMLRAR B
alpha I
cDNA I
in O
myeloid O
cells O
of O
transgenic O
mice O
. O

In O
earlier O
studies O
, O
we O
have O
identified O
the O
transcription B
factors I
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
as O
molecular O
targets O
for O
oxidative O
signalling O
processes O
during O
cell O
cycle O
entry O
, O
and O
have O
shown O
that O
oxidative O
signalling O
is O
involved O
in O
the O
regulation O
of O
early O
changes O
in O
gene O
expression O
during O
the O
G0 O
to O
G1 O
phase O
transition O
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
for O
proteins O
which O
interact O
with O
Tax1 B
, O
we O
isolated O
the O
B B
subunit I
of O
the O
CCAAT B
binding I
protein I
NF B
- I
Y I
from O
a O
HeLa B
cDNA I
library I
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
for O
proteins O
which O
interact O
with O
Tax1 B
, O
we O
isolated O
the O
B B
subunit I
of O
the O
CCAAT B
binding I
protein I
NF B
- I
Y I
from O
a O
HeLa B
cDNA I
library I
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
for O
proteins O
which O
interact O
with O
Tax1 B
, O
we O
isolated O
the O
B B
subunit I
of O
the O
CCAAT B
binding I
protein I
NF B
- I
Y I
from O
a O
HeLa B
cDNA I
library I
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human B
immunodeficiency I
virus I
Tat I
, O
human B
papillomavirus I
E6 I
, O
and O
Bicoid B
, O
or O
with O
the O
M7 B
( I
amino I
acids I
29CP I
- I
AS I
) I
Tax1 I
mutant I
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human B
immunodeficiency I
virus I
Tat I
, O
human B
papillomavirus I
E6 I
, O
and O
Bicoid B
, O
or O
with O
the O
M7 B
( I
amino I
acids I
29CP I
- I
AS I
) I
Tax1 I
mutant I
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human B
immunodeficiency I
virus I
Tat I
, O
human B
papillomavirus I
E6 I
, O
and O
Bicoid B
, O
or O
with O
the O
M7 B
( I
amino I
acids I
29CP I
- I
AS I
) I
Tax1 I
mutant I
. O

However O
, O
NF B
- I
YB I
did O
interact O
with O
the O
C B
- I
terminal I
Tax1 I
mutants I
M22 B
( O
130TL B
- I
AS I
) O
and O
M47 B
( O
319LL B
- I
RS I
) O
. O

However O
, O
NF B
- I
YB I
did O
interact O
with O
the O
C B
- I
terminal I
Tax1 I
mutants I
M22 B
( O
130TL B
- I
AS I
) O
and O
M47 B
( O
319LL B
- I
RS I
) O
. O

However O
, O
NF B
- I
YB I
did O
interact O
with O
the O
C B
- I
terminal I
Tax1 I
mutants I
M22 B
( O
130TL B
- I
AS I
) O
and O
M47 B
( O
319LL B
- I
RS I
) O
. O

Through O
activation O
of O
this O
and O
other O
NF B
- I
Y I
driven O
promoters B
, O
the O
Tax1 B
- B
NF I
- I
Y I
interaction O
may O
play O
a O
critical O
role O
in O
causing O
cellular O
transformation O
and O
HTLV O
- O
1 O
pathogenesis O
. O

In O
murine O
Ba O
/ O
F3 O
cells O
transfected O
with O
the O
human B
G I
- I
CSFR I
and O
NFS O
- O
60 O
cells O
constitutively O
expressing O
the O
murine B
G I
- I
CSFR I
, O
G B
- I
CSF I
induced O
tyrosine O
phosphorylation O
and O
activation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Tyk2 B
. O

Using O
a O
mitogenically B
incompetent I
human I
G I
- I
CSFR I
mutant I
in O
which O
Pro639 O
and O
Pro641 O
were O
substituted O
by O
alanine O
, O
the O
box B
1 I
PDP I
motif I
was O
found O
to O
be O
required O
for O
activation O
of O
Jak B
kinases I
, O
tyrosine O
phosphorylation O
of O
the O
G B
- I
CSFR I
, O
and O
recruitment O
of O
Stat B
proteins I
. O

Activation O
of O
the O
Jak B
- B
Stat I
pathway O
correlates O
with O
proliferative O
signaling O
by O
the O
G B
- I
CSFR I
and O
requires O
the O
membrane B
- I
proximal I
box I
1 I
PXP I
motif I
, O
which O
is O
conserved O
in O
members O
of O
the O
cytokine B
receptor I
superfamily I
. O

Activation O
of O
the O
Jak B
- B
Stat I
pathway O
correlates O
with O
proliferative O
signaling O
by O
the O
G B
- I
CSFR I
and O
requires O
the O
membrane B
- I
proximal I
box I
1 I
PXP I
motif I
, O
which O
is O
conserved O
in O
members O
of O
the O
cytokine B
receptor I
superfamily I
. O

Impaired O
induction O
of O
c B
- I
fos I
/ I
c I
- I
jun I
genes I
and O
of O
transcriptional B
regulatory I
proteins I
binding O
distinct O
c B
- I
fos I
/ I
c I
- I
jun I
promoter I
elements I
in O
activated O
human O
T O
cells O
during O
aging O
. O

Interleukin B
- I
6 I
levels O
are O
increased O
in O
lung O
transplant O
patients O
clinically O
diagnosed O
with O
CMV O
pneumonitis O
. O

The O
function O
of O
LEF B
- I
1 I
is O
dependent O
, O
in O
part O
, O
on O
the O
HMG B
domain I
that O
induces O
a O
sharp O
bend O
in O
the O
DNA O
helix O
, O
and O
on O
an O
activation B
domain I
that O
stimulates O
transcription O
only O
in O
a O
specific O
context O
of O
other O
enhancer B
- I
binding I
proteins I
. O

Overexpression O
of O
ALY B
stimulates O
the O
activity O
of O
the O
TCR B
alpha I
enhancer I
complex I
reconstituted O
in O
transfected O
nonlymphoid O
HeLa O
cells O
, O
whereas O
down O
- O
regulation O
of O
ALY B
by O
anti O
- O
sense O
oligonucleotides O
virtually O
eliminates O
TCR B
alpha I
enhancer I
activity O
in O
T O
cells O
. O

We O
have O
cloned O
and O
sequenced O
a O
portion O
of O
the O
ER B
upstream B
regulatory I
region I
from O
the O
ER O
- O
positive O
MCF O
- O
7 O
and O
the O
ER O
- O
negative O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cell O
lines O
to O
determine O
if O
sequence O
alterations O
in O
this O
region O
account O
for O
the O
ER B
- O
negative O
phenotype O
of O
some O
tumors O
. O

In O
addition O
, O
both O
inducible O
nitric B
oxide I
synthase I
- O
mRNA O
level O
and O
NO O
generation O
in O
mouse O
peritoneal O
macrophages O
were O
suppressed O
by O
10 O
( O
- O
5 O
) O
M O
Azeptin O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

A O
molecular O
basis O
for O
induction O
of O
antibodies B
to O
DNA O
and O
eukaryotic B
transcription I
factors I
. O

Secondly O
, O
we O
investigated O
whether O
polyomavirus O
reactivation O
occurs O
in O
SLE O
patients O
, O
and O
whether O
antibodies B
to O
T B
- I
antigen I
, O
DNA O
, O
and O
to O
TBP B
and O
CREB B
are O
linked O
to O
such O
events O
. O

Thus O
, O
gammac B
is O
not O
necessary O
to O
trigger O
IL B
- I
4 I
- O
mediated O
responses O
in O
B O
cells O
, O
but O
its O
presence O
is O
important O
for O
optimal O
IL B
- I
4 I
- O
signaling O
. O

Thus O
, O
gammac B
is O
not O
necessary O
to O
trigger O
IL B
- I
4 I
- O
mediated O
responses O
in O
B O
cells O
, O
but O
its O
presence O
is O
important O
for O
optimal O
IL B
- I
4 I
- O
signaling O
. O

Cell O
- O
to O
- O
cell O
contact O
activates O
the O
long B
terminal I
repeat I
of O
human O
immunodeficiency O
virus O
1 O
through O
its O
kappaB B
motif I
. O

Cell O
- O
to O
- O
cell O
contact O
between O
peripheral O
blood O
lymphocytes O
and O
transfected O
human O
colonic O
carcinoma O
cell O
line O
HT29 O
activates O
transcription O
of O
the O
long B
terminal I
repeats I
( O
LTR B
) O
of O
human O
immunodeficiency O
virus O
. O

Identification O
of O
nucleotide B
sequences I
that O
regulate O
transcription O
of O
the O
MCF13 O
murine O
leukemia O
virus O
long B
terminal I
repeat I
in O
activated O
T O
cells O
. O

Differentiation O
of O
U O
- O
937 O
promonocytic O
cells O
by O
etoposide O
and O
ICRF O
- O
193 O
, O
two O
antitumour O
DNA B
topoisomerase I
II I
inhibitors O
with O
different O
mechanisms O
of O
action O
. O

By O
contrast O
, O
the O
binding O
activity O
of O
the O
NF B
- I
kappa I
( I
B I
) I
and O
EGR B
- I
1 I
transcription B
factors I
was O
little O
affected O
. O

GATA B
- I
1 I
DNA O
binding O
activity O
is O
down O
- O
regulated O
in O
late O
S O
phase O
in O
erythroid O
cells O
. O

These O
results O
may O
also O
relate O
to O
recent O
data O
implicating O
GATA B
- I
1 I
function O
in O
apoptosis O
and O
cell O
cycle O
progression O

Following O
neutrophil O
stimulation O
with O
proinflammatory O
agonists O
( O
such O
as O
lipopolysaccharide O
[ O
LPS O
] O
, O
tumor B
necrosis I
factor I
- I
alpha I
[ O
TNF B
- I
alpha I
] O
, O
and O
fMet O
- O
Leu O
- O
Phe O
) O
that O
induce O
the O
production O
of O
cytokines B
and O
chemokines B
in O
these O
cells O
, O
NF B
- I
kappaB I
/ I
Rel I
proteins I
translocated O
to O
nuclear O
fractions O
, O
resulting O
in O
a O
transient O
induction O
of O
NF B
- I
kappaB I
DNA O
binding O
activity O
, O
as O
determined O
in O
gel O
mobility O
shift O
assays O
. O

Following O
neutrophil O
stimulation O
with O
proinflammatory O
agonists O
( O
such O
as O
lipopolysaccharide O
[ O
LPS O
] O
, O
tumor B
necrosis I
factor I
- I
alpha I
[ O
TNF B
- I
alpha I
] O
, O
and O
fMet O
- O
Leu O
- O
Phe O
) O
that O
induce O
the O
production O
of O
cytokines B
and O
chemokines B
in O
these O
cells O
, O
NF B
- I
kappaB I
/ I
Rel I
proteins I
translocated O
to O
nuclear O
fractions O
, O
resulting O
in O
a O
transient O
induction O
of O
NF B
- I
kappaB I
DNA O
binding O
activity O
, O
as O
determined O
in O
gel O
mobility O
shift O
assays O
. O

The O
onset O
of O
both O
processes O
was O
found O
to O
be O
closely O
paralleled O
by O
, O
and O
dependent O
on O
, O
IkappaB B
- I
alpha I
degradation O
. O

Two O
distinct O
pathways O
of O
interleukin B
- I
5 I
synthesis O
in O
allergen O
- O
specific O
human O
T O
- O
cell O
clones O
are O
suppressed O
by O
glucocorticoids O
. O

GC O
efficiently O
suppressed O
IL B
- I
5 I
synthesis O
of O
T O
- O
cell O
clones O
activated O
via O
either O
T B
- I
cell I
receptor I
( O
TCR B
) O
or O
IL B
- I
2 I
receptor I
( O
IL B
- I
2R I
) O
. O

GC O
efficiently O
suppressed O
IL B
- I
5 I
synthesis O
of O
T O
- O
cell O
clones O
activated O
via O
either O
T B
- I
cell I
receptor I
( O
TCR B
) O
or O
IL B
- I
2 I
receptor I
( O
IL B
- I
2R I
) O
. O

Stimulation O
of O
CD2 B
or O
TCR B
/ I
CD3 I
induced O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
, O
the O
binding B
site I
of O
which O
is O
included O
in O
the O
IL B
- I
2 I
gene I
promoter I
. O

IL O
- O
4 O
treatment O
rapidly O
induced O
tyrosine O
phosphorylation O
of O
insulin B
receptor I
substrate I
( I
IRS I
) I
- I
1 I
and O
IRS B
- I
2 I
in O
1D4 O
but O
not O
in O
E1C3 O
cells O
. O

Nuclear B
transcription I
factor I
kB I
( O
NF B
- I
kappa I
B I
) O
is O
a O
ubiquitous B
transcription I
factor I
and O
pleiotropic B
regulator I
of O
numerous O
genes O
involved O
in O
the O
immune O
and O
inflammatory O
responses O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

Understanding O
the O
cis B
- I
and I
transacting I
factors I
that O
regulate O
the O
tissue O
- O
specific O
expression O
of O
PECAM B
- I
1 I
should O
increase O
our O
understanding O
of O
the O
mechanisms O
by O
which O
vascular O
- O
specific O
gene O
expression O
is O
achieved O
. O

However O
, O
little O
is O
known O
about O
negative O
regulation O
of O
IL B
- I
1beta I
expression O
at O
the O
transcriptional O
level O
, O
which O
may O
play O
an O
important O
role O
in O
anti O
- O
inflammatory O
and O
immunosuppressive O
effects O
. O

Interaction O
of O
transcription B
factors I
RFX1 B
and O
MIBP1 B
with O
the O
gamma B
motif I
of O
the O
negative B
regulatory I
element I
of O
the O
hepatitis B
B I
virus I
core I
promoter I
. O

The O
negative B
regulatory I
element I
( O
NRE B
) O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
core I
promoter I
contains O
three O
subregions O
which O
act O
synergistically O
to O
suppress O
core O
promoter O
activity O
. O

LR1 B
also O
binds O
Ig B
heavy I
chain I
switch O
region O
sequences O
and O
may O
function O
in O
class O
switch O
recombination O
. O

The O
additional O
function O
that O
is O
required O
for O
initiation O
of O
the O
lytic O
viral O
life O
cycle O
is O
likely O
to O
require O
phosphorylation O
of O
serine O
186 O
of O
the O
ZEBRA B
protein I
, O
which O
may O
influence O
either O
DNA O
recognition O
or O
transcriptional O
activation O
of O
lytic B
viral I
promoters I
in O
a O
chromatinized B
viral I
episome I
. O

The O
additional O
function O
that O
is O
required O
for O
initiation O
of O
the O
lytic O
viral O
life O
cycle O
is O
likely O
to O
require O
phosphorylation O
of O
serine O
186 O
of O
the O
ZEBRA B
protein I
, O
which O
may O
influence O
either O
DNA O
recognition O
or O
transcriptional O
activation O
of O
lytic B
viral I
promoters I
in O
a O
chromatinized B
viral I
episome I
. O

We O
demonstrated O
that O
constitutive O
expression O
of O
NF B
- I
kappaB I
in O
primary O
human O
monocytes O
changed O
significantly O
with O
differentiation O
in O
vitro O
to O
monocyte O
- O
derived O
macrophages O
( O
MDMs O
) O
and O
differentiation O
in O
vivo O
to O
alveolar O
macrophages O
( O
AMs O
) O
. O

Pretreatment O
of O
ACH O
- O
2 O
T O
cells O
by O
NAC O
followed O
by O
stimulation O
with O
PMA O
, O
TNF B
- I
alpha I
, O
or O
hydrogen O
peroxide O
( O
H2O2 O
) O
resulted O
in O
strong O
suppression O
of O
NF B
- I
kappa I
B I
activation O
. O

Interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
a O
cytokine B
that O
is O
expressed O
primarily O
in O
activated O
T O
cells O
. O

Interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
a O
cytokine B
that O
is O
expressed O
primarily O
in O
activated O
T O
cells O
. O

It O
has O
been O
shown O
that O
this O
E1B B
19K I
protein I
is O
not O
necessary O
for O
viral O
DNA O
replication O
in O
human O
cell O
lines O
, O
such O
as O
HeLa O
and O
KB O
. O

Activation O
of O
Ras O
and O
mitogen B
- I
activated I
protein I
kinase I
pathway O
by O
terminal B
complement I
complexes I
is O
G B
protein I
dependent O
. O

Mutants O
of O
type O
5 O
adenovirus O
( O
Ad5 O
) O
with O
reiterated B
DNA I
sequences I
in O
the O
E1a B
region I
appeared O
in O
a O
human O
T O
- O
lymphocyte O
cell O
line O
, O
Molt O
- O
4 O
, O
persistently O
infected O
with O
H5sub304 O
, O
a O
deletion O
/ O
substitution O
mutant O
that O
has O
a O
wild O
- O
type O
phenotype O
in O
viral O
replication O
. O

The O
hypothesis O
that O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
may O
influence O
HIV O
- O
1 O
replication O
is O
therefore O
compelling O
given O
the O
tight O
correlation O
of O
HIV O
- O
1 O
transcriptional O
induction O
to O
T O
cell O
activation O
. O

eTh2 O
cells O
are O
the O
major O
source O
of O
IL B
- I
4 I
, O
while O
gamma B
interferon I
is O
produced O
by O
eTh1 O
cells O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

However O
, O
V3 B
- I
BH10 I
enhanced O
IL B
- I
2 I
- B
induced I
mRNA I
expression O
of O
c B
- I
fos I
but O
not O
c B
- I
myc I
or O
junB B
. O

However O
, O
V3 B
- I
BH10 I
enhanced O
IL B
- I
2 I
- B
induced I
mRNA I
expression O
of O
c B
- I
fos I
but O
not O
c B
- I
myc I
or O
junB B
. O

However O
, O
V3 B
- I
BH10 I
enhanced O
IL B
- I
2 I
- B
induced I
mRNA I
expression O
of O
c B
- I
fos I
but O
not O
c B
- I
myc I
or O
junB B
. O

However O
, O
V3 B
- I
BH10 I
enhanced O
IL B
- I
2 I
- B
induced I
mRNA I
expression O
of O
c B
- I
fos I
but O
not O
c B
- I
myc I
or O
junB B
. O

However O
, O
V3 B
- I
BH10 I
enhanced O
IL B
- I
2 I
- B
induced I
mRNA I
expression O
of O
c B
- I
fos I
but O
not O
c B
- I
myc I
or O
junB B
. O

Pax B
- I
5a I
was O
detectable O
in O
pro O
- O
, O
pre O
- O
, O
and O
mature O
B O
- O
cell O
lines O
, O
but O
not O
in O
two O
plasmacytomas O
; O
Pax B
- I
5b I
was O
shown O
to O
be O
present O
at O
low O
levels O
in O
mature O
B O
- O
cell O
lines O
and O
, O
unexpectedly O
, O
in O
one O
plasma O
cell O
line O
, O
but O
not O
in O
pro O
- O
B O
- O
cell O
or O
T O
- O
cell O
lines O
. O

Pax B
- I
5a I
was O
detectable O
in O
pro O
- O
, O
pre O
- O
, O
and O
mature O
B O
- O
cell O
lines O
, O
but O
not O
in O
two O
plasmacytomas O
; O
Pax B
- I
5b I
was O
shown O
to O
be O
present O
at O
low O
levels O
in O
mature O
B O
- O
cell O
lines O
and O
, O
unexpectedly O
, O
in O
one O
plasma O
cell O
line O
, O
but O
not O
in O
pro O
- O
B O
- O
cell O
or O
T O
- O
cell O
lines O
. O

The O
predominant O
E2F B
complex I
in O
human O
primary O
haemopoietic O
cells O
and O
in O
AML O
blasts O
contains O
E2F B
- I
4 I
, O
DP B
- I
1 I
and O
p130 B
. O

The O
predominant O
E2F B
complex I
in O
human O
primary O
haemopoietic O
cells O
and O
in O
AML O
blasts O
contains O
E2F B
- I
4 I
, O
DP B
- I
1 I
and O
p130 B
. O

Associated O
with O
its O
inhibitor O
, O
I B
kappaB I
, O
NF B
- I
kappaB I
resides O
as O
an O
inactive O
form O
in O
the O
cytoplasm O
. O

In O
this O
study O
, O
we O
have O
characterized O
a O
cellular O
mutant O
, O
the O
70 O
/ O
Z3 O
- O
derived O
1 O
. O
3E2 O
murine O
pre O
- O
B O
cell O
line O
, O
that O
does O
not O
activate O
NF B
- I
kappaB I
in O
response O
to O
several O
stimuli O
. O

Our O
results O
demonstrate O
that O
1 O
. O
3E2 O
is O
a O
cellular B
transduction I
mutant I
exhibiting O
a O
defect O
in O
a O
step O
that O
is O
required O
by O
several O
different O
stimuli O
to O
activate O
NF B
- I
kappaB I
. O

Our O
results O
demonstrate O
that O
1 O
. O
3E2 O
is O
a O
cellular B
transduction I
mutant I
exhibiting O
a O
defect O
in O
a O
step O
that O
is O
required O
by O
several O
different O
stimuli O
to O
activate O
NF B
- I
kappaB I
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
proteins I
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV B
glycoprotein I
E I
( O
gE B
) O
, O
encoded O
by O
ORF B
68 I
and O
the O
VZV B
product I
of O
ORF B
62 I
, O
an O
immediate B
- I
early I
major I
tegument I
protein I
( O
IE62 B
) O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
the O
active O
form O
of O
NF B
- I
AT1 I
is O
also O
present O
in O
the O
nuclei O
of O
HTLV O
- O
I O
- O
transformed O
T O
cells O
that O
express O
the O
Tax B
protein I
. O

Interestingly O
, O
the O
constitutive O
activation O
of O
NF B
- I
AT1 I
in O
these O
T O
cells O
is O
associated O
with O
its O
dephosphorylation O
. O

In O
contrast O
to O
ionomycin O
treatment O
, O
exposure O
of O
cells O
to O
phorbol O
myristate O
acetate O
( O
PMA O
) O
plus O
anti B
- I
CD28 I
did O
not O
induce O
NFATc B
, O
indicating O
that O
under O
these O
conditions O
, O
interleukin B
- I
2 I
synthesis O
by O
these O
cells O
is O
apparently O
independent O
of O
NFATc B
. O

In O
contrast O
to O
ionomycin O
treatment O
, O
exposure O
of O
cells O
to O
phorbol O
myristate O
acetate O
( O
PMA O
) O
plus O
anti B
- I
CD28 I
did O
not O
induce O
NFATc B
, O
indicating O
that O
under O
these O
conditions O
, O
interleukin B
- I
2 I
synthesis O
by O
these O
cells O
is O
apparently O
independent O
of O
NFATc B
. O

Cotransfection O
experiments O
revealed O
that O
both O
hGATA B
- I
4 I
and O
PMA O
/ O
A23187 O
stimulation O
are O
necessary O
for O
the O
IL B
- I
5 I
promoter I
activation O
. O

The O
electrophoretic O
mobility O
shift O
assay O
with O
extracts O
of O
COS O
cells O
expressing O
GATA B
- I
binding I
proteins I
showed O
that O
GATA B
- I
4 I
has O
the O
highest O
binding O
affinity O
to O
the O
- B
70 I
GATA I
site I
among O
the O
three O
GATA B
- I
binding I
proteins I
. O

These O
results O
demonstrate O
the O
selective O
role O
of O
GATA B
- I
4 I
in O
the O
transcriptional O
regulation O
of O
the O
IL B
- I
5 I
gene I
in O
a O
circumstance O
where O
multiple O
members O
of O
the O
GATA B
- I
binding I
proteins I
are O
expressed O
. O

Involvement O
of O
Stat3 B
in O
interleukin B
- I
6 I
- O
induced O
IgM B
production O
in O
a O
human O
B O
- O
cell O
line O
. O

EGF O
treatment O
induced O
IgM B
production O
in O
cells O
transfected O
with O
an O
intact O
gp130 B
cytoplasmic I
tail I
, O
but O
not O
in O
untransfected O
cells O
or O
cells O
transfected O
with O
a O
cytoplasmic B
tail I
lacking O
all O
four O
signal B
transducers I
and I
activators I
of I
transcription I
( I
Stat I
) I
binding I
sites I
. O

One O
of O
the O
latter O
elements O
, O
the O
IgH B
3 I
' I
enhancer I
, O
is O
of O
particular O
interest O
: O
( O
1 O
) O
it O
is O
B O
cell O
- O
specific O
and O
active O
only O
in O
late O
B O
cell O
development O
; O
( O
2 O
) O
in O
rodent O
plasmacytomas O
and O
in O
some O
human O
Burkitt O
' O
s O
lymphomas O
it O
is O
part O
of O
a O
locus B
control I
region I
( O
LCR B
) O
that O
is O
involved O
in O
deregulation O
of O
the O
c B
- I
myc I
oncogene I
as O
a O
result O
of O
translocation O
into O
the O
IgH B
locus I
; O
and O
( O
3 O
) O
it O
has O
been O
implicated O
in O
the O
mechanisms O
that O
control O
Ig B
gene I
class I
switch O
recombination O

One O
of O
the O
latter O
elements O
, O
the O
IgH B
3 I
' I
enhancer I
, O
is O
of O
particular O
interest O
: O
( O
1 O
) O
it O
is O
B O
cell O
- O
specific O
and O
active O
only O
in O
late O
B O
cell O
development O
; O
( O
2 O
) O
in O
rodent O
plasmacytomas O
and O
in O
some O
human O
Burkitt O
' O
s O
lymphomas O
it O
is O
part O
of O
a O
locus B
control I
region I
( O
LCR B
) O
that O
is O
involved O
in O
deregulation O
of O
the O
c B
- I
myc I
oncogene I
as O
a O
result O
of O
translocation O
into O
the O
IgH B
locus I
; O
and O
( O
3 O
) O
it O
has O
been O
implicated O
in O
the O
mechanisms O
that O
control O
Ig B
gene I
class I
switch O
recombination O

Reactive O
oxygen O
species O
( O
ROS O
) O
such O
as O
hydrogen O
peroxide O
serve O
as O
second O
messengers O
in O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
, O
and O
hence O
in O
the O
activation O
and O
replication O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
in O
human O
cells O
. O

NF B
- I
kappaB I
activation O
was O
very O
effective O
when O
cells O
were O
subjected O
to O
hyperthermia O
before O
being O
treated O
with O
HOCl O
. O

Collectively O
, O
these O
results O
suggest O
that O
HOCl O
should O
be O
considered O
as O
an O
oxidative O
species O
capable O
of O
inducing O
NF B
- I
kappaB I
in O
a O
T O
- O
lymphocytic O
cell O
line O
through O
a O
transduction O
mechanism O
involving O
ROS O
, O
and O
having O
a O
long O
- O
distance O
effect O
through O
subsequent O
TNF B
- I
alpha I
release O
. O

Collectively O
, O
these O
results O
suggest O
that O
HOCl O
should O
be O
considered O
as O
an O
oxidative O
species O
capable O
of O
inducing O
NF B
- I
kappaB I
in O
a O
T O
- O
lymphocytic O
cell O
line O
through O
a O
transduction O
mechanism O
involving O
ROS O
, O
and O
having O
a O
long O
- O
distance O
effect O
through O
subsequent O
TNF B
- I
alpha I
release O
. O

Stimulation O
of O
blood O
platelets O
with O
alpha B
- I
thrombin I
or O
other O
platelet O
activators O
caused O
a O
rapid O
and O
strong O
induction O
of O
Rap1 B
that O
associated O
with O
RBD B
in O
vitro O
. O

The O
transcriptional B
regulatory I
elements I
of O
many O
inducible B
T I
- I
cell I
genes I
contain O
adjacent O
or O
overlapping B
binding I
sites I
for O
the O
Ets B
and I
NF I
- I
kappaB I
/ I
NFAT I
families I
of O
transcription B
factors I
. O

The O
transcriptional B
regulatory I
elements I
of O
many O
inducible B
T I
- I
cell I
genes I
contain O
adjacent O
or O
overlapping B
binding I
sites I
for O
the O
Ets B
and I
NF I
- I
kappaB I
/ I
NFAT I
families I
of O
transcription B
factors I
. O

When O
introduced O
into O
interleukin B
3 I
( O
IL B
- I
3 I
) O
- O
dependent O
mouse O
pro O
- O
B O
lymphocytes O
, O
E2A B
- I
HLF I
prevents O
apoptosis O
induced O
by O
growth B
factor I
deprivation O
, O
suggesting O
that O
IL B
- I
3 I
mediates O
cell O
survival O
through O
activation O
of O
a O
transcription B
factor I
whose O
activity O
can O
be O
constitutively O
replaced O
by O
the O
chimeric B
oncoprotein I
. O

When O
introduced O
into O
interleukin B
3 I
( O
IL B
- I
3 I
) O
- O
dependent O
mouse O
pro O
- O
B O
lymphocytes O
, O
E2A B
- I
HLF I
prevents O
apoptosis O
induced O
by O
growth B
factor I
deprivation O
, O
suggesting O
that O
IL B
- I
3 I
mediates O
cell O
survival O
through O
activation O
of O
a O
transcription B
factor I
whose O
activity O
can O
be O
constitutively O
replaced O
by O
the O
chimeric B
oncoprotein I
. O

When O
introduced O
into O
interleukin B
3 I
( O
IL B
- I
3 I
) O
- O
dependent O
mouse O
pro O
- O
B O
lymphocytes O
, O
E2A B
- I
HLF I
prevents O
apoptosis O
induced O
by O
growth B
factor I
deprivation O
, O
suggesting O
that O
IL B
- I
3 I
mediates O
cell O
survival O
through O
activation O
of O
a O
transcription B
factor I
whose O
activity O
can O
be O
constitutively O
replaced O
by O
the O
chimeric B
oncoprotein I
. O

The O
expression O
and O
binding O
activity O
of O
the O
Nfil3 B
protein I
( O
also O
called O
E4bp4 B
) O
, O
but O
not O
of O
Hlf B
, O
Dbp B
, O
or O
Tef B
, O
was O
found O
to O
be O
regulated O
by O
IL B
- I
3 I
in O
mouse O
pro O
- O
B O
cell O
lines O
( O
Baf O
- O
3 O
and O
FL5 O
. O
12 O
) O
. O

Common O
and O
distinct O
intracellular O
signaling O
pathways O
in O
human O
neutrophils O
utilized O
by O
platelet B
activating I
factor I
and O
FMLP B
. O

Stimulation O
of O
human O
neutrophils O
with O
chemoattractants B
FMLP B
or O
platelet B
activating I
factor I
( O
PAF B
) O
results O
in O
different O
but O
overlapping O
functional O
responses O
. O

Chicken B
NF I
- I
M I
transcription I
factor I
, O
in O
cooperation O
with O
either O
c B
- I
Myb I
or O
v B
- I
Myb I
, O
is O
active O
in O
the O
combinatorial O
activation O
of O
myeloid B
- I
cell I
- I
specific I
genes I
in O
heterologous O
cell O
types O
, O
such O
as O
embryonic O
fibroblasts O
. O

Chicken B
NF I
- I
M I
transcription I
factor I
, O
in O
cooperation O
with O
either O
c B
- I
Myb I
or O
v B
- I
Myb I
, O
is O
active O
in O
the O
combinatorial O
activation O
of O
myeloid B
- I
cell I
- I
specific I
genes I
in O
heterologous O
cell O
types O
, O
such O
as O
embryonic O
fibroblasts O
. O

Co O
- O
ligation O
of O
the O
A6H B
antigen O
and O
the O
CD3 B
complex I
induced O
expression O
of O
the O
transcription B
factor I
AP B
- I
1 I
in O
CD4 O
+ O
T O
cells O
, O
whereas O
no O
increase O
in O
NF B
- I
kappa I
B I
and O
octamer B
- I
binding I
( I
Oct I
) I
proteins I
was O
seen O
compared O
to O
T O
cells O
stimulated O
with O
anti B
- I
CD3 I
alone O
. O

Co O
- O
ligation O
of O
the O
A6H B
antigen O
and O
the O
CD3 B
complex I
induced O
expression O
of O
the O
transcription B
factor I
AP B
- I
1 I
in O
CD4 O
+ O
T O
cells O
, O
whereas O
no O
increase O
in O
NF B
- I
kappa I
B I
and O
octamer B
- I
binding I
( I
Oct I
) I
proteins I
was O
seen O
compared O
to O
T O
cells O
stimulated O
with O
anti B
- I
CD3 I
alone O
. O

Molecular O
differences O
of O
the O
A6H B
molecule I
or O
distinct O
regulation O
of O
the O
A6H B
transduced O
AP B
- I
1 I
activation O
pathway O
may O
exist O
in O
CD4 O
+ O
and O
CD8 O
+ O
T O
cell O
subpopulations O
. O

Expressions O
of O
human O
and O
squirrel O
monkey O
glucocorticoid B
receptors I
and O
a O
squirrel B
monkey I
receptor I
in O
which O
Phe774 O
was O
mutated O
to O
Leu O
( O
F774L O
) O
were O
similar O
. O

In O
this O
study O
we O
determined O
the O
effects O
of O
SAC O
on O
NF B
- I
kappa I
B I
activation O
in O
human O
T O
lymphocytes O
( O
Jurkat O
cells O
) O
induced O
by O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
and O
H2O2 O
. O

Elf B
- I
2 I
, O
a O
rhombotin B
- I
2 I
binding I
ets I
transcription I
factor I
: O
discovery O
and O
potential O
role O
in O
T O
cell O
leukemia O
. O

By O
screening O
a O
T O
cell O
cDNA B
library I
, O
we O
identified O
a O
novel B
ets I
transcription I
factor I
that O
binds O
RBTN B
- I
2 I
. O

The O
expression O
patterns O
suggest O
that O
RBTN B
- I
2 I
normally O
interacts O
equally O
with O
elf B
- I
2a I
and O
elf B
- I
2b I
. O

The O
expression O
patterns O
suggest O
that O
RBTN B
- I
2 I
normally O
interacts O
equally O
with O
elf B
- I
2a I
and O
elf B
- I
2b I
. O

The O
expression O
patterns O
suggest O
that O
RBTN B
- I
2 I
normally O
interacts O
equally O
with O
elf B
- I
2a I
and O
elf B
- I
2b I
. O

In O
contrast O
, O
when O
RBTN B
- I
2 I
is O
inappropriately O
expressed O
in O
T O
cells O
, O
RBTN B
- I
2 I
would O
interact O
predominantly O
with O
elf B
- I
2b I
; O
this O
interaction O
may O
lead O
to O
T O
cell O
proliferation O
. O

In O
contrast O
, O
when O
RBTN B
- I
2 I
is O
inappropriately O
expressed O
in O
T O
cells O
, O
RBTN B
- I
2 I
would O
interact O
predominantly O
with O
elf B
- I
2b I
; O
this O
interaction O
may O
lead O
to O
T O
cell O
proliferation O
. O

In O
contrast O
, O
when O
RBTN B
- I
2 I
is O
inappropriately O
expressed O
in O
T O
cells O
, O
RBTN B
- I
2 I
would O
interact O
predominantly O
with O
elf B
- I
2b I
; O
this O
interaction O
may O
lead O
to O
T O
cell O
proliferation O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
and O
AP B
- I
1 I
are O
insufficient O
for O
IL B
- I
2 I
promoter I
activation O
: O
requirement O
for O
CD28 B
up O
- O
regulation O
of O
RE B
/ I
AP I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
and O
AP B
- I
1 I
are O
insufficient O
for O
IL B
- I
2 I
promoter I
activation O
: O
requirement O
for O
CD28 B
up O
- O
regulation O
of O
RE B
/ I
AP I
. O

Furthermore O
, O
recombinant O
TIMP B
- I
1 I
, O
but O
not O
TIMP B
- I
2 I
or O
a O
synthetic O
metalloproteinase O
inhibitor O
( O
BB O
- O
94 O
) O
, O
confers O
resistance O
to O
apoptosis O
induced O
by O
both O
CD95 O
- O
dependent O
and O
- O
independent O
( O
cold O
shock O
, O
serum O
deprivation O
, O
and O
gamma O
- O
radiation O
) O
pathways O
in O
TIMP O
- O
1 O
- O
negative O
BL O
lines O
. O

Furthermore O
, O
recombinant O
TIMP B
- I
1 I
, O
but O
not O
TIMP B
- I
2 I
or O
a O
synthetic O
metalloproteinase O
inhibitor O
( O
BB O
- O
94 O
) O
, O
confers O
resistance O
to O
apoptosis O
induced O
by O
both O
CD95 O
- O
dependent O
and O
- O
independent O
( O
cold O
shock O
, O
serum O
deprivation O
, O
and O
gamma O
- O
radiation O
) O
pathways O
in O
TIMP O
- O
1 O
- O
negative O
BL O
lines O
. O

To O
investigate O
in O
vivo O
regulatory O
mechanisms O
that O
control O
the O
population O
of O
type O
2 O
T O
cells O
and O
disease O
susceptibility O
, O
we O
have O
created O
lines O
of O
transgenic O
mice O
in O
which O
expression O
of O
a O
chimeric B
cytokine I
receptor I
( O
the O
mouse B
interleukin I
2 I
receptor I
beta I
chain I
[ I
IL I
- I
2Rbeta I
] I
extracellular I
domain I
fused O
to O
the O
cytoplasmic B
tail I
of O
IL B
- I
4Ralpha I
) O
is O
targeted O
to O
the O
T O
lymphoid O
lineage O
using O
the O
proximal B
lck I
promoter I
. O

To O
investigate O
in O
vivo O
regulatory O
mechanisms O
that O
control O
the O
population O
of O
type O
2 O
T O
cells O
and O
disease O
susceptibility O
, O
we O
have O
created O
lines O
of O
transgenic O
mice O
in O
which O
expression O
of O
a O
chimeric B
cytokine I
receptor I
( O
the O
mouse B
interleukin I
2 I
receptor I
beta I
chain I
[ I
IL I
- I
2Rbeta I
] I
extracellular I
domain I
fused O
to O
the O
cytoplasmic B
tail I
of O
IL B
- I
4Ralpha I
) O
is O
targeted O
to O
the O
T O
lymphoid O
lineage O
using O
the O
proximal B
lck I
promoter I
. O

To O
investigate O
in O
vivo O
regulatory O
mechanisms O
that O
control O
the O
population O
of O
type O
2 O
T O
cells O
and O
disease O
susceptibility O
, O
we O
have O
created O
lines O
of O
transgenic O
mice O
in O
which O
expression O
of O
a O
chimeric B
cytokine I
receptor I
( O
the O
mouse B
interleukin I
2 I
receptor I
beta I
chain I
[ I
IL I
- I
2Rbeta I
] I
extracellular I
domain I
fused O
to O
the O
cytoplasmic B
tail I
of O
IL B
- I
4Ralpha I
) O
is O
targeted O
to O
the O
T O
lymphoid O
lineage O
using O
the O
proximal B
lck I
promoter I
. O

We O
have O
recently O
cloned O
the O
carboxylesterase B
upstream I
sequence I
and O
showed O
its O
basal B
promoter I
activity O
in O
CHO O
cells O
. O

Furthermore O
, O
Ikaros O
- O
null O
thymocytes O
hyperproliferate O
in O
response O
to O
T B
cell I
receptor I
( O
TCR B
) O
signaling O
; O
within O
days O
after O
their O
appearance O
in O
the O
thymus O
, O
clonally O
expanding O
populations O
are O
detected O
. O

These O
data O
are O
well O
in O
line O
with O
the O
long O
- O
standing O
notion O
that O
interindividual O
differences O
in O
platelet B
monoamine I
oxidase I
may O
represent O
differences O
in O
expression O
of O
the O
enzyme O
rather O
than O
genotypic O
variation O
. O

The O
molecular O
mechanisms O
by O
which O
IL B
- I
4 I
induces O
expression O
of O
the O
IL B
- I
4 I
gene I
are O
not O
known O
, O
although O
the O
IL B
- I
4 I
- I
activated I
transcription I
factor I
signal I
transducer I
and I
activator I
of I
transcription I
6 I
( O
Stat6 B
) O
is O
required O
for O
this O
effect O
. O

CONCLUSIONS O
: O
Intestinal O
epithelial O
cells O
initiate O
an O
inflammatory O
response O
with O
resulting O
neutrophil O
- O
mediated O
tissue O
damage O
in O
response O
to O
E O
. O
histolytica O
infection O
; O
this O
inflammatory O
cascade O
can O
be O
blocked O
by O
inhibiting O
the O
transcription O
of O
genes O
regulated O
by O
nuclear B
factor I
kappaB I
. O

In O
mobility O
shift O
assays O
, O
a O
nuclear B
factor I
from O
THP O
- O
1 O
and O
U O
- O
937 O
cells O
was O
identified O
that O
binds O
to O
several O
AP B
- I
2 I
response I
elements I
within O
the O
B2 B
promoter I
, O
but O
does O
not O
react O
with O
AP B
- I
2 I
antibodies I
, O
and O
has O
a O
DNA B
sequence I
binding O
affinity O
profile O
that O
differs O
from O
AP B
- I
2 I
. O

Time O
- O
course O
experiments O
showed O
that O
nuclear O
levels O
of O
GATA B
- I
1 I
and O
p45 B
NF I
- I
E2 I
proteins O
increased O
during O
BA O
treatment O
. O

The O
upstream O
regions O
UAS3 B
( O
- B
1168 I
to I
- I
440 I
) O
and O
UAS2 B
( O
- B
352 I
to I
- I
264 I
) O
both O
functioned O
in O
a O
cell O
lineage O
- O
independent O
manner O
and O
were O
together O
responsible O
for O
the O
bulk O
of O
Wp O
activity O
in O
non O
- O
B O
cells O
; O
mutational O
analysis O
indicated O
the O
importance O
of O
a O
YY1 B
binding I
site I
in O
UAS2 B
in O
that O
context O
. O

When O
mutations O
that O
abolished O
factor O
binding O
in O
bandshift O
assays O
were O
introduced O
into O
a O
Wp B
reporter I
construct I
, O
the O
loss O
of O
any O
one O
of O
the O
three O
UAS1 B
binding I
sites I
was O
sufficient O
to O
reduce O
promoter O
activity O
by O
10 O
- O
to O
30 O
- O
fold O
in O
B O
cells O
. O

When O
mutations O
that O
abolished O
factor O
binding O
in O
bandshift O
assays O
were O
introduced O
into O
a O
Wp B
reporter I
construct I
, O
the O
loss O
of O
any O
one O
of O
the O
three O
UAS1 B
binding I
sites I
was O
sufficient O
to O
reduce O
promoter O
activity O
by O
10 O
- O
to O
30 O
- O
fold O
in O
B O
cells O
. O

The O
first O
step O
in O
the O
nuclear O
import O
process O
is O
recognition O
of O
a O
nuclear B
localization I
sequence I
( O
NLS B
) O
within O
the O
karyophilic B
protein I
by O
a O
cytoplasmic B
receptor I
such O
as O
the O
importin B
( I
karyopherin I
) I
- I
alpha I
subunit I
. O

NLS B
peptide O
- O
mediated O
disruption O
of O
the O
nuclear O
import O
of O
these O
transcription B
factors I
results O
in O
inhibition O
of O
I O
kappa O
B O
alpha O
and O
IL O
- O
2 O
gene O
expression O
, O
processes O
dependent O
on O
NF B
- I
kappa I
B I
or O
the O
combination O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
and O
NFAT B
. O

CONCLUSIONS O
: O
Human O
NK O
cell O
membrane O
- O
bound O
LT O
signals O
across O
species O
via O
TNFRI B
, O
leading O
to O
NF B
- I
kappaB I
nuclear O
translocation O
and O
transcription O
of O
E B
- I
selectin I
and O
IL B
- I
8 I
, O
which O
results O
in O
EC O
activation O
. O

CONCLUSIONS O
: O
Human O
NK O
cell O
membrane O
- O
bound O
LT O
signals O
across O
species O
via O
TNFRI B
, O
leading O
to O
NF B
- I
kappaB I
nuclear O
translocation O
and O
transcription O
of O
E B
- I
selectin I
and O
IL B
- I
8 I
, O
which O
results O
in O
EC O
activation O
. O

CONCLUSIONS O
: O
Human O
NK O
cell O
membrane O
- O
bound O
LT O
signals O
across O
species O
via O
TNFRI B
, O
leading O
to O
NF B
- I
kappaB I
nuclear O
translocation O
and O
transcription O
of O
E B
- I
selectin I
and O
IL B
- I
8 I
, O
which O
results O
in O
EC O
activation O
. O

Blood O
monocytes O
spontaneously O
activate O
endothelial O
cells O
in O
culture O
, O
leading O
to O
adhesion O
of O
monocytic O
cells O
onto O
the O
endothelial O
surface O
and O
overproduction O
of O
endothelial O
proteins O
such O
as O
von B
Willebrand I
factor I
( O
vWf B
) O
and O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
. O

Blood O
monocytes O
spontaneously O
activate O
endothelial O
cells O
in O
culture O
, O
leading O
to O
adhesion O
of O
monocytic O
cells O
onto O
the O
endothelial O
surface O
and O
overproduction O
of O
endothelial O
proteins O
such O
as O
von B
Willebrand I
factor I
( O
vWf B
) O
and O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
. O

Under O
these O
conditions O
HUVEC B
adhesion I
molecules I
, O
E B
- I
selectin I
, O
VCAM B
- I
1 I
and O
ICAM B
- I
1 I
, O
were O
increased O
at O
3 O
h O
with O
only O
ICAM B
- I
1 I
remaining O
overexpressed O
at O
24 O
h O
. O

Under O
these O
conditions O
HUVEC B
adhesion I
molecules I
, O
E B
- I
selectin I
, O
VCAM B
- I
1 I
and O
ICAM B
- I
1 I
, O
were O
increased O
at O
3 O
h O
with O
only O
ICAM B
- I
1 I
remaining O
overexpressed O
at O
24 O
h O
. O

Under O
these O
conditions O
HUVEC B
adhesion I
molecules I
, O
E B
- I
selectin I
, O
VCAM B
- I
1 I
and O
ICAM B
- I
1 I
, O
were O
increased O
at O
3 O
h O
with O
only O
ICAM B
- I
1 I
remaining O
overexpressed O
at O
24 O
h O
. O

Under O
these O
conditions O
HUVEC B
adhesion I
molecules I
, O
E B
- I
selectin I
, O
VCAM B
- I
1 I
and O
ICAM B
- I
1 I
, O
were O
increased O
at O
3 O
h O
with O
only O
ICAM B
- I
1 I
remaining O
overexpressed O
at O
24 O
h O
. O

Under O
these O
conditions O
HUVEC B
adhesion I
molecules I
, O
E B
- I
selectin I
, O
VCAM B
- I
1 I
and O
ICAM B
- I
1 I
, O
were O
increased O
at O
3 O
h O
with O
only O
ICAM B
- I
1 I
remaining O
overexpressed O
at O
24 O
h O
. O

In O
the O
present O
report O
we O
show O
that O
in O
various O
transiently O
or O
stably O
transfected O
cell O
lines O
, O
X O
- O
ray O
irradiation O
up O
- O
regulates O
HIV B
- I
1 I
LTR I
transcription O
through O
the O
kappaB B
regulatory I
elements I
. O

Restoration O
of O
the O
CCAAT B
box I
at O
- B
70 I
bp I
, O
or O
insertion O
of O
an O
EKLF B
binding I
site I
at O
- B
85 I
bp I
or O
- B
95 I
bp I
in O
the O
promoter B
significantly O
increased O
delta O
globin O
gene O
expression O
in O
hAEC O
. O

Restoration O
of O
the O
CCAAT B
box I
at O
- B
70 I
bp I
, O
or O
insertion O
of O
an O
EKLF B
binding I
site I
at O
- B
85 I
bp I
or O
- B
95 I
bp I
in O
the O
promoter B
significantly O
increased O
delta O
globin O
gene O
expression O
in O
hAEC O
. O

Restoration O
of O
the O
CCAAT B
box I
at O
- B
70 I
bp I
, O
or O
insertion O
of O
an O
EKLF B
binding I
site I
at O
- B
85 I
bp I
or O
- B
95 I
bp I
in O
the O
promoter B
significantly O
increased O
delta O
globin O
gene O
expression O
in O
hAEC O
. O

Restoration O
of O
the O
CCAAT B
box I
at O
- B
70 I
bp I
, O
or O
insertion O
of O
an O
EKLF B
binding I
site I
at O
- B
85 I
bp I
or O
- B
95 I
bp I
in O
the O
promoter B
significantly O
increased O
delta O
globin O
gene O
expression O
in O
hAEC O
. O

Constitutive O
association O
of O
JAK1 B
and O
STAT5 B
in O
pro O
- O
B O
cells O
is O
dissolved O
by O
interleukin B
- I
4 I
- O
induced O
tyrosine O
phosphorylation O
of O
both O
proteins O
. O

Based O
on O
the O
high O
specificity O
of O
this O
compound O
for O
PKC B
, O
we O
conclude O
that O
PKC B
is O
necessary O
for O
FN B
- O
induced O
IL B
- I
1beta I
protein O
production O
. O

Overexpression O
of O
TRAMP B
leads O
to O
two O
major O
responses O
, O
NF B
- I
kappaB I
activation O
and O
apoptosis O
. O

Using O
a O
nuclear O
run O
- O
on O
assay O
, O
IL B
- I
4 I
stimulation O
was O
shown O
to O
enhance O
transcription O
by O
two O
- O
to O
threefold O
. O

Conversely O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
markedly O
and O
significantly O
inhibited O
HIV O
replication O
at O
the O
transcriptional O
level O
in O
monocyte O
- O
derived O
macrophages O
, O
and O
this O
occurred O
whether O
these O
cytokines B
were O
added O
before O
or O
after O
HIV O
infection O
. O

Conversely O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
markedly O
and O
significantly O
inhibited O
HIV O
replication O
at O
the O
transcriptional O
level O
in O
monocyte O
- O
derived O
macrophages O
, O
and O
this O
occurred O
whether O
these O
cytokines B
were O
added O
before O
or O
after O
HIV O
infection O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
protects O
animals O
from O
lethal O
endotoxemia O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
protects O
animals O
from O
lethal O
endotoxemia O
. O

Evidence O
suggests O
that O
IL B
- I
10 I
may O
inhibit O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
through O
an O
unknown O
mechanism O
. O

Evidence O
suggests O
that O
IL B
- I
10 I
may O
inhibit O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
through O
an O
unknown O
mechanism O
. O

We O
hypothesized O
that O
IL B
- I
10 I
prevents O
human O
monocyte O
NF B
- I
kappaB I
activation O
and O
resultant O
TNF B
- I
alpha I
production O
by O
stabilization O
of O
IkappaB B
- I
alpha I
. O

We O
hypothesized O
that O
IL B
- I
10 I
prevents O
human O
monocyte O
NF B
- I
kappaB I
activation O
and O
resultant O
TNF B
- I
alpha I
production O
by O
stabilization O
of O
IkappaB B
- I
alpha I
. O

We O
hypothesized O
that O
IL B
- I
10 I
prevents O
human O
monocyte O
NF B
- I
kappaB I
activation O
and O
resultant O
TNF B
- I
alpha I
production O
by O
stabilization O
of O
IkappaB B
- I
alpha I
. O

We O
hypothesized O
that O
IL B
- I
10 I
prevents O
human O
monocyte O
NF B
- I
kappaB I
activation O
and O
resultant O
TNF B
- I
alpha I
production O
by O
stabilization O
of O
IkappaB B
- I
alpha I
. O

Cells O
were O
stimulated O
with O
endotoxin B
( O
LPS O
, O
100 O
ng O
/ O
mL O
) O
with O
and O
without O
human O
IL B
- I
10 I
( O
10 O
ng O
/ O
mL O
) O
. O

IL B
- I
10 I
attenuated O
LPS O
- O
stimulated O
TNF B
- I
alpha I
production O
( O
297 O
+ O
/ O
- O
54 O
; O
p O
< O
. O
001 O
versus O
LPS O
alone O
) O
. O

IL B
- I
10 I
attenuated O
LPS O
- O
stimulated O
TNF B
- I
alpha I
production O
( O
297 O
+ O
/ O
- O
54 O
; O
p O
< O
. O
001 O
versus O
LPS O
alone O
) O
. O

IL B
- I
10 I
appears O
to O
prevent O
activation O
of O
NF B
- I
kappaB I
by O
preserving O
IkappaB B
- I
alpha I
protein O
levels O
, O
leading O
to O
a O
reduction O
in O
TNF B
- I
alpha I
release O
. O

IL B
- I
10 I
appears O
to O
prevent O
activation O
of O
NF B
- I
kappaB I
by O
preserving O
IkappaB B
- I
alpha I
protein O
levels O
, O
leading O
to O
a O
reduction O
in O
TNF B
- I
alpha I
release O
. O

IL B
- I
10 I
appears O
to O
prevent O
activation O
of O
NF B
- I
kappaB I
by O
preserving O
IkappaB B
- I
alpha I
protein O
levels O
, O
leading O
to O
a O
reduction O
in O
TNF B
- I
alpha I
release O
. O

IL B
- I
10 I
appears O
to O
prevent O
activation O
of O
NF B
- I
kappaB I
by O
preserving O
IkappaB B
- I
alpha I
protein O
levels O
, O
leading O
to O
a O
reduction O
in O
TNF B
- I
alpha I
release O
. O

BASH B
, O
a O
novel B
signaling I
molecule I
preferentially O
expressed O
in O
B O
cells O
of O
the O
bursa O
of O
Fabricius O
. O

These O
studies O
revealed O
that O
the O
major B
protein I
in O
extracts O
of O
PMN O
activated O
by O
G B
- I
CSF I
to O
bind O
the O
high B
- I
affinity I
serum I
- I
inducible I
element I
( O
hSIE B
) O
is O
a O
72 B
- I
kDa I
protein I
that O
cross O
- O
reacts O
with O
Stat3 B
monoclonal I
antibody I
, O
which O
we O
have O
designated O
Stat3gamma B
. O

These O
studies O
revealed O
that O
the O
major B
protein I
in O
extracts O
of O
PMN O
activated O
by O
G B
- I
CSF I
to O
bind O
the O
high B
- I
affinity I
serum I
- I
inducible I
element I
( O
hSIE B
) O
is O
a O
72 B
- I
kDa I
protein I
that O
cross O
- O
reacts O
with O
Stat3 B
monoclonal I
antibody I
, O
which O
we O
have O
designated O
Stat3gamma B
. O

In O
order O
to O
investigate O
the O
factors O
that O
influence O
the O
induction O
of O
ICAM B
- I
1 I
molecules O
, O
Northern O
blot O
analysis O
to O
measure O
the O
expression O
level O
of O
ICAM B
- I
1 I
mRNAs I
and O
Southern O
blot O
hybridization O
to O
analyze O
the O
integration O
of O
human O
T O
- O
cell O
- O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
provirus O
were O
done O
. O

These O
concentrations O
are O
lower O
than O
concentrations O
reported O
to O
activate O
effector O
function O
of O
CTL O
recognizing O
other O
epithelial B
tumor I
Ag I
. O

Since O
the O
AES B
proteins I
are O
part O
of O
a O
set O
of O
transcriptional O
repressors O
encoded O
by O
the O
Enhancer B
of I
split I
[ I
E I
( I
spl I
) I
] I
genes I
, O
and O
since O
these O
repressors O
are O
activated O
to O
suppress O
cell O
differentiation O
in O
response O
to O
Notch B
receptors I
signalling O
, O
the O
AES O
peptides O
may O
represent O
a O
novel O
class O
of O
self B
- I
antigens I
that O
deserve O
further O
consideration O
as O
tumor B
Ag I
in O
epithelial O
cancers O
. O

Our O
data O
show O
that O
IFNs B
and O
IL B
- I
1 I
upregulate O
PML O
transcript O
and O
protein O
expression O
in O
a O
time O
and O
dose O
- O
dependent O
manner O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
and O
transforming B
growth I
factor I
beta I
( O
TGF B
- I
beta I
) O
are O
inhibitory O
for O
B O
and O
T O
cells O
, O
IgE B
production O
, O
and O
mast O
cell O
proliferation O
, O
and O
they O
induce O
apoptosis O
in O
eosinophils O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
and O
transforming B
growth I
factor I
beta I
( O
TGF B
- I
beta I
) O
are O
inhibitory O
for O
B O
and O
T O
cells O
, O
IgE B
production O
, O
and O
mast O
cell O
proliferation O
, O
and O
they O
induce O
apoptosis O
in O
eosinophils O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
and O
transforming B
growth I
factor I
beta I
( O
TGF B
- I
beta I
) O
are O
inhibitory O
for O
B O
and O
T O
cells O
, O
IgE B
production O
, O
and O
mast O
cell O
proliferation O
, O
and O
they O
induce O
apoptosis O
in O
eosinophils O
. O

The O
IL B
- I
10 I
gene O
polymorphism O
was O
a O
C O
- O
to O
- O
A O
exchange O
571 B
base I
pairs I
upstream I
from O
the O
translation B
start I
site I
and O
was O
present O
between O
consensus B
binding I
sequences I
for O
Sp1 B
and O
elevated O
total O
serum O
. O

The O
IL B
- I
10 I
gene O
polymorphism O
was O
a O
C O
- O
to O
- O
A O
exchange O
571 B
base I
pairs I
upstream I
from O
the O
translation B
start I
site I
and O
was O
present O
between O
consensus B
binding I
sequences I
for O
Sp1 B
and O
elevated O
total O
serum O
. O

The O
IL B
- I
10 I
gene O
polymorphism O
was O
a O
C O
- O
to O
- O
A O
exchange O
571 B
base I
pairs I
upstream I
from O
the O
translation B
start I
site I
and O
was O
present O
between O
consensus B
binding I
sequences I
for O
Sp1 B
and O
elevated O
total O
serum O
. O

This O
polymorphism O
was O
associated O
with O
elevated O
total B
serum I
IgE I
in O
subjects O
heterozygotic O
or O
homozygotic O
for O
this O
base O
exchange O
( O
p O
< O
0 O
. O
009 O
) O
. O

This O
polymorphism O
represented O
a O
C O
- O
to O
- O
T O
base O
exchange O
which O
induced O
a O
YY1 B
consensus I
sequence I
and O
is O
present O
in O
a O
region O
of O
the O
promoter O
associated O
with O
negative O
transcription O
regulation O
. O

However O
, O
it O
was O
only O
the O
IL B
- I
2 I
promoter I
whose O
activation O
by O
Tpl B
- I
2 I
was O
fully O
blocked O
by O
the O
dominant B
negative I
mutant I
MEK1S218 I
/ I
222A I
and O
the O
MEK1 O
/ O
MEK2 O
inhibitor O
PD098059 O
. O

The O
action O
of O
adenoviral B
E1A I
oncoprotein I
on O
host B
immune I
- I
response I
genes I
has O
been O
attributed O
to O
interaction O
with O
p300 B
/ I
CBP I
- I
type I
transcriptional I
coactivators I
in O
competition O
with O
endogenous B
transcription I
factors I
such O
as O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
proteins I
. O

The O
action O
of O
adenoviral B
E1A I
oncoprotein I
on O
host B
immune I
- I
response I
genes I
has O
been O
attributed O
to O
interaction O
with O
p300 B
/ I
CBP I
- I
type I
transcriptional I
coactivators I
in O
competition O
with O
endogenous B
transcription I
factors I
such O
as O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
proteins I
. O

Here O
we O
evaluated O
whether O
xenogeneic O
serum O
, O
as O
a O
source O
of O
xenoreactive B
natural I
antibodies I
and O
complement O
, O
induced O
endothelial O
cell O
activation O
with O
consequent O
leukocyte O
adhesion O
under O
flow O
conditions O
. O

Anaphylatoxins B
C5a B
and O
C3a B
induce O
nuclear B
factor I
kappaB I
activation O
in O
human O
peripheral O
blood O
monocytes O
. O

The O
Mpl B
receptor I
is O
a O
member O
of O
the O
hematopoietin B
receptor I
superfamily I
lacking O
intrinsic O
kinase O
activity O
. O

Recently O
, O
a O
technique O
of O
clonal O
analysis O
has O
been O
devised O
that O
takes O
advantage O
of O
a O
highly O
polymorphic O
short B
tandem I
repeat I
within O
the O
X B
- I
linked I
human I
androgen I
receptor I
( I
AR I
) I
gene I
, O
resulting O
in O
a O
heterozygosity O
rate O
approaching O
90 O
% O
. O

The O
rapid O
expansion O
of O
the O
number O
of O
women O
now O
suitable O
for O
X O
inactivation O
analysis O
has O
however O
given O
rise O
to O
new O
controversies O
, O
one O
of O
the O
more O
troublesome O
being O
the O
possibility O
of O
a O
modification O
of O
the O
pattern O
of O
X B
- I
chromosome I
inactivation O
pattern O
in O
blood O
cells O
of O
elderly O
women O
. O

We O
show O
here O
that O
IFN B
- I
alpha I
/ I
beta I
act O
directly O
on O
human O
T O
cells O
to O
drive O
Th1 O
development O
, O
bypassing O
the O
need O
for O
IL B
- I
12 I
- O
induced O
signaling O
, O
whereas O
IFN B
- I
alpha I
can O
not O
substitute O
IL B
- I
12 I
for O
mouse O
Th1 O
development O
. O

We O
show O
here O
that O
IFN B
- I
alpha I
/ I
beta I
act O
directly O
on O
human O
T O
cells O
to O
drive O
Th1 O
development O
, O
bypassing O
the O
need O
for O
IL B
- I
12 I
- O
induced O
signaling O
, O
whereas O
IFN B
- I
alpha I
can O
not O
substitute O
IL B
- I
12 I
for O
mouse O
Th1 O
development O
. O

We O
show O
here O
that O
IFN B
- I
alpha I
/ I
beta I
act O
directly O
on O
human O
T O
cells O
to O
drive O
Th1 O
development O
, O
bypassing O
the O
need O
for O
IL B
- I
12 I
- O
induced O
signaling O
, O
whereas O
IFN B
- I
alpha I
can O
not O
substitute O
IL B
- I
12 I
for O
mouse O
Th1 O
development O
. O

Unlike O
IL B
- I
12 I
, O
which O
acts O
only O
on O
Th1 O
cells O
, O
IFN B
- I
alpha I
/ I
beta I
can O
activate O
Stat4 B
not O
only O
in O
human O
Th1 O
, O
but O
also O
in O
Th2 O
cells O
. O

Inhibition O
of O
Th1 O
development O
mediated O
by O
GATA B
- I
3 I
through O
an O
IL O
- O
4 O
- O
independent O
mechanism O
. O

These O
motifs O
are O
regulatory B
sequences I
within O
the O
so O
- O
called O
AU B
- I
rich I
elements I
( O
AREs B
) O
often O
found O
in O
3 B
' I
untranslated I
regions I
of O
genes O
such O
as O
cytokines B
, O
proto B
- I
oncogenes I
, O
and O
transcription B
factors I
. O

Transcription O
factor O
NF B
- I
kappaB I
regulation O
of O
renal O
fibrosis O
during O
ureteral O
obstruction O
. O

At O
the O
same O
time O
there O
was O
no O
change O
in O
the O
level O
of O
expression O
of O
the O
cell B
surface I
antigenes I
CD33 B
, O
CD34 B
, O
CD45 B
, O
CD71 B
and O
glycophorin B
A I
. O

The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
essential O
for O
the O
expression O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class I
II I
antigens I
. O

In O
contrast O
, O
luciferase B
expression O
was O
not O
stimulated O
after O
IFN B
- I
gamma I
treatment O
when O
the O
construct O
was O
transfected O
in O
macrophage O
or O
in O
epithelial O
cell O
lines O
. O

These O
studies O
investigate O
the O
relationship O
between O
leukocyte O
populations O
, O
steroid B
hormone I
receptor I
expression O
, O
proliferative O
activity O
, O
bcl B
- I
2 I
expression O
and O
apoptosis O
in O
eutopic O
and O
ectopic O
endometrium O
from O
women O
with O
endometriosis O
or O
adenomyosis O
at O
different O
phases O
of O
the O
menstrual O
cycle O
. O

These O
studies O
investigate O
the O
relationship O
between O
leukocyte O
populations O
, O
steroid B
hormone I
receptor I
expression O
, O
proliferative O
activity O
, O
bcl B
- I
2 I
expression O
and O
apoptosis O
in O
eutopic O
and O
ectopic O
endometrium O
from O
women O
with O
endometriosis O
or O
adenomyosis O
at O
different O
phases O
of O
the O
menstrual O
cycle O
. O

Here O
, O
we O
demonstrate O
through O
the O
use O
of O
intracellular O
staining O
that O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
is O
expressed O
in O
LCLs O
and O
investigate O
the O
influence O
of O
the O
individual O
latent B
proteins I
on O
the O
expression O
of O
IL B
- I
1beta I
. O

Here O
, O
we O
demonstrate O
through O
the O
use O
of O
intracellular O
staining O
that O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
is O
expressed O
in O
LCLs O
and O
investigate O
the O
influence O
of O
the O
individual O
latent B
proteins I
on O
the O
expression O
of O
IL B
- I
1beta I
. O

Here O
, O
we O
demonstrate O
through O
the O
use O
of O
intracellular O
staining O
that O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
is O
expressed O
in O
LCLs O
and O
investigate O
the O
influence O
of O
the O
individual O
latent B
proteins I
on O
the O
expression O
of O
IL B
- I
1beta I
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
demonstrated O
that O
the O
- O
300 O
region O
of O
the O
IL B
- I
1beta I
promoter O
, O
which O
contains O
a O
nuclear B
factor I
- I
kappaB I
( I
NF I
- I
kappaB I
) I
binding I
site I
, O
contained O
a O
functional B
RBP I
binding I
site I
. O

CD27 B
/ O
CD70 O
interaction O
enhanced O
B O
cell O
proliferation O
in O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
4 I
plus O
anti B
- I
CD40 I
. O

CD27 B
/ O
CD70 O
interaction O
enhanced O
B O
cell O
proliferation O
in O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
4 I
plus O
anti B
- I
CD40 I
. O

CD27 B
/ O
CD70 O
interaction O
enhanced O
B O
cell O
proliferation O
in O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
4 I
plus O
anti B
- I
CD40 I
. O

Regulation O
of O
PAK O
activation O
and O
the O
T O
cell O
cytoskeleton O
by O
the O
linker B
protein I
SLP B
- I
76 I
. O

LOX B
- I
1 I
is O
an O
endothelial B
receptor I
for O
oxidized B
low I
- I
density I
lipoprotein I
that O
plays O
essential O
roles O
in O
atherogenesis O
. O

In O
contrast O
, O
the O
expression O
pattern O
of O
LOX B
- I
1 I
is O
different O
from O
that O
of O
the O
natural B
killer I
cell I
receptors I
; O
LOX B
- I
1 I
is O
expressed O
in O
vascular O
- O
rich O
organs O
, O
but O
not O
in O
lymphocytes O
. O

In O
contrast O
, O
the O
expression O
pattern O
of O
LOX B
- I
1 I
is O
different O
from O
that O
of O
the O
natural B
killer I
cell I
receptors I
; O
LOX B
- I
1 I
is O
expressed O
in O
vascular O
- O
rich O
organs O
, O
but O
not O
in O
lymphocytes O
. O

Coincidentally O
, O
a O
deletion O
of O
this O
region O
enhanced O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
beta B
- I
casein I
. O

Coincidentally O
, O
a O
deletion O
of O
this O
region O
enhanced O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
beta B
- I
casein I
. O

In O
addition O
, O
Ras B
( I
G12V I
) I
complemented O
signaling O
by O
an O
erythropoietin B
receptor I
mutant I
defective O
in O
Ras B
activation O
and O
augmented O
the O
activation O
of O
the O
beta B
- I
casein I
promoter I
by O
the O
mutant B
erythropoietin I
receptor I
signaling O
, O
suggesting O
a O
possible O
role O
of O
Ras B
in O
Stat5 B
- O
mediated O
gene O
expression O
. O

In O
addition O
, O
Ras B
( I
G12V I
) I
complemented O
signaling O
by O
an O
erythropoietin B
receptor I
mutant I
defective O
in O
Ras B
activation O
and O
augmented O
the O
activation O
of O
the O
beta B
- I
casein I
promoter I
by O
the O
mutant B
erythropoietin I
receptor I
signaling O
, O
suggesting O
a O
possible O
role O
of O
Ras B
in O
Stat5 B
- O
mediated O
gene O
expression O
. O

GATA B
- I
3 I
represses O
gp91phox B
gene I
expression O
in O
eosinophil O
- O
committed O
HL O
- O
60 O
- O
C15 O
cells O
. O

In O
addition O
, O
Northern O
blot O
analysis O
of O
cord O
and O
adult O
samples O
revealed O
similar O
maximal O
increases O
in O
c B
- I
fos I
( O
99 O
+ O
/ O
- O
15 O
and O
126 O
+ O
/ O
- O
11 O
% O
, O
p O
= O
0 O
. O
0126 O
) O
and O
c B
- I
jun I
( I
123 I
+ I
/ I
- I
9 I
and I
185 I
+ I
/ I
- I
38 I
% I
, I
p I
= I
0 I
. I
0291 I
) I
mRNA I
expression O
, O
respectively O
, O
as O
early O
as O
15 O
min O
post O
- O
alphaCD3 B
stimulation O
. O

Cross O
- O
linking O
of O
FcR B
, O
on O
the O
THP O
- O
1 O
monocytic O
cell O
line O
, O
by O
immune B
complexes I
resulted O
in O
both O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
interleukin B
1 I
production O
. O

BCL B
- I
6 I
mutations O
in O
normal O
germinal O
center O
B O
cells O
: O
evidence O
of O
somatic O
hypermutation O
acting O
outside O
Ig B
loci I
. O

Thirty O
percent O
of O
GC O
B O
cells O
, O
but O
not O
naive O
B O
cells O
, O
displayed O
mutations O
in O
the O
742 B
bp I
region I
analyzed O
within O
the O
first O
intron O
of O
BCL B
- I
6 I
( O
overall O
frequency O
: O
5 O
x O
10 O
( O
- O
4 O
) O
/ O
bp O
) O
. O

Thirty O
percent O
of O
GC O
B O
cells O
, O
but O
not O
naive O
B O
cells O
, O
displayed O
mutations O
in O
the O
742 B
bp I
region I
analyzed O
within O
the O
first O
intron O
of O
BCL B
- I
6 I
( O
overall O
frequency O
: O
5 O
x O
10 O
( O
- O
4 O
) O
/ O
bp O
) O
. O

The O
ability O
of O
E2A B
- I
HLF I
to O
prolong O
the O
survival O
of O
interleukin O
- O
3 O
( O
IL O
- O
3 O
) O
- O
dependent O
murine O
pro O
- O
B O
cells O
after O
IL B
- I
3 I
withdrawal O
suggests O
that O
it O
disrupts O
signaling O
pathways O
normally O
responsible O
for O
cell O
suicide O
, O
allowing O
the O
cells O
to O
accumulate O
as O
transformed O
lymphoblasts O
. O

The O
ability O
of O
E2A B
- I
HLF I
to O
prolong O
the O
survival O
of O
interleukin O
- O
3 O
( O
IL O
- O
3 O
) O
- O
dependent O
murine O
pro O
- O
B O
cells O
after O
IL B
- I
3 I
withdrawal O
suggests O
that O
it O
disrupts O
signaling O
pathways O
normally O
responsible O
for O
cell O
suicide O
, O
allowing O
the O
cells O
to O
accumulate O
as O
transformed O
lymphoblasts O
. O

Neither O
the O
E12 B
nor O
the O
E47 B
product O
of O
the O
E2A B
gene I
nor O
the O
wild B
- I
type I
HLF I
protein I
was O
able O
to O
protect O
the O
cells O
from O
apoptosis O
induced O
by O
IL B
- I
3 I
deprivation O
. O

Surprisingly O
, O
different O
combinations O
of O
disabling O
mutations O
within O
the O
HLF B
bZIP I
domain I
had O
little O
effect O
on O
the O
antiapoptotic O
property O
of O
the O
chimeric B
protein I
, O
so O
long O
as O
the O
amino O
- O
terminal O
portion O
of O
E2A B
remained O
intact O
. O

The O
DNA O
sequence O
at O
- B
120 I
also O
contains O
two O
DNA B
motifs I
homologous O
to O
the O
binding O
site O
for O
NF B
- I
AT I
. O

NF B
- I
AT I
does O
not O
directly O
bind O
to O
this O
element O
. O

Progesterone O
acts O
distally O
to O
the O
initial O
steps O
of O
T B
cell I
receptor I
( O
TCR B
) O
- O
mediated O
signal O
transduction O
, O
since O
it O
blocks O
sustained O
Ca2 O
+ O
signals O
after O
thapsigargin O
stimulation O
, O
as O
well O
as O
oscillatory O
Ca2 O
+ O
signals O
, O
but O
not O
the O
Ca2 O
+ O
transient O
after O
TCR B
stimulation O
. O

Progesterone O
effectively O
blocked O
a O
broad O
spectrum O
of O
K B
+ I
channels I
, O
reducing O
both O
Kv1 B
. I
3 I
and O
charybdotoxin B
- I
resistant I
components I
of O
KV B
current O
and O
KCa B
current O
in O
T O
cells O
, O
as O
well O
as O
blocking O
several O
cloned B
KV I
channels I
expressed O
in O
cell O
lines O
. O

Progesterone O
effectively O
blocked O
a O
broad O
spectrum O
of O
K B
+ I
channels I
, O
reducing O
both O
Kv1 B
. I
3 I
and O
charybdotoxin B
- I
resistant I
components I
of O
KV B
current O
and O
KCa B
current O
in O
T O
cells O
, O
as O
well O
as O
blocking O
several O
cloned B
KV I
channels I
expressed O
in O
cell O
lines O
. O

Progesterone O
effectively O
blocked O
a O
broad O
spectrum O
of O
K B
+ I
channels I
, O
reducing O
both O
Kv1 B
. I
3 I
and O
charybdotoxin B
- I
resistant I
components I
of O
KV B
current O
and O
KCa B
current O
in O
T O
cells O
, O
as O
well O
as O
blocking O
several O
cloned B
KV I
channels I
expressed O
in O
cell O
lines O
. O

Nor O
was O
fragmentation O
observed O
after O
treatment O
with O
RU38486 O
, O
indicating O
that O
repression O
of O
AP B
- I
1 I
activity O
is O
not O
involved O
. O

Dexamethasone O
treatment O
completely O
blocked O
12 O
- O
O O
- O
tetradecanoylphorbol O
13 O
- O
acetate O
induction O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
activity O
and O
elicited O
an O
increase O
in O
the O
amount O
of O
immunoreactive B
IkappaB I
alpha I
in O
sensitive O
6TG1 O
. O
1 O
cells O
but O
not O
in O
resistant O
ICR27TK O
. O
3 O
cells O
. O

Dexamethasone O
treatment O
completely O
blocked O
12 O
- O
O O
- O
tetradecanoylphorbol O
13 O
- O
acetate O
induction O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
activity O
and O
elicited O
an O
increase O
in O
the O
amount O
of O
immunoreactive B
IkappaB I
alpha I
in O
sensitive O
6TG1 O
. O
1 O
cells O
but O
not O
in O
resistant O
ICR27TK O
. O
3 O
cells O
. O

It O
was O
proposed O
that O
the O
mechanism O
of O
antiviral O
action O
of O
S9a O
was O
on O
the O
host O
cell O
, O
by O
blocking O
TNF B
- I
alpha I
transcription O
via O
a O
Tat B
- O
induced O
tar O
- O
independent O
loop O
, O
which O
decreases O
downstream O
NF B
- I
kappaB I
activation O
of O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
. O

It O
was O
proposed O
that O
the O
mechanism O
of O
antiviral O
action O
of O
S9a O
was O
on O
the O
host O
cell O
, O
by O
blocking O
TNF B
- I
alpha I
transcription O
via O
a O
Tat B
- O
induced O
tar O
- O
independent O
loop O
, O
which O
decreases O
downstream O
NF B
- I
kappaB I
activation O
of O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
. O

We O
determined O
whether O
Hsp70 B
induction O
by O
TS O
was O
mediated O
by O
the O
activation O
of O
the O
HS B
transcription I
factor I
, O
HSF B
. O

The O
capacity O
of O
neonatal O
T O
cells O
to O
secrete O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
has O
been O
reported O
to O
be O
variable O
. O

The O
capacity O
of O
neonatal O
T O
cells O
to O
secrete O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
has O
been O
reported O
to O
be O
variable O
. O

PDBu O
+ O
iono O
induced O
equally O
high O
IL B
- I
2 I
levels O
in O
both O
groups O
and O
, O
when O
stimulated O
with O
plate O
- O
bound O
anti B
- I
CD3 I
monoclonal I
antibody I
( O
mAb B
) O
, O
the O
IL B
- I
2 I
secretion O
by O
neonatal O
cells O
was O
undetectable O
and O
adult O
cells O
produced O
low O
amounts O
of O
IL B
- I
2 I
( O
mean O
331 O
+ O
/ O
- O
86 O
pg O
/ O
ml O
) O
. O

PDBu O
+ O
iono O
induced O
equally O
high O
IL B
- I
2 I
levels O
in O
both O
groups O
and O
, O
when O
stimulated O
with O
plate O
- O
bound O
anti B
- I
CD3 I
monoclonal I
antibody I
( O
mAb B
) O
, O
the O
IL B
- I
2 I
secretion O
by O
neonatal O
cells O
was O
undetectable O
and O
adult O
cells O
produced O
low O
amounts O
of O
IL B
- I
2 I
( O
mean O
331 O
+ O
/ O
- O
86 O
pg O
/ O
ml O
) O
. O

PDBu O
+ O
iono O
induced O
equally O
high O
IL B
- I
2 I
levels O
in O
both O
groups O
and O
, O
when O
stimulated O
with O
plate O
- O
bound O
anti B
- I
CD3 I
monoclonal I
antibody I
( O
mAb B
) O
, O
the O
IL B
- I
2 I
secretion O
by O
neonatal O
cells O
was O
undetectable O
and O
adult O
cells O
produced O
low O
amounts O
of O
IL B
- I
2 I
( O
mean O
331 O
+ O
/ O
- O
86 O
pg O
/ O
ml O
) O
. O

As O
NF B
- I
kappa I
B I
is O
a O
critical O
transcription B
factor I
in O
the O
control O
of O
IL B
- I
2 I
expression O
, O
we O
next O
analysed O
its O
nuclear O
translocation O
in O
neonatal O
and O
adult O
T O
cells O
using O
the O
electrophoretic O
mobility O
shift O
assay O
and O
, O
because O
induction O
of O
reactive O
oxygen O
intermediates O
( O
ROI O
) O
is O
required O
for O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
we O
also O
analysed O
levels O
of O
intracellular O
ROI O
in O
these O
cells O
using O
the O
ROI O
- O
reactive O
fluorochrome O
DCFH O
- O
DA O
and O
flow O
cytometry O
. O

Our O
results O
suggest O
that O
reduced O
IL B
- I
2 I
production O
by O
neonatal O
T O
cells O
is O
specific O
for O
anti B
- I
CD3 I
and O
anti B
- I
CD3 I
+ O
anti B
- I
CD28 I
- O
mediated O
stimulation O
and O
that O
these O
activators O
can O
not O
effectively O
activate O
the O
ROI O
- B
NF I
- I
kappa I
B I
signalling O
pathway O
in O
neonatal O
T O
cells O
. O

Our O
results O
suggest O
that O
reduced O
IL B
- I
2 I
production O
by O
neonatal O
T O
cells O
is O
specific O
for O
anti B
- I
CD3 I
and O
anti B
- I
CD3 I
+ O
anti B
- I
CD28 I
- O
mediated O
stimulation O
and O
that O
these O
activators O
can O
not O
effectively O
activate O
the O
ROI O
- B
NF I
- I
kappa I
B I
signalling O
pathway O
in O
neonatal O
T O
cells O
. O

Our O
results O
suggest O
that O
reduced O
IL B
- I
2 I
production O
by O
neonatal O
T O
cells O
is O
specific O
for O
anti B
- I
CD3 I
and O
anti B
- I
CD3 I
+ O
anti B
- I
CD28 I
- O
mediated O
stimulation O
and O
that O
these O
activators O
can O
not O
effectively O
activate O
the O
ROI O
- B
NF I
- I
kappa I
B I
signalling O
pathway O
in O
neonatal O
T O
cells O
. O

Our O
results O
suggest O
that O
reduced O
IL B
- I
2 I
production O
by O
neonatal O
T O
cells O
is O
specific O
for O
anti B
- I
CD3 I
and O
anti B
- I
CD3 I
+ O
anti B
- I
CD28 I
- O
mediated O
stimulation O
and O
that O
these O
activators O
can O
not O
effectively O
activate O
the O
ROI O
- B
NF I
- I
kappa I
B I
signalling O
pathway O
in O
neonatal O
T O
cells O
. O

CL O
- O
01 O
cells O
are O
IgM B
+ O
IgD B
+ O
CD30 B
+ O
and O
switch O
to O
IgG B
, O
IgA B
, O
and O
IgE B
when O
exposed O
to O
CD40L B
and O
IL B
- I
4 I
. O

Switching O
is O
hampered O
by O
CD30 B
coengagement O
, O
possibly O
through O
interference O
with O
the O
CD40 B
- O
mediated O
NF B
- I
kappaB I
- O
dependent O
transcriptional O
activation O
of O
downstream B
C I
( I
H I
) I
genes I
. O

It O
is O
unknown O
which O
Stat3 B
isoform I
( O
s O
) O
is O
activated O
in O
response O
to O
interleukin B
( I
IL I
) I
- I
2 I
and O
IL B
- I
15 I
. O

It O
is O
shown O
here O
that O
during O
monocyte O
to O
macrophage O
differentiation O
, O
the O
expression O
of O
LAL B
- I
mRNA I
is O
induced O
. O

In O
order O
to O
understand O
the O
role O
of O
NF B
- I
kappaB I
in O
EBV O
transformation O
we O
have O
established O
stably O
transfected O
IkappaBalpha B
into O
lymphoblastoid O
cells O
. O

Our O
results O
suggest O
that O
the O
TNFalpha B
gene I
could O
be O
one O
of O
the O
targets O
of O
NF B
- I
kappaB I
in O
EBV O
infected O
cells O
and O
that O
NF O
- O
kappaB O
protects O
EBV O
- O
infected O
cells O
from O
apoptosis O
induced O
by O
TNFalpha B
, O
which O
may O
favour O
the O
proliferative O
effect O
of O
this O
cytokine B
. O

Two O
chronically O
HIV O
- O
1 O
- O
infected O
cell O
lines O
, O
U1 O
( O
monocytic O
) O
and O
ACH O
- O
2 O
( O
T O
lymphocytic O
) O
, O
were O
stimulated O
with O
TNF B
- I
alpha I
or O
PMA O
and O
cultured O
in O
the O
presence O
of O
various O
concentrations O
of O
the O
compound O
. O

This O
study O
shows O
that O
expression O
of O
LMP1 B
activates O
transcription O
from O
p50 B
/ I
p65 I
- I
and I
c I
- I
Rel I
- I
responsive I
promoters I
, O
and O
that O
this O
activity O
can O
be O
completely O
inhibited O
by O
expression O
of O
a O
dominant O
inhibitory B
IkappaB I
mutant I
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

To O
examine O
the O
hypothesis O
that O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
contributes O
to O
PMN O
infiltration O
and O
lung O
damage O
in O
HS O
, O
we O
examined O
the O
lungs O
of O
rats O
subjected O
to O
unresuscitated O
and O
resuscitated O
HS O
for O
the O
production O
of O
IL B
- I
6 I
and O
activation O
of O
Stat3 B
. O

To O
examine O
the O
hypothesis O
that O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
contributes O
to O
PMN O
infiltration O
and O
lung O
damage O
in O
HS O
, O
we O
examined O
the O
lungs O
of O
rats O
subjected O
to O
unresuscitated O
and O
resuscitated O
HS O
for O
the O
production O
of O
IL B
- I
6 I
and O
activation O
of O
Stat3 B
. O

To O
examine O
the O
hypothesis O
that O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
contributes O
to O
PMN O
infiltration O
and O
lung O
damage O
in O
HS O
, O
we O
examined O
the O
lungs O
of O
rats O
subjected O
to O
unresuscitated O
and O
resuscitated O
HS O
for O
the O
production O
of O
IL B
- I
6 I
and O
activation O
of O
Stat3 B
. O

The O
MHC B
class I
II I
transactivator I
( O
CIITA B
) O
requires O
conserved O
leucine B
charged I
domains I
for O
interactions O
with O
the O
conserved O
W B
box I
promoter I
element I
. O

The O
ability O
of O
mutants O
to O
activate O
a O
reporter O
gene O
under O
the O
control O
of O
MHC B
class I
II I
conserved O
W B
- I
X I
- I
Y I
or I
X I
- I
Y I
regulatory I
elements I
was O
determined O
. O

We O
determined O
whether O
the O
interaction O
of O
SS O
RBC O
with O
cultured O
endothelial O
cells O
induced O
cellular O
oxidant O
stress O
that O
would O
culminate O
in O
expression O
of O
cell B
adhesion I
molecules I
( O
CAMs B
) O
involved O
in O
the O
adhesion O
and O
diapedesis O
of O
monocytes O
and O
the O
adherence O
of O
SS O
reticulocytes O
. O

In O
the O
majority O
of O
patients O
with O
advanced O
RCC O
, O
peripheral O
blood O
T O
cells O
express O
TCRzeta B
and O
p56 B
( I
lck I
) I
, O
and O
in O
a O
subset O
, O
reduced O
levels O
of O
these O
TCRzeta B
associated I
molecules I
are O
seen O
that O
may O
increase O
during O
cytokine B
- O
based O
therapy O
. O

p21ras B
initiates O
Rac B
- I
1 I
but O
not O
phosphatidyl B
inositol I
3 I
kinase I
/ I
PKB I
, O
mediated O
signaling O
pathways O
in O
T O
lymphocytes O
. O

We O
also O
examined O
the O
possibility O
that O
Akt B
/ I
PKB I
is O
regulated O
by O
Ras O
signaling O
pathways O
in O
T O
lymphocytes O
. O

Moreover O
, O
neither O
TCR B
or O
Ras B
activation O
of O
AP B
- I
1 I
is O
dependent O
on O
PtdIns B
3 I
- I
kinase I
. O

The O
present O
data O
thus O
highlight O
that O
PtdIns B
3 I
- I
kinase I
and O
Akt B
/ I
PKB I
are O
not O
universal O
Ras B
effector I
molecules I
. O

The O
present O
data O
thus O
highlight O
that O
PtdIns B
3 I
- I
kinase I
and O
Akt B
/ I
PKB I
are O
not O
universal O
Ras B
effector I
molecules I
. O

In O
addition O
, O
recombinant O
IL B
- I
1beta I
was O
able O
to O
replace O
MCM O
for O
the O
inhibition O
of O
proliferation O
and O
down O
- O
regulation O
of O
AR B
and O
PSA B
proteins O
. O

LNCaP O
cells O
were O
shown O
to O
express O
the O
IL B
- I
1beta I
receptor O
type O
1 O
, O
which O
transduces O
IL B
- I
1beta I
signal O
. O

LNCaP O
cells O
were O
shown O
to O
express O
the O
IL B
- I
1beta I
receptor O
type O
1 O
, O
which O
transduces O
IL B
- I
1beta I
signal O
. O

Here O
, O
we O
show O
that O
ectopic O
expression O
of O
GATA B
- I
3 I
is O
sufficient O
to O
drive O
IL B
- I
5 I
but O
not O
IL B
- I
4 I
gene O
expression O
. O

Here O
, O
we O
show O
that O
ectopic O
expression O
of O
GATA B
- I
3 I
is O
sufficient O
to O
drive O
IL B
- I
5 I
but O
not O
IL B
- I
4 I
gene O
expression O
. O

Here O
, O
we O
show O
that O
ectopic O
expression O
of O
GATA B
- I
3 I
is O
sufficient O
to O
drive O
IL B
- I
5 I
but O
not O
IL B
- I
4 I
gene O
expression O
. O

Mutations O
of O
sites O
that O
suppress O
NF B
- I
AT I
binding O
impair O
the O
induction O
and O
strong O
NF B
- I
ATp I
- O
mediated O
transactivation O
of O
the O
CD25 B
promoter I
in O
T O
cells O
. O

Mutations O
of O
sites O
that O
suppress O
NF B
- I
AT I
binding O
impair O
the O
induction O
and O
strong O
NF B
- I
ATp I
- O
mediated O
transactivation O
of O
the O
CD25 B
promoter I
in O
T O
cells O
. O

The O
Fy O
( O
a O
- O
b O
- O
) O
phenotype O
has O
been O
associated O
with O
a O
mutation O
in O
the O
FY B
* I
B I
promoter I
at O
the O
GATA B
box I
that O
abolishes O
the O
expression O
of O
erythrocyte B
Duffy I
protein I
. O

In O
both O
activated O
peripheral O
blood O
T O
lymphocytes O
and O
activated O
tumorigenic O
T O
cell O
lines O
, O
IL B
- I
2 I
gene O
expression O
was O
blocked O
at O
the O
transcriptional O
level O
by O
okadaic O
acid O
. O

These O
results O
establish O
an O
independent O
role O
for O
enhanced O
p75TNF B
- I
R I
production O
in O
the O
pathogenesis O
of O
inflammatory O
disease O
and O
implicate O
the O
direct O
involvement O
of O
this O
receptor O
in O
a O
wide O
range O
of O
human O
inflammatory O
pathologies O
. O

We O
have O
determined O
how O
the O
phosphorylation O
of O
the O
retinoblastoma B
family I
( O
pRb B
, O
p107 B
, O
and O
p130 B
) O
is O
governed O
in O
individual O
cell O
cycle O
phases O
of O
Daudi O
B O
- O
cells O
during O
cell O
cycle O
exit O
triggered O
by O
alpha B
- I
interferon I
( O
alpha B
- I
IFN I
) O
. O

We O
have O
determined O
how O
the O
phosphorylation O
of O
the O
retinoblastoma B
family I
( O
pRb B
, O
p107 B
, O
and O
p130 B
) O
is O
governed O
in O
individual O
cell O
cycle O
phases O
of O
Daudi O
B O
- O
cells O
during O
cell O
cycle O
exit O
triggered O
by O
alpha B
- I
interferon I
( O
alpha B
- I
IFN I
) O
. O

alpha B
- I
IFN I
causes O
dephosphorylation O
of O
pRb B
and O
loss O
of O
p130 B
phosphorylated I
Form I
3 I
. O

However O
, O
the O
change O
in O
p130 B
phosphorylation O
in O
response O
to O
alpha B
- I
IFN I
occurs O
before O
dephosphorylation O
of O
pRb B
is O
complete O
because O
loss O
of O
p130 B
Form I
3 I
occurs O
throughout O
the O
cell O
cycle O
prior O
to O
complete O
arrest O
in O
G1 O
, O
whereas O
pRb B
is O
dephosphorylated O
only O
in O
G1 O
. O

However O
, O
the O
change O
in O
p130 B
phosphorylation O
in O
response O
to O
alpha B
- I
IFN I
occurs O
before O
dephosphorylation O
of O
pRb B
is O
complete O
because O
loss O
of O
p130 B
Form I
3 I
occurs O
throughout O
the O
cell O
cycle O
prior O
to O
complete O
arrest O
in O
G1 O
, O
whereas O
pRb B
is O
dephosphorylated O
only O
in O
G1 O
. O

p130 B
, O
predominantly O
in O
Form O
1 O
, O
and O
hypophosphorylated B
pRb I
bind O
an O
E2F B
DNA I
binding I
site I
; O
p130 B
complexes O
E2F B
- I
4 I
, O
whereas O
pRb B
binds O
both O
E2F O
- O
4 O
and O
E2F B
- I
1 I
. O

p130 B
, O
predominantly O
in O
Form O
1 O
, O
and O
hypophosphorylated B
pRb I
bind O
an O
E2F B
DNA I
binding I
site I
; O
p130 B
complexes O
E2F B
- I
4 I
, O
whereas O
pRb B
binds O
both O
E2F O
- O
4 O
and O
E2F B
- I
1 I
. O

The O
phosphorylated O
forms O
of O
E2F B
- I
4 I
that O
bind O
to O
the O
E2F B
DNA I
site I
are O
different O
from O
hyperphosphorylated O
E2F B
- I
4 I
, O
which O
predominates O
in O
primary O
hemopoietic O
cells O
in O
G0 O
. O

The O
phosphorylated O
forms O
of O
E2F B
- I
4 I
that O
bind O
to O
the O
E2F B
DNA I
site I
are O
different O
from O
hyperphosphorylated O
E2F B
- I
4 I
, O
which O
predominates O
in O
primary O
hemopoietic O
cells O
in O
G0 O
. O

The O
phosphorylated O
forms O
of O
E2F B
- I
4 I
that O
bind O
to O
the O
E2F B
DNA I
site I
are O
different O
from O
hyperphosphorylated O
E2F B
- I
4 I
, O
which O
predominates O
in O
primary O
hemopoietic O
cells O
in O
G0 O
. O

In O
contrast O
, O
v B
- I
myb I
reduces O
MRP14 B
promoter I
activity O
. O

This O
pathway O
resulted O
in O
the O
induction O
of O
the O
transcription B
factors I
NF B
- I
kappa I
B I
, O
NF B
- I
AT I
, O
and O
proteins O
binding O
to O
the O
CD28 B
response O
element O
of O
the O
IL B
- I
2 I
promoter I
. O

In O
contrast O
to O
the O
differential O
signaling O
of O
BW B
828 I
and O
9 B
. I
3 I
in O
resting O
T O
cells O
, O
the O
two O
mAbs O
exhibited O
a O
similar O
pattern O
of O
early O
signaling O
events O
in O
activated O
T O
cells O
and O
Jurkat O
cells O
( O
p56 B
( I
lck I
) I
activation O
, O
association O
of O
phosphatidylinositol B
3 I
- I
kinase I
with O
CD28 B
) O
, O
indicating O
that O
the O
signaling O
capacity O
of O
CD28 B
changes O
with O
activation O
. O

IL B
- I
12 I
is O
a O
75 B
- I
kDa I
heterodimeric I
cytokine I
composed O
of O
two O
covalently O
linked O
p35 B
and I
p40 I
chains I
. O

Metabolic O
labeling O
combined O
with O
pulse O
- O
chase O
experiments O
and O
biochemical O
analysis O
showed O
that O
the O
majority O
of O
class B
II I
molecules I
in O
infected O
cells O
became O
resistant O
to O
endoglycosidase B
H I
, O
consistent O
with O
normal O
Golgi O
processing O
. O

However O
, O
results O
of O
intracellular O
staining O
and O
dual O
color O
confocal O
microscopy O
revealed O
a O
significant O
defect O
in O
transport O
of O
newly O
synthesized O
class B
II I
molecules I
through O
the O
endocytic O
compartment O
. O

Thus O
, O
compared O
with O
findings O
in O
control O
cells O
, O
class B
II I
molecules I
in O
infected O
cells O
colocalized O
to O
a O
minimal O
extent O
with O
a O
lysosomal B
- I
associated I
membrane I
protein I
- I
1 I
+ O
endosomal O
compartment O
. O

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

In O
CAT B
reporter I
constructions I
no O
appreciable O
level O
of O
CAT B
activity O
was O
supported O
by O
the O
beta B
globin I
promoter I
, O
and O
only O
low O
level O
activity O
by O
the O
delta B
promoter I
. O

In O
CAT B
reporter I
constructions I
no O
appreciable O
level O
of O
CAT B
activity O
was O
supported O
by O
the O
beta B
globin I
promoter I
, O
and O
only O
low O
level O
activity O
by O
the O
delta B
promoter I
. O

Fusion O
of O
the O
upstream B
portion I
of O
the O
delta B
promoter I
to O
the O
truncated O
beta B
globin I
promoter I
yielded O
a O
modest O
increase O
in O
promoter O
strength O
relative O
to O
the O
truncated B
beta I
gene I
promoter I
, O
indicating O
the O
presence O
of O
a O
positive B
transcriptional I
element I
( O
s O
) O
in O
the O
upstream B
delta I
globin I
regulatory I
region I
. O

Fusion O
of O
the O
upstream B
portion I
of O
the O
delta B
promoter I
to O
the O
truncated O
beta B
globin I
promoter I
yielded O
a O
modest O
increase O
in O
promoter O
strength O
relative O
to O
the O
truncated B
beta I
gene I
promoter I
, O
indicating O
the O
presence O
of O
a O
positive B
transcriptional I
element I
( O
s O
) O
in O
the O
upstream B
delta I
globin I
regulatory I
region I
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular B
signal I
- I
transducing I
protein I
Stat6 I
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon B
- I
y I
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl B
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular B
signal I
- I
transducing I
protein I
Stat6 I
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon B
- I
y I
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl B
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular B
signal I
- I
transducing I
protein I
Stat6 I
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon B
- I
y I
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl B
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular B
signal I
- I
transducing I
protein I
Stat6 I
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon B
- I
y I
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl B
. O

5 B
' I
HS3 I
contains O
six O
G O
- O
rich O
motifs O
that O
are O
essential O
for O
its O
activity O
. O

We O
show O
that O
the O
function O
of O
such O
closely O
related O
proteins O
can O
be O
distinguished O
in O
vivo O
by O
matching O
point O
mutations O
in O
5 B
' I
HS3 I
with O
amino O
acid O
changes O
in O
the O
zinc B
fingers I
of O
Sp1 B
and O
EKLF B
. O

We O
first O
demonstrate O
, O
in O
human O
and O
mouse O
intraspecies O
hybrids O
, O
the O
coordinate O
suppression O
of O
MHC B
class I
II I
, O
Ii B
( O
invariant B
chain I
) O
and O
HLA B
- I
DM I
gene I
transcription O
, O
and O
the O
release O
of O
the O
silencing O
by O
the O
addition O
of O
interferon B
gamma I
. O

These O
data O
indicate O
that O
the O
IFN B
- I
gamma I
- O
independent O
component O
of O
the O
target O
cell O
HLA B
- I
DR I
expression O
induced O
by O
lymphocyte O
adhesion O
uses O
a O
signaling O
pathway O
that O
is O
distinct O
from O
the O
IFN B
- I
gamma I
- O
dependent O
mechanism O
and O
also O
suggest O
that O
CIITA B
is O
not O
required O
. O

These O
data O
indicate O
that O
the O
IFN B
- I
gamma I
- O
independent O
component O
of O
the O
target O
cell O
HLA B
- I
DR I
expression O
induced O
by O
lymphocyte O
adhesion O
uses O
a O
signaling O
pathway O
that O
is O
distinct O
from O
the O
IFN B
- I
gamma I
- O
dependent O
mechanism O
and O
also O
suggest O
that O
CIITA B
is O
not O
required O
. O

These O
data O
indicate O
that O
the O
IFN B
- I
gamma I
- O
independent O
component O
of O
the O
target O
cell O
HLA B
- I
DR I
expression O
induced O
by O
lymphocyte O
adhesion O
uses O
a O
signaling O
pathway O
that O
is O
distinct O
from O
the O
IFN B
- I
gamma I
- O
dependent O
mechanism O
and O
also O
suggest O
that O
CIITA B
is O
not O
required O
. O

Transient O
transfection O
analysis O
with O
target B
plasmids I
containing O
either O
DRA B
promoter I
( O
wild O
- O
type O
or O
mutated O
) O
or O
TPA B
response I
elements I
demonstrated O
that O
pretreatment O
with O
the O
selective O
PKC B
inhibitor O
GF O
109203X O
repressed O
TPA O
- O
mediated O
activation O
. O

Together O
, O
these O
results O
show O
that O
activated O
HLA B
- I
DRA I
expression O
in O
response O
to O
TPA O
treatment O
is O
strictly O
dependent O
on O
PKC B
activation O
acting O
on O
the O
X2 B
box I
of O
the O
DRA B
promoter I
and O
that O
selective O
inhibition O
of O
PKC B
enzymatic O
activity O
does O
not O
influence O
subcellular O
localization O
of O
expressed O
PKC B
isoenzymes I
. O

Previously O
, O
we O
demonstrated O
that O
granulocyte B
colony I
- I
stimulating I
factor I
( I
G I
- I
CSF I
) I
receptor I
mRNA I
was O
undetectable O
and O
granulocyte O
maturation O
blocked O
in O
CCAAT B
enhancer I
binding I
protein I
alpha I
( O
C B
/ I
EBPalpha I
) O
- O
deficient O
mice O
. O

Anti B
- I
CD40 I
+ O
IL B
- I
4 I
- O
mediated O
proliferation O
of O
PBMC O
and O
B O
cells O
was O
inhibited O
by O
RA O
in O
a O
dose O
- O
dependent O
manner O
, O
with O
maximal O
inhibition O
of O
62 O
% O
+ O
/ O
- O
5 O
% O
in O
PBMC O
and O
55 O
% O
+ O
/ O
- O
4 O
. O
4 O
% O
in O
B O
cells O
by O
all O
- O
trans O
RA O
, O
and O
58 O
% O
+ O
/ O
- O
6 O
. O
7 O
% O
and O
51 O
% O
+ O
/ O
- O
4 O
. O
7 O
% O
, O
respectively O
by O
13 O
- O
cis O
RA O
. O

Anti B
- I
CD40 I
+ O
IL B
- I
4 I
- O
mediated O
proliferation O
of O
PBMC O
and O
B O
cells O
was O
inhibited O
by O
RA O
in O
a O
dose O
- O
dependent O
manner O
, O
with O
maximal O
inhibition O
of O
62 O
% O
+ O
/ O
- O
5 O
% O
in O
PBMC O
and O
55 O
% O
+ O
/ O
- O
4 O
. O
4 O
% O
in O
B O
cells O
by O
all O
- O
trans O
RA O
, O
and O
58 O
% O
+ O
/ O
- O
6 O
. O
7 O
% O
and O
51 O
% O
+ O
/ O
- O
4 O
. O
7 O
% O
, O
respectively O
by O
13 O
- O
cis O
RA O
. O

To O
differentiate O
whether O
the O
RA O
effect O
was O
mediated O
by O
RA B
receptors I
alpha I
, I
beta I
, I
and I
gamma I
, O
the O
expression O
of O
the O
retinoic B
acid I
receptors I
( O
RAR B
) O
was O
examined O
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
. O

In O
contrast O
, O
a O
mutant O
of O
Tax B
termed O
M22 B
, O
which O
does O
not O
induce O
NF B
- I
kappaB I
, O
fails O
to O
activate O
either O
IKKalpha B
or O
IKKbeta B
. O

The O
pathological O
alteration O
of O
this O
cytokine O
pathway O
leading O
to O
NF B
- I
kappaB I
activation O
by O
Tax B
may O
play O
a O
central O
role O
in O
HTLV O
- O
1 O
- O
mediated O
transformation O
of O
human O
T O
cells O
, O
clinically O
manifested O
as O
the O
adult O
T O
- O
cell O
leukemia O

Recently O
, O
we O
have O
reported O
that O
the O
tumor B
necrosis I
factor I
and O
interleukin B
1 I
signaling O
pathways O
activate O
two O
kinases O
, O
IKK1 B
and O
IKK2 B
. O

IL B
- I
7 I
did O
not O
maintain O
v B
- I
Abl I
- O
mediated O
differentiation O
arrest O
of O
the O
pre O
- O
B O
cells O
, O
as O
activation O
of O
NF B
- I
kappaB I
and O
RAG B
gene I
transcription O
was O
unaffected O
by O
IL B
- I
7 I
. O

IL B
- I
7 I
did O
not O
maintain O
v B
- I
Abl I
- O
mediated O
differentiation O
arrest O
of O
the O
pre O
- O
B O
cells O
, O
as O
activation O
of O
NF B
- I
kappaB I
and O
RAG B
gene I
transcription O
was O
unaffected O
by O
IL B
- I
7 I
. O

IL B
- I
7 I
did O
not O
maintain O
v B
- I
Abl I
- O
mediated O
differentiation O
arrest O
of O
the O
pre O
- O
B O
cells O
, O
as O
activation O
of O
NF B
- I
kappaB I
and O
RAG B
gene I
transcription O
was O
unaffected O
by O
IL B
- I
7 I
. O

IL B
- I
7 I
did O
not O
maintain O
v B
- I
Abl I
- O
mediated O
differentiation O
arrest O
of O
the O
pre O
- O
B O
cells O
, O
as O
activation O
of O
NF B
- I
kappaB I
and O
RAG B
gene I
transcription O
was O
unaffected O
by O
IL B
- I
7 I
. O

Functional O
analysis O
of O
the O
promoter O
by O
transient O
transfection O
assays O
indicated O
that O
synergistic O
action O
between O
an O
SP B
- I
1 I
- I
like I
element I
at O
- O
21 O
/ O
- O
12 O
, O
a O
GATA B
site I
at O
- O
59 O
/ O
- O
54 O
, O
and O
a O
novel B
regulatory I
element I
, O
CPRE B
( O
- O
GGACTACAG B
- O
) O
at O
- O
49 O
/ O
- O
41 O
, O
is O
essential O
for O
the O
promoter O
activity O
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
. O

Administration O
of O
the O
cytokine B
interleukin I
- I
2 I
( O
IL B
- I
2 I
) O
can O
result O
in O
therapeutic O
benefits O
for O
individuals O
with O
renal O
cell O
carcinoma O
and O
melanoma O
. O

Here O
we O
report O
an O
analysis O
of O
the O
transcription O
factor O
families O
AP O
- O
1 O
, O
Sp1 O
, O
NF B
- I
kappaB I
, O
and O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STAT B
) O
in O
cancer O
patients O
' O
lymphocytes O
before O
and O
after O
IL B
- I
2 I
immunotherapy O
, O
as O
assessed O
by O
a O
gel O
- O
shift O
assay O
. O

Here O
we O
report O
an O
analysis O
of O
the O
transcription O
factor O
families O
AP O
- O
1 O
, O
Sp1 O
, O
NF B
- I
kappaB I
, O
and O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STAT B
) O
in O
cancer O
patients O
' O
lymphocytes O
before O
and O
after O
IL B
- I
2 I
immunotherapy O
, O
as O
assessed O
by O
a O
gel O
- O
shift O
assay O
. O

The O
role O
of O
platelets O
for O
monocyte B
chemotactic I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
secretion O
and O
surface O
expression O
of O
intercellular O
adhesion O
molecule O
- O
1 O
( O
ICAM B
- I
1 I
) O
on O
endothelial O
cells O
has O
been O
assessed O
. O

The O
role O
of O
platelets O
for O
monocyte B
chemotactic I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
secretion O
and O
surface O
expression O
of O
intercellular O
adhesion O
molecule O
- O
1 O
( O
ICAM B
- I
1 I
) O
on O
endothelial O
cells O
has O
been O
assessed O
. O

Here O
we O
investigated O
the O
impact O
of O
retinoid B
X I
receptor I
( O
RXR B
) O
, O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
of O
the O
c B
- I
erbA I
/ I
thyroid I
hormone I
( I
T3 I
) I
receptor I
( O
c B
- I
erbA I
/ I
TR I
) O
on O
growth O
and O
differentiation O
of O
erythroid O
cells O
using O
an O
in O
vitro O
culture O
system O
of O
stem O
cell O
factor O
- O
dependent O
erythroid O
progenitors O
. O

Here O
we O
investigated O
the O
impact O
of O
retinoid B
X I
receptor I
( O
RXR B
) O
, O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
of O
the O
c B
- I
erbA I
/ I
thyroid I
hormone I
( I
T3 I
) I
receptor I
( O
c B
- I
erbA I
/ I
TR I
) O
on O
growth O
and O
differentiation O
of O
erythroid O
cells O
using O
an O
in O
vitro O
culture O
system O
of O
stem O
cell O
factor O
- O
dependent O
erythroid O
progenitors O
. O

T O
lymphocytes O
from O
6 O
of O
the O
14 O
patients O
also O
exhibited O
an O
increased O
expression O
of O
the O
dual O
specificity B
phosphatase I
, O
map B
kinase I
phosphatase I
- I
1 I
( O
MKP B
- I
1 I
) O
. O

The O
small B
GTP I
- I
binding I
protein I
Rho I
potentiates O
AP B
- I
1 I
transcription O
in O
T O
cells O
. O

The O
effect O
of O
Rho B
on O
AP B
- I
1 I
is O
independent O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
, O
as O
a O
dominant B
- I
negative I
MEK I
and O
a O
MEK B
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho B
- O
induced O
AP B
- I
1 I
activity O
. O

The O
effect O
of O
Rho B
on O
AP B
- I
1 I
is O
independent O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
, O
as O
a O
dominant B
- I
negative I
MEK I
and O
a O
MEK B
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho B
- O
induced O
AP B
- I
1 I
activity O
. O

The O
activation O
of O
NF B
- I
kappaB I
has O
been O
recognized O
to O
regulate O
a O
number O
of O
genes O
necessary O
for O
normal O
T O
cell O
responses O
including O
IL B
- I
2 I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
and O
several O
T B
cell I
surface I
receptors I
. O

The O
activation O
of O
NF B
- I
kappaB I
has O
been O
recognized O
to O
regulate O
a O
number O
of O
genes O
necessary O
for O
normal O
T O
cell O
responses O
including O
IL B
- I
2 I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
and O
several O
T B
cell I
surface I
receptors I
. O

The O
activation O
of O
NF B
- I
kappaB I
has O
been O
recognized O
to O
regulate O
a O
number O
of O
genes O
necessary O
for O
normal O
T O
cell O
responses O
including O
IL B
- I
2 I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
and O
several O
T B
cell I
surface I
receptors I
. O

The O
activation O
of O
NF B
- I
kappaB I
has O
been O
recognized O
to O
regulate O
a O
number O
of O
genes O
necessary O
for O
normal O
T O
cell O
responses O
including O
IL B
- I
2 I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
and O
several O
T B
cell I
surface I
receptors I
. O

Uncoupling O
of O
nonreceptor O
tyrosine B
kinases I
from O
PLC B
- I
gamma1 I
in O
an O
SLP O
- O
76 O
- O
deficient O
T O
cell O
. O

SLP B
- I
76 I
was O
not O
required O
for O
TCR B
- O
induced O
tyrosine O
phosphorylation O
of O
most O
proteins O
, O
but O
was O
required O
for O
optimal O
tyrosine O
phosphorylation O
and O
activation O
of O
phospholipase B
C I
- I
gamma1 I
( O
PLC B
- I
gamma1 I
) O
, O
as O
well O
as O
Ras B
pathway O
activation O
. O

SLP B
- I
76 I
was O
not O
required O
for O
TCR B
- O
induced O
tyrosine O
phosphorylation O
of O
most O
proteins O
, O
but O
was O
required O
for O
optimal O
tyrosine O
phosphorylation O
and O
activation O
of O
phospholipase B
C I
- I
gamma1 I
( O
PLC B
- I
gamma1 I
) O
, O
as O
well O
as O
Ras B
pathway O
activation O
. O

Thus O
, O
coupling O
of O
TCR B
- I
regulated I
PTKs I
to O
downstream O
signaling O
pathways O
requires O
SLP B
- I
76 I
. O

In O
conclusion O
, O
our O
data O
suggest O
the O
involvement O
of O
the O
Jak B
/ I
Stat I
signal O
pathway O
in O
MHC B
- I
I I
- O
induced O
signal O
transduction O
in O
T O
cells O
. O

In O
conclusion O
, O
our O
data O
suggest O
the O
involvement O
of O
the O
Jak B
/ I
Stat I
signal O
pathway O
in O
MHC B
- I
I I
- O
induced O
signal O
transduction O
in O
T O
cells O
. O

We O
further O
demonstrate O
that O
0 O
. O
1 O
- O
0 O
. O
5 O
microM O
DMDTC O
inhibits O
intracellular O
IL B
- I
2 I
production O
and O
decreases O
surface O
expression O
of O
CD25 B
( O
the O
alpha B
subunit I
of O
the O
IL B
- I
2 I
receptor I
) O
in O
T O
cells O
stimulated O
with O
phorbol O
ester O
. O

Using O
deletion B
constructs I
, O
we O
have O
defined O
an O
active B
promoter I
region I
of O
1056 O
bp O
. O

Ex O
vivo O
activation O
of O
tumor O
- O
draining O
lymph O
node O
T O
cells O
reverses O
defects O
in O
signal B
transduction I
molecules I
. O

In O
contrast O
, O
the O
cytoplasmic O
levels O
of O
c B
- I
Rel I
and O
Rel B
A I
were O
normal O
in O
freshly O
isolated O
tumor O
- O
draining O
LN O
, O
as O
was O
nuclear O
kappaB B
DNA O
- O
binding O
activity O
induced O
by O
anti B
- I
CD3 I
mAb I
or O
phorbol O
myristate O
acetate O
. O

BACKGROUND O
: O
The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multifunctional I
domain I
protein I
that O
acts O
as O
a O
transcriptional B
activator I
and O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

Macrophages O
in O
human O
atheroma O
contain O
PPARgamma B
: O
differentiation B
- I
dependent I
peroxisomal I
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
expression O
and O
reduction O
of O
MMP B
- I
9 I
activity O
through O
PPARgamma B
activation O
in O
mononuclear O
phagocytes O
in O
vitro O
. O

Mononuclear O
phagocytes O
play O
an O
important O
role O
in O
atherosclerosis O
and O
its O
sequela O
plaque O
rupture O
in O
part O
by O
their O
secretion O
of O
matrix B
metalloproteinases I
( O
MMPs B
) O
, O
including O
MMP B
- I
9 I
. O

Effects O
of O
oxidative O
stress O
on O
stimulation O
- O
dependent O
signal O
transduction O
, O
leading O
to O
IL B
- I
2 I
expression O
, O
were O
studied O
. O

IL B
- I
3 I
, O
IL B
- I
4 I
, O
and O
IL B
- I
5 I
independently O
up O
- O
regulated O
TGF B
- I
beta1 I
mRNA I
and O
product O
expression O
by O
eosinophils O
in O
all O
donors O
. O

IL B
- I
3 I
, O
IL B
- I
4 I
, O
and O
IL B
- I
5 I
independently O
up O
- O
regulated O
TGF B
- I
beta1 I
mRNA I
and O
product O
expression O
by O
eosinophils O
in O
all O
donors O
. O

IL B
- I
3 I
, O
IL B
- I
4 I
, O
and O
IL B
- I
5 I
independently O
up O
- O
regulated O
TGF B
- I
beta1 I
mRNA I
and O
product O
expression O
by O
eosinophils O
in O
all O
donors O
. O

The O
observation O
that O
IL B
- I
4 I
can O
differentially O
regulate O
the O
expression O
of O
TGF B
- I
alpha I
and O
TGF B
- I
beta1 I
suggests O
that O
IL B
- I
4 I
may O
serve O
as O
a O
physiologic O
molecular O
switch O
of O
TGF B
expression O
by O
the O
infiltrating O
eosinophils O
in O
wound O
healing O
and O
carcinogenesis O
. O

The O
observation O
that O
IL B
- I
4 I
can O
differentially O
regulate O
the O
expression O
of O
TGF B
- I
alpha I
and O
TGF B
- I
beta1 I
suggests O
that O
IL B
- I
4 I
may O
serve O
as O
a O
physiologic O
molecular O
switch O
of O
TGF B
expression O
by O
the O
infiltrating O
eosinophils O
in O
wound O
healing O
and O
carcinogenesis O
. O

The O
observation O
that O
IL B
- I
4 I
can O
differentially O
regulate O
the O
expression O
of O
TGF B
- I
alpha I
and O
TGF B
- I
beta1 I
suggests O
that O
IL B
- I
4 I
may O
serve O
as O
a O
physiologic O
molecular O
switch O
of O
TGF B
expression O
by O
the O
infiltrating O
eosinophils O
in O
wound O
healing O
and O
carcinogenesis O
. O

The O
observation O
that O
IL B
- I
4 I
can O
differentially O
regulate O
the O
expression O
of O
TGF B
- I
alpha I
and O
TGF B
- I
beta1 I
suggests O
that O
IL B
- I
4 I
may O
serve O
as O
a O
physiologic O
molecular O
switch O
of O
TGF B
expression O
by O
the O
infiltrating O
eosinophils O
in O
wound O
healing O
and O
carcinogenesis O
. O

In O
particular O
, O
one O
class O
of O
helix B
- I
loop I
- I
helix I
proteins I
, O
termed O
E B
- I
proteins I
, O
have O
been O
implicated O
in O
the O
regulation O
of O
gene O
expression O
during O
B O
- O
cell O
development O
. O

Dominant B
negative I
mutants I
of O
NIK B
, O
IKKalpha B
, O
or O
IKKbeta B
substantially O
inhibited O
NF B
- I
kappaB I
activation O
by O
LMP1 B
or O
by O
each O
of O
its O
effector B
sites I
. O

Dominant B
negative I
mutants I
of O
NIK B
, O
IKKalpha B
, O
or O
IKKbeta B
substantially O
inhibited O
NF B
- I
kappaB I
activation O
by O
LMP1 B
or O
by O
each O
of O
its O
effector B
sites I
. O

MyD88 B
, O
originally O
isolated O
as O
a O
myeloid O
differentiation O
primary B
response I
gene I
, O
is O
shown O
to O
act O
as O
an O
adaptor O
in O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
signaling O
by O
interacting O
with O
both O
the O
IL B
- I
1 I
receptor I
complex I
and O
IL B
- I
1 I
receptor I
- I
associated I
kinase I
( O
IRAK B
) O
. O

MyD88 B
, O
originally O
isolated O
as O
a O
myeloid O
differentiation O
primary B
response I
gene I
, O
is O
shown O
to O
act O
as O
an O
adaptor O
in O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
signaling O
by O
interacting O
with O
both O
the O
IL B
- I
1 I
receptor I
complex I
and O
IL B
- I
1 I
receptor I
- I
associated I
kinase I
( O
IRAK B
) O
. O

MyD88 B
, O
originally O
isolated O
as O
a O
myeloid O
differentiation O
primary B
response I
gene I
, O
is O
shown O
to O
act O
as O
an O
adaptor O
in O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
signaling O
by O
interacting O
with O
both O
the O
IL B
- I
1 I
receptor I
complex I
and O
IL B
- I
1 I
receptor I
- I
associated I
kinase I
( O
IRAK B
) O
. O

Furthermore O
, O
IL B
- I
18 I
- O
induced O
activation O
of O
NF B
- I
kappaB I
and O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
is O
blocked O
in O
MyD88 O
- O
/ O
- O
Th1 O
- O
developing O
cells O
. O

Furthermore O
, O
IL B
- I
18 I
- O
induced O
activation O
of O
NF B
- I
kappaB I
and O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
is O
blocked O
in O
MyD88 O
- O
/ O
- O
Th1 O
- O
developing O
cells O
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein B
enhancer I
and I
promoter I
regions I
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein B
enhancer I
and I
promoter I
regions I
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein B
enhancer I
and I
promoter I
regions I
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein B
enhancer I
and I
promoter I
regions I
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

Thrombopoietin B
supports O
in O
vitro O
erythroid O
differentiation O
via O
its O
specific O
receptor O
c B
- I
Mpl I
in O
a O
human O
leukemia O
cell O
line O
. O

Because O
the O
GATA B
- I
1 I
gene I
is O
located O
on O
the O
X B
chromosome I
, O
which O
is O
randomly O
inactivated O
in O
every O
cell O
, O
heterozygous O
females O
can O
bear O
either O
an O
active O
wild O
- O
type O
or O
mutant O
( O
referred O
to O
as O
GATA B
- I
1 I
. I
05 I
) O
GATA B
- I
1 I
allele O
, O
consequently O
leading O
to O
variable O
anemic O
severity O
. O

The O
GATA B
- I
1 I
heterozygous O
mutant O
mouse O
shows O
a O
phenotype O
that O
is O
analogous O
to O
human O
myelodysplastic O
syndrome O
and O
thus O
may O
serve O
as O
a O
useful O
model O
for O
this O
disorder O
. O

Differential O
regulation O
of O
the O
Janus B
kinase I
- B
STAT I
pathway O
and O
biologic O
function O
of O
IL B
- I
13 I
in O
primary O
human O
NK O
and O
T O
cells O
: O
a O
comparative O
study O
with O
IL B
- I
4 I
. O

Differential O
regulation O
of O
the O
Janus B
kinase I
- B
STAT I
pathway O
and O
biologic O
function O
of O
IL B
- I
13 I
in O
primary O
human O
NK O
and O
T O
cells O
: O
a O
comparative O
study O
with O
IL B
- I
4 I
. O

These O
findings O
show O
that O
IL B
- I
13 I
and O
IL B
- I
4 I
have O
the O
ability O
to O
regulate O
NK O
and O
T O
cell O
activation O
and O
that O
IL B
- I
13 I
is O
a O
potent O
regulator O
of O
STAT6 B
and O
JAK3 B
in O
these O
cell O
types O
. O

These O
findings O
show O
that O
IL B
- I
13 I
and O
IL B
- I
4 I
have O
the O
ability O
to O
regulate O
NK O
and O
T O
cell O
activation O
and O
that O
IL B
- I
13 I
is O
a O
potent O
regulator O
of O
STAT6 B
and O
JAK3 B
in O
these O
cell O
types O
. O

These O
findings O
show O
that O
IL B
- I
13 I
and O
IL B
- I
4 I
have O
the O
ability O
to O
regulate O
NK O
and O
T O
cell O
activation O
and O
that O
IL B
- I
13 I
is O
a O
potent O
regulator O
of O
STAT6 B
and O
JAK3 B
in O
these O
cell O
types O
. O

Loss O
- O
and O
gain O
- O
of O
- O
function O
mutations O
reveal O
an O
important O
role O
of O
BSAP B
( O
Pax B
- I
5 I
) O
at O
the O
start O
and O
end O
of O
B O
cell O
differentiation O
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation B
region I
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

A O
nondegradable O
mutant O
of O
I B
kappa I
B I
blocked O
both O
FasL B
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas B
ligation O
. O

The O
implication O
of O
protein B
tyrosine I
kinase I
( I
s I
) I
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV B
- I
1 I
LTR I
- I
driven I
gene I
expression O
using O
herbimycin O
A O
and O
H7 O
. O

The O
implication O
of O
protein B
tyrosine I
kinase I
( I
s I
) I
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV B
- I
1 I
LTR I
- I
driven I
gene I
expression O
using O
herbimycin O
A O
and O
H7 O
. O

These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF B
/ I
LEF I
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG B
box I
proteins I
in O
lymphoid O
development O

These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF B
/ I
LEF I
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG B
box I
proteins I
in O
lymphoid O
development O

Elf B
- I
1 I
binds O
exclusively O
to O
the O
underphosphorylated O
form O
of O
Rb B
and O
fails O
to O
bind O
to O
Rb B
mutants I
derived O
from O
patients O
with O
retinoblastoma O
. O

Sequence O
analysis O
of O
nine O
different O
2 O
. O
3 O
- O
kb O
cDNA O
clones O
obtained O
from O
NK O
- O
derived O
polyA O
+ O
RNA O
confirmed O
that O
they O
corresponded O
to O
an O
unrearranged O
TcR B
delta I
gene I
. O

All O
NK O
clones O
and O
cell O
lines O
studied O
were O
found O
to O
express O
hGATA B
- I
3 I
- I
specific I
mRNA I
, O
suggesting O
that O
hGATA B
- I
3 I
may O
be O
involved O
in O
the O
regulation O
of O
the O
unrearranged O
TcR B
delta I
gene I
expression O
in O
NK O
cells O
. O

All O
NK O
clones O
and O
cell O
lines O
studied O
were O
found O
to O
express O
hGATA B
- I
3 I
- I
specific I
mRNA I
, O
suggesting O
that O
hGATA B
- I
3 I
may O
be O
involved O
in O
the O
regulation O
of O
the O
unrearranged O
TcR B
delta I
gene I
expression O
in O
NK O
cells O
. O

Other O
bacterial O
toxins O
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
T B
cell I
mitogens I
, O
UV O
light O
, O
gamma O
rays O
and O
oxidative O
stress O
were O
reported O
to O
induce O
NF B
- I
kappa I
B I
. O

Other O
bacterial O
toxins O
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
T B
cell I
mitogens I
, O
UV O
light O
, O
gamma O
rays O
and O
oxidative O
stress O
were O
reported O
to O
induce O
NF B
- I
kappa I
B I
. O

Other O
bacterial O
toxins O
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
T B
cell I
mitogens I
, O
UV O
light O
, O
gamma O
rays O
and O
oxidative O
stress O
were O
reported O
to O
induce O
NF B
- I
kappa I
B I
. O

We O
further O
characterize O
which O
AP1 B
family I
members I
can O
assume O
this O
role O
. O

Antisera O
to O
Fos B
inhibits O
NF B
- I
AT I
DNA O
binding O
as O
does O
an O
oligonucleotide O
containing O
a O
binding B
site I
for I
AP1 I
. O

Activation O
of O
the O
HIV O
- O
1 O
provirus O
correlated O
with O
the O
activation O
of O
binding O
of O
55 B
- I
and I
85 I
- I
kDa I
proteins I
to O
the O
kappa B
B I
enhancer I
and O
binding O
of O
the O
50 B
- I
kDa I
HLP I
- I
1 I
protein I
to O
the O
LBP B
- I
1 I
sequences I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
. O

Transcriptional O
activation O
of O
the O
macrophage B
colony I
- I
stimulating I
factor I
gene I
by O
IL B
- I
2 I
is O
associated O
with O
secretion O
of O
bioactive O
macrophage B
colony I
- I
stimulating I
factor I
protein I
by O
monocytes O
and O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
. O

Transcriptional O
activation O
of O
the O
M B
- I
CSF I
gene I
by O
IL B
- I
2 I
is O
preceded O
by O
enhanced O
binding O
activity O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
to O
its O
recognition O
sequence O
in O
the O
5 O
' O
regulatory O
enhancer O
region O
of O
the O
M B
- I
CSF I
gene I
. O

We O
localized O
the O
LAM O
- O
, O
lipopolysaccharide O
( O
LPS O
) O
- O
, O
and O
TNF B
- I
alpha I
- B
inducible I
promoter I
activity O
to O
a O
- O
131 O
/ O
+ O
15 O
( O
positions O
- O
131 O
to O
+ O
15 O
) O
DNA O
fragment O
of O
the O
IL B
- I
1 I
beta I
gene I
by O
deletion O
analysis O
and O
chloramphenicol B
acetyltransferase I
assay O
. O

We O
localized O
the O
LAM O
- O
, O
lipopolysaccharide O
( O
LPS O
) O
- O
, O
and O
TNF B
- I
alpha I
- B
inducible I
promoter I
activity O
to O
a O
- O
131 O
/ O
+ O
15 O
( O
positions O
- O
131 O
to O
+ O
15 O
) O
DNA O
fragment O
of O
the O
IL B
- I
1 I
beta I
gene I
by O
deletion O
analysis O
and O
chloramphenicol B
acetyltransferase I
assay O
. O

Site O
- O
directed O
mutagenesis O
demonstrated O
that O
the O
two O
NF B
- I
IL I
- I
6 I
motifs I
could O
be O
independently O
activated O
by O
LAM O
, O
LPS O
, O
or O
TNF B
- I
alpha I
and O
that O
they O
acted O
in O
an O
orientation O
- O
independent O
manner O
. O

A O
serum B
response I
element I
and O
a O
binding B
site I
for I
NF I
- I
Y I
mediate O
the O
serum O
response O
of O
the O
human B
thrombospondin I
1 I
gene I
. O

ACH O
- O
2 O
can O
be O
converted O
to O
productive O
infection O
by O
stimulation O
of O
the O
cells O
with O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
, O
mitogen O
or O
cytokines B
( O
TNF B
- I
alpha I
) O
, O
or O
infection O
with O
HSV O
. O

The O
promoter O
activity O
from O
HIV B
long I
terminal I
repeat I
was O
greatly O
augmented O
by O
co O
- O
transfecting O
the O
Trx B
- I
expressing I
plasmid I
, O
whose O
effect O
was O
dependent O
on O
the O
NF B
kappa I
B I
- O
binding O
sites O
. O

Northern O
analysis O
demonstrated O
coordinate O
downregulation O
of O
alpha B
globin I
and O
gamma B
globin I
in O
addition O
to O
the O
two O
lineage O
- O
restricted O
transcription B
factors I
, O
SCL B
and O
GATA B
- I
1 I
. O

Long O
- O
lasting O
IL B
- I
2 I
receptivity O
is O
associated O
with O
high O
- O
level O
expression O
of O
the O
inducible O
IL B
- I
2 I
receptor I
alpha I
chain I
( I
IL I
- I
2R I
alpha I
) I
gene I
that O
is O
regulated O
at O
both O
transcriptional O
and O
posttranscriptional O
levels O
. O

We O
show O
that O
the O
ability O
to O
detect O
NF B
- I
ATp I
in O
a O
gel O
shift O
assay O
, O
which O
is O
essential O
for O
purification O
and O
biochemical O
studies O
of O
this O
protein O
, O
is O
strikingly O
dependent O
on O
the O
precise O
sequence O
of O
the O
NF B
- I
AT I
oligonucleotide O
used O
as O
the O
labeled O
probe O
. O

We O
show O
that O
the O
ability O
to O
detect O
NF B
- I
ATp I
in O
a O
gel O
shift O
assay O
, O
which O
is O
essential O
for O
purification O
and O
biochemical O
studies O
of O
this O
protein O
, O
is O
strikingly O
dependent O
on O
the O
precise O
sequence O
of O
the O
NF B
- I
AT I
oligonucleotide O
used O
as O
the O
labeled O
probe O
. O

Since O
TPA O
activates O
protein B
kinase I
C I
( O
PKC B
) O
, O
we O
examined O
translocation O
of O
PKC B
from O
the O
cytosol O
to O
the O
membrane O
fraction O
. O

In O
contrast O
, O
the O
binding O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
to O
its O
response O
element O
in O
the O
IL2 B
enhancer I
and O
to O
an O
NF B
- I
AT I
- I
like I
response I
element I
present O
in O
the O
IL4 B
enhancer I
was O
abnormal O
. O

Association O
with O
the O
precursors O
is O
sufficient O
for O
cytoplasmic O
retention O
of O
either O
p65 B
or O
c B
- I
Rel I
, O
both O
of O
which O
are O
otherwise O
nuclear O
. O

Together O
, O
these O
results O
show O
that O
NF B
- I
kappa I
B I
controls O
the O
expression O
of O
I B
kappa I
B I
alpha O
by O
means O
of O
an O
inducible O
autoregulatory O
pathway O
. O

A O
cell B
- I
type I
- I
independent I
lipopolysaccharide I
( I
LPS I
) I
- I
responsive I
enhancer I
element I
located O
between O
- B
3757 I
and I
- I
2729 I
bp I
upstream I
from O
the O
transcription B
start I
site I
( O
cap B
site I
) O
consisted O
of O
at O
least O
six O
discrete O
subregions O
which O
were O
essential O
to O
the O
maximal O
induction O
by O
LPS O
in O
transfected O
monocytes O
. O

Few O
known O
genes B
( O
IL B
- I
2 I
, O
members O
of O
the O
IL B
- I
8 I
family I
, O
interferon B
- I
gamma I
) O
are O
induced O
in O
T O
cells O
only O
through O
the O
combined O
effect O
of O
phorbol O
myristic O
acetate O
( O
PMA O
) O
and O
a O
Ca O
( O
2 O
+ O
) O
- O
ionophore O
, O
and O
expression O
of O
only O
these O
genes B
can O
be O
fully O
suppressed O
by O
Cyclosporin O
A O
( O
CyA O
) O
. O

Few O
known O
genes B
( O
IL B
- I
2 I
, O
members O
of O
the O
IL B
- I
8 I
family I
, O
interferon B
- I
gamma I
) O
are O
induced O
in O
T O
cells O
only O
through O
the O
combined O
effect O
of O
phorbol O
myristic O
acetate O
( O
PMA O
) O
and O
a O
Ca O
( O
2 O
+ O
) O
- O
ionophore O
, O
and O
expression O
of O
only O
these O
genes B
can O
be O
fully O
suppressed O
by O
Cyclosporin O
A O
( O
CyA O
) O
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

Overexpression O
of O
p65 B
increases O
endogenous O
I B
kappa I
B I
protein O
in O
both O
carcinoma O
and O
lymphoid O
cells O
by O
two O
mechanisms O
: O
protein O
stabilization O
and O
increased O
transcription O
of O
I B
kappa I
B I
mRNA I
. O

Dimerization O
of O
NF B
- I
KB2 I
with O
RelA B
( I
p65 I
) I
regulates O
DNA O
binding O
, O
transcriptional O
activation O
, O
and O
inhibition O
by O
an O
I B
kappa I
B I
- I
alpha I
( O
MAD B
- I
3 I
) O
. O

Dimerization O
of O
NF B
- I
KB2 I
with O
RelA B
( I
p65 I
) I
regulates O
DNA O
binding O
, O
transcriptional O
activation O
, O
and O
inhibition O
by O
an O
I B
kappa I
B I
- I
alpha I
( O
MAD B
- I
3 I
) O
. O

Transcriptional O
activation O
of O
the O
HIV O
enhancer O
was O
also O
subject O
to O
regulation O
by O
recently O
cloned O
I B
kappa I
B I
- I
alpha I
( O
MAD B
- I
3 I
) O
. O

We O
now O
demonstrate O
that O
nuclear O
expression O
of O
human O
c B
- I
Rel I
, O
which O
is O
induced O
by O
either O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
with O
delayed O
kinetics O
relative O
to O
p65 B
, O
markedly O
represses O
p65 B
- O
mediated O
activation O
of O
these O
transcription O
units O
. O

The O
ras O
- O
transformed O
lymphocytes O
displayed O
a O
fully O
functional O
IL B
- I
2r I
, O
as O
assessed O
by O
c B
- I
fos I
induction O
following O
treatment O
with O
IL B
- I
2 I
; O
nevertheless O
, O
they O
were O
not O
growth O
stimulated O
by O
this O
lymphokine B
. O

The O
ras O
- O
transformed O
lymphocytes O
displayed O
a O
fully O
functional O
IL B
- I
2r I
, O
as O
assessed O
by O
c B
- I
fos I
induction O
following O
treatment O
with O
IL B
- I
2 I
; O
nevertheless O
, O
they O
were O
not O
growth O
stimulated O
by O
this O
lymphokine B
. O

The O
ras O
- O
transformed O
lymphocytes O
displayed O
a O
fully O
functional O
IL B
- I
2r I
, O
as O
assessed O
by O
c B
- I
fos I
induction O
following O
treatment O
with O
IL B
- I
2 I
; O
nevertheless O
, O
they O
were O
not O
growth O
stimulated O
by O
this O
lymphokine B
. O

Somewhat O
unexpectedly O
, O
the O
constitutive O
p21ras B
activity O
did O
not O
cause O
an O
increased O
DNA O
binding O
of O
transcription B
factors I
PEA1 B
( O
AP1 B
) O
, O
PEA3 B
, O
Oct B
- I
2 I
or O
NF B
- I
kB I

Competition O
with O
an O
AP B
- I
1 I
motif I
or O
with O
anti B
- I
Jun I
and O
anti B
- I
Fos I
antibodies I
abolished O
binding O
to O
the O
NFAT B
motif I
in O
both O
T O
and O
B O
cells O
, O
indicating O
that O
Jun O
and O
Fos O
are O
critical O
for O
NFAT B
complex I
formation O
in O
both O
cell O
types O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
is O
a O
transcriptional B
activator I
involved O
in O
the O
induction O
of O
IL B
- I
2 I
gene O
expression O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
is O
a O
transcriptional B
activator I
involved O
in O
the O
induction O
of O
IL B
- I
2 I
gene O
expression O
. O

Serum B
response I
factor I
( O
SRF B
) O
binds O
to O
a O
site O
adjacent O
to O
the O
NF B
- I
kappa I
B I
site I
in O
the O
IL B
- I
2R I
enhancer I
, O
and O
both O
sites O
together O
have O
strong O
transcriptional O
activity O
specifically O
in O
T O
cells O
. O

In O
previous O
transfection O
analyses O
using O
the O
chloramphenicol B
acetyltransferase I
reporter B
gene I
system O
, O
we O
determined O
that O
linker O
substitution O
( O
LS O
) O
mutations O
between O
- B
201 I
and I
- I
130 I
( O
relative O
to O
the O
transcription O
start O
site O
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
caused O
moderate O
decreases O
in O
LTR B
transcriptional O
activity O
in O
a O
T O
- O
cell O
line O
( O
S O
. O
L O
. O
Zeichner O
, O
J O
. O
Y O
. O
H O
. O
Kim O
, O
and O
J O
. O
C O
. O
Alwine O
, O
J O
. O
Virol O
. O
65 O
: O
2436 O
- O
2444 O
, O
1991 O
) O
. O

Comparison O
of O
group O
1 O
human B
and I
mouse I
genomic I
sequences I
shows O
high O
conservation O
in O
the O
5 B
' I
flank I
and O
exons B
. O

A O
microB B
binding I
protein I
is O
encoded O
by O
the O
PU B
. I
1 I
/ I
Spi I
- I
1 I
proto I
- I
oncogene I
. O

Site O
- O
directed O
mutagenesis O
demonstrated O
that O
this O
HS B
- I
40 I
enhancer O
- O
zeta B
2 I
globin I
promoter I
interaction O
is O
mediated O
by O
the O
two O
GATA O
- O
1 O
factor O
binding O
motifs O
located O
at O
- O
230 O
and O
- O
104 O
, O
respectively O
. O

Site O
- O
directed O
mutagenesis O
further O
demonstrated O
that O
the O
enhancer B
function O
of O
one O
of O
the O
two O
NF O
- O
E2 O
/ O
AP1 O
motifs O
of O
HS B
- I
40 I
is O
mediated O
through O
its O
binding O
to O
NF B
- I
E2 I
but O
not O
AP1 B
transcription I
factor I
. O

Site O
- O
directed O
mutagenesis O
further O
demonstrated O
that O
the O
enhancer B
function O
of O
one O
of O
the O
two O
NF O
- O
E2 O
/ O
AP1 O
motifs O
of O
HS B
- I
40 I
is O
mediated O
through O
its O
binding O
to O
NF B
- I
E2 I
but O
not O
AP1 B
transcription I
factor I
. O

Site O
- O
directed O
mutagenesis O
further O
demonstrated O
that O
the O
enhancer B
function O
of O
one O
of O
the O
two O
NF O
- O
E2 O
/ O
AP1 O
motifs O
of O
HS B
- I
40 I
is O
mediated O
through O
its O
binding O
to O
NF B
- I
E2 I
but O
not O
AP1 B
transcription I
factor I
. O

Mutations O
and O
deletions O
of O
both O
sites O
indicate O
that O
only O
the O
association O
of O
CCACC B
/ I
Sp1 I
and O
GATA B
binding I
sites I
can O
drive O
efficient O
and O
tissue O
- O
specific O
expression O
of O
this O
R B
- I
PK I
minimal B
promoter I
. O

Mutations O
and O
deletions O
of O
both O
sites O
indicate O
that O
only O
the O
association O
of O
CCACC B
/ I
Sp1 I
and O
GATA B
binding I
sites I
can O
drive O
efficient O
and O
tissue O
- O
specific O
expression O
of O
this O
R B
- I
PK I
minimal B
promoter I
. O

Mutations O
and O
deletions O
of O
both O
sites O
indicate O
that O
only O
the O
association O
of O
CCACC B
/ I
Sp1 I
and O
GATA B
binding I
sites I
can O
drive O
efficient O
and O
tissue O
- O
specific O
expression O
of O
this O
R B
- I
PK I
minimal B
promoter I
. O

The O
X B
box I
region I
is O
critical O
for O
directing O
the O
expression O
of O
class B
II I
major I
histocompatibility I
complex I
genes I
in O
B O
lymphocytes O
. O

To O
further O
evaluate O
the O
role O
of O
X B
box I
DNA I
- I
binding I
proteins I
in O
class B
II I
gene I
expression O
, O
the O
role O
of O
the O
X B
box I
region I
was O
examined O
in O
both O
class O
II O
- O
positive O
and O
- O
negative O
lymphoid O
cells O
. O

To O
further O
evaluate O
the O
role O
of O
X B
box I
DNA I
- I
binding I
proteins I
in O
class B
II I
gene I
expression O
, O
the O
role O
of O
the O
X B
box I
region I
was O
examined O
in O
both O
class O
II O
- O
positive O
and O
- O
negative O
lymphoid O
cells O
. O

To O
determine O
whether O
these O
different O
X1 O
box O
activities O
represented O
distinct O
DNA B
binding I
proteins I
or O
multimeric O
forms O
of O
the O
same O
factor O
( O
s O
) O
, O
protease B
treatment O
of O
the O
crude O
nuclear O
extracts O
followed O
by O
DNA O
- O
binding O
assays O
were O
carried O
out O
and O
demonstrated O
that O
B O
cell O
extracts O
contain O
at O
least O
two O
X1 B
- I
specific I
factors I
. O

Enhanced O
TR75 B
expression O
on O
OM O
- O
10 O
. O
1 O
cells O
followed O
the O
same O
TNF B
- I
alpha I
- O
dose O
dependency O
as O
that O
observed O
for O
HIV O
- O
1 O
production O
. O

Although O
TR55 B
expression O
was O
unaltered O
during O
TNF B
- I
alpha I
- O
induced O
HIV O
activation O
, O
this O
receptor O
was O
still O
involved O
in O
the O
viral O
activation O
process O
. O

A O
reporter B
gene I
under O
the O
control O
of O
a O
T B
- I
cell I
antigen I
receptor I
element I
was O
activated O
in O
Jurkat O
cells O
by O
antigen O
receptor O
triggering O
or O
by O
a O
combination O
of O
phorbol O
myristate O
acetate O
, O
which O
activates O
protein B
kinase I
C I
, O
and O
a O
calcium O
ionophore O
. O

By O
Northern O
analysis O
, O
UT O
- O
7 O
cells O
expressed O
detectable O
levels O
of O
beta B
- I
and I
gamma I
- I
globin I
but O
not O
alpha B
- I
globin I
. O

The O
myeloid B
integrin I
CD11b I
is O
expressed O
selectively O
on O
the O
surface O
of O
mature O
macrophages O
, O
monocytes O
, O
neutrophils O
, O
and O
natural O
killer O
cells O
. O

Target O
antigens O
defined O
by O
autoantibodies B
in O
IDDM O
include O
insulin O
, O
a O
putative O
glycolipid O
that O
reacts O
with O
islet B
cell I
antibodies I
, O
and O
a O
64 B
, I
000 I
- I
M I
( I
r I
) I
protein I
recently O
identified O
as O
glutamic B
acid I
decarboxylase I
. O

Target O
antigens O
defined O
by O
autoantibodies B
in O
IDDM O
include O
insulin O
, O
a O
putative O
glycolipid O
that O
reacts O
with O
islet B
cell I
antibodies I
, O
and O
a O
64 B
, I
000 I
- I
M I
( I
r I
) I
protein I
recently O
identified O
as O
glutamic B
acid I
decarboxylase I
. O

Expression O
of O
tal B
- I
1 I
and O
GATA B
- I
binding I
proteins I
during O
human O
hematopoiesis O
. O

Because O
the O
GATA B
- I
1 I
gene I
is O
known O
to O
transactivate O
several O
genes O
specific O
for O
the O
erythroid O
, O
megakaryocytic O
, O
and O
mastocytic O
/ O
basophilic O
lineages O
, O
we O
studied O
GATA B
- I
1 I
expression O
in O
these O
purified O
hematopoietic O
cells O
. O

Costimulation O
of O
cAMP O
and O
protein B
kinase I
C I
pathways O
inhibits O
the O
CD3 B
- O
dependent O
T O
cell O
activation O
and O
leads O
to O
a O
persistent O
expression O
of O
the O
AP B
- I
1 I
transcription I
factor I
. O

The O
observation O
that O
a O
mutated B
LT I
- I
kappa I
B I
construct I
( O
M1 B
- I
CAT I
) O
was O
inactive O
in O
C81 O
- O
66 O
- O
45 O
, O
confirmed O
the O
importance O
of O
NF B
- I
kappa I
B I
in O
LT B
gene O
expression O
. O

In O
JM O
T O
cells O
, O
tax B
induced O
LT B
- I
293 I
activity O
by O
two O
- O
to O
four O
- O
fold O
, O
though O
there O
was O
no O
induction O
of O
M1 B
- I
CAT I
. O

In O
JM O
T O
cells O
, O
tax B
induced O
LT B
- I
293 I
activity O
by O
two O
- O
to O
four O
- O
fold O
, O
though O
there O
was O
no O
induction O
of O
M1 B
- I
CAT I
. O

This O
indicates O
an O
increase O
in O
either O
episomal B
DNA I
or O
concatameric B
linear I
DNA I
. O

This O
paper O
describes O
how O
the O
expression O
of O
the O
monocyte B
- I
macrophage I
Ag I
, O
CD14 B
, O
and O
the O
low O
affinity B
Fc I
receptor I
for O
IgE B
, O
CD23 B
, O
were O
inversely O
regulated O
during O
VitD3 O
- O
and O
RA O
- O
induced O
monocytic O
differentiation O
of O
human O
U O
- O
937 O
monoblasts O
. O

Increased O
c B
- I
jun I
, O
jun B
- I
B I
, O
and O
jun B
- I
D I
expression O
above O
basal O
levels O
and O
increased O
transcriptional O
activity O
of O
AP B
- I
1 I
/ I
TPA I
responsive I
elements I
fused O
to O
chloramphenicol B
acetyl I
- I
transferase I
vectors I
were O
observed O
in O
T O
cells O
treated O
with O
TPA O
alone O
or O
in O
combination O
with O
dexamethasone O
. O

Increased O
c B
- I
jun I
, O
jun B
- I
B I
, O
and O
jun B
- I
D I
expression O
above O
basal O
levels O
and O
increased O
transcriptional O
activity O
of O
AP B
- I
1 I
/ I
TPA I
responsive I
elements I
fused O
to O
chloramphenicol B
acetyl I
- I
transferase I
vectors I
were O
observed O
in O
T O
cells O
treated O
with O
TPA O
alone O
or O
in O
combination O
with O
dexamethasone O
. O

Increased O
c B
- I
jun I
, O
jun B
- I
B I
, O
and O
jun B
- I
D I
expression O
above O
basal O
levels O
and O
increased O
transcriptional O
activity O
of O
AP B
- I
1 I
/ I
TPA I
responsive I
elements I
fused O
to O
chloramphenicol B
acetyl I
- I
transferase I
vectors I
were O
observed O
in O
T O
cells O
treated O
with O
TPA O
alone O
or O
in O
combination O
with O
dexamethasone O
. O

Studies O
with O
5 B
' I
deletion I
CD20 I
promoter I
- I
CAT I
constructs I
have O
previously O
revealed O
two O
regions O
of O
the O
promoter B
between O
bases O
- O
186 O
and O
- O
280 O
and O
between O
bases O
- O
280 O
and O
- O
454 O
which O
contained O
positive B
regulatory I
elements I
. O

Cross O
competition O
experiments O
with O
an O
octamer O
sequence O
from O
the O
Ig O
heavy O
chain O
promoter O
, O
the O
BAT B
box I
, O
and O
a O
TA O
- O
rich O
sequence O
present O
in O
the O
CD21 B
promoter I
revealed O
that O
all O
three O
sequences O
bound O
the O
same O
nuclear B
proteins I
suggesting O
that O
the O
BAT B
box I
binding I
proteins I
were O
Oct B
- I
1 I
and O
Oct B
- I
2 I
. O

Cross O
competition O
experiments O
with O
an O
octamer O
sequence O
from O
the O
Ig O
heavy O
chain O
promoter O
, O
the O
BAT B
box I
, O
and O
a O
TA O
- O
rich O
sequence O
present O
in O
the O
CD21 B
promoter I
revealed O
that O
all O
three O
sequences O
bound O
the O
same O
nuclear B
proteins I
suggesting O
that O
the O
BAT B
box I
binding I
proteins I
were O
Oct B
- I
1 I
and O
Oct B
- I
2 I
. O

Despite O
this O
lower O
affinity O
, O
a O
trimer O
of O
the O
BAT B
box I
sequence I
was O
as O
efficiently O
transactivated O
by O
an O
Oct B
- I
2 I
expression I
vector I
as O
was O
a O
trimer O
of O
the O
octamer B
sequence I
in O
HeLa O
cells O
. O

Control O
peptides O
corresponding O
to O
the O
normal O
pml B
and O
RAR B
alpha I
proteins I
were O
not O
recognized O
. O

One O
cDNA B
clone I
of O
a O
primary O
response O
gene O
, O
expressed O
upon O
macrophage O
differentiation O
, O
encoded O
for O
Egr B
- I
1 I
, O
a O
zinc B
finger I
transcription I
factor I
. O

These O
observations O
indicate O
that O
expression O
of O
Egr B
- I
1 I
is O
essential O
for O
and O
restricts O
differentiation O
of O
myeloblasts O
along O
the O
macrophage O
lineage O
. O

Electrophoretic O
mobility O
shift O
assays O
revealed O
three O
specific O
protein B
- I
DNA I
complexes I
formed O
with O
sequences O
of O
the O
EBNA2 B
responsive I
element I
. O

Agents O
which O
increased O
cAMP O
levels O
, O
including O
cholera O
toxin O
, O
pertussis O
toxin O
, O
dibutyryl O
cAMP O
, O
and O
isoproterenol O
mimicked O
the O
actions O
of O
MM B
- I
LDL I
. O

One O
member O
of O
this O
multigene O
family O
, O
GATA B
- I
3 I
, O
is O
most O
abundantly O
expressed O
in O
T O
lymphocytes O
, O
a O
cellular O
target O
for O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
and O
replication O
. O

Cotransfection O
of O
an O
hGATA B
- I
3 I
expression I
plasmid I
with O
a O
reporter B
plasmid I
whose O
transcription O
is O
directed O
by O
the O
HIV B
- I
1 I
LTR I
resulted O
in O
6 O
- O
to O
10 O
- O
fold O
stimulation O
of O
LTR B
- O
mediated O
transcription O
, O
whereas O
site O
specific O
mutation O
of O
these O
GATA B
sites I
resulted O
in O
virtual O
abrogation O
of O
the O
activation O
by O
hGATA B
- I
3 I
. O

A O
73 B
kDa I
protein I
was O
identified O
by O
this O
analysis O
: O
this O
protein O
is O
highly O
enriched O
in O
cell O
lines O
of O
B O
lymphoid O
origin O
as O
compared O
to O
pancreatic O
beta O
- O
cells O
and O
fibroblast O
cells O
. O

The O
detection O
of O
this O
protein O
selectively O
in O
extracts O
of O
lymphoid O
cells O
correlates O
with O
the O
presence O
of O
the O
E B
box I
- O
binding O
activity O
LEF1 B
/ I
BCF1 I
in O
these O
cells O
; O
this O
binding O
activity O
was O
previously O
shown O
to O
be O
efficiently O
recognized O
by O
antiserum O
directed O
against O
E2A B
gene I
products I
. O

The O
detection O
of O
this O
protein O
selectively O
in O
extracts O
of O
lymphoid O
cells O
correlates O
with O
the O
presence O
of O
the O
E B
box I
- O
binding O
activity O
LEF1 B
/ I
BCF1 I
in O
these O
cells O
; O
this O
binding O
activity O
was O
previously O
shown O
to O
be O
efficiently O
recognized O
by O
antiserum O
directed O
against O
E2A B
gene I
products I
. O

The O
divergent O
effects O
of O
hemin O
and O
TPA O
on O
gene O
expression O
in O
K562 O
cells O
are O
mediated O
, O
in O
part O
, O
by O
their O
contrasting O
effects O
on O
the O
transcription B
factor I
NF B
- I
E2 I
. O

We O
studied O
the O
effect O
of O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
the O
lipopolysaccharide O
( O
LPS O
) O
induction O
of O
two O
immediate O
early O
genes O
c B
- I
fos I
and O
c B
- I
jun I
. O

We O
studied O
the O
effect O
of O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
the O
lipopolysaccharide O
( O
LPS O
) O
induction O
of O
two O
immediate O
early O
genes O
c B
- I
fos I
and O
c B
- I
jun I
. O

We O
studied O
the O
effect O
of O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
the O
lipopolysaccharide O
( O
LPS O
) O
induction O
of O
two O
immediate O
early O
genes O
c B
- I
fos I
and O
c B
- I
jun I
. O

We O
studied O
the O
effect O
of O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
the O
lipopolysaccharide O
( O
LPS O
) O
induction O
of O
two O
immediate O
early O
genes O
c B
- I
fos I
and O
c B
- I
jun I
. O

The O
inhibition O
of O
c B
- I
fos I
and O
c O
- O
jun O
expression O
by O
IL B
- I
4 I
in O
LPS O
- O
treated O
cells O
was O
shown O
to O
be O
due O
to O
a O
lower O
transcription O
rate O
of O
the O
c B
- I
fos I
and I
c I
- I
jun I
genes I
. O

The O
inhibition O
of O
c B
- I
fos I
and O
c O
- O
jun O
expression O
by O
IL B
- I
4 I
in O
LPS O
- O
treated O
cells O
was O
shown O
to O
be O
due O
to O
a O
lower O
transcription O
rate O
of O
the O
c B
- I
fos I
and I
c I
- I
jun I
genes I
. O

Because O
previous O
work O
has O
demonstrated O
that O
T O
cells O
from O
elderly O
individuals O
may O
display O
normal O
proliferative O
responses O
when O
activated O
via O
the O
anti B
- I
CD2 I
pathway O
, O
c O
- O
jun O
and O
jun O
B O
mRNA O
expression O
was O
also O
studied O
in O
anti O
- O
CD2 O
- O
activated O
purified O
T O
cells O
. O

Small O
apolar O
substitutions O
( O
11 O
alpha O
- O
methyl O
, O
11 O
alpha O
- O
fluoromethyl O
) O
did O
not O
markedly O
decrease O
the O
affinity O
for O
the O
vitamin B
D I
receptor I
, O
but O
larger O
( O
11 O
alpha O
- O
chloromethyl O
or O
11 O
alpha O
- O
or O
11 O
beta O
- O
phenyl O
) O
or O
more O
polar O
substitutions O
( O
11 O
alpha O
- O
hydroxymethyl O
, O
11 O
alpha O
- O
( O
2 O
- O
hydroxyethyl O
] O
decreased O
the O
affinity O
to O
less O
than O
5 O
% O
of O
that O
of O
1 O
alpha O
, O
25 O
- O
OH O
) O
2D3 O
. O

This O
variation O
was O
the O
result O
of O
a O
duplication O
of O
a O
short B
DNA I
sequence I
( O
CTG B
- I
motif I
) O
. O

This O
variation O
was O
the O
result O
of O
a O
duplication O
of O
a O
short B
DNA I
sequence I
( O
CTG B
- I
motif I
) O
. O

No O
positive O
effect O
of O
the O
duplicated O
CTG B
- I
motif I
could O
be O
detected O
. O

Possible O
relationship O
between O
the O
changes O
in O
IL B
- I
1 I
and O
GR B
in O
aged O
long O
- O
distance O
runner O
and O
its O
physiological O
significance O
are O
discussed O
. O

Kinetics O
of O
nuclear O
translocation O
and O
turnover O
of O
the O
vitamin B
D I
receptor I
in O
human O
HL60 O
leukemia O
cells O
and O
peripheral O
blood O
lymphocytes O
- O
- O
coincident O
rise O
of O
DNA O
- O
relaxing O
activity O
in O
nuclear O
extracts O
. O

Pulse O
exposure O
of O
HL60 O
to O
radiolabeled O
hormone O
for O
3 O
h O
followed O
by O
culture O
in O
medium O
without O
serum O
and O
calcitriol O
lead O
to O
nuclear O
retention O
of O
approximately O
1600 B
radiolabeled I
VDR I
by O
8 O
h O
and O
approximately O
1000 O
VDR B
by O
24 O
h O
. O

The O
long B
terminal I
repeat I
( I
LTR I
) I
region I
of O
HIV B
proviral I
DNA I
contains O
binding O
sites O
for O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
and O
this O
transcriptional B
activator I
appears O
to O
regulate O
HIV O
activation O
. O

Thus O
, O
Elf B
- I
1 I
is O
a O
novel B
transcription I
factor I
that O
appears O
to O
be O
required O
for O
the O
T O
- O
cell O
- O
receptor O
- O
mediated O
trans O
activation O
of O
HIV O
- O
2 O
gene O
expression O
. O

Thus O
, O
Elf B
- I
1 I
is O
a O
novel B
transcription I
factor I
that O
appears O
to O
be O
required O
for O
the O
T O
- O
cell O
- O
receptor O
- O
mediated O
trans O
activation O
of O
HIV O
- O
2 O
gene O
expression O
. O

Okadaic O
acid O
is O
a O
potent O
inducer O
of O
AP B
- I
1 I
, O
NF B
- I
kappa I
B I
, O
and O
tumor B
necrosis I
factor I
- I
alpha I
in O
human O
B O
lymphocytes O
. O

Treatment O
of O
human O
B O
lymphocytes O
with O
an O
optimal O
concentration O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
phosphatases B
1 I
and I
2A I
, O
resulted O
in O
the O
induction O
of O
the O
transcription B
factor I
, O
AP B
- I
1 I
and O
a O
marked O
increase O
in O
NF B
- I
kappa I
B I
levels O
. O

Although O
okadaic O
acid O
provides O
a O
potent O
inductive O
signal O
for O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
it O
did O
not O
induce O
either O
B O
cell O
proliferation O
or O
immunoglobulin B
secretion O
. O

IL B
- I
4 I
secreted O
by O
activated O
T O
cells O
is O
a O
pleiotropic B
cytokine I
affecting O
growth O
and O
differentiation O
of O
diverse O
cell O
types O
such O
as O
T O
cells O
, O
B O
cells O
, O
and O
mast O
cells O
. O

A O
novel B
T I
cell I
- I
specific I
negative I
regulatory I
element I
( O
NRE B
) O
composed O
of O
two O
protein O
- O
binding O
sites O
were O
mapped O
in O
the O
5 O
' O
flanking O
region O
of O
the O
IL B
- I
4 I
gene I
: O
- O
311CTCCCTTCT O
- O
303 O
( O
NRE B
- I
I I
) O
and O
- O
288CTTTTTGCTT O
- O
TGC O
- O
300 O
( O
NRE B
- I
II I
) O
. O

A O
novel B
T I
cell I
- I
specific I
negative I
regulatory I
element I
( O
NRE B
) O
composed O
of O
two O
protein O
- O
binding O
sites O
were O
mapped O
in O
the O
5 O
' O
flanking O
region O
of O
the O
IL B
- I
4 I
gene I
: O
- O
311CTCCCTTCT O
- O
303 O
( O
NRE B
- I
I I
) O
and O
- O
288CTTTTTGCTT O
- O
TGC O
- O
300 O
( O
NRE B
- I
II I
) O
. O

A O
T B
cell I
- I
specific I
protein I
Neg B
- I
1 I
and O
a O
ubiquitous B
protein I
Neg B
- I
2 I
binding O
to O
NRE B
- I
I I
and O
NRE B
- I
II I
, O
respectively O
, O
were O
identified O
. O

A O
T B
cell I
- I
specific I
protein I
Neg B
- I
1 I
and O
a O
ubiquitous B
protein I
Neg B
- I
2 I
binding O
to O
NRE B
- I
I I
and O
NRE B
- I
II I
, O
respectively O
, O
were O
identified O
. O

A O
T B
cell I
- I
specific I
protein I
Neg B
- I
1 I
and O
a O
ubiquitous B
protein I
Neg B
- I
2 I
binding O
to O
NRE B
- I
I I
and O
NRE B
- I
II I
, O
respectively O
, O
were O
identified O
. O

A O
T B
cell I
- I
specific I
protein I
Neg B
- I
1 I
and O
a O
ubiquitous B
protein I
Neg B
- I
2 I
binding O
to O
NRE B
- I
I I
and O
NRE B
- I
II I
, O
respectively O
, O
were O
identified O
. O

The O
addition O
of O
antisense O
oligonucleotides O
to O
c B
- I
fos I
significantly O
inhibited O
IL B
6 I
- O
induced O
IgM B
production O
by O
SKW O
6 O
. O
4 O
cells O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
whereas O
control O
oligonucleotides O
had O
no O
inhibitory O
effect O
. O

These O
observations O
indicate O
that O
during O
chronic O
HIV O
infection O
of O
U937 O
cells O
, O
continuous O
NF B
- I
kappa I
B I
( O
p50 B
/ I
p65 I
) O
translocation O
results O
in O
p105 O
promoter O
upregulation O
with O
subsequent O
cytosolic O
NF B
- I
kappa I
B I
accumulation O
, O
ready O
for O
further O
translocation O
. O

Similarly O
, O
IL B
- I
2 I
activates O
NF B
- I
kappa I
B I
in O
the O
human O
monocytic O
cell O
line O
U O
937 O
, O
but O
not O
in O
resting O
human O
T O
- O
cells O
. O

Blockade O
of O
the O
DNA B
- I
binding I
complexes I
with O
an O
anti B
- I
Fos I
mAb I
demonstrated O
a O
direct O
participation O
of O
c B
- I
Fos I
in O
the O
AP B
- I
1 I
complexes I
induced O
by O
anti B
- I
AIM I
mAb I
. O

These O
data O
provide O
the O
evidence O
that O
activation O
of O
human O
peripheral O
blood O
T O
cells O
through O
the O
AIM O
activation O
pathway O
regulate O
the O
activity O
of O
AP B
- I
1 I
. O

Gangliosides O
suppress O
tumor B
necrosis I
factor I
production O
in O
human O
monocytes O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
95 I
and I
- I
36 I
bp I
relative O
to O
the O
transcription B
start I
site I
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
95 I
and I
- I
36 I
bp I
relative O
to O
the O
transcription B
start I
site I
. O

The O
inhibition O
of O
HIV O
infection O
in O
cells O
stably O
expressing O
a O
transdominant B
Rev I
protein I
, O
in O
the O
absence O
of O
any O
deleterious O
effect O
on O
T O
cell O
function O
, O
suggests O
that O
such O
a O
strategy O
could O
provide O
a O
therapeutic O
effect O
in O
the O
T O
lymphocytes O
of O
acquired O
immunodeficiency O
syndrome O
patients O
. O

The O
present O
work O
has O
examined O
the O
effects O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
type B
1 I
and I
2A I
protein I
phosphatases I
, O
on O
the O
regulation O
of O
c B
- I
jun I
expression O
during O
monocytic O
differentiation O
of O
U O
- O
937 O
leukemia O
cells O
. O

Mitogen O
stimulation O
of O
T O
- O
cells O
increases O
c B
- I
Fos I
and O
c B
- I
Jun I
protein O
levels O
, O
AP O
- O
1 O
binding O
and O
AP O
- O
1 O
transcriptional O
activity O
. O

Mitogen O
stimulation O
of O
T O
- O
cells O
increases O
c B
- I
Fos I
and O
c B
- I
Jun I
protein O
levels O
, O
AP O
- O
1 O
binding O
and O
AP O
- O
1 O
transcriptional O
activity O
. O

Both O
c B
- I
Fos I
and O
c B
- I
Jun I
protein O
levels O
were O
increased O
after O
Con O
A O
and O
PHA O
stimulation O
. O

Both O
c B
- I
Fos I
and O
c B
- I
Jun I
protein O
levels O
were O
increased O
after O
Con O
A O
and O
PHA O
stimulation O
. O

The O
kinetics O
of O
expression O
of O
the O
two O
genes O
were O
also O
slightly O
different O
, O
with O
c B
- I
fos I
mRNA I
reaching O
a O
peak O
at O
15 O
min O
after O
stimulation O
and O
c B
- I
jun I
at O
30 O
min O
. O

Modulation O
of O
normal O
erythroid O
differentiation O
by O
the O
endogenous O
thyroid O
hormone O
and O
retinoic B
acid I
receptors I
: O
a O
possible O
target O
for O
v B
- I
erbA I
oncogene I
action O
. O

Pit B
- I
1 I
is O
a O
pituitary B
- I
specific I
transcription I
factor I
that O
binds O
to O
and O
transactivates O
promoters B
of O
growth B
hormone I
and I
prolactin I
genes I
. O

Activation O
of O
protein B
kinase I
C I
and O
elevation O
of O
cAMP O
interact O
synergistically O
to O
raise O
c B
- I
Fos I
and O
AP B
- I
1 I
activity O
in O
Jurkat O
cells O
. O

Activation O
of O
protein B
kinase I
C I
and O
elevation O
of O
cAMP O
interact O
synergistically O
to O
raise O
c B
- I
Fos I
and O
AP B
- I
1 I
activity O
in O
Jurkat O
cells O
. O

Activation O
of O
protein B
kinase I
C I
and O
elevation O
of O
cAMP O
interact O
synergistically O
to O
raise O
c B
- I
Fos I
and O
AP B
- I
1 I
activity O
in O
Jurkat O
cells O
. O

We O
have O
earlier O
found O
that O
in O
Jurkat O
cells O
activation O
of O
protein B
kinase I
C I
( O
PKC B
) O
enhances O
the O
cyclic O
adenosine O
monophosphate O
( O
cAMP O
) O
accumulation O
induced O
by O
adenosine O
receptor O
stimulation O
or O
activation O
of O
Gs B
. O

The O
IL B
- I
2 I
promoter I
contains O
binding B
sites I
for O
nuclear B
factors I
including O
NFAT B
- I
1 I
, O
Oct B
, O
NF B
- I
kappa I
B I
, O
and O
AP B
- I
1 I
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B
. O

The O
IL B
- I
2 I
promoter I
contains O
binding B
sites I
for O
nuclear B
factors I
including O
NFAT B
- I
1 I
, O
Oct B
, O
NF B
- I
kappa I
B I
, O
and O
AP B
- I
1 I
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B
. O

Our O
results O
indicate O
that O
the O
AP B
- I
1 I
site I
at O
- B
150 I
bp I
represents O
a O
major O
, O
if O
not O
the O
only O
, O
site O
of O
PKC B
responsiveness O
in O
the O
IL B
- I
2 I
promoter I
. O

Leukotriene O
B4 O
transcriptionally O
activates O
interleukin B
- I
6 I
expression O
involving O
NK B
- I
chi I
B I
and O
NF B
- I
IL6 I
. O

Leukotriene O
B4 O
transcriptionally O
activates O
interleukin B
- I
6 I
expression O
involving O
NK B
- I
chi I
B I
and O
NF B
- I
IL6 I
. O

We O
furthermore O
demonstrate O
that O
this O
process O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
chi I
B I
and O
, O
to O
a O
lesser O
extent O
, O
of O
NF B
- I
IL6 I
, O
while O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
, O
shown O
to O
otherwise O
confer O
IL B
- I
6 I
inducibility O
, O
appeared O
to O
be O
unaffected O
by O
LTB4 O
. O

We O
furthermore O
demonstrate O
that O
this O
process O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
chi I
B I
and O
, O
to O
a O
lesser O
extent O
, O
of O
NF B
- I
IL6 I
, O
while O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
, O
shown O
to O
otherwise O
confer O
IL B
- I
6 I
inducibility O
, O
appeared O
to O
be O
unaffected O
by O
LTB4 O
. O

We O
furthermore O
demonstrate O
that O
this O
process O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
chi I
B I
and O
, O
to O
a O
lesser O
extent O
, O
of O
NF B
- I
IL6 I
, O
while O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
, O
shown O
to O
otherwise O
confer O
IL B
- I
6 I
inducibility O
, O
appeared O
to O
be O
unaffected O
by O
LTB4 O
. O

The O
signaling O
events O
mediating O
this O
effect O
appeared O
to O
involve O
the O
release O
of O
H2O2 O
, O
since O
LTB4 O
failed O
to O
induce O
NF B
- I
chi I
B I
or O
NF B
- I
IL6 I
in O
the O
presence O
of O
the O
scavenger O
of O
H2O2 O
, O
N O
- O
acetyl O
- O
L O
- O
cysteine O
. O

The O
insertion O
was O
not O
required O
for O
Fc B
gamma I
RII I
to O
modulate O
surface B
immunoglobulin I
- O
triggered O
B O
- O
cell O
activation O
. O

Here O
, O
Stuart O
Schreiber O
and O
Gerald O
Crabtree O
review O
recent O
findings O
that O
indicate O
CsA O
and O
FK506 O
operate O
as O
prodrugs O
: O
they O
bind O
endogenous B
intracellular I
receptors I
, O
the O
immunophilins B
, O
and O
the O
resulting O
complex O
targets O
the O
protein B
phosphatase I
, I
calcineurin B
, O
to O
exert O
the O
immunosuppressive O
effect O
. O

Here O
, O
Stuart O
Schreiber O
and O
Gerald O
Crabtree O
review O
recent O
findings O
that O
indicate O
CsA O
and O
FK506 O
operate O
as O
prodrugs O
: O
they O
bind O
endogenous B
intracellular I
receptors I
, O
the O
immunophilins B
, O
and O
the O
resulting O
complex O
targets O
the O
protein B
phosphatase I
, I
calcineurin B
, O
to O
exert O
the O
immunosuppressive O
effect O
. O

Mutations O
affecting O
the O
5 B
' I
guanine I
residues I
of O
the O
kappa B
B I
site I
were O
unable O
to O
compete O
for O
these O
NF B
- I
kappa I
B I
- I
related I
proteins I
. O

It O
seems O
that O
the O
rearrangement O
of O
the O
TCR B
gamma I
loci I
in O
the O
gamma O
delta O
lineage O
may O
not O
always O
take O
place O
at O
a O
developmental O
stage O
strictly O
equivalent O
to O
the O
rearrangement O
of O
TCR B
beta I
in O
the O
alpha O
beta O
lineage O
, O
and O
it O
is O
not O
clear O
just O
how O
early O
the O
two O
lineages O
diverge O
. O

In O
contrast O
, O
NF B
- I
kappa I
B I
p50 I
alone O
fails O
to O
stimulate O
kappa O
B O
- O
directed O
transcription O
, O
and O
based O
on O
prior O
in O
vitro O
studies O
, O
is O
not O
directly O
regulated O
by O
I B
kappa I
B I
. O

We O
have O
biochemically O
and O
functionally O
characterized O
a O
new O
transcription B
factor I
, O
NP B
- I
TCII I
, O
which O
is O
present O
in O
nuclei O
from O
unstimulated O
T O
and O
B O
lymphocytes O
but O
is O
not O
found O
in O
nonhematopoietic O
cells O
. O

Chloramphenicol B
acetyl I
transferase I
( O
CAT B
) O
assays O
using O
the O
HIV B
- I
1 I
( I
- I
139 I
) I
long I
terminal I
repeat I
- I
CAT I
construct I
showed O
no O
PMA O
induction O
of O
CAT B
activity O
in O
these O
subclones O
( O
unlike O
the O
parental O
line O
and O
other O
subclones O
) O
. O

Although O
NF B
- I
AT I
has O
not O
been O
cloned O
or O
purified O
, O
there O
is O
evidence O
that O
it O
is O
a O
major O
target O
for O
immunosuppression O
by O
cyclosporin O
A O
( O
CsA O
) O
and O
FK506 O
( O
refs O
2 O
- O
7 O
) O
. O

After O
the O
DNA B
fragment I
containing O
the O
CAG B
repeats I
is O
amplified O
by O
the O
polymerase O
chain O
reaction O
, O
a O
primer O
extension O
is O
carried O
out O
; O
the O
extension O
of O
the O
end B
- I
labelled I
reverse I
primer I
adjacent O
to O
3 B
' I
end I
of O
CAG B
repeats I
stops O
at O
the O
first O
T O
after O
CAG B
repeats I
with O
the O
incorporation O
of O
dideoxy O
ATP O
in O
the O
reaction O
mixture O
. O

NF B
kappa I
B I
is O
a O
potent O
mediator O
of O
specific O
gene O
expression O
in O
human O
monocytes O
and O
has O
been O
shown O
to O
play O
a O
role O
in O
transcription O
of O
the O
HIV O
- O
1 O
genome O
in O
promonocytic O
leukemias O
. O

There O
is O
little O
information O
available O
on O
the O
response O
of O
NF B
kappa I
B I
to O
cytokines B
in O
normal O
human O
monocytes O
. O

The O
endothelium O
plays O
a O
critical O
role O
in O
inflammation O
by O
directing O
circulating O
leukocytes O
into O
extravascular O
tissues O
by O
expressing O
adhesive B
molecules I
for O
leukocytes O
[ O
e O
. O
g O
. O
, O
endothelial B
- I
leukocyte I
adhesion I
molecule I
1 I
( O
ELAM B
- I
1 I
) O
and O
intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
] O
. O

The O
endothelium O
plays O
a O
critical O
role O
in O
inflammation O
by O
directing O
circulating O
leukocytes O
into O
extravascular O
tissues O
by O
expressing O
adhesive B
molecules I
for O
leukocytes O
[ O
e O
. O
g O
. O
, O
endothelial B
- I
leukocyte I
adhesion I
molecule I
1 I
( O
ELAM B
- I
1 I
) O
and O
intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
] O
. O

Biochemical O
purification O
and O
cDNA O
cloning O
has O
now O
revealed O
that O
BSAP B
belongs O
to O
the O
family O
of O
paired B
domain I
proteins I
. O

We O
have O
found O
that O
the O
p49 B
( I
100 I
) I
DNA I
binding I
subunit I
, O
together O
with O
p65 B
, O
can O
act O
in O
concert O
with O
Tat B
- I
I I
to O
stimulate O
the O
expression O
of O
HIV B
- I
CAT I
plasmid I
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets B
binding I
sites I
, O
EBS1 O
and O
EBS2 B
, O
which O
are O
conserved O
in O
both O
the O
human B
and I
murine I
interleukin I
- I
2 I
enhancers I
. O

Further O
, O
we O
observe O
that O
TAR B
- I
deleted I
mutants I
of O
HIV O
- O
1 O
demonstrate O
normal O
late O
gene O
expression O
in O
glial O
cells O
as O
evidenced O
by O
syncytia O
formation O
and O
production O
of O
viral B
p24 I
antigen I
. O

At O
least O
two O
21 B
bp I
repeats I
were O
required O
for O
high O
levels O
of O
AP B
- I
2 I
activation O
and O
mutagenesis O
of O
the O
AP B
- I
2 I
consensus I
binding I
sequences I
in O
the O
21 B
bp I
repeats I
eliminate O
this O
activation O
. O

At O
least O
two O
21 B
bp I
repeats I
were O
required O
for O
high O
levels O
of O
AP B
- I
2 I
activation O
and O
mutagenesis O
of O
the O
AP B
- I
2 I
consensus I
binding I
sequences I
in O
the O
21 B
bp I
repeats I
eliminate O
this O
activation O
. O

At O
least O
two O
21 B
bp I
repeats I
were O
required O
for O
high O
levels O
of O
AP B
- I
2 I
activation O
and O
mutagenesis O
of O
the O
AP B
- I
2 I
consensus I
binding I
sequences I
in O
the O
21 B
bp I
repeats I
eliminate O
this O
activation O
. O

Activation O
of O
the O
human B
immunodeficiency I
virus I
type I
1 I
enhancer I
is O
not O
dependent O
on O
NFAT B
- I
1 I
. O

Activation O
by O
the O
T B
- I
cell I
antigen I
receptor I
is O
minimal O
in O
Jurkat O
cells O
and O
is O
mediated O
by O
the O
kappa B
B I
sites I
. O

In O
vitro O
transcription O
analysis O
using O
protein O
fractions O
enriched O
for O
the O
octamer O
- O
binding O
protein O
OTF B
- I
2 I
demonstrate O
a O
positive O
functional O
role O
for O
OTF B
- I
2 I
in O
DRA B
gene I
transcription O
. O

In O
vitro O
transcription O
analysis O
using O
protein O
fractions O
enriched O
for O
the O
octamer O
- O
binding O
protein O
OTF B
- I
2 I
demonstrate O
a O
positive O
functional O
role O
for O
OTF B
- I
2 I
in O
DRA B
gene I
transcription O
. O

However O
, O
the O
increase O
in O
ISGF3 B
activity O
ultimately O
correlates O
with O
the O
accumulation O
of O
ISGF3 B
gamma I
induced O
by O
IFN B
- I
alpha I
or O
IFN B
- I
gamma I
. O

However O
, O
the O
increase O
in O
ISGF3 B
activity O
ultimately O
correlates O
with O
the O
accumulation O
of O
ISGF3 B
gamma I
induced O
by O
IFN B
- I
alpha I
or O
IFN B
- I
gamma I
. O

It O
was O
found O
that O
lipopolysaccharide O
induced O
strongly O
both O
c B
- I
fos I
and O
c B
- I
jun I
expression O
as O
well O
as O
AP1 B
formation O
. O

It O
was O
found O
that O
lipopolysaccharide O
induced O
strongly O
both O
c B
- I
fos I
and O
c B
- I
jun I
expression O
as O
well O
as O
AP1 B
formation O
. O

Nuclear B
transcription I
factors I
that O
bind O
to O
elements O
of O
the O
IL B
- I
2 I
promoter I
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B
( O
identical O
to O
50 B
kDa I
NF I
- I
kappa I
B I
protein I
) O
reacted O
with O
the O
p50 B
of O
NF B
- I
GM2 I
, O
indicating O
that O
the O
NF B
- I
GM2 I
polypeptide I
can O
not O
be O
immunologically O
differentiated O
from O
the O
50 B
kDa I
subunit I
of O
NF B
- I
kappa I
B I
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B
( O
identical O
to O
50 B
kDa I
NF I
- I
kappa I
B I
protein I
) O
reacted O
with O
the O
p50 B
of O
NF B
- I
GM2 I
, O
indicating O
that O
the O
NF B
- I
GM2 I
polypeptide I
can O
not O
be O
immunologically O
differentiated O
from O
the O
50 B
kDa I
subunit I
of O
NF B
- I
kappa I
B I
. O

This O
suggests O
that O
the O
activation O
mechanism O
of O
the O
GM B
- I
CSF I
gene I
through O
the O
GM2 B
/ I
GC I
- I
box I
sequence I
is O
different O
from O
that O
of O
genes O
carrying O
the O
kappa B
B I
enhancer I
alone O
. O

Characterization O
of O
an O
immediate B
- I
early I
gene I
induced O
in O
adherent O
monocytes O
that O
encodes O
I B
kappa I
B I
- O
like O
activity O
. O

The O
C B
- I
terminus I
has O
a O
putative O
protein B
kinase I
C I
phosphorylation I
site I
. O

A O
DNA B
probe I
that O
spanned O
a O
domain O
conserved O
among O
the O
proto B
- I
oncogene I
c I
- I
rel I
, O
the O
Drosophila B
morphogen I
dorsal I
, O
and O
the O
p50 B
DNA I
binding I
subunit I
of O
NF B
- I
kappa I
B I
was O
generated O
from O
Jurkat B
T I
cell I
complementary I
DNA I
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
degenerate O
oligonucleotides O
. O

Regulation O
of O
M B
- I
CSF I
expression O
by O
M B
- I
CSF I
: O
role O
of O
protein B
kinase I
C I
and O
transcription B
factor I
NF I
kappa I
B I
. O

Regulation O
of O
M B
- I
CSF I
expression O
by O
M B
- I
CSF I
: O
role O
of O
protein B
kinase I
C I
and O
transcription B
factor I
NF I
kappa I
B I
. O

Regulation O
of O
M B
- I
CSF I
expression O
by O
M B
- I
CSF I
: O
role O
of O
protein B
kinase I
C I
and O
transcription B
factor I
NF I
kappa I
B I
. O

To O
date O
, O
little O
is O
known O
about O
the O
intracellular O
pathway O
of O
M B
- I
CSF I
signal O
transduction O
. O

The O
pAT B
133 I
gene I
is O
immediately O
induced O
, O
with O
FOS B
- O
like O
kinetics O
, O
in O
human O
T O
cells O
and O
in O
fibroblasts O
. O

v B
- I
erbA I
overexpression O
is O
required O
to O
extinguish O
c B
- I
erbA I
function O
in O
erythroid O
cell O
differentiation O
and O
regulation O
of O
the O
erbA B
target I
gene I
CAII B
. O

v B
- I
erbA I
overexpression O
is O
required O
to O
extinguish O
c B
- I
erbA I
function O
in O
erythroid O
cell O
differentiation O
and O
regulation O
of O
the O
erbA B
target I
gene I
CAII B
. O

v B
- I
erbA I
overexpression O
is O
required O
to O
extinguish O
c B
- I
erbA I
function O
in O
erythroid O
cell O
differentiation O
and O
regulation O
of O
the O
erbA B
target I
gene I
CAII B
. O

The O
effect O
is O
mediated O
by O
the O
NF B
- I
kappa I
B I
transcription B
factor I
which O
is O
potently O
and O
rapidly O
activated O
by O
an O
H2O2 O
treatment O
of O
cells O
from O
its O
inactive B
cytoplasmic I
form I
. O

ROI O
appear O
to O
serve O
as O
messengers O
mediating O
directly O
or O
indirectly O
the O
release O
of O
the O
inhibitory B
subunit I
I B
kappa I
B I
from O
NF B
- I
kappa I
B I
. O

Inhibition O
of O
transcription B
factors I
belonging O
to O
the O
rel B
/ I
NF I
- I
kappa I
B I
family I
by O
a O
transdominant B
negative I
mutant I
. O

A O
mutant O
of O
KBF1 B
/ I
p50 I
( O
delta B
SP I
) O
, O
unable O
to O
bind O
to O
DNA O
but O
able O
to O
form O
homo O
- O
or O
heterodimers B
, O
has O
been O
constructed O
. O

The O
conversion O
of O
the O
TCEd B
to O
a O
' B
perfect I
' I
NF I
- I
kB I
binding I
site I
leads O
to O
a O
tighter O
binding O
of O
NF B
- I
kB I
to O
TCEd B
DNA I
and O
, O
as O
a O
functional O
consequence O
, O
to O
the O
activity O
of O
the O
' B
converted I
' I
TCEd I
motifs I
in O
HeLa O
cells O
. O

A O
region O
upstream O
to O
the O
first O
exon O
, O
and O
highly O
conserved O
between O
mouse O
and O
man O
, O
acts O
as O
an O
erythroid O
specific O
enhancer O
in O
transient O
assays O
, O
if O
linked O
to O
the O
GATA B
- I
1 I
or O
to O
the O
SV40 O
promoter O
. O

Previously O
, O
transcription O
of O
the O
c B
- I
fos I
gene I
has O
been O
reported O
to O
be O
transactivated O
by O
the O
viral B
transcription I
factor I
, O
Tax1 B
. O

Vitamin B
D I
receptor I
expression O
in O
human O
lymphocytes O
. O

Finally O
, O
RNA O
from O
activated O
lymphocytes O
was O
amplified O
by O
polymerase O
chain O
reaction O
using O
oligonucleotide O
primers O
flanking O
the O
196 B
base I
pair I
long I
region I
encoding O
the O
DNA B
- I
binding I
domain I
of O
the O
human B
intestinal I
receptor I
. O

The O
kappa B
B I
sequence I
( O
GGGACTTTCC O
) O
binds O
a O
factor O
, O
NF B
- I
kappa I
B I
, O
that O
is O
constitutively O
found O
in O
its O
functional O
, O
DNA O
binding O
form O
only O
in O
B O
lymphocytes O
. O

However O
, O
in O
either O
EL O
- O
4 O
( O
T O
) O
cells O
or O
S194 O
cells O
, O
both O
lower O
- O
affinity O
sites O
can O
be O
significantly O
induced O
by O
the O
tax B
gene I
product I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
, O
showing O
that O
NF B
- I
kappa I
B I
activity O
can O
be O
modulated O
even O
in O
a O
B O
- O
cell O
line O
that O
constitutively O
expresses O
this O
factor O
. O

Previously O
, O
a O
nuclear B
factor I
, O
IRF B
- I
1 I
( O
interferon B
regulatory I
factor I
1 I
) O
, O
which O
binds O
to O
type B
I I
IFN I
and O
some O
IFN B
- I
inducible I
gene I
promoters I
, O
was O
identified O
and O
cloned O
. O

Previously O
, O
a O
nuclear B
factor I
, O
IRF B
- I
1 I
( O
interferon B
regulatory I
factor I
1 I
) O
, O
which O
binds O
to O
type B
I I
IFN I
and O
some O
IFN B
- I
inducible I
gene I
promoters I
, O
was O
identified O
and O
cloned O
. O

Although O
absent O
in O
nonexpressing O
erythroleukemia O
cell O
lines O
, O
the O
DNase B
I I
site I
is O
present O
in O
uninduced O
myelomonocytic O
cell O
lines O
and O
is O
not O
changed O
after O
PMA O
induction O
. O

One O
of O
the O
members O
of O
this O
multigene O
family O
, O
cGATA B
- I
3 I
, O
is O
most O
abundantly O
expressed O
in O
the O
T O
- O
lymphocyte O
cell O
lineage O
. O

We O
have O
found O
that O
purified O
human O
peripheral O
- O
blood O
granulocytes O
express O
constitutively O
significant O
levels O
of O
proto B
- I
oncogenes I
c B
- I
jun I
, I
jun I
B I
and I
jun I
D I
mRNA I
. O

We O
have O
isolated O
a O
human B
cDNA I
clone I
encoding O
a O
zinc B
finger I
protein I
( O
NF B
- I
E1 I
) O
that O
binds O
to O
the O
negative B
- I
acting I
segment I
of O
the O
kappa B
E3 I
' I
enhancer I
. O

We O
have O
isolated O
a O
human B
cDNA I
clone I
encoding O
a O
zinc B
finger I
protein I
( O
NF B
- I
E1 I
) O
that O
binds O
to O
the O
negative B
- I
acting I
segment I
of O
the O
kappa B
E3 I
' I
enhancer I
. O

We O
have O
isolated O
a O
human B
cDNA I
clone I
encoding O
a O
zinc B
finger I
protein I
( O
NF B
- I
E1 I
) O
that O
binds O
to O
the O
negative B
- I
acting I
segment I
of O
the O
kappa B
E3 I
' I
enhancer I
. O

NF B
- I
E1 I
is O
also O
the O
human B
homologue I
of O
the O
mouse B
delta I
protein I
, O
which O
binds O
to O
ribosomal B
protein I
gene I
promoters I
. O

NF B
- I
E1 I
is O
also O
the O
human B
homologue I
of O
the O
mouse B
delta I
protein I
, O
which O
binds O
to O
ribosomal B
protein I
gene I
promoters I
. O

An O
upstream B
segment I
contains O
tandem B
dinucleotide I
repeats I
( B
CT I
) I
19 I
/ I
( I
CA I
) I
16 I
. O

HIV B
- I
TF1 I
had O
a O
molecular O
weight O
of O
39 O
, O
000 O
. O

A O
thymus B
- I
specific I
member I
of O
the O
HMG B
protein I
family I
regulates O
the O
human B
T I
cell I
receptor I
C I
alpha I
enhancer I
. O

The O
human B
T I
cell I
- I
specific I
transcription I
factor I
TCF B
- I
1 I
alpha I
plays O
a O
key O
role O
in O
the O
tissue O
- O
specific O
activation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
C O
alpha O
enhancer O
and O
binds O
to O
pyrimidine B
- I
rich I
elements I
( O
5 O
' O
- O
PyCTTTG O
- O
3 O
' O
) O
present O
in O
a O
variety O
of O
other O
T B
cell I
- I
specific I
control I
regions I
. O

Ectopic O
expression O
of O
cloned B
Oct2 I
cDNA I
was O
shown O
to O
be O
sufficient O
to O
reconstitute O
at O
least O
some O
aspects O
of O
this O
regulation O
in O
non O
- O
lymphoid O
cells O
. O

Binding O
of O
the O
65 B
- I
kDa I
plus O
50 B
- I
kDa I
heterodimer I
to O
the O
HIV B
- I
1 I
enhancer I
can O
be O
negatively O
regulated O
in O
monocytes O
, O
providing O
one O
mechanism O
restricting O
HIV B
- I
1 I
gene I
expression O
. O

NF B
- I
kB I
is O
a O
eukaryotic B
transcription I
regulatory I
factor I
. O

Moreover O
, O
M B
- I
CSF I
- O
induced O
expression O
of O
the O
fos B
- I
related I
gene I
, O
fra B
- I
1 I
, O
was O
delayed O
compared O
to O
that O
for O
both O
c B
- I
fos I
and O
fos B
- I
B I
. O

Moreover O
, O
M B
- I
CSF I
- O
induced O
expression O
of O
the O
fos B
- I
related I
gene I
, O
fra B
- I
1 I
, O
was O
delayed O
compared O
to O
that O
for O
both O
c B
- I
fos I
and O
fos B
- I
B I
. O

Moreover O
, O
M B
- I
CSF I
- O
induced O
expression O
of O
the O
fos B
- I
related I
gene I
, O
fra B
- I
1 I
, O
was O
delayed O
compared O
to O
that O
for O
both O
c B
- I
fos I
and O
fos B
- I
B I
. O

Moreover O
, O
M B
- I
CSF I
- O
induced O
expression O
of O
the O
fos B
- I
related I
gene I
, O
fra B
- I
1 I
, O
was O
delayed O
compared O
to O
that O
for O
both O
c B
- I
fos I
and O
fos B
- I
B I
. O

DNA O
binding O
by O
all O
four O
of O
these O
Rel B
- I
related I
factors I
is O
blocked O
by O
selective O
chemical O
modification O
of O
lysine O
and O
arginine O
residues O
, O
suggesting O
that O
both O
of O
these O
basic O
amino O
acids O
are O
required O
for O
binding O
to O
the O
kappa B
B I
element I
. O

Immune O
response O
of O
peripheral O
blood O
mononuclear O
cells O
to O
HBx B
- I
antigen I
of O
hepatitis O
B O
virus O
. O

[ O
Changes O
in O
leucocytic B
estrogen I
receptor I
levels O
in O
patients O
with O
gynecomastia O
] O

The O
rate O
of O
transcription O
initiation O
directed O
by O
the O
long B
terminal I
repeat I
( O
LTR O
) O
of O
HIV O
- O
1 O
increases O
in O
response O
to O
mitogenic O
stimuli O
of O
T O
cells O
. O

The O
rate O
of O
LTR B
- O
directed O
gene O
expression O
increased O
in O
response O
to O
treatment O
with O
either O
a O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
if O
either O
the O
NFAT B
- I
1 I
or O
NF B
kappa I
B I
binding I
sites I
were O
deleted O
, O
but O
failed O
to O
respond O
to O
these O
mitogenic O
stimuli O
if O
both O
sequences O
were O
absent O
. O

This O
tight O
correlation O
between O
c B
- I
jun I
expression O
, O
the O
generation O
of O
AP B
- I
1 I
activity O
, O
and O
differentiation O
suggests O
a O
critical O
role O
for O
this O
gene O
and O
transcriptional B
complex I
during O
this O
process O
. O

This O
tight O
correlation O
between O
c B
- I
jun I
expression O
, O
the O
generation O
of O
AP B
- I
1 I
activity O
, O
and O
differentiation O
suggests O
a O
critical O
role O
for O
this O
gene O
and O
transcriptional B
complex I
during O
this O
process O
. O

A O
transcription B
factor I
, O
NF B
- I
AT I
, O
which O
is O
essential O
for O
early O
T O
- O
cell O
gene O
activation O
, O
seems O
to O
be O
a O
specific O
target O
of O
cyclosporin O
A O
and O
FK506 O
action O
because O
transcription O
directed O
by O
this O
protein O
is O
blocked O
in O
T O
cells O
treated O
with O
these O
drugs O
, O
with O
little O
or O
no O
effect O
on O
other O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
. O

A O
transcription B
factor I
, O
NF B
- I
AT I
, O
which O
is O
essential O
for O
early O
T O
- O
cell O
gene O
activation O
, O
seems O
to O
be O
a O
specific O
target O
of O
cyclosporin O
A O
and O
FK506 O
action O
because O
transcription O
directed O
by O
this O
protein O
is O
blocked O
in O
T O
cells O
treated O
with O
these O
drugs O
, O
with O
little O
or O
no O
effect O
on O
other O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
. O

TCF B
- I
1 I
belonged O
to O
a O
novel O
family O
of O
genes O
that O
contain O
the O
so O
- O
called O
high O
mobility B
group I
1 I
( I
HMG I
) I
box I
. O

Third O
, O
TCF B
- I
1 I
bound O
specifically O
to O
a O
functional O
T B
cell I
- I
specific I
element I
in O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
- I
alpha I
) I
enhancer I
. O

Northern O
blot O
analysis O
of O
polyadenylated B
RNA I
purified O
from O
activated O
human O
B O
cells O
revealed O
a O
single B
mRNA I
transcript I
of O
approximately O
2 O
. O
3 O
kb O
. O

There O
is O
a O
single O
methionine B
codon I
- I
initiated I
open I
reading I
frame I
of O
1 O
, O
458 O
nt O
in O
frame O
with O
a O
homeobox B
and O
a O
CAX B
repeat I
, O
and O
the O
open B
reading I
frame I
is O
predicted O
to O
encode O
a O
protein O
of O
51 O
, O
659 O
daltons O
. O

Tandem O
copies O
of O
this O
67 B
- I
bp I
MnlI I
- I
AluI I
fragment I
, O
when O
fused O
to O
the O
chloramphenicol B
acetyltransferase I
gene I
driven O
by O
the O
conalbumin B
promoter I
, O
stimulated O
transcription O
in O
B O
cells O
but O
not O
in O
Jurkat O
T O
cells O
or O
HeLa O
cells O
. O

Gel O
mobility O
shift O
assays O
using O
a O
synthetic B
E6 I
motif I
detected O
a O
B B
- I
cell I
- I
specific I
complex I
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T O
cells O
and O
HeLa O
cells O
. O

However O
, O
blockade O
of O
the O
Ca B
( I
2 I
+ I
) I
- I
activated I
K I
+ I
channel I
is O
not O
associated O
with O
changes O
in O
cell O
- O
cycle O
gene O
activation O
, O
IL B
- I
2 I
production O
, O
IL B
- I
2R I
expression O
or O
B O
and O
T O
cell O
mitogenesis O
. O

However O
, O
blockade O
of O
the O
Ca B
( I
2 I
+ I
) I
- I
activated I
K I
+ I
channel I
is O
not O
associated O
with O
changes O
in O
cell O
- O
cycle O
gene O
activation O
, O
IL B
- I
2 I
production O
, O
IL B
- I
2R I
expression O
or O
B O
and O
T O
cell O
mitogenesis O
. O

NF B
- I
kappa I
B I
activation O
by O
tumor B
necrosis I
factor I
alpha I
in O
the O
Jurkat O
T O
cell O
line O
is O
independent O
of O
protein B
kinase I
A I
, O
protein B
kinase I
C I
, O
and O
Ca B
( I
2 I
+ I
) I
- I
regulated I
kinases I
. O

NF B
- I
kappa I
B I
activation O
by O
tumor B
necrosis I
factor I
alpha I
in O
the O
Jurkat O
T O
cell O
line O
is O
independent O
of O
protein B
kinase I
A I
, O
protein B
kinase I
C I
, O
and O
Ca B
( I
2 I
+ I
) I
- I
regulated I
kinases I
. O

In O
nuclear O
extracts O
from O
monocytes O
or O
macrophages O
, O
induction O
of O
NF B
- I
KB I
occurred O
only O
if O
the O
cells O
were O
previously O
infected O
with O
HIV O
- O
1 O
. O

These O
results O
indicate O
that O
in O
monocytic O
cell O
lineage O
, O
HIV O
- O
1 O
could O
mimic O
some O
differentiation O
/ O
activation O
stimuli O
allowing O
nuclear O
NF B
- I
KB I
expression O
. O

Disruption O
of O
the O
human B
SCL I
locus I
by O
` O
` O
illegitimate O
' O
' O
V O
- O
( O
D O
) O
- O
J O
recombinase O
activity O
. O

The O
fusion B
cDNA I
results O
from O
an O
interstitial O
deletion O
between O
a O
previously O
unknown B
locus I
, O
SIL B
( O
SCL B
interrupting I
locus I
) O
, O
and O
the O
5 B
' I
untranslated I
region I
of O
SCL B
. O

Incubation O
of O
each O
of O
the O
TRs B
with O
NE O
from O
COS O
- O
7 O
cells O
, O
which O
do O
not O
possess O
sufficient O
endogenous O
TRs B
to O
mediate O
T3 O
- O
responses O
, O
resulted O
in O
formation O
of O
a O
new O
, O
more O
greatly B
shifted I
complex I
. O

Cell O
- O
specific O
differences O
in O
activation O
of O
NF B
- I
kappa I
B I
regulatory I
elements I
of O
human B
immunodeficiency I
virus I
and I
beta I
interferon I
promoters I
by O
tumor B
necrosis I
factor I
. O

Functional O
analysis O
of O
cis B
- I
linked I
regulatory I
sequences I
in O
the O
HLA B
DRA I
promoter I
by O
transcription O
in O
vitro O
. O

Furthermore O
, O
point O
mutations O
that O
abolish O
binding O
of O
NF B
- I
E1 I
result O
in O
a O
70 O
% O
decrease O
in O
the O
transcriptional O
activity O
of O
a O
megakaryocytic B
- I
specific I
promoter I
. O

Transcriptional O
down O
- O
regulation O
of O
c B
- I
myc I
expression O
by O
protein O
synthesis O
- O
dependent O
and O
- O
independent O
pathways O
in O
a O
human O
T O
lymphoblastic O
tumor O
cell O
line O
. O

Two O
glucocorticoid B
binding I
sites I
on O
the O
human B
glucocorticoid I
receptor I
. O

Two O
glucocorticoid B
binding I
sites I
on O
the O
human B
glucocorticoid I
receptor I
. O

These O
data O
indicate O
that O
CVZ O
is O
recognizing O
two O
glucocorticoid B
binding I
sites I
on O
the O
human O
GR B
or O
a O
protein O
very O
similar O
to O
it O
. O

ER B
content O
in O
lymphocytes O
of O
each O
sample O
was O
expressed O
by O
both O
fmol O
/ O
mg O
of O
lymphocyte B
cytosolic I
protein I
and O
fmol O
/ O
micrograms O
of O
lymphocyte B
DNA I
. O

When O
the O
human B
epsilon I
- I
or I
beta I
- I
globin I
genes I
driven O
by O
the O
dominant B
control I
region I
( O
DCR B
) O
are O
introduced O
into O
this O
system O
, O
the O
human B
epsilon I
- I
globin I
gene I
, O
in O
contrast O
to O
the O
beta B
- I
globin I
gene I
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR B
and O
is O
expressed O
strictly O
as O
an O
embryonic B
gene I
. O

ZRE B
- I
B I
is O
therefore O
not O
part O
of O
the O
R B
- I
inducible I
enhancer I
. O

We O
studied O
the O
effects O
of O
TPA O
on O
the O
regulation O
of O
c B
- I
jun I
gene O
expression O
in O
HL O
- O
60 O
cells O
during O
monocytic O
differentiation O
. O

Characterization O
of O
defensin B
resistance O
phenotypes O
associated O
with O
mutations O
in O
the O
phoP B
virulence I
regulon I
of O
Salmonella O
typhimurium O
. O

The O
defensin B
sensitivities O
of O
Salmonella O
typhimurium O
strains O
with O
mutations O
in O
the O
phoP B
/ I
phoQ I
two I
- I
component I
virulence I
regulon I
were O
tested O
by O
using O
purified B
defensins I
NP B
- I
1 I
and O
NP B
- I
2 I
. O

The O
defensin B
sensitivities O
of O
Salmonella O
typhimurium O
strains O
with O
mutations O
in O
the O
phoP B
/ I
phoQ I
two I
- I
component I
virulence I
regulon I
were O
tested O
by O
using O
purified B
defensins I
NP B
- I
1 I
and O
NP B
- I
2 I
. O

Stimulation O
of O
a O
human O
T O
- O
cell O
clone O
with O
anti B
- I
CD3 I
or O
tumor B
necrosis I
factor I
induces O
NF B
- I
kappa I
B I
translocation O
but O
not O
human O
immunodeficiency O
virus O
1 O
enhancer O
- O
dependent O
transcription O
. O

Stimulation O
of O
a O
human O
T O
- O
cell O
clone O
with O
anti B
- I
CD3 I
or O
tumor B
necrosis I
factor I
induces O
NF B
- I
kappa I
B I
translocation O
but O
not O
human O
immunodeficiency O
virus O
1 O
enhancer O
- O
dependent O
transcription O
. O

It O
appears O
that O
the O
B O
cell O
- O
specific O
expression O
of O
Ig B
genes I
is O
mediated O
at O
least O
in O
part O
by O
cell O
type B
- I
specific I
Oct I
factors I
, O
and O
that O
there O
are O
both O
quantitative O
and O
qualitative O
differences O
between O
Oct B
- I
1 I
and O
Oct B
- I
2 I
factors I
. O

Recently O
, O
a O
number O
of O
other O
octamer B
factor I
variants I
were O
identified O
. O

We O
find O
that O
the O
factor O
that O
binds O
to O
the O
E3 B
enhancer I
motif I
, O
CATGTGGC O
, O
is O
a O
ubiquitous B
transcription I
factor I
. O

We O
find O
that O
the O
factor O
that O
binds O
to O
the O
E3 B
enhancer I
motif I
, O
CATGTGGC O
, O
is O
a O
ubiquitous B
transcription I
factor I
. O

However O
, O
despite O
its O
ability O
to O
activate O
transcription O
of O
a O
transfected B
reporter I
gene I
, O
the O
factor O
is O
apparently O
unable O
to O
bind O
to O
the O
endogenous B
Ig I
heavy I
chain I
enhancer I
in O
non O
- O
lymphoid O
cells O
: O
In O
previous O
experiments O
by O
others O
, O
the O
characteristic O
in O
vivo O
footprint O
of O
this O
factor O
, O
designated O
NF B
- I
muE3 I
, O
was O
detected O
in O
B O
cells O
but O
not O
in O
non O
- O
B O
cells O
. O

However O
, O
despite O
its O
ability O
to O
activate O
transcription O
of O
a O
transfected B
reporter I
gene I
, O
the O
factor O
is O
apparently O
unable O
to O
bind O
to O
the O
endogenous B
Ig I
heavy I
chain I
enhancer I
in O
non O
- O
lymphoid O
cells O
: O
In O
previous O
experiments O
by O
others O
, O
the O
characteristic O
in O
vivo O
footprint O
of O
this O
factor O
, O
designated O
NF B
- I
muE3 I
, O
was O
detected O
in O
B O
cells O
but O
not O
in O
non O
- O
B O
cells O
. O

Multiple B
regulatory I
elements I
in O
the O
human B
immunodeficiency I
virus I
long I
terminal I
repeat I
( O
HIV B
LTR I
) O
are O
required O
for O
activation O
of O
HIV O
gene O
expression O
. O

Results O
in O
all O
cell O
lines O
indicated O
that O
mutations O
of O
the O
SP1 B
, O
TATA B
and O
the O
TAR O
loop O
and O
stem O
secondary O
structure O
resulted O
in O
marked O
decreases O
in O
gene O
expression O
while O
mutations O
of O
the O
enhancer B
motif I
or O
TAR B
primary I
sequence I
resulted O
in O
only O
slight O
decreases O
. O

The O
clinical O
course O
and O
the O
laboratory O
data O
suggest O
that O
the O
tachycardia O
crises O
are O
the O
consequence O
of O
a O
hypersensitivity O
of O
the O
heart O
to O
thyroid O
hormones O
, O
associated O
with O
an O
increased O
number O
of O
T3 B
nuclear I
receptor I
sites O
in O
lymphocytes O
. O

The O
c B
- I
jun I
gene I
expression O
was O
very O
transient O
and O
was O
not O
detectable O
by O
60 O
min O
after O
M B
- I
CSF I
addition O
. O

The O
protein O
synthesis O
inhibitor O
cycloheximide O
did O
not O
block O
the O
induction O
of O
any O
of O
these O
genes O
, O
and O
in O
fact O
, O
super O
- O
induced O
the O
expression O
of O
c B
- I
jun I
and O
hck B
. O

Inducible O
nuclear B
factor I
binding O
to O
the O
kappa B
B I
elements I
of O
the O
human B
immunodeficiency I
virus I
enhancer I
in O
T O
cells O
can O
be O
blocked O
by O
cyclosporin O
A O
in O
a O
signal O
- O
dependent O
manner O
. O

Curiously O
, O
the O
TCF B
- I
1 I
alpha I
binding O
element O
was O
inactive O
in O
vivo O
when O
removed O
from O
its O
neighboring O
elements O
on O
the O
TCR B
alpha I
enhancer I
and O
positioned O
in O
one O
or O
more O
copies O
upstream O
of O
a O
heterologous B
promoter I
. O

The O
same O
agents O
induce O
transcription O
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
and I
interleukin I
- I
2 I
genes I
, O
depending O
on O
promoter B
elements I
that O
bind O
the O
inducible B
transcription I
factor I
NF B
- I
kappa I
B I
( O
or O
an O
NF B
- I
kappa I
B I
- I
like I
factor I
) O
. O

Unexpectedly O
, O
stimulation O
of O
cloned O
stably O
transfected O
Jurkat O
T O
cells O
leads O
to O
a O
bimodal O
pattern O
of O
beta O
- O
gal O
expression O
in O
which O
some O
cells O
express O
no O
beta B
- I
gal I
and O
others O
express O
high O
levels O
. O

Further O
results O
, O
in O
which O
beta B
- I
gal I
activity O
is O
correlated O
with O
NF B
- I
AT I
- O
binding O
activity O
, O
indicate O
that O
the O
concentration O
of O
NF B
- I
AT I
must O
exceed O
a O
critical O
threshold O
before O
transcription O
initiates O
. O

Further O
results O
, O
in O
which O
beta B
- I
gal I
activity O
is O
correlated O
with O
NF B
- I
AT I
- O
binding O
activity O
, O
indicate O
that O
the O
concentration O
of O
NF B
- I
AT I
must O
exceed O
a O
critical O
threshold O
before O
transcription O
initiates O
. O

Further O
results O
, O
in O
which O
beta B
- I
gal I
activity O
is O
correlated O
with O
NF B
- I
AT I
- O
binding O
activity O
, O
indicate O
that O
the O
concentration O
of O
NF B
- I
AT I
must O
exceed O
a O
critical O
threshold O
before O
transcription O
initiates O
. O

In O
lymphoid O
cells O
, O
only O
the O
upstream B
sequences I
are O
required O
for O
transactivation O
by O
the O
Z B
/ I
R I
combination O
, O
and O
the O
AP B
- I
1 I
site I
is O
dispensable O
. O

DNase O
footprinting O
analysis O
corroborated O
the O
functional O
data O
showing O
that O
a O
lymphoid B
- I
specific I
protein I
binds O
to O
the O
microB B
DNA I
motif I
. O

Int B
- I
2 I
was O
amplified O
in O
13 O
. O
1 O
% O
and O
c B
- I
myc I
was O
amplified O
in O
10 O
. O
3 O
% O
. O

Int B
- I
2 I
was O
amplified O
in O
13 O
. O
1 O
% O
and O
c B
- I
myc I
was O
amplified O
in O
10 O
. O
3 O
% O
. O

Transcription B
factor I
IID I
( O
TFIID B
) O
binds O
to O
the O
TATA B
box I
promoter I
element I
and O
regulates O
the O
expression O
of O
most O
eukaryotic B
genes I
transcribed O
by O
RNA B
polymerase I
II I
. O

Transcription B
factor I
IID I
( O
TFIID B
) O
binds O
to O
the O
TATA B
box I
promoter I
element I
and O
regulates O
the O
expression O
of O
most O
eukaryotic B
genes I
transcribed O
by O
RNA B
polymerase I
II I
. O

Complementary B
DNA I
( O
cDNA B
) O
encoding O
a O
human B
TFIID I
protein I
has O
been O
cloned O
. O

Third O
, O
only O
the O
50 B
kD I
protein I
was O
retained O
on O
a O
biotinylated O
DNA O
- O
streptavidin O
matrix O
when O
the O
DNA O
fragment O
contained O
the O
TRE B
- I
DNA I
. O

Third O
, O
only O
the O
50 B
kD I
protein I
was O
retained O
on O
a O
biotinylated O
DNA O
- O
streptavidin O
matrix O
when O
the O
DNA O
fragment O
contained O
the O
TRE B
- I
DNA I
. O

Fourth O
, O
extensive O
purification O
by O
several O
cycles O
of O
TRE B
- O
DNA O
affinity O
chromatography O
resulted O
in O
the O
32 B
, I
36 I
to I
42 I
and I
110 I
kD I
proteins I
and O
to O
less O
extent O
the O
50 B
kD I
factor I
. O

Human O
T O
- O
cell O
leukemia O
virus O
types O
I O
( O
HTLV O
- O
I O
) O
and O
II O
( O
HTLV O
- O
II O
) O
have O
two O
nonstructural B
trans I
- I
acting I
regulatory I
genes I
, O
tax B
and O
rex B
, O
located O
in O
the O
3 B
' I
region I
of O
the O
viral B
genome I
. O

Rex B
acts O
posttranscriptionall O
to O
facilitate O
accumulation O
of O
full O
- O
length O
gag B
/ I
pol I
and O
singly O
spliced O
env B
mRNA I
in O
the O
cytoplasm O
of O
HTLV O
- O
infected O
cells O
. O

In O
lymphocytes O
, O
the O
octamer B
- I
binding I
protein I
Oct B
- I
2A I
and O
variants O
thereof O
are O
thought O
to O
contribute O
to O
the O
B B
- I
cell I
specific I
gene I
expression O
, O
while O
the O
ubiquitous O
protein O
Oct O
- O
1 O
seems O
to O
control O
general O
octamer B
site I
- O
dependent O
transcription O
. O

All O
immunoglobulin B
genes I
contain O
a O
conserved O
octanucleotide B
promoter I
element I
, O
ATGCAAAT O
, O
which O
has O
been O
shown O
to O
be O
required O
for O
their O
normal O
B O
- O
cell O
- O
specific O
transcription O
. O

Addition O
of O
a O
highly O
enriched O
preparation O
of O
OTF B
- I
1 I
made O
from O
one O
of O
these O
pre O
- O
B O
cells O
or O
from O
HeLa O
cells O
specifically O
stimulated O
in O
vitro O
transcription O
of O
an O
immunoglobulin B
gene I
. O

Thus O
, O
EBNA B
- I
2 I
transactivation O
of O
LMP1 B
amplifies O
the O
biological O
impact O
of O
EBNA B
- I
2 I
and O
underscores O
its O
central O
role O
in O
EBV O
- O
induced O
growth O
transformation O
. O

Thus O
, O
EBNA B
- I
2 I
transactivation O
of O
LMP1 B
amplifies O
the O
biological O
impact O
of O
EBNA B
- I
2 I
and O
underscores O
its O
central O
role O
in O
EBV O
- O
induced O
growth O
transformation O
. O

Lt B
- I
4 I
reacted O
with O
all O
HTLV O
- O
I O
- O
bearing O
cell O
lines O
tested O
and O
five O
out O
of O
eight O
simian O
cell O
lines O
bearing O
STLV O
- O
I O
, O
but O
not O
with O
an O
HTLV O
- O
II O
- O
bearing O
cell O
line O
. O

In O
the O
STLV O
- O
I O
- O
bearing O
T O
cell O
lines O
, O
tax1 B
- I
related I
antigen I
molecules I
detected O
by O
Lt B
- I
4 I
were O
heterogeneous O
, O
having O
molecular O
weights O
in O
the O
range O
of O
36 O
- O
41 O
kd O
. O

Instead O
of O
NF B
kappa I
B I
, O
the O
activator B
protein I
3 I
binds O
to O
the O
divergent O
site O
in O
HIV O
- O
2 O
. O

Instead O
of O
NF B
kappa I
B I
, O
the O
activator B
protein I
3 I
binds O
to O
the O
divergent O
site O
in O
HIV O
- O
2 O
. O

Expression O
cloning O
of O
c B
- I
Jun I
. O

Whereas O
c B
- I
Fos I
/ I
c I
- I
Jun I
heterodimers I
do O
not O
exist O
in O
B O
cells O
, O
they O
form O
and O
bind O
to O
the O
X2 B
- I
box I
in O
class O
II O
nonexpressing O
cells O
. O

When O
tested O
in O
a O
radioreceptor O
assay O
in O
human O
mononuclear O
leukocytes O
the O
synthesized O
compounds O
showed O
only O
low O
relative O
binding O
affinities O
( O
RBA O
) O
to O
type B
1 I
receptor I
, O
the O
highest O
being O
0 O
. O
72 O
% O
for O
13 O
( O
aldosterone O
= O
100 O
% O
) O
. O

We O
have O
developed O
a O
system O
to O
monitor O
the O
transcriptional O
activity O
of O
NFAT B
- I
1 I
at O
the O
single O
cell O
level O
in O
whole O
animals O
. O

This O
similarity O
in O
expression O
and O
the O
fact O
that O
NFAT B
- I
1 I
has O
been O
shown O
to O
bind O
functional B
sequences I
in O
HIV B
- I
LTR I
suggest O
a O
role O
for O
NFAT B
- I
1 I
in O
dermal O
activation O
of O
the O
HIV B
- I
LTR I
. O

This O
similarity O
in O
expression O
and O
the O
fact O
that O
NFAT B
- I
1 I
has O
been O
shown O
to O
bind O
functional B
sequences I
in O
HIV B
- I
LTR I
suggest O
a O
role O
for O
NFAT B
- I
1 I
in O
dermal O
activation O
of O
the O
HIV B
- I
LTR I
. O

This O
similarity O
in O
expression O
and O
the O
fact O
that O
NFAT B
- I
1 I
has O
been O
shown O
to O
bind O
functional B
sequences I
in O
HIV B
- I
LTR I
suggest O
a O
role O
for O
NFAT B
- I
1 I
in O
dermal O
activation O
of O
the O
HIV B
- I
LTR I
. O

This O
similarity O
in O
expression O
and O
the O
fact O
that O
NFAT B
- I
1 I
has O
been O
shown O
to O
bind O
functional B
sequences I
in O
HIV B
- I
LTR I
suggest O
a O
role O
for O
NFAT B
- I
1 I
in O
dermal O
activation O
of O
the O
HIV B
- I
LTR I
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
proto B
- I
oncoprotein I
ets B
- I
1 I
defines O
a O
transcriptional B
activator I
sequence I
within O
the O
long B
terminal I
repeat I
of O
the O
Moloney O
murine O
sarcoma O
virus O
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
proto B
- I
oncoprotein I
ets B
- I
1 I
defines O
a O
transcriptional B
activator I
sequence I
within O
the O
long B
terminal I
repeat I
of O
the O
Moloney O
murine O
sarcoma O
virus O
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
proto B
- I
oncoprotein I
ets B
- I
1 I
defines O
a O
transcriptional B
activator I
sequence I
within O
the O
long B
terminal I
repeat I
of O
the O
Moloney O
murine O
sarcoma O
virus O
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
proto B
- I
oncoprotein I
ets B
- I
1 I
defines O
a O
transcriptional B
activator I
sequence I
within O
the O
long B
terminal I
repeat I
of O
the O
Moloney O
murine O
sarcoma O
virus O
. O

We O
propose O
that O
ets B
- I
1 I
functions O
as O
a O
transcriptional O
activator O
of O
mammalian O
type O
- O
C O
retroviruses O
and O
speculate O
that O
ets B
- I
related I
genes I
constitute O
a O
new O
group O
of O
eukaryotic B
DNA I
- I
binding I
proteins I
. O

We O
have O
previously O
reported O
that O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
contain O
type O
II B
estrogen I
binding I
sites I
( O
type B
II I
EBS I
) O
. O

In O
postmenopausal O
women O
the O
mean O
type B
II I
EBS I
levels O
were O
similar O
to O
those O
observed O
in O
the O
follicular O
phase O
of O
the O
cycle O
. O

Tamoxifen O
was O
also O
found O
to O
compete O
with O
17 O
beta O
- O
estradiol O
for O
type B
II I
EBS I
in O
PBMC O
, O
although O
to O
a O
lesser O
extent O
than O
diethylstilbestrol O
. O

We O
previously O
identified O
the O
DNA B
consensus I
binding I
site I
recognized O
by O
the O
two O
DNA B
binding I
domains I
. O

The O
expression O
vector O
was O
cotransfected O
with O
the O
chloramphenicol B
acetyl I
transferase I
( I
CAT I
) I
reporter I
gene I
regulated O
by O
the O
thymidine B
kinase I
promoter I
containing O
GAL4 B
DNA I
binding I
sites I
into O
NIH O
3T3 O
, O
293 O
, O
K562 O
, O
and O
Jurkat O
cell O
lines O
. O

In O
contrast O
, O
MZF B
- I
1 I
activates O
CAT B
reporter I
gene I
expression O
in O
the O
hematopoietic O
cell O
lines O
K562 O
and O
Jurkat O
. O

In O
contrast O
, O
MZF B
- I
1 I
activates O
CAT B
reporter I
gene I
expression O
in O
the O
hematopoietic O
cell O
lines O
K562 O
and O
Jurkat O
. O

The O
role O
of O
BSAP B
( O
Pax B
- I
5 I
) O
in O
B O
- O
cell O
development O
. O

Since O
many O
cytokines B
that O
activate O
Jak B
kinases I
also O
lead O
to O
the O
tyrosine O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Stat B
family I
of O
transcription B
factors I
, O
the O
ability O
of O
IL B
- I
2 I
to O
trigger O
Stat O
phosphorylation O
was O
examined O
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL B
- I
2 I
leads O
to O
the O
phosphorylation O
of O
Stat1 B
alpha I
, O
Stat1 O
beta O
, O
and O
Stat3 B
, O
as O
well O
as O
of O
two O
Stat B
- I
related I
proteins I
, O
p94 B
and O
p95 B
. O

These O
Stat B
proteins I
were O
found O
to O
translocate O
to O
the O
nucleus O
and O
to O
bind O
to O
a O
specific B
DNA I
sequence I
. O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c B
- I
fos I
transcript I
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN B
- I
alpha I
therapy O
( O
p O
< O
0 O
. O
01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0 O
. O
6895 O
, O
p O
< O
0 O
. O
01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
- O
0 O
. O
568 O
, O
p O
< O
0 O
. O
01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive B
mRNA I
levels O
of O
the O
hybrid B
bcr I
/ I
abl I
, O
c B
- I
myc I
and O
p53 B
are O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c B
- I
fos I
transcript I
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN B
- I
alpha I
therapy O
( O
p O
< O
0 O
. O
01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0 O
. O
6895 O
, O
p O
< O
0 O
. O
01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
- O
0 O
. O
568 O
, O
p O
< O
0 O
. O
01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive B
mRNA I
levels O
of O
the O
hybrid B
bcr I
/ I
abl I
, O
c B
- I
myc I
and O
p53 B
are O

positively O
correlated O
with O
each O
other O
, O
but O
failed O
to O
relate O
to O
disease O
parameters O
, O
and O
( O
iii O
) O
acute O
and O
chronic O
in O
vivo O
exposure O
to O
IFN B
- I
alpha I
is O
accompanied O
by O
upregulation O
of O
c B
- I
fos I
and O
downregulation O
of O
c B
- I
myc I
mRNA I
levels O
in O
responder O
patients O
. O

positively O
correlated O
with O
each O
other O
, O
but O
failed O
to O
relate O
to O
disease O
parameters O
, O
and O
( O
iii O
) O
acute O
and O
chronic O
in O
vivo O
exposure O
to O
IFN B
- I
alpha I
is O
accompanied O
by O
upregulation O
of O
c B
- I
fos I
and O
downregulation O
of O
c B
- I
myc I
mRNA I
levels O
in O
responder O
patients O
. O

In O
parallel O
experiments O
, O
IL B
- I
2 I
- O
driven O
proliferation O
was O
inhibited O
significantly O
. O

Yet O
, O
IL B
- I
2 I
- O
driven O
proliferation O
remained O
profoundly O
inhibited O
, O
suggesting O
that O
signaling O
events O
other O
than O
Jak3 B
/ B
Stat I
activation O
had O
also O
been O
changed O
following O
SE B
stimulation O
. O

Moreover O
, O
the O
induction O
of O
both O
Jak B
1 I
and I
3 I
, O
and O
STAT B
5 I
activity O
strongly O
correlated O
with O
the O
growth O
- O
promoting O
effects O
of O
IL B
- I
7 I
, O
suggesting O
that O
this O
signal O
transduction O
mechanism O
may O
play O
a O
key O
role O
in O
IL B
- I
7 I
- O
induced O
proliferation O
. O

Moreover O
, O
the O
induction O
of O
both O
Jak B
1 I
and I
3 I
, O
and O
STAT B
5 I
activity O
strongly O
correlated O
with O
the O
growth O
- O
promoting O
effects O
of O
IL B
- I
7 I
, O
suggesting O
that O
this O
signal O
transduction O
mechanism O
may O
play O
a O
key O
role O
in O
IL B
- I
7 I
- O
induced O
proliferation O
. O

Tepoxalin O
also O
inhibits O
the O
activation O
of O
NF B
kappa I
B I
, O
a O
transcription B
factor I
which O
acts O
on O
several O
cytokine B
genes I
. O

An O
IRF B
- I
1 I
- O
dependent O
pathway O
of O
DNA O
damage O
- O
induced O
apoptosis O
in O
mitogen O
- O
activated O
T O
lymphocytes O
. O

Deoxycholate O
treatment O
of O
the O
cytoplasmic O
extract O
prepared O
from O
cells O
stimulated O
by O
TNF B
- I
alpha I
in O
the O
presence O
of O
Cu2 O
+ O
resulted O
in O
the O
release O
of O
NF B
kappa I
B I
from O
I B
kappa I
B I
alpha I
, O
indicating O
that O
Cu2 O
+ O
interferes O
with O
the O
dissociation O
of O
the O
NF B
kappa I
B I
- I
I I
kappa I
B I
complex I
. O

Deoxycholate O
treatment O
of O
the O
cytoplasmic O
extract O
prepared O
from O
cells O
stimulated O
by O
TNF B
- I
alpha I
in O
the O
presence O
of O
Cu2 O
+ O
resulted O
in O
the O
release O
of O
NF B
kappa I
B I
from O
I B
kappa I
B I
alpha I
, O
indicating O
that O
Cu2 O
+ O
interferes O
with O
the O
dissociation O
of O
the O
NF B
kappa I
B I
- I
I I
kappa I
B I
complex I
. O

Neither O
phosphorylation O
nor O
degradation O
of O
I B
kappa I
B I
alpha I
was O
observed O
upon O
TNF B
- I
alpha I
stimulation O
in O
the O
presence O
of O
Cu2 O
+ O
. O

The O
present O
study O
verified O
the O
ability O
of O
IL B
- I
2 I
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 B
and O
JAK3 B
, O
but O
demonstrated O
that O
IL B
- I
2 I
stimulated O
JAK3 B
to O
a O
significantly O
larger O
extent O
than O
JAK1 B
in O
human O
T O
lymphocytes O
and O
the O
YT O
cell O
line O
. O

The O
present O
study O
verified O
the O
ability O
of O
IL B
- I
2 I
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 B
and O
JAK3 B
, O
but O
demonstrated O
that O
IL B
- I
2 I
stimulated O
JAK3 B
to O
a O
significantly O
larger O
extent O
than O
JAK1 B
in O
human O
T O
lymphocytes O
and O
the O
YT O
cell O
line O
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

This O
novel O
enzyme O
is O
distinct O
from O
E6 B
- I
AP I
, O
the O
p53 B
- I
conjugating I
ligase I
, O
and O
from O
E3 B
alpha I
, O
the O
` B
` I
N I
- I
end I
rule I
' I
' I
ligase I
. O

To O
identify O
osteoblast B
- I
specific I
cis I
- I
acting I
elements I
and O
trans B
- I
acting I
factors I
, O
we O
initiated O
an O
analysis O
of O
the O
promoter B
of O
a O
mouse B
osteocalcin I
gene I
, O
an O
osteoblast B
- I
specific I
gene I
. O

By O
DNA O
cotransfection O
experiments O
, O
we O
also O
demonstrate O
that O
AML B
- I
1B I
can O
increase O
the O
activity O
of O
a O
short O
osteocalcin B
promoter I
through O
its O
binding O
to O
OSE2 O
. O

The O
lack O
of O
Jak3 B
expression O
correlated O
with O
impaired O
B O
cell O
signaling O
, O
as O
demonstrated O
by O
the O
inability O
of O
IL B
- I
4 I
to O
activate O
Stat6 B
in O
the O
EBV O
- O
transformed O
cell O
line O
from O
the O
patient O
. O
These O
observations O
indicate O
that O
the O
functions O
of O
gamma B
c I
are O
dependent O
on O
Jak3 B
and O
that O
Jak3 B
is O
essential O
for O
lymphoid O
development O
and O
signaling O
. O

L B
- I
selectin I
is O
an O
adhesion O
molecule O
of O
the O
selectin O
family O
that O
mediates O
the O
initial O
step O
of O
leukocyte O
adhesion O
to O
vascular O
endothelium O
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

Promoter O
function O
of O
the O
5 B
' I
flanking I
region I
of O
the O
thromboxane B
receptor I
gene I
was O
evaluated O
by O
transfection O
of O
thromboxane B
receptor I
gene I
promoter I
/ I
chloramphenicol I
acetyltransferase I
( I
CAT I
) I
chimera I
plasmids I
into O
platelet O
- O
like O
K562 O
cells O
. O

These O
studies O
are O
the O
first O
to O
determine O
the O
structure O
and O
organization O
of O
the O
5 O
' O
end O
of O
the O
thromboxane B
receptor I
gene I
and O
demonstrate O
that O
thromboxane B
receptor I
gene I
expression O
can O
be O
regulated O
by O
activation O
of O
protein B
kinase I
C I
via O
induction O
of O
an O
AP B
- I
2 I
- I
like I
nuclear I
factor I
binding O
to O
upstream B
promoter I
elements I
. O

These O
studies O
are O
the O
first O
to O
determine O
the O
structure O
and O
organization O
of O
the O
5 O
' O
end O
of O
the O
thromboxane B
receptor I
gene I
and O
demonstrate O
that O
thromboxane B
receptor I
gene I
expression O
can O
be O
regulated O
by O
activation O
of O
protein B
kinase I
C I
via O
induction O
of O
an O
AP B
- I
2 I
- I
like I
nuclear I
factor I
binding O
to O
upstream B
promoter I
elements I
. O

These O
studies O
are O
the O
first O
to O
determine O
the O
structure O
and O
organization O
of O
the O
5 O
' O
end O
of O
the O
thromboxane B
receptor I
gene I
and O
demonstrate O
that O
thromboxane B
receptor I
gene I
expression O
can O
be O
regulated O
by O
activation O
of O
protein B
kinase I
C I
via O
induction O
of O
an O
AP B
- I
2 I
- I
like I
nuclear I
factor I
binding O
to O
upstream B
promoter I
elements I
. O

These O
studies O
are O
the O
first O
to O
determine O
the O
structure O
and O
organization O
of O
the O
5 O
' O
end O
of O
the O
thromboxane B
receptor I
gene I
and O
demonstrate O
that O
thromboxane B
receptor I
gene I
expression O
can O
be O
regulated O
by O
activation O
of O
protein B
kinase I
C I
via O
induction O
of O
an O
AP B
- I
2 I
- I
like I
nuclear I
factor I
binding O
to O
upstream B
promoter I
elements I
. O

The O
abundant O
chromosomal B
protein I
HMG B
- I
1 I
belongs O
to O
this O
subgroup O
. O

As O
in O
HMG1B B
, O
the O
overall O
structure O
of O
the O
Sox B
- I
4 I
HMG B
box I
is O
L O
- O
shaped O
and O
is O
maintained O
by O
a O
cluster O
of O
conserved O
, O
mainly O
aromatic O
residues O
. O

Nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
is O
stored O
in O
the O
cytoplasm O
as O
an O
inactive O
form O
through O
interaction O
with O
I B
kappa I
B I
. O

This O
death O
- O
promoting O
activity O
of O
Bik B
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B
- I
2 I
, O
Bcl B
- I
XL I
, O
EBV B
- I
BHRF1 I
and O
E1B B
- I
19 I
kDa I
proteins O
suggesting O
that O
Bik B
may O
be O
a O
common O
target O
for O
both O
cellular B
and I
viral I
anti I
- I
apoptotic I
proteins I
. O

This O
death O
- O
promoting O
activity O
of O
Bik B
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B
- I
2 I
, O
Bcl B
- I
XL I
, O
EBV B
- I
BHRF1 I
and O
E1B B
- I
19 I
kDa I
proteins O
suggesting O
that O
Bik B
may O
be O
a O
common O
target O
for O
both O
cellular B
and I
viral I
anti I
- I
apoptotic I
proteins I
. O

This O
death O
- O
promoting O
activity O
of O
Bik B
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B
- I
2 I
, O
Bcl B
- I
XL I
, O
EBV B
- I
BHRF1 I
and O
E1B B
- I
19 I
kDa I
proteins O
suggesting O
that O
Bik B
may O
be O
a O
common O
target O
for O
both O
cellular B
and I
viral I
anti I
- I
apoptotic I
proteins I
. O

We O
have O
examined O
the O
role O
of O
CD28 B
in O
modulating O
the O
' O
naive O
' O
neonatal O
T O
cell O
response O
to O
anti B
- I
CD2 I
- O
mediated O
activation O
. O

Although O
IL B
- I
2 I
secretion O
was O
increased O
in O
the O
presence O
of O
anti B
- I
CD28 I
MoAb I
, O
neonatal O
T O
cell O
IL B
- I
2 I
production O
remained O
lower O
than O
in O
adults O
. O

Although O
IL B
- I
2 I
secretion O
was O
increased O
in O
the O
presence O
of O
anti B
- I
CD28 I
MoAb I
, O
neonatal O
T O
cell O
IL B
- I
2 I
production O
remained O
lower O
than O
in O
adults O
. O

Fluorescence O
in O
situ O
hybridization O
of O
the O
TCL1 B
genomic I
locus I
to O
lymphocyte O
metaphases O
from O
the O
AT O
patient O
with O
the O
T O
- O
cell O
clonal O
expansion O
showed O
that O
the O
breakpoint O
of O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
lies O
within O
the O
TCL1 B
locus I
and O
is O
accompanied O
by O
an O
inverted O
duplication O
of O
the O
distal B
part I
of O
chromosome B
14 I
. O

Northern O
( O
RNA O
) O
blots O
and O
binding O
assays O
showed O
that O
NF B
- I
IL6 I
is O
the O
only O
known O
C B
/ I
EBP I
family I
member I
which O
is O
increased O
when O
U937 O
cells O
are O
activated O
. O

Since O
expression O
of O
the O
viruses O
is O
in O
large O
part O
regulated O
by O
the O
sequence B
elements I
in O
their O
long B
terminal I
repeats I
( O
LTRs B
) O
, O
this O
study O
was O
directed O
to O
an O
analysis O
of O
the O
regulatory B
elements I
in O
the O
HIV B
- I
2 I
LTR I
. O

A O
comparison O
with O
the O
Stat B
proteins I
induced O
by O
interferon B
- I
gamma I
, O
PRL B
, O
and O
IL B
- I
6 I
in O
T47D O
mammary O
tumor O
cells O
was O
made O
. O

A O
comparison O
with O
the O
Stat B
proteins I
induced O
by O
interferon B
- I
gamma I
, O
PRL B
, O
and O
IL B
- I
6 I
in O
T47D O
mammary O
tumor O
cells O
was O
made O
. O

Granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
is O
one O
such O
cytokine B
whose O
increased O
expression O
results O
partly O
from O
increases O
in O
transcription O
. O

No O
up O
- O
regulation O
of O
hTR B
beta I
1 I
was O
seen O
in O
hypothyroid O
relative O
to O
euthyroid O
patients O
. O

DNA O
binding O
specificity O
of O
complex O
3 O
overlaps O
with O
that O
of O
upstream B
stimulatory I
factor I
but O
is O
clearly O
distinct O
. O

The O
hematopoietic B
transcription I
factor I
PU B
. I
1 I
is O
downregulated O
in O
human O
multiple O
myeloma O
cell O
lines O
. O

The O
hematopoietic B
transcription I
factor I
PU B
. I
1 I
is O
downregulated O
in O
human O
multiple O
myeloma O
cell O
lines O
. O

PU B
. I
1 I
is O
a O
hematopoietic B
transcription I
factor I
belonging O
to O
the O
Ets B
- I
family I
. O

PU B
. I
1 I
is O
a O
hematopoietic B
transcription I
factor I
belonging O
to O
the O
Ets B
- I
family I
. O

PU B
. I
1 I
is O
a O
hematopoietic B
transcription I
factor I
belonging O
to O
the O
Ets B
- I
family I
. O

We O
have O
analyzed O
the O
expression O
and O
activity O
of O
PU B
. I
1 I
during O
human O
B O
- O
cell O
development O
using O
a O
panel O
of O
B O
- O
cell O
lines O
representing O
different O
stages O
of O
maturation O
, O
from O
early O
precursors O
to O
differentiated O
plasma O
cells O
. O

The O
effects O
of O
CsA O
on O
endothelial O
cells O
were O
also O
detected O
at O
the O
chromatin B
structure O
level O
, O
as O
DNasel B
hypersensitive I
sites I
within O
both O
the O
GM B
- I
CSF I
enhancer O
and O
the O
E B
- I
selectin I
promoter I
were O
suppressed O
by O
CsA O
. O

The O
effects O
of O
CsA O
on O
endothelial O
cells O
were O
also O
detected O
at O
the O
chromatin B
structure O
level O
, O
as O
DNasel B
hypersensitive I
sites I
within O
both O
the O
GM B
- I
CSF I
enhancer O
and O
the O
E B
- I
selectin I
promoter I
were O
suppressed O
by O
CsA O
. O

Protein O
phosphorylation O
has O
an O
important O
role O
in O
the O
regulation O
of O
these O
two O
factors O
: O
( O
1 O
) O
it O
induces O
the O
transactivating O
capacity O
of O
the O
AP B
- I
1 I
protein I
c B
- I
Jun I
; O
and O
( O
2 O
) O
it O
is O
involved O
in O
the O
release O
of O
the O
cytoplasmic B
inhibitor I
, O
I B
kappa I
B I
, O
from O
NF B
- I
kappa I
B I
, O
allowing O
translocation O
of O
the O
latter O
into O
the O
nucleus O
. O

Protein O
phosphorylation O
has O
an O
important O
role O
in O
the O
regulation O
of O
these O
two O
factors O
: O
( O
1 O
) O
it O
induces O
the O
transactivating O
capacity O
of O
the O
AP B
- I
1 I
protein I
c B
- I
Jun I
; O
and O
( O
2 O
) O
it O
is O
involved O
in O
the O
release O
of O
the O
cytoplasmic B
inhibitor I
, O
I B
kappa I
B I
, O
from O
NF B
- I
kappa I
B I
, O
allowing O
translocation O
of O
the O
latter O
into O
the O
nucleus O
. O

Integration O
of O
the O
signals O
generated O
by O
TCR B
and O
CD28 B
engagement O
occurs O
along O
this O
pathway O
, O
which O
then O
bifurcates O
to O
induce O
I B
kappa I
B I
phosphorylation O
and O
NF B
- I
kappa I
B I
activation O
on O
the O
one O
hand O
, O
and O
JNK B
activation O
and O
c B
- I
Jun I
phosphorylation O
on O
the O
other O
. O

Integration O
of O
the O
signals O
generated O
by O
TCR B
and O
CD28 B
engagement O
occurs O
along O
this O
pathway O
, O
which O
then O
bifurcates O
to O
induce O
I B
kappa I
B I
phosphorylation O
and O
NF B
- I
kappa I
B I
activation O
on O
the O
one O
hand O
, O
and O
JNK B
activation O
and O
c B
- I
Jun I
phosphorylation O
on O
the O
other O
. O

We O
are O
currently O
engaged O
in O
defining O
where O
the O
two O
signals O
integrate O
along O
the O
AP B
- I
1 I
/ O
NF B
- I
kappa I
B I
pathway O
. O

Enhancement O
of O
HIV O
- O
1 O
replication O
is O
related O
in O
part O
to O
increased O
DNA O
- O
binding O
activity O
of O
cellular B
transcription I
factors I
such O
as O
NF B
- I
kappa I
B I
. O

The O
DNA B
binding I
region I
specifying O
high O
affinity O
for O
GRE B
sites I
is O
required O
. O

As O
this O
phosphorylation O
was O
independent O
of O
protein B
kinase I
C I
activity O
, O
we O
tested O
whether O
a O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( O
CaM B
kinase I
) O
might O
phosphorylate O
the O
Ets B
- I
1 I
protein I
after O
elevation O
of O
intracellular O
free O
calcium O
concentrations O
. O

Furthermore O
, O
we O
identified O
a O
repression O
domain O
at O
the O
N O
- O
terminus O
of O
Oct B
- I
2a I
. O

The O
results O
define O
essential O
cis B
- I
acting I
elements I
responsible O
for O
the O
expression O
of O
GP B
Ib I
alpha I
and O
provide O
insights O
into O
molecular O
events O
coinciding O
with O
the O
release O
of O
normal O
platelets O
into O
the O
bloodstream O
. O

The O
expression O
of O
MHC B
class I
II I
genes I
in O
mouse O
T O
cells O
can O
be O
reconstituted O
upon O
transfection O
with O
the O
human B
CIITA I
cDNA I
. O

Because O
HLA B
class I
II I
molecules I
present O
antigen O
to O
T B
cell I
receptors I
( O
TCRs B
) O
, O
we O
have O
searched O
for O
a O
TCR B
gene I
associated O
with O
the O
production O
of O
anti B
- I
Ro I
( I
SSA I
) I
antibodies I
. O

However O
, O
while O
IL2 B
expression O
requires O
the O
contribution O
of O
Ca O
( O
2 O
+ O
) O
- O
and O
protein B
kinase I
C I
- O
dependent O
signals O
, O
we O
report O
that O
activation O
of O
human B
IL4 I
transcription O
through O
the O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathway O
is O
diminished O
by O
protein B
kinase I
C I
stimulation O
in O
Jurkat O
T O
cells O
. O

However O
, O
while O
IL2 B
expression O
requires O
the O
contribution O
of O
Ca O
( O
2 O
+ O
) O
- O
and O
protein B
kinase I
C I
- O
dependent O
signals O
, O
we O
report O
that O
activation O
of O
human B
IL4 I
transcription O
through O
the O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathway O
is O
diminished O
by O
protein B
kinase I
C I
stimulation O
in O
Jurkat O
T O
cells O
. O

Human B
IL4 I
promoter I
- O
mediated O
transcription O
is O
downregulated O
in O
Jurkat O
cells O
stimulated O
with O
the O
NF B
- I
kappa I
B I
- I
activating I
cytokine I
tumor B
necrosis I
factor I
alpha I
and O
suppressed O
in O
RelA O
- O
overexpressing O
cells O
. O

The O
present O
study O
demonstrates O
that O
triggering O
of O
complement B
receptors I
CR1 B
( O
CD35 B
) O
and O
CR3 B
( O
CD11b B
/ I
CD18 I
) O
enhances O
viral O
replication O
in O
HIV O
- O
infected O
human O
monocytic O
cells O
. O

Implications O
for O
regulation O
of O
immunoglobulin B
heavy I
chain I
expression O
. O

To O
understand O
the O
role O
of O
MARs B
in O
IgH B
enhancer I
regulation O
, O
we O
have O
identified O
a O
novel O
MAR B
- I
binding I
protein I
, O
MAR B
- I
BP1 I
, O
from O
soluble O
nuclear O
matrix O
preparations O
based O
on O
its O
ability O
to O
bind O
to O
the O
MARs B
associated O
with O
the O
IgH B
enhancer I
. O

Purified O
MAR B
- I
BP1 I
migrates O
as O
a O
33 B
- I
kDa I
protein I
, O
and O
it O
can O
be O
found O
in O
nuclear O
matrix O
preparations O
from O
a O
number O
of O
different O
types O
of O
lymphoid O
cell O
lines O
. O

C B
/ I
EBP I
alpha I
is O
the O
major O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
( O
C B
/ I
EBP I
) O
form O
binding O
to O
this O
site O
in O
nuclear O
extracts O
of O
U937 O
cells O
. O

HU O
induced O
a O
dose O
- O
dependent O
stimulation O
of O
c B
- I
jun I
synthesis O
. O

Transcriptional O
repression O
of O
the O
interleukin B
- I
2 I
gene I
by O
vitamin O
D3 O
: O
direct O
inhibition O
of O
NFATp B
/ I
AP I
- I
1 I
complex I
formation O
by O
a O
nuclear B
hormone I
receptor I
. O

We O
therefore O
examined O
vitamin O
D3 O
- O
mediated O
repression O
of O
activated O
IL B
- I
2 I
expression O
by O
cotransfecting O
Jurkat O
cells O
with O
IL B
- I
2 I
promoter I
/ I
reporter I
constructs I
and O
a O
VDR B
overexpression I
vector I
and O
by O
DNA O
binding O
. O

We O
therefore O
examined O
vitamin O
D3 O
- O
mediated O
repression O
of O
activated O
IL B
- I
2 I
expression O
by O
cotransfecting O
Jurkat O
cells O
with O
IL B
- I
2 I
promoter I
/ I
reporter I
constructs I
and O
a O
VDR B
overexpression I
vector I
and O
by O
DNA O
binding O
. O

Cysteamine O
treatment O
inhibited O
both O
expression O
of O
the O
IL B
- I
2 I
mRNA I
and O
secretion O
of O
IL B
- I
2 I
into O
the O
culture O
medium O
. O

Critical O
role O
for O
IL B
- I
6 I
. O

As O
neutralizing B
anti I
- I
IL I
- I
6 I
Abs I
effectively O
down O
- O
regulated O
the O
early O
induction O
of O
STAT B
proteins I
and O
as O
exogenously O
added O
IL B
- I
6 I
rapidly O
activated O
DNA O
binding O
similar O
to O
TCR B
- O
mediated O
bindings O
, O
it O
can O
be O
concluded O
that O
IL B
- I
6 I
is O
the O
factor O
responsible O
for O
the O
activation O
of O
STAT B
proteins I
in O
a O
primary O
T O
cell O
response O
. O

As O
neutralizing B
anti I
- I
IL I
- I
6 I
Abs I
effectively O
down O
- O
regulated O
the O
early O
induction O
of O
STAT B
proteins I
and O
as O
exogenously O
added O
IL B
- I
6 I
rapidly O
activated O
DNA O
binding O
similar O
to O
TCR B
- O
mediated O
bindings O
, O
it O
can O
be O
concluded O
that O
IL B
- I
6 I
is O
the O
factor O
responsible O
for O
the O
activation O
of O
STAT B
proteins I
in O
a O
primary O
T O
cell O
response O
. O

Lymphoid B
enhancer I
- I
binding I
factor I
1 I
( O
LEF B
- I
1 I
) O
is O
a O
regulatory B
high I
mobility I
group I
( I
HMG I
) I
protein I
that O
activates O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
alpha I
) I
enhancer I
in O
a O
context O
- O
restricted O
manner O
in O
T O
cells O
. O

We O
conclude O
that O
transcription O
activation O
by O
LEF B
- I
1 I
in O
vitro O
is O
a O
chromatin B
- O
dependent O
process O
that O
requires O
a O
functional O
trans B
- I
activation I
domain I
in O
addition O
to O
the O
HMG B
domain I
. O

HIV B
- I
1 I
envelope I
glycoproteins I
induce O
activation O
of O
activated O
protein B
- I
1 I
in O
CD4 O
+ O
T O
cells O
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1995 O
Dec O
1 O
; O
270 O
( O
48 O
) O
: O
29038 O
] O

This O
stimulation O
can O
also O
be O
abolished O
by O
inhibitors O
of O
protein B
kinase I
C I
, O
but O
it O
is O
unaffected O
by O
calcium O
channel O
blocker O
or O
cyclosporine O
A O
. O

